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Abstract 
CD8^ T cells help to control virus infections and tumours . Two main pathways, 
namely direct and cross presentation, are involved in generating and presenting 
antigenic peptides to induce C D S ' T cell responses. In general, antigens that require 
minimal processing or are rapidly degraded al low better direct presentation while 
only stable antigens can be cross presented. Currently, several vaccinia virus 
( V A C V ) recombinants are being tested in clinical trials as vaccines to induce 
protective immunity, including CD8^ T cell responses, against heterologous 
pathogens and cancers. The current paradigm, based on work with the virulent 
V A C V strain Western Reserve (WR). suggests an important role of direct 
presentation for CD8^ T cell priming. However , a study has reported that cross 
presentation is the major pathway for priming CDS" T cells against the highly 
attenuated modified V A C V Ankara (MVA) . a candidate vaccine vector. 
Unders tanding this disparity between WR and M V A may improve the design of 
VACV-based recombinant vaccines. 
The priming pathway of native antigens expressed f rom WR and M V A was first 
examined in mice pre-treated with Toll-like receptor 9 ligand or cytochrome c. These 
methods have been reported to selectively inhibit cross presentation. However, 
results in this thesis demonstrate that these treatments also suppress direct 
presentation. Further investigations show that the extent of inhibition on CDS^ T cell 
pr iming by CpG is dependent on the immunisat ion route, the viral replicative ability 
and. more crucially, the immunisation dose. Similarly, the replicative ability of 
V A C V influences the inhibition effect of cytochrome c treatment. Overall, these two 
strategies do not reveal how V A C V antigens are presented. 
The immunogenici ty of recombinant antigens expressed as minigenes f rom WR and 
M V A was then examined. The magnitude of CDS^ T cell responses induced by the 
minigenes, which can only be directly presented, are at least similar to. if not higher 
than, the full-length antigens when expressed f rom W R and MVA. Contrary to the 
published work, the model antigen ovalbumin expressed as a minigene can be more 
immunogenic than the full-length antigen when expressed f rom M V A . This suggests 
that M V A behaves similarly to WR to pr ime CDS"^ T cells, i.e. by direct presentation. 
We further demonstrate that the location where the transgene encoding the foreign 
antigen is inserted in the MVA genome determines its immunogenicity. 
Two unexpected phenomena observed in this thesis were also explored. Firstly, a 
CD8^ T cell response to an immunogenic peptide of influenza A virus, known as NP-
366. can only be induced if the peptide is processed from a full-length protein from 
WR. but not as a minigene. This contradicts our studies described above and most of 
the VACV literature. Several hypotheses were tested to identify the possible 
mechanisms responsible. Secondly, we found that completely inactivated VACV 
induces CD8^ T cell responses in vivo. Its application as a recombinant vaccine was 
examined. 
In summary', this thesis has expanded our understanding on how antigens expressed 
from VACV strains WR and MVA are presented for CDS" T cell priming. The 
findings presented here provide important insights for VACV-based recombinant 
vaccine design. 
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1.1 Innate and adaptive immune systems to fight infections 
The mammalian immune system is a complex defence mechanism that eliminates 
tumour ceils and fights infections caused by a wide range of pathogens including 
viruses. The immune system is comprised of innate immunity and adaptive 
immunity. Both are essential for controlling infections. 
Innate immunity is the first defence system employed during a pathogenic 
infection. Although it was thought to function non-specifically. it still needs to 
recognise incoming pathogens in order to target them (Akira et al.. 2006). Certain 
components available across different pathogens, including bacterial and viral 
DNA. RNA. lipopolysaccharides and proteins, can be recognised by the innate 
immune system. These are called pathogen-associated molecular patterns 
(Medzhitov and .laneway. 1997). Once the innate immune system is stimulated, 
muhiple arms of the innate immune system will start to mediate pathogen 
clearance. These include (i) antimicrobial peptides to limit the infectivity of 
pathogens and stop their replication (Klotman and Chang. 2006). (ii) complement 
components to opsonise and lyse bacteria and viruses (Blue et al.. 2004), (iii) the 
secretion of cytokines by multiple cell types which have direct anti-pathogenic 
properties (Guidotti and Chisari, 2000) . and (iv) a range of innate immune cells, 
including neutrophils and macrophages, that phagocytose virions and kill infected 
cells (Guidotti and Chisari, 2001). 
During the early infection period when infection control is largely the duty of the 
innate immune system, the adaptive immune system is activated and becomes 
functional. The heart of this arm of immunity is the ability of a subset of immune 
cells to recognise a particular antigen via their unique antigen-binding receptors 
and the selective expansion of these cells to specifically target the invading 
pathogen (Burnet. 1957). This theory is known as clonal selection and has been 
confirmed by years of research. After clearance of an infection, memory is 
provided to allow rapid secondary responses against the same antigens if 
encountered later. Adaptive immunity can be subdivided into two branches: (i) 
humoral immunity, which involves antibodies produced by B cells that develop in 
the bone marrow (Mitchell and Miller, 1968; Nossal et a l . 1968; Roitt et al.. 
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1969; Playfair and Purves, 1971; Ryser and Vassalli, 1974), and (ii) cell-mediated 
immunity, which involves the functions exerted by T cells that develop in the 
thymus (Roitt et a l , 1969; Bevan. 1977; Zinkernagel et al., 1978a). Both arms of 
adaptive immunity are essential for controlling virus infection (Guidotti and 
Chisari, 2001). 
The innate and adaptive immune systems do not act independently. They engage 
in crosstalk to regulate the overall immune response induced during an infection. 
For instance, direct recognition o f pathogen-associated molecular patterns by a 
specialised cell type, called dendritic cells (DCs), leads to their activation, 
enabling them to induce potent cell-mediated adaptive immunity (Sporri and Reis 
e Sousa. 2005; Kratky et al.. 2011). In addition, neutrophils have been found to 
facilitate T cell responses via activation o f DCs (van Gisbergen et al.. 2005). 
Reciprocally, the adaptive immune response can also enhance innate immunity. 
One example is that the activity o f complements can be induced by antibodies 
complexed with antigens (Porter and Reid. 1978; Ziccardi, 1984; Duncan and 
Winter. 1988). As another example, activated T cells can trigger the recruitment 
and activation of macrophages (Stout and Bottomly, 1989; Cantor and Haskins. 
2007; Nishimura et al.. 2009). Collectively, all arms of the immune system 
function as a whole to protect the host against disease. 
1.2 T cells in the cell-mediated adaptive immunity 
There are two main types of T cells involved in the cell-mediated adaptive 
immunity and they are distinguished based on the co-receptors they express on the 
cell surface: CD4'^ and CD8 ' T cells. Notably, these T cells play different roles in 
the immune response to infection. 
1.2.1 c o r T cells 
CD4^ T cells are sometimes referred to as helper T cells because of their potential 
involvement in promoting other branches of the immune response, such as 
antibody production by B cells (Tony and Parker. 1985; Hodgkin et a l , 1990) and 
CD8^ T cell immunity (Husmann and Bevan. 1988). CD4^ T cells recognise 
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peptides presented on major histocompatibility complex class II molecules 
(MHC-l l ) on the surface of antigen-presenting cells (APCs) through their T cell 
receptors ( I C R s ; Ziegler and Unanue, 1981; Allen et al., 1984; Babbitt et al., 
1985; Reinherz et al., 1999). These cells can be further subdivided into several 
subsets based on the cytokines they produce and their main immune functions, 
namely type 1. type 2, interleukin(IL)-17-producing CD4^ T cells, and follicular 
helper T cells (Mosmann et al., 1986; Breitfeld et al.. 2000; Schaerli et al., 2000; 
Harrington et al., 2005: Park et al.. 2005). Besides promoting immunity, some 
CD4 T cells, namely regulatory T cells, can suppress the magnitude of immunity 
and play a role in establishing tolerance (Sakaguchi et al.. 1995; Thornton and 
Shevach. 1998). 
1.2.2 CDS'^T cells 
CDB^ T cells are directly involved in controlling infection by intracellular 
pathogens. Activated effector CD8^ T cells can lyse infected cells via perforin and 
Fas pathways (Kagi et al., 1994; Lowin et al., 1994). They also secrete cytokines 
which have direct anti-microbial properties (Morris et al.. 1982: Guidotti et al.. 
1996: Badovinac et al.. 2000; Slifka and Whitton. 2000a). Furthermore, various 
chemokines can be expressed by activated CD8^ T cells, which in turn help attract 
other immune cells to the site of infection (Cocchi et a l , 1995; Conlon et al., 
1995; Wagner et a l , 1998: Cook et al., 1999). In addhion to clearing infections. 
CD8^ T cells are also involved in fighting tumours (Anichini et al.. 1987). In order 
to exert these functions. CD8^ T cells must first recognise peptides presented on 
major histocompatibility complex class 1 molecules (MHC-I) on the surface of 
APCs (Zinkernagel and Doherty, 1974; Townsend et a l , 1986b). 
1.3 Interaction between a CDS"^  T cell and its ligand 
1.3.1 Peptide/MHC-1 complex: the ligand recognised by CDS"^ T cells 
MHC-1 is a heterodimer involved in presenting peptides on the surface of a cell. It 
consists of a membrane-anchored heavy chain and a soluble Pi-microglobulin 
(P2m) that are non-convalently linked together (Cresswell et al., 1973; Grey et a l , 
1973; Peterson et al., 1974; Silver and Hood, 1974). There are three extracellular 
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domains in the heavy chain: the ai and 02 domains form the top of the molecule 
where an antigenic peptide can bind, while the 03 domain extends from the 
membrane anchoring sequence and associates with p^m (Bjorkman et a!., 1987b). 
The as domain is also the site that the CDS co-receptor molecule on T cells binds 
(Connolly et al., 1988; Potter et al., 1989; Connolly et a l . 1990; Salter et al., 
1990). The MHC-I heavy chain is polygenic and highly polymorphic, allowing 
each individual host to express several variants of MHC-l (Lawlor et al., 1990). 
These two features of MHC-I ensure that a diverse set of peptides can be 
presented within individual hosts and across the whole population. 
In term of the three-dimensional structure, the ai and ai domains of MHC-l are 
folded into a tertiary structure containing two parallel a-helices. sitting on top of a 
P-pleated sheet, forming a groove for peptide binding (Bjorkman et al.. 1987a: 
Bjorkman et al., 1987b). Within this groove, there are several regions, known as 
"pockets", which interact with particular amino acids along the bound peptide 
(Fremont et al.. 1992; Matsumura et al.. 1992; Zhang et al., 1992). To secure the 
binding of a peptide, multiple hydrogen bonds are formed between both termini of 
the peptide and the binding pockets at the two ends of the groove (Madden et al., 
1993). Amino acid residues found in the pockets along the groove of MHC-I are 
polymorphic and they allow allele-specific interactions with anchor residues in the 
peptides to determine the sequence specificity of MHC-I (Matsumura et al.. 1992; 
Madden et al., 1993). The presented peptides that can be recognised by CD8^ T 
cells during an immune response are termed "CDS"^ T cell epitopes'. 
1.3.2 T cell receptors recognise peptide/MHC-I complexes 
CD8^ T cells express TCRs that recognise peptides presented on MHC-I 
molecules on the surface of APCs (Bjorkman et al., 1987b). Each TCR is a 
heterodimer consisting of a TCR-a and a TCR-P chain linked by a disulfide bond 
(Allison et al., 1982; Raskins et al., 1983; Meuer et al., 1983; Chien et al., 1984; 
Hedrick et al., 1984; Saito et al., 1984; Yanagi et al., 1984). Each TCR chain is 
folded into variable and constant domains, and the top of the variable domain 
interacts directly with the exposed amino acid residues of the MHC-l-bound 
peptides and some regions of the a-helices of MHC-I (Garboczi et al., 1996; 
Chapter 1 
Garcia et al., 1996; Ding et al., 1998; Rudolph et a l , 2006). The CDS co-receptor 
also binds to MHC-I to increase stability of the TCR-peptide/MHC-I interaction 
(Luescher et al., 1995; Daniels and Jameson. 2000). T cells can also express TCR 
consisting of TCR-y and 5 chains and these cells represent a separate lineage from 
the TCR-a/p-expressing T cells, with specialised functions (Lew et al., 1986; 
Bom et al.. 1987; Janis et al.. 1989). Conventional TCR-a/(3 T cells will be the 
focus here. 
In order to recognise all the possible peptide/MHC-1 complexes, a diverse 
repertoire of T cells, each expressing a TCR with a unique specificity, is needed. 
This diversity is generated by the following mechanisms. Firstly, there are 
multiple variable (V). diversity (D; only for p chain), and joining (.1) gene 
segments in each TCR chain locus (Toyonaga et al.. 1985; Yoshikai et al.. 1985). 
The variable domain of a TCR chain is formed by random rearrangement and 
recombination of each of these gene segments (Chicn et al., 1984; Hedrick et al.. 
1984; Saito et al.. 1984; Yanagi et al.. 1985). This variable domain is joined with 
a constant domain, which contains a transmembrane region for anchoring to the 
cell membrane (Malissen et al.. 1984). This recombination process was firstly 
identified for the generation of the antibody-encoding gene in B cells, and similar 
to TCRs. this process allows the generation of antibodies with a diverse 
specificity (Hozumi and Tonegawa. 1976; Brack et al.. 1978). V(D)J 
rearrangement is initiated by two related enzymes called recombination activating 
genes (RAG) 1 and 2. which allow the cleavage of the double-stranded 
deoxyribonucleic acid (DNA) around the gene segments (Schatz et al.. 1989; 
Oettinger et al., 1990). The ends of the DNA are then joined by several DNA 
ligases (Taccioli et al., 1993; Baumann and West. 1998). This recombination 
process allows gene segments that are far apart to be joined to form the final TCR 
genes by removing the DNA sequences in between DNA breaks (Chien et al., 
1984; Hedrick et a l , 1984; Saito et a l , 1984). Secondly, nucleotides can be 
inserted into or removed from the junctions between gene segments to increase 
the diversity of TCR genes (Lieber et al., 1988; Lafaille et al., 1989; Feeney, 
1991). Part of the process is catalysed by terminal deoxynucleotidyl transferase, 
which adds random nucleotides to the ends of DNA breaks (Desiderio et a l , 1984; 
Kallenbach et al., 1992; Gilfillan et al., 1993; Komori et al., 1993). 
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When a productive TCR chain is generated from a rearranged gene on one 
chromosome, the rearrangement of this allele on the other chromosome will be 
stopped (Uematsu et al., 1988). This allelic exclusion of the TCR ensures that 
each T cell only expresses one form of TCR-a/p molecule with a single specificity 
in most cases. However, this process is not absolute as T cells may express two 
functional TCR-a or P chains in some cases (Padovan et al.. 1993; Balomenos et 
al., 1995; Elliott and Altmann. 1995; Heath et al., 1995). After generating a 
diverse range of TCRs by V(D).I recombination, a selection process is then 
required in the thymus to eliminate unwanted rearranged products and keep those 
that can recognise self MHC-1 complexed with peptides. 
1.4 Development of CD8^ T cells in thymus 
To create a diverse set of CD8' T cells that can recognise foreign, but not self, 
peptides presented on MHC-I. T cells are subjected to two selection processes 
during their development in the thymus. They are called positive and negative 
selection. Firstly. T cell progenitors migrate from the bone marrow to the thymus 
via the blood stream (Moore and Owen. 1967; Doria and Agarossi, 1969; Le 
Douarin and Jotereau. 1975). These newly-arrived progenitors do not express 
CD4 or CD8 co-receptors and are yet to express TCRs (Bluestone et al., 1987). 
These cells undergo TCR-p chain rearrangement followed by TCR-a chain 
rearrangement (Petrie et a l , 1995). The TCR-a chain locus can undergo muhiple 
rounds of V(D)J recombination, allowing for selection of a functional TCR that 
can successfully recognise peptides presented on self MHC-I in the thymus when 
paired with a TCR-P chain (Borgulya et al., 1992; Brandle et al., 1992; Petrie et 
al., 1993). 
T cells expressing TCR-a/p molecules are first subjected to positive selection and 
only those carrying TCRs that bind to self peptide/MHC-l molecules with 
sufficient affinity will survive, forming a pool of CD8^ T cells that are restricted 
to self MHC-I (Bevan, 1977; Fink and Sevan, 1978; Zinkemagel et al., 1978b). T 
cells at this stage express both CD4 and CDS co-receptors and they are positively 
selected against the cortical thymic epithelial cells which express self 
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peptide/MHC-1 as the ligands for this process (Fink and Bevan. 1978; Zinkernagel 
et al., 1978b; Lo and Sprent, 1986; Anderson et al., 1994; Wilkinson et al., 1995). 
T cells expressing I C R s that fail to bind to self pept ide/MHC-l will die by neglect 
via apoptosis while T cells with functional I C R s will express the anti-apoptotic 
Bcl-2 protein and survive (Kisielow and Miazek. 1995). During this process, the 
CD4/CD8-l ineage fate of the T cells is also determined, such that T cells 
recognising peptide/MHC-l will express the C D 8 co-receptor only and become 
CD8^ T cells (Teh et al.. 1988; reviewed Singer et a l . 2008). The surviving CD8" 
T cells then undergo negative selection in which those recognising self 
pept ide/MHC-l with too high affinity are eliminated (Ashton-Rickardt et al., 
1994; Sebzda et al.. 1994). This process happens in the cortex as well as the 
medulla region of the thymus and involves DCs and thymic epithelial cells as the 
APCs (Gao et al.. 1990a; Webb and Sprent. 1990; Gallegos and Bevan. 2004; 
Mayerova and Hogquist. 2004; McCaughtry et al.. 2008; Le Borgne et al.. 2009; 
Hubert et al.. 2011). Autoreactive T cells are removed by this process to induce 
central tolerance and prevent autoimmunity. To induce tolerance against tissue-
specific antigens, medullary thymic epithelial cells express a protein called 
auto immune regulator (AIRE). AIRE allows expression of antigens normally 
produced in peripheral tissues only (Anderson et al., 2002; Listen et al.. 
2003).This allows for negative selection against tissue-specific autoreactive CD8^ 
T cells (Gallegos and Bevan. 2004; Hubert et a l , 2011). T cells that are selected 
against during negative selection are eliminated by apoptosis (Surh and Sprent. 
1994). This process involves expression of several pro-apoptotic molecules, 
including B-cell lymphoma 2 interacting mediator of cell death (Bim) and p53-up-
regulated modulator of apoptosis (Puma; Bouillet et al., 1999; Bouillet et al., 
2002; Erlacher et al., 2006; Gray et al., 2012). Overall , the surviving CD8^ T cells 
express TCRs that weakly recognise self pept ide/MHC-I , ensuring that they can 
recognise self MHC-I , but not react to self antigens. 
1.5 Activation of naive CD8^ T cells in periphery 
Once CD8^ T cells are developed, they are released into the circulatory system. It 
is generally accepted that these cells are fully mature based on the similar 
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phenotypes and potential functionality between T cells that have recently left the 
thymus and peripheral T cells isolated from secondary lymphoid organs (Scollay 
et al., 1978; Scollay, 1982; Scollay et al., 1984). However, more recent studies 
suggest that some T cells continue the maturation process within secondary 
lymphoid organs (Boursalian et al., 2004; Houston et al.. 2008). In either scenario, 
naive mature T cells are available in the periphery. To survive in the periphery 
and maintain their homeostatic proliferation ability, naive CD8^ T cells require 
TCR signalling by interacting weakly with self peptide/MHC-l on peripheral cells 
(Tanchot et al., 1997; Goldrath and Bevan. 1999; Kieper and .lameson. 1999; 
Murali-Krishna et al.. 1999). The cytokine IL-7 is also required for T cell 
homeostatic proliferation and survival (Schluns et al., 2000; Tan et al., 2001). 
These naive CD8^ T cells circulate around the host and wait for activation in case 
of an infection. 
During an infection. CD8^ T cell activation mostly happens in secondary 
lymphoid organs, such as the spleen and lymph nodes (LNs). Naive CD8^ T cells 
express various LN-homing receptors including CD62L and CC-chemokine 
receptor 7 (CCR7; Gallatin et al., 1983; Mobley and Dailey, 1992; Forster et al., 
1999; Sallusto et al., 1999). As a result, naive CD8^ T cells readily migrate 
between LNs via the blood and lymph (Mackay et al., 1990; Weninger et al., 
2001). In addition, secondary lymphoid organs are architecturally organised to 
allow optimal opportunities for CD8^ T cells to interact with specialised APCs, 
mainly DCs, for CD8^ T cell activation (Schaefer et al., 2001; Bousso and Robey, 
2003; Mempel et al., 2004). Induction of CD8^ T cell responses against viral and 
bacterial infections is significantly impaired in splenectomised mice and 
lymphotoxin a-deficient mice, which lack proper secondary lymphoid organs 
(Karrer et al., 1997; Suresh et al., 2002; Klonowski et al., 2006). demonstrating 
the importance of these organs for CDS"^ T cell activation. 
While MHC-I is expressed on many cell types, but it is generally accepted that 
naive CD8^ T cells can only be activated (or primed) after recognising cognate 
peptides presented on MHC-I by professional APCs. Although macrophages have 
been considered as professional APCs for activating CD8^ T cells, targeted 
depletion o f DCs inhibits CD8^ T cell immunity during various types of infections 
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( Jung et al., 2002 ; Probst and van den Broek . 2005 ; Ciavar ra et al., 2006; Kass im 
et al. , 2006 ; John et al.. 2009 ; H ickman et al., 201 lb ) . In addi t ion, cluster ing of 
CDS"^ T cel ls a round D C s that leads to CD8^ T cell act ivat ion has been observed 
as early as six hours a f te r infect ion o f mice wi th vacc in ia virus ( V A C V ) and 
ves icu lar s tomat i t i s v i rus ( V S V ; Norbury et al. , 2002 ; H ickman et al.. 2008) . 
A l though naive CD8^ T cells can interact stably wi th infected mac rophages in 
d ra in ing L N s af te r V A C V infect ion if D C s are deple ted , this interaction does not 
a l l ow full act ivat ion and e f fec to r d i f ferent ia t ion of the CD8^ T cells (H ickman et 
al . . 201 lb) . These data suggest an essential role for D C s in pr iming CD8^ T cell 
immun i ty in vivo. In support of this mode l . D C s have several character is t ics that 
are essential for act ivat ing T cells, inc luding the express ion of co-s t imulatory 
molecu le s and the necessary machinery for p resen t ing ant igens . These fea tures are 
d iscussed in Sect ions 1.5.2 and 1.7 respect ively . 
T o pr ime a product ive CD8^ T cell response , three separa te yet integrated signals 
f r o m D C s are required, namely s ignal l ing f r o m the TCR-pep t ide /MHC-I complex 
interact ion, signal 2 f rom co-s t imulatory molecules , and signal 3 f rom 
in f l ammato ry cytokines . 
1.5.1 Signal 1: T C R signal l ing pathway 
O n c e a T C R on a naive C D 8 " T cell recognises a pep t ide /MHC-I complex on an 
A P C , several s ignal l ing cascades will be act ivated to induce CD8'^ T cell 
ac t ivat ion. M a n y of the s tudies on the T C R signal l ing pa thway have focused on a 
C D 4 ^ T cell l eukaemia cell line k n o w n as Jurkat cel ls (Abraham and Weiss , 
2004) . H o w e v e r , the T C R signal l ing t ransduct ion pa thway is conserved be tween 
CD4^ and CD8^ T cells. On the T cell m e m b r a n e , the T C R - a / p d imer fo rms a 
larger c o m p l e x wi th mul t ip le C D 3 subuni ts , inc luding the CDSy, 6, E, cha ins 
(Bors t et al. , 1982; Kane l lopou los et al., 1983; Borst et al., 1984; Weiss and 
S tobo , 1984; W e i s s m a n et al., 1986). Each C D 3 subuni t has a cy toplasmic tail 
con ta in ing at least one immunog lobu l in receptor f ami ly tyros ine-based activation 
mot i f ( I T A M ) which is important for T C R s ignal l ing (Reth, 1989; R o m e o et a l , 
1992). Speci f ic tyros ine res idues in these mot i f s are phosphory la ted dur ing T cell 
ac t ivat ion, main ly by the lymphocy te - spec i f i c prote in tyros ine kinase (Lck; Stein 
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et al., 1992; Straus and Weiss. 1992; Iwashima et al., 1994; van Oers et al., 
1996a). Once the ITAMs of the CD3 subunits are phosphorylated, multiple 
adaptor molecules are recruited (Iwashima et al., 1994; Finco et a!., 1998; Zhang 
et a!., 1998a). Further signal transduction occurs via phosphorylation of these 
adaptors, resulting in increased expression of several important transcriptional 
factors required for T cell activation, including nuclear factor K-light-chain-
enhancer of activated B cells (NF-kB). nuclear factor of activated T-cells and 
activator protein 1 (.lamieson et al., 1991; Chan et al.. 1992; Iwashima et al., 1994; 
Wu et al., 1996; Finco et al.. 1998; Zhang et al.. 1998a). 
To demonstrate the importance of this signalling pathway, T cell development in 
the thymus is arrested in mice lacking Lck or other adaptor molecules (Negishi et 
al.. 1995; van Oers et al.. 1996b; Zhang et al.. 1999). To dissect the role of Lck in 
T cell activation after their development, a transgenic mouse model, in which the 
expression of Lck can be induced by doxycycline, has been used (Tewari et al., 
2006). This study demonstrated that Lck expression is necessary for CD8^ T cell 
activation for primary responses against lymphocytic choriomeningitis virus 
(LCMV) and VACV infections in vivo (Tewari et al.. 2006). Surprisingly, the 
same study showed that the secondary anti-LCMV response seems to be 
independent of Lck expression although the authors noted that this could be 
influenced by the TCR affinity for its peptide/MHC-I ligand (Tewari et al., 2006). 
The role of the duration of TCR signalling in determining CDB^ T cell immunity 
has also been examined. It has been suggested that the TCR signalling pathway 
may simply be required for programming CD8^ T cells into a stage that can 
undergo proliferation without the presence of further TCR stimulation (Mercado 
et al., 2000; Kaech and Ahmed, 2001; van Stipdonk et a l , 2001; Wong and 
Pamer, 2001). On the other hand, during an acute infection, an antigen will be 
present for a period of time in the host before the pathogen is eliminated. Using an 
in vivo immunisation model involving transfer of peptide-pulsed DCs that could 
be depleted at various times, Priic et al (2006) showed that the size of CD8^ T cell 
immunity is directly proportional to duration of antigen presentation by MHC-I on 
DCs. Similarly, the magnitude of immunity is positively influenced by the dose of 
pathogen during infections and the duration of antigen expression in DNA 
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immunisation (Kaech and Ahmed. 2001; Badovinac et a!., 2002; Hovav et al., 
2007), suggesting that the length of TCR signalHng is important for programming 
and tuning CD8^ T cell immunity. 
1.5.2 Signal 2: co-stimulatory signalling 
Without appropriate co-stimulator>' signals. T cells fail to proliferate even with the 
presence of TCR signalling and these T cells can be driven into an anergic state 
where they become non-responsive, even after subsequent antigen encounter 
(Weiss et al.. 1984; .lenkins and Schwartz. 1987; Otten and Germain. 1991; 
Harding et al.. 1992; Gett et al.. 2003). Multiple co-stimulatory molecules have 
been identified, but the CD28-CD80/CD86 costimulatory pathway is the best 
studied. CD28 is expressed on CD8^ T cells (Turka et a l . 1990; Tan et al.. 1992). 
When CD8^ T cells are activated in vitro via TCR stimulation, engagement of 
CD28 with a stimulatory antibody increases the production of multiple cytokines 
by the T cells, including IL-2 which acts as an autocrine growth factor to promote 
T cell proliferation (Thompson et al., 1989). It was later found that CD80 and 
CD86 are the natural ligands for CD28 and they are expressed on DCs (Larsen et 
al., 1992; Hathcock et al.. 1993; Caux et a l . 1994b). The expression of these two 
ligands can be further enhanced after DC maturation (Larsen et a l . 1992; Caux et 
al., 1994b; Larsen et al.. 1994). By binding to CD28. these two ligands provide 
similar co-stimulation to T cells (Freeman et al., 1995; Lanier et al., 1995). 
Mechanistically, the CD28-CD80/CD86 interaction results in an activation of the 
pathways that are also involved in the TCR signalling transduction (Verweij et al., 
1991; Su et al., 1994; Coudronniere et al., 2000; Michel et a l , 2000). As a result, 
this co-stimulatory pathway helps to reduce the activation threshold required for 
inducing a productive TCR signal (Pardigon et al., 1998; Acuto and Michel. 
2003). 
CD80 and CD86 can also bind to another receptor called cytotoxic T lymphocyte 
antigen 4 (CTLA-4) which is highly expressed on the cell surface of activated T 
cells (Linsley et al., 1991; Linsley et al., 1992). The interaction of CD80/CD86 
with CTLA-4 down-regulates co-stimulatory signal transduction and inhibits T 
cell proliferation and functions (Walunas et al., 1994; Walunas et a l , 1996). It has 
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been recently shown that CTLA-4 on CD4^ T cells can reduce surface expression 
of CD80 and CD86 on APCs by trans-endocytosing them into the T cells (Qureshi 
et a l , 2011). This inhibitory receptor provides a balance of co-stimulation during 
T cell activation. 
During infection by a pathogen. CD28-CD80/CD86 costimulation plays an 
important role in eliciting CD8^ T cell immunity. CD8^ T cell responses are 
altered, reduced and/or delayed if this costimulatory signal is missing during (a) 
viral infections, including ectromelia virus, murine y-herpesvirus 68. herpes 
simplex virus 1 (HSV-1), influenza A virus (lAV). LCMV, VACV and VSV 
infection (KUndig et al.. 1996: Edelmann and Wilson. 2001; Bertram et al.. 2002: 
Fang and Sigal. 2006: Fuse et al.. 2008: Salek-Ardakani et al.. 2009; Grujic et al., 
2010; Dolfi et al.. 2011: Eberlein et al., 2012). (b) bacterial infection with Lislevia 
monocyiogenes (LM: Mittrucker et al., 2001; Shedlock et al., 2003), and (c) 
parasitic infections with Toxoplasma gondii and Plasmodium chabuudi. a cause of 
murine malaria (Villegas et al., 1999; Elias et al., 2005). In some early studies 
based on in vitro cytotoxicity alone, it was suggested that CD28 is not important 
for inducing primary CD8^ T cell responses against LCMV and VACV 
(Shahinian et al.. 1993; Kundig et al., 1996). However, it was later identified that 
responses against these viral infections are actually reduced and altered when 
antigen-specific cell numbers and their functionality were directly measured ex 
vivo using peptide/MHC-I tetramers and specific phenotypic markers (Fuse et a l , 
2008; Grujic et al., 2010). 
Other co-stimulatory signalling molecules can also be involved in activating CD8^ 
T cells, including interactions between CD137 and CD137 ligand, between CD27 
and CD70, between OX40 and OX40 ligand. as well as between ICOS and B7h 
(reviewed in Watts. 2004; Chen and Flies, 2013). These co-stimulatory 
interactions play a role in priming optimal CD8'^ T cell responses. It should be 
noted that co-stimulatory interactions can be enhanced by CD4^ T cells and this 
will be discussed in Section 1.6.1. Overall, the co-stimulatory pathways provide 
an essential companion signal for the TCR-peptide/MHC-I signal to induce CD8^ 
T cell immunity. 
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1.5.3 Signal 3: Inflammator} signalling - the danger signal 
The role of inflammatory signals in T cell activation is a relatively new discovery 
compared to the other two signals, and the mechanisms involved are still under 
extensive investigation. In vitro experiments demonstrated that an external supply 
of the inflammatory cytokine lL-12 can significantly enhance the in vitro 
proliferation, survival and effector functions of naive CD8^ T cells when they are 
stimulated in the presence of the TCR and co-stimulatory signals (Curtsinger et 
al.. 1999; Curtsinger et al.. 2003a). This cytokine can replace conventional 
adjuvants to induce CD8* T cell immunity during in vivo peptide immunisation, 
which would otherwise induce a tolerant CDS"^ T cell state if there is no adjuvant 
(Curtsinger et al.. 1999; Curtsinger et al.. 2003b). Other than lL-12. type I 
interferon (IFN-I. including IFN-a and P) can also provide signal 3 to naive T 
cells (Curtsinger et al.. 2005; Le Bon et al.. 2006). Other types of signal 3. 
including lL-21 and interferon-y (IFN-y), have been proposed and their 
importance has started to emerge via recent studies (Whitmire et al.. 2005; Sercan 
et al.. 2006; Casey and Mescher. 2007). As these cytokines are produced by DCs 
after maturation (Cella et a l . 1996). CD8^ T cells will receive all the required 
signals by interacting with activated antigen-presenting DCs. 
Signal 3 is also important to elicit optimal CD8^ T cell immunity during 
pathogenic infections. Mutant TCR-transgenic CD8'^ T cells specific to a LCMV 
CD8^ T cell epitope that lacked the IFN-I receptor showed a significant reduction 
in survival during the expansion phase compared with wildtype cells after 
adoptive transfer into mice that were subsequently infected with LCMV 
(Kolumam et al., 2005). A similar requirement for IFN-I has been reported for 
VACV, VSV, and LM infections, although the reduction in CD8^ T cell 
expansion was not as dramatic as for LCMV (Thompson el al., 2006). Two 
reports have suggested that the dependence on IFN-I and IL-12 for CD8'^ T cell 
expansion is minimal during the primary response induced by VACV infection 
(Aichele et al., 2006; Keppler et al., 2012). In contrast. IL-12, but not IFN-I, is 
necessary for optimal memory and secondary CD8'^ T cell immunity to VACV 
infection (Xiao et al.. 2009). These data imply that the type of pathogen influences 
the dependence of CD8^ T cell immunity on the source of signal 3. 
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Collectively, all the three signals discussed above are required for the optimal 
priming of a CD8^ T cell response. Loss of these signals severely affects the 
magnitude of response induced. 
1.6 Progression of a CD8^ T cell response during an acute infection 
After CD8* T cells receive all the required signals for activation during an 
infection, they will differentiate and expand into effector cells to control infection. 
After the resolution of the infection, the effector CD8^ T cell population goes 
through a contraction phase where only memory cells survive. The memory 
population provides protective immunity against future infections by the same 
pathogen. This phenomenon was first reported with experiments based on in vitro 
cytotoxicity assays (Marker and Volkert. 1973; Moskophidis et al.. 1987; Oehen 
et al.. 1992; Moskophidis et al., 1993; Lau et a l , 1994; Tripp et al.. 1995), and 
later confirmed by the direct measurement of antigen-specific T cells with 
peptide/MHC-I tetramers or ex vivo peptide stimulation followed by labelling of 
intracellular cytokines (Butz and Bevan. 1998; Murali-Krishna et al.. 1998; Flynn 
et al., 1999; Harrington et al., 2002; Yang et al.. 2003). The progress of a CD8^ T 
cell response during an acute infection is illustrated in Figure 1-1. 
A single naive CDS T cell has the potential to differentiate into effector and 
memory cells, as demonstrated using a DNA-barcoding technique to label 
individual cells, as well as single cell transfer (Stemberger et al., 2007; Gerlach et 
al., 2010). This indicates that the fate of T cells is not imprinted during their 
development in the thymus, but is influenced by T cell activation. After 
interacting with APCs, naive CD8^ T cells become activated and undergo 
asymmetric cell division, where the two daughter cells receive different amounts 
o f molecules critical for the TCR signalling pathway and differentiation (Chang et 
al.. 2007). This leads to the generation of cells that are committed to the effector 
and memory lineages from the same progenitors (Chang et al., 2007; Oliaro et al., 
2010). Various pathways are involved in the expansion and development o f naive 
CDS"^ T cells into effector cells and they are discussed below. 
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Figure 1-1| A CD8^ T cell response induced during an acute virus infection. (1) 
Within a host, there are naive CD8 T cells that are maintained in homeostasis. (2) During 
an acute virus infection, some naive CD8 T cells become activated via recognition of 
cognate peptides presented on professional APCs. These CD8 T cells undergo 
proliferation and differentiation into effectors cells. (3) During the peak of the response, a 
large population of effector CDS' T cells is available for controlling the infection. (4) 
After the clearance of the infection, the effector CDS T cell population contracts and only 
long-lived memory cells survive. (5) The established memory population is in a greater 
number than the naive population, allowing a rapid induction of response against 
subsequent infections with the same virus. 
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1.6.1 Factors involved in the expansion of antigen-specific CD8^ T cells 
When naive CD8^ T cells are activated witliin LNs, expression of the early 
activation marker CD69 is induced on the cell surface (Yokoyama et a l , 1988; 
Testi et al., 1989). CD69 can in turn down-regulate surface expression of 
sphingosine-1-phosphate receptor 1, a chemotactic receptor which is responsible 
for lymphocyte migration out from secondary lymphoid organs (Shiow et al., 
2006). The reduced level of sphingosine-1-phosphate receptor 1 allows T cells to 
stay within LNs (Matloubian et al.. 2004). The activated CD8^ T cells will begin 
to proliferate in the LNs after interacting with antigen-presenting DCs (Mempel et 
al., 2004). IL-2 plays a role in promoting CD8^ T cell proliferation here. IL-2 is 
produced as an autocrine growlh factor by activated CD8^ T cells, or can be 
supplied by CD4^ T cells or DCs during early activation (Granucci et a l , 2001; 
van Stipdonk et al., 2003: Lai et al., 2009). Early studies showed that IL-2 can 
drive expansion of T cell clones in vitro, and that blocking IL-2 or the a chain of 
the lL-2 receptor (also known as CD25) reduces T cell proliferation (Gillis et al., 
1978; Mier and Gallo. 1980; Leonard et al., 1982; Stern and Smith, 1986). 
Expression of the lL-2 receptor is induced on the surface of CD8^ T cells once 
they have been stimulated via TCR signalling in vitro or in vivo, allowing them to 
proliferate in response to IL-2 (Larsson, 1981; Robb et al., 1981: Hemler et al., 
1984: D'Souza and Lefran?ois, 2003; van Stipdonk et a l , 2003; Kalia et al., 
2010). During VACV infection in mice, IL-2 signalling via the IL-2 receptor is 
essential for the continuous proliferation and maximal expansion of primed CD8^ 
T cells (Obar et al., 2010). Endogenous IL-2 expression by CD8'^ T cells 
themselves is important in this infection model, suggesting again a role for IL-2 as 
an autocrine factor (Feau et al., 2011). A similar requirement for IL-2 receptor 
signalling for optimal expansion of CD8^ T cells is detected during LCMV and 
VSV infections, as well as immunisation with soluble antigens (D'Souza and 
Lefran^ois, 2003: Bachmann et al., 2007; Pipkin et al., 2010). Moreover, further 
studies found that IL-2 is essential to induce protective secondary CD8^ T cell 
immunity against LCMV and LM infections (Williams et al., 2006; Feau et al., 
2011). 
In addition to IL-2, it is generally accepted that CD4'^ T cells can facilitate CD8'^ 
T cell immunity. CD4^ T cells express the CD40 ligand which can be further up-
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regula ted a f te r act ivat ion (Roy et al., 1993; Lesley et al., 2006) . Th is l igand is 
r ecogn i sed by C D 4 0 expressed on D C s and this will result in act ivat ion of DCs , 
inc lud ing induct ion of co-s t imula tory molecu les and lL-12 express ion (Caux et 
al . . 1994a: Cel la et a!., 1996; Koch et al., 1996; Schulz et al., 2000) . Ant igen-
p resen t ing D C s act ivated via C D 4 0 in vitro can pr ime strong in v ivo CD8^ T cell 
i m m u n i t y w h e n in jec ted into mice that are def ic ient in CD4^ T cel ls (R idge et al.. 
1998). M o r e o v e r . CD8^ T cell responses to cel l -associated an t igens depend on 
CD4^ T cell help (Bennet t et al.. 1997). This requi rement can be o v e r c o m e in 
mice dep le ted o f C D 4 ' T cells by an t i -CD40 act ivat ing ant ibody t reatment 
(Bennet t et al. , 1998; Schoenberger et al., 1998). Bes ides the C D 4 0 - d e p e n d e n t 
m e c h a n i s m , it has been suggested that CD4^ T cells may a lso provide help in a 
C D 4 0 - i n d e p e n d e n t m a n n e r (Lu et al.. 2000) . One such way could be by lL-2 
p roduc t ion , wh ich directly enhances CD8^ T cell immuni ty (Wi lson and 
Liv ings tone . 2008) . 
He lp f r o m CD4^ T cells dur ing infect ions is not a lways necessary dur ing pr imary 
CDS"^ T cell immuni ty . However , it is essential for es tabl ishing opt imal levels of 
m e m o r y and secondary immuni ty . This observat ion is based on s tudies us ing 
va r ious infec t ion mode l s , inc luding l A V , L C M V and L M (Belz et al.. 2002; 
. lanssen et al., 2003 ; Shedlock et al.. 2003) . Important ly , it has been shown that 
lack o f CD4^ T cell help dur ing pr imary CD8^ T cell pr iming, but not dur ing the 
r echa l l enge phase , directly reduces the activation o f m e m o r y cells ( Janssen et al., 
2003 ; Shed lock and Shen . 2003 ; Sun and Bevan . 2003) . T w o mode l s expla in ing 
this CD4'^ T cell requ i rement dur ing pr iming for secondary responses have been 
put f o rward . First ly, CD4^ T cells may be involved in "programming" CD8^ T 
cel ls such that they can react ivate better dur ing secondary cha l lenge (Janssen et 
al., 2003 ; Janssen et al., 2005) . Al ternat ively , CD4^ T cells m a y a l low better 
m a i n t e n a n c e o f m e m o r y CD8^ T cells over t ime (Sun et al., 2004) . However , the 
type o f p a t h o g e n s e x a m i n e d clearly inf luences the dependence on CD4^ T cell 
he lp . Fo r ins tance , CD4^ T cell he lp is needed in both pr imary and secondary 
r e s p o n s e s dur ing V A C V infect ion for opt imal CD8^ T cell immuni ty (Novy et al., 
2007) . Expe r imen ta l m o d e l s can also af fec t the ou tcome , as indicated by the 
oppos i t e conc lus ions d rawn f r o m exper iments us ing MHC-I I def ic ient mice and 
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wildtype mice depleted of CD4 T cells with anti-CD4 antibody during LM 
infection (Sun and Bevan. 2003; Marzo et a!., 2004). 
1.6.2 Functions of CD8^ effector T cells to control infections 
After naive CDS"^ T cells have proliferated and differentiated into effector cells, 
their expression of LN-homing receptors, such as CD62L, is reduced, allowing the 
cells to migrate out from the LNs (Weninger et al.. 2001; Calzascia et al., 2005; 
Liu et al.. 2006b). At the same time, expression of multiple chemokine receptors 
that promote peripher>' entry and retention are induced on these activated T cells, 
and the type of receptors up-regulated is influenced by the route and type of 
infection and immunisation (Weninger et al.. 2001: Calzascia et al.. 2005; Liu et 
al.. 2006b; Sandoval et al.. 2013). Once an activated T cell recognises its cognate 
peptide/MHC-l expressed on the infected cell surface, they can exert their effector 
functions, including the killing of infected cells and the release of cytokines and 
chemokines. 
1.6.2.1 Killing of infected cells 
The capacity of activated CDS" T cell to kill infected cells has long been 
recognised and this forms the basis of the classical in vhro cytotoxicity assay 
which has been used to measure the magnitude of CDS" T cell responses since the 
1960s (Brunner et al.. 1968; Marker and Volkert. 1973). CDS" T cells kill infected 
cells by inducing their apoptosis through two main pathways, namely the 
perforin/granzyme pathway and the Fas-Fas ligand pathway (Kagi et al., 1994; 
Lowine t a l , 1994). 
Expression of perforin and several types of granzymes is induced in activated 
CDS" T cells and these molecules are located in secretory vesicles that are known 
as lytic granules (Garcia-Sanz et al., 19S7; Garcia-Sanz et al., 1990; Ebnet et al., 
1991; Peters et al., 1991). Multiple studies have demonstrated that perforin and 
granzymes work together to induce apoptosis of infected cells, in which perforin 
promotes the transport of granzymes into the target cells by several possible 
models (Podack et al., I9S5; Podack et al., I9SS; Metkar et al., 2002; Keefe et al., 
2005; Raja et al., 2005; Thiery et al., 2011). Once in the cytoplasm, granzymes, 
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especially the well-studied granzymes A and B, trigger apoptosis in the infected 
cells by caspase-dependent and independent pathways (Hayes et al., 1989; Heusel 
et al., 1994; Talanian et al., 1997; Andrade et al.. 1998; Beresford et al., 1999; 
Goping et al., 2003; Martinvalet et al., 2008). Mice that are deficient in perforin or 
granzymes show increased pathogenic burdens in multiple infection models (Kagi 
et al., 1994; Kagi et al., 1994; Walsh et al., 1994; MOllbacher et al.. 1996; 
Mullbacher et al.. 1999; Pereira et al., 2000; Balkow et al., 2001; Gupta et al., 
2005). These molecules can be produced by other cell types, such as natural killer 
(NK) cells. However, using an adoptive transfer strategy, it was later directly 
shown that this pathway mediated by CD8^ T cells is indeed necessar)' to control 
infections (Topham et al.. 1997; White and Harty, 1998; White et al.. 1999; 
Messingham et al.. 2003; Shrestha et al.. 2006). 
Interaction between Fas on target cells with Fas ligand on activated CD8^ T cells 
is another major pathway to induce apoptosis in target cells (Trauth et al.. 1989; 
Itoh et al., 1991; Suda et al., 1993; Lynch et al., 1994). Fas ligand expression on 
CD8^ T cells is enhanced after activation (Suda et al., 1995; Suzuki and Fink. 
2000). Fas surface expression can be enhanced on target cells after recognition by 
antigen-specific CD8^ T cells (Simon et al., 2000; Mullbacher et al., 2002), in the 
presence of IFN-y (Xu et al., 1998) or when they become infected (Takizawa et 
al., 1995; Shrestha and Diamond. 2007). It has been shown that the Fas-Fas ligand 
pathway is required for providing protection against LM and lAV infection 
(Topham et al., 1997; Jensen et al.. 1998). In contrast, this apoptosis-inducing 
mechanism seems to play a minor role in controlling other commonly studied 
infections, including LCMV , V A C V and ectromelia virus (Kagi et al., 1995; 
Mullbacher, 2003). 
CD8^ T cells can also kill infected cells through another pathway that is mediated 
by tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL). 
Binding of TRAIL death receptors expressed on infected cells by TRAIL triggers 
apoptosis o f the infected cells (Wiley et al., 1995; Sedger et a l , 1999; Kotelkin et 
al., 2003; Ishikawa et al., 2005). The role of TRAIL in CD8^ T cell immunity was 
demonstrated by adoptive transfer experiments, which showed that TRAIL-
deficient CD8^ T cells provided less protection and increased viral burden in 
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recipient mice compared witii thiose received wildtype CD8^ T ceils during lAV 
and West Nile virus infection (Brinclis et a l . 2008; Slirestha et al., 2012). TRAIL 
is not expressed exclusively on CDS^ T cells, so other cells may also contribute to 
the killing of target cells via this pathway (Smyth et al., 2001; Dorothee et al.. 
2002). 
1.6.2.2 Release of cytokines and cheniokines 
Besides their cytolytic capacity, effector CD8^ T cells can also produce a range of 
cytokines, including IFN-y and TNF-a. to control infections. These cytokines are 
not constitutively expressed in activated CD8^ T cells, instead their expression is 
induced upon TCR-peptide/MHC-I engagement (Slifka et al.. 1999; Slifka and 
Whitton. 2000b). These cytokines have direct anti-pathogenic effects, inhibiting 
pathogen replication in vitro and in vivo (Ulker and Samuel. 1985; Schofield et 
al.. 1987; Karupiah et al.. 1993; Campen. 1994: Harris et al.. 1995; Guidotti et al.. 
1996; Guidotti and Chisari. 2000: Janssen et al.. 2002; Ostler et al.. 2002; Biermer 
et al.. 2003). In addition, they can facilitate the functions of other immune cell 
types, for example by activating macrophages and DCs to control infections 
(Buchmeier and Schreiber, 1985; Suzuki et al., 1988; Leenen et al.. 1994; Harty 
and Bevant. 1995; White and Harty. 1998; Trevejo et al.. 2001). Direct 
involvement of CDS" T cell help to other immune cells via cytokine production 
has been suggested during LM infection where CD8^ T cells can promote the 
function of macrophages for bacterial clearance (Berg et al., 2005). These 
cytokines can also facilitate the killing of target cells. IFN-y has been shown to 
increase MHC-I expression on infected cells in vivo, which is essential for their 
elimination during infection with adenovirus (Yang et al., 1995) while TNF-a can 
bind to its receptors on infected target cells to trigger apoptosis (Holler et al., 
1992; Tartaglia et al., 1993; Wohlleber et al., 2012). Activated CD8^ T cells also 
release chemokines or aid chemokine release by other cell types in peripheral 
sites, which helps to attract other immune cells and orchestrate the overall 
immune response (Kirn et al., 1998; Wagner et al., 1998; Cook et al., 1999; Zhao 
et al., 2000; Kakimi et al., 2001). 
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Overall, CD8^ effector T cells help to control infection during a primary response 
via multiple pathways that are triggered by the TCR signalling pathway. The 
direct interaction between an infected cell and an activated CD8^ T cell has been 
visualised in vitro and in vivo (Stinchcombe et al., 2001; McGavern et al., 2002; 
O X e e f e and Gajewski , 2005; Barcia et al., 2006; Barcia et al., 2008; Sanderson et 
al., 2012). The recognition of peptide/MHC-l on infected cells by an activated 
CD8^ T cell causes relocation of surface TCR and various TCR signalling 
molecules, such as Lck, to the contact site to form an immunological synapse with 
the infected cell (Stinchcombe et al.. 2001; Barcia et al.. 2008). This interaction 
allows targeted release of effector molecules, including perforin, granzymes and 
cytokines, from the CD8^ T cells directly to the interacting infected cell 
(Stinchcombe et al., 2001; McGavern et a l , 2002; O 'Keefe and Gajewski, 2005; 
Barcia et al.. 2008). All these functions of CD8'^ effector T cells are important and 
work together to control infections. 
1.6.3 Memory CD8 T cell immunity 
After the primary CD8^ T cell response, the population size of the activated CD8'^ 
T cells contracts as the majority of the effector cells are eliminated. Although the 
contraction period generally occurs when the infection starts to be cleared, the 
duration of antigen availability and the rate of infection clearance do not 
necessarily influence the kinetics of the contraction phase, as shown in LM and 
acute LCMV infection models (Badovinac et al., 2002). However, the contraction 
phase can be influenced by inflammation during early T cell priming (Badovinac 
et al., 2004). Only memory cells will survive the contraction phase, and these cells 
are functionally superior to naive cells as they can be activated faster and produce 
a stronger immune response in the presence of a lower antigen level (Pihlgren et 
al., 1996; Curtsinger et al., 1998). 
In most acute infections, pathogens are cleared after the primary response and so 
there should be no antigen available for memory immunity maintenance. Indeed, 
antigens and MHC-I expression are not required for the maintenance of the 
memory CD8^ T cells (Hou et a l , 1994; Lau et al., 1994; Tanchot et al., 1997; 
Murali-Krishna et al., 1999). However, similar to naive CD8^ T cells, cytokines, 
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including iL-7 and lL-15. are required for the homeostasis of memory cells in the 
periphery (Lodolce et a l , 1998; Zhang et al.. 1998b; Kennedy et al., 2000; 
Schluns et al., 2000; Burkett et a l . 2003; Kaech et al.. 2003). 
1.6.3.1 Memorj precursors 
Memory precursor effector cells are formed alongside terminally-differentiated 
effector cells from naive T cells during CD8^ T cell priming (.Jacob and 
Baltimore. 1999; Opferman et a l . 1999). Several factors have been shown to 
affect the differentiation of CDS" T cells into these two subsets, including the 
extent of cell proliferation, the level and duration of TCR stimulation, and the 
strength of the intlammator)- signal during priming (.loshi et al.. 2007; Kaech and 
Wherry. 2007; Sarkar et a l . 2008; Obar and Lefran9ois. 2010). The two effector 
subsets can be identified and isolated based on IL-7 receptor expression together 
with the use of other functional markers, such as the LN-homing receptor CD62L 
and the senescence marker killer cell lectin-like receptor G1 ( K L R G l ) (Kaech et 
al.. 2003; Huster et al.. 2004; .loshi et al.. 2007; Sarkar et al.. 2008). Generally, 
terminally-differentiated effector cells are identified as CD62L'™ KLRGl'"'®'' 
IL-7R'". while memory precursor cells are CD62L"' KLRGl ' " IL-7R'''. These 
two subsets of effector cells seem to share similar effector functionality and the 
only major difference is that the terminally-differentiated effector cells are less 
able to produce IL-2 and have reduced survival and proliferation ability than 
memory precursor cells (Voehringer et al.. 2001; Joshi et al.. 2007; Sarkar et al., 
2008). 
1.6.3.2 Memory CDS"^ T cell subsets 
Circulating memory CDS"^ T cells can be grouped into two major subsets, as 
defined by the expression of LN-homing receptors CCR7 and CD62L (Sallusto et 
al., 1999; Wherry et al., 2003b; Huster et al., 2004). They are known as central-
memory CD8" T cells (with a CCR7'" CD62L'' ' phenotype) and effector-memory 
CD8^ T cells (CCR7'" CD62L'"). These subsets differ in their ability to proliferate 
during secondary challenge (Unsoeld et al., 2002; Wherr>' et al., 2003b). Wherry 
et al (2003b) demonstrated that the adoptive transfer of central-memory CDS'" T 
cells into mice allows quicker clearance of pathogens after systemic LM. LCMV 
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and VACV infections than mice transferred with effector-memory T ceils. 
Enhanced protection by central-memory T cells against LCMV has been 
confirmed in another study (Nolz and Harty. 2011). However, a different study 
found that effector-memory CD8^ T cells allow better protection than central-
memory T cells against VACV infection (Bachmann et al., 2005). The 
investigators speculated that this inconsistency between their study and Wherry et 
al (2003b) might be explained by the difference in number of cells transferred 
between their experiments (Bachmann et al.. 2005). Using a VSV intranasal (i.n.) 
infection model, it was shown that effector-memory CDS* T cells dominate the 
induced responses in the adoptively transferred recipients compared to central-
memory T cells (Roberts and Woodland. 2004). In contrast, the opposite result 
was observed in an intravenous (i.v.) Sendai virus infection model (Klonowski et 
al.. 2006). This implies that the types of infections influence the ability of various 
memory T cell subsets to respond to secondary infection. 
Besides the circulating memory cell subsets, memory T cells known as tissue-
resident memory cells can be maintained within peripheral tissues (Marshall et al.. 
2001; Masopust et al., 2001). These tissues include skin (Gebhardt et al.. 2009; 
Liu et al., 2010), intestine (Masopust et al., 2010; Casey et a l , 2012). and lung 
(Salek-Ardakani et al.. 2011b; Wakim et al., 2013), as well as the central and 
peripheral nervous systems (Wakim et al., 2008; Wakim et al.. 2010). 
Inflammation at the peripheral sites, but not the presence of antigens, is important 
for the recruitment of activated CD8^ T cells and formation of this memory 
population (Casey et al., 2012; Mackay et al.. 2012a). Skin-resident memory 
CD8^ T cells formed during dermal infection with HSV or VACV provide better 
protection against subsequent dermal viral challenges compared to the circulating-
memory T cells (Gebhardt et al., 2009; Liu et al., 2010; Jiang et al., 2012; Mackay 
et al., 2012b). This superior protection by tissue-resident memory T cells during 
local challenges can be explained by their proximity to the site of infection for a 
rapid secondary response (Ariotti et al., 2012). higher cytotoxicity than those 
memory cells found in secondary lymphoid organs (Masopust et al., 2001), and 
ability to rapidly recruit circuiting memory CD8^ T cells (Schenkel et al., 2013). 
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In addition to the memory cells, effector-like cells that are IL7R'" KLRG-l'" ' are 
found to persist into the memory phase, although they disappear over time 
(Bachmann et al., 2005; Masopust et al., 2006; Hikono et a!., 2007). These cells 
express high levels of granzyme B and it has been demonstrated that they can 
participate in controlling viral infection against LM, LCMV and VACV infection 
based on adoptive transfer experiments (Bachmann et al., 2005; Olson et al., 
2013). In contrast to these findings, Laouar et al. (2008) suggested that central-
memory T cells, but not the effector-like cells, are essential to clear V A C V 
infection. This disparity is probably because of the differences in their 
experimental setups, including the length of resting period between adoptive 
transfer of sorted CD8^ T cells and infection challenge in the recipients, as a 
longer waiting period would favour the survival of central-memory T cells over 
effector-like cells. 
Overall, it is reasonable to suggest that all subsets of memory CD8^ T cells are 
involved in providing protective immunity during secondary infections. The 
involvement of individual subsets depends on the pathogen. 
1.6.4 CD8^ T cell exhaustion after chronic infection 
Some types of chronic infections, in which antigens are available constantly, can 
lead to CDS'" T cell exhaustion and result in a reduced responsiveness by T cells. 
LCMV is commonly used as a chronic infection model because virus strains that 
induce acute and chronic infections in mice have been identified and characterised 
(Ahmed et al., 1984; Matloubian et al., 1993). Compared to acute infection where 
LCMV can be effectively cleared, chronic LCMV infection results in a reduction 
of antigen-specific CD8^ T cells during the primary response phase and 
progressive loss of cytokine production and cytolytic ability, and a failure to 
proliferate during subsequent challenge (Moskophidis et al., 1993; Wherry et al., 
2003a; Wherry et al., 2005; Wherry et al., 2007; Utzschneider et al., 2013). A 
similar loss of functionality of CD8^ T cells has been reported from patients 
infected with human immunodeficiency virus (HIV) or hepatitis C virus (Appay et 
al., 2000; Goepfert et al., 2000; Gruener et al., 2001). It has been suggested that 
the high antigen dose available during chronic LCMV infection promotes 
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exhaustion of CD8^ T cells over time (Mueller and Ahmed. 2009). The 
importance of antigen persistence in inducing this exhaustion stage in CD8^ T 
cells is supported with another infection model, where mice were immunised with 
lAV twice a week for 4 consecutive weeks (Bucks et al., 2009). Exhausted CD8^ 
T cells expressed high level of a surface protein called programmed cell death 1 
(PD-1). which is commonly used as an exhaustion marker (Urbani et al., 2006. 
Barber et al., 2006. Wherr>' et al.. 2007, Day et al.. 2006). This molecule inhibits 
•f cell migration and functions by interacting with PD-1 Ligand 1 and Ligand 2. 
which can be expressed on many immune cell types during chronic infections 
(Ishida et al.. 1992. Freeman et a l . 2000, Latchman et al.. 2001. Zinselmeyer et 
al., 2013. Blackburn et a l , 2010). 
It is important to note that chronic infection does not always lead to T cell 
exhaustion. During murine cytomegalovirus infection where the virus can persist 
in the salivary glands, the induced CD8^ T cells retain a similar level of cytokine 
production after stimulation during acute and chronic phases of infections 
(Cavanaugh et al., 2003; Munks et al.. 2006). Similarly, functional CD8^ T cells 
can be found in mice chronically infected with mouse polyomavirus (Lukacher et 
al., 1999; Wilson et al., 2011). In addition, some viruses, such as HSV and murine 
y-herpesvirus 68, can enter a latency stage within infected cells where they remain 
dormant until reactivation (Walz et al., 1974; Sunil-Chandra et al., 1992). CDB^ T 
cells induced during infection with this type of virus in mice remain poly-
functional and can further proliferate (Freeman et al., 2010; Mackay et al., 
2012b). It is speculated that only a low level of antigen is produced from a small 
percentage of the latently-infected cell population during this type of infection and 
so CD8^ T cells are not exhausted (Wherry and Ahmed. 2004). 
1,7 Antigen presentation on MHC-I 
Professional APCs utilise two mechanisms to present peptides on MHC-I, namely 
direct presentation and cross presentation. Components of these two presentation 
pathways can affect the immunogenicity of a peptide. The mechanisms involved 
in antigen processing and presentation via these two pathways are discussed here. 
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1.7.1 Direct presentation 
In direct presentatioti. antigens are expressed and processed endogenously within 
APCs to generate peptides for presentation on MHC-1. Early studies on anti-viral 
CD8^ T cell immunity frequently used virus-infected cells as the target cells to 
measure the cytotoxicity function of the activated CD8^ T cells isolated from 
immunised mice (Marker and Volkert. 1973; Zinkernagel and Doherty. 1973). 
Studies using DNA transfection or recombinant VACV infection to drive 
expression of antigens of interest in the target cells directly demonstrated that 
antigens expressed endogenously within the cytoplasm of APCs are utilised for 
MHC-1 presentation (Gooding and O'Connell. 1983: Bennink et al., 1984: 
Townsend et al.. 1984: Townsend et al.. 1985: Townsend et al., 1986a). The 
molecular mechanism for antigen processing and peptide presentation in this 
pathway is illustrated in Figure 1-2. 
Proteasomes play an important role in processing antigens into peptides that can 
bind to MHC-1 (Rock et al.. 1994: Harding et al.. 1995; Craiu et al., 1997). 
Proteasomes can generate peptides of various lengths, including peptides of the 
same length as mature eptiopes or as peptide precursors with extensions at the 
amino-terminus (Cascio et al., 2001). They are also essential for defining the 
carboxyl-termini of many presented peptides (Beninga et al., 1998: Mo et al.. 
1999). Several proteasomal subunits can be induced in APCs after exposure to 
stimulants (e.g. IFN-y) to form a variant known as the immunoproteasome with 
altered cleavage specificity (Morel et al., 2000; van Hall et al., 2000: Chen et al., 
2001b). The amino-terminal-extended peptides generated by proteasomes can be 
further trimmed by cytosolic aminopeptidases, such as tripeptidyl peptidase II 
(Reits et al., 2004), leucine aminopeptidase (Beninga et al., 1998), puromycin-
sensitive aminopeptidase and bleomycin hydrolase (Stohze et al., 2000). 
However, it should be noted that peptide liberation from antigens is not perfect. 
Proteasomes and these peptidases do not always liberate peptides from antigens 
effectively and they can cleave and destroy the antigenic peptides in some cases 
(Del Val et al., 1991; Niedermann et al., 1995; Anton et al., 1998; Luckey et al., 
1998; Preta et al., 2008; Shen et al., 2011). Proteasomal-independent antigen 
processing has also been described and it involves many of the proteases 
mentioned above (Lopez and Del Val, 1997; Seifert et a l , 2003; Guil et al., 2006). 
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Antigen-presenting cell 
Figure 1-2| Components involved in the direct MHC-I presentation pathway. 
Cytosolic antigens expressed within APCs are degraded by the proteasome to generate 
partially-processed peptides. These peptides can be further trimmed by other cytosolic 
peptidases. They are then translocated into the ER via TAP. Within the ER, peptides can 
be further processed into appropriate lengths by the ER-located peptidases and are loaded 
onto MHC-I. This loading process is facilitated by several chaperones, including tapasin 
and calreticulin. The peptide/MHC-l complexes are then transported to the surface of the 
presenting cell via the Golgi apparatus. The peptide/MHC-I complexes presented on the 
cell surface can be recognised by TCRs expressed on CDS ' T cells via an antigen-specific 
manner. 
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How an antigen is processed for presentation depends on its physical form and 
this will be discussed in Section 1.7.4. 
The peptides generated in the cytosol are then transported into the lumen of the 
endoplasmic reticulum (ER) through the transporter associated with antigen 
processing (TAP), a heterodimer formed from two related proteins called TAPl 
and TAP2 on the ER membrane (Kelly et al., 1992: Kleijmeer et al., 1992: Spies 
et al.. 1992). TAP-mediated peptide transfer requires ATP (Neetjes et al.. 1993) 
and the length of peptides translocated normally ranges from 8 to 13 amino acids 
(Momburg et al., 1994a; Schumacher et al.. 1994). In addition, peptides with 
certain sequences are more readily transported via TAP than others (Momburg et 
al., 1994b; Schumacher et al.. 1994). Importantly, it has been identified that some 
minimal peptides presented on MHC-I do not transport efficiently into the ER via 
l AP unless they are tlanked by extra amino acid residues (Neisig et al., 1995: 
Lauvau et al.. 1999), supporting a role for further peptide processing in the ER 
(York et al.. 2006. Hearn et al.. 2009). 
Amino-tenninal extended peptides in the ER are trimmed by the ER 
aminopeptidases (ERAP) into mature peptides. Two ERAPs, ERAPI and ERAP2. 
are expressed in humans while mice only express an ERAPI homolog. called ER 
aminopeptidase associated with antigen processing (ERAAP; Saric et al., 2002; 
Serwold et al., 2002; York et al., 2002; Saveanu et al., 2005). These proteases can 
process antigenic peptide precursors into minimal peptides that are 8 to 9 amino 
acids long. It has been suggested that peptide precursors need to bind to MHC-I 
such that the MHC-I could act as a template to allow ERAPs to trim peptides to 
their optimal length and prevent complete peptide degradation (Kanaseki et al., 
2006). However, it is well demonstrated that minimal antigenic peptides can be 
generated from amino-terminal extended precursors by purified ERAP molecules 
alone in vitro (Saric et al., 2002, Serwold et al., 2002, York et al., 2002, Saveanu 
et al., 2005). In addition, ERAPI prefers substrates that are 9 to 16 residues long 
and has minimal activity against shorter peptides (Chang et al., 2005; Nguyen et 
al., 2011). These data imply that amino-terminal extended peptides are processed 
in the ER lumen by ERAPs before MHC-I presentation. A carboxyl dipeptidase 
located in the ER. called angiotensin-converting enzyme, can also remove extra 
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amino acid residues from tiie carboxyl-terminus of extended precursors that are 
generated by proteasomes (Eiseniohr et a!., 1992a; Shen et a!., 2011). However, 
its role is lii<ely to be minor because the carboxyl-termini of many examined 
peptides are defined by cytosoiic proteasomes as discussed above. 
The processed peptides in the ER are then loaded onto the peptide-binding site of 
MHC-I. Multiple proteins, including TAP. tapasin. calreticulin and ERp57. are 
associated with the empty MHC-I/p^m complex in the ER and form a peptide-
loading complex to help stabilise the empty MHC-1 and facilitate the peptide 
loading process (Sadasivan et al., 1996: Ortmann et al.. 1997; Hughes and 
Cresswell. 1998; Gao et al.. 2002). Tapasin links MHC-1 and TAP together and is 
required for assembling the peptide-loading complex (Sadasivan et al.. 1996; Suh 
et al.. 1999). The stability of the peptide-loaded MHC-1 in cells is reduced in the 
absence of tapasin. suggesting a role of tapasin in facilitating peptides with high 
affinity to bind to MHC-1 (Garbi et al., 2000; Tan et al.. 2002; Williams et a l , 
2002; Howarth et al.. 2004), ERp57 is another protein found in the peptide-
loading complex (Hughes and Cresswell, 1998; Lindquist et al., 1998; Morrice 
and Powis, 1998). This protein can bind to tapasin to form a dimer which 
facilitates peptide loading onto MHC-1 and also promotes the replacement of low-
affinity peptides from MHC-1 with those that have higher affinity (Wearsch and 
Cresswell, 2007). Calreticulin is another chaperone that plays a role in loading 
optimal peptides onto MHC-1, but knockout studies show that it is not essential 
for formation of funcdonal peptide-loading complexes (Gao et al., 2002) 
Most short peptides are very unstable and are degraded within seconds in the 
cytoplasm (Reits et al., 2003). In contrast, some peptides may bind to chaperones, 
such as heat shock proteins (HSPs), to facilitate direct presentation in certain 
scenarios. Knocking down expression or functional inhibition of cytosoiic 
chaperone HSP90a can reduce direct presentation (Kunisawa and Shastri, 2006; 
Callahan et al., 2008). Moreover, the ER-located chaperone gp96 may be involved 
in delivering precursor peptides to calreticulin after TAP-mediated translocation 
(Kropp et al., 2010). The interactions between chaperones and peptides cannot be 
too strong as this would prevent the transfer of peptides onto MHC-I. 
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After peptide binding to MHC-I. the loaded MHC-1 complex dissociates from the 
peptide-loading complex (Ortmann et al., 1994: Suh et al., 1994; Li et al., 1999). 
The peptide/MHC-I complex is then transferred onto the cell surface via the Golgi 
apparatus (Nuchtem et al., 1989; Yewdell and Bennink. 1989; Cox et al.. 1990). 
Secreted and membrane antigens generated in the ER can be transferred back into 
the cytoplasm before being processed by the antigen processing mechanism 
mentioned above (Hammond et al.. 1995; Skipper et al.. 1996; Bacik et al.. 1997; 
Mosse et al.. 1998; Selby et a l . 1999). The retrotranslocation of the ER-targeted 
antigens may be facilitated by the ER-associated protein degradation (ERAD) 
pathway (Meusser et al.. 2005). Other pathways are also involved in generating 
peptides from these antigens. ER-targeted antigens can be processed directly by 
proteasomes within the cytoplasm without first being translocated into the ER 
(Schlosser et al.. 2007). Alternatively, some other secreted and membrane proteins 
have been found to be proteolysed exclusiveU in the secretory pathway for direct 
MHC-1 presentation. This processing pathway can involve ER-located signal 
peptidases and signal peptide peptidases (Henderson et al.. 1992; Wei and 
Cresswell. 1992; El Hage et al.. 2008). as well as furin. a protease which is mainly 
located in the trans-Golgi network (Gil-Torregrosa et al.. 1998; Gil-Torregrosa et 
al.. 2000; Medina et al.. 2009). In these scenarios, the antigen presentation will be 
TAP-independent. 
1.7.2 Cross presentation of exogenous antigens 
Exogenous antigens can also be presented on MHC-I and this pathway is called 
cross presentation (Heath et a l , 1998). Bevan (1976b; 1976a) first discovered that 
CD8'^ T cell responses against minor histocompatibility antigens restricted to one 
MHC-I haplotype could be induced in vivo by cells carrying the same antigens 
but that had a different MHC-1 haplotype. This phenomenon is known as cross 
priming. Since then, more cross-presented antigens have been identified, 
including soluble antigens (Staerz et al.. 1987), cells artificially loaded with stable 
antigens (Carbone and Bevan, 1990), virus and protozoan antigens (Jin et al., 
1988; Denkers et a l . 1993). and tumour cells (Huang et a l , 1994). This process is 
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particularly important for eliciting CDS"^  T cell responses against pathogens that 
do not infect professional APCs. 
It is largely agreed that DCs are the major cell type that presents exogenous 
antigens in vivo (Kurts et al., 2001; Jung et al.. 2002; Joffre et al., 2012). In 
particular, LN-resident CD8a^ DCs (equivalent to human C D U T DCs (Bachem 
et al.. 2010)) and the closely-related migratory CD103^ DCs are the major cross-
presenting subsets (den Haan et al.. 2000; Bedoui et al.. 2009; Henri et al., 2010; 
Desch et al.. 2011). Other immune cell types, such as CD8a" DCs (den Haan and 
Bevan. 2002; McDonnell et al.. 2010). plasmacytoid DCs (Mouries et al.. 2008). 
macrophages (Asano et al.. 2011), B cells (Hon et al.. 2005) and neutrophils 
(Beauvillain et al.. 2007). may also be involved in cross presentation in some 
circumstances. Although many DC subsets can capture exogenous antigens 
effectively, their ability to process these antigens for MHC-I presentation varies 
and this is the major factor that determines their cross presentation capacity 
(Schnorrer et al.. 2006). Several receptors have been shown to be involved in 
cross presentation, including DEC-205 (.Hang et al., 1995; Bonifaz et a l , 2004), 
mannose receptor (Burgdorf et al., 2007) and C-type lectin domain Family 9 
member A (Clec9A, also known as DNGR-1; Sancho et al., 2009; Zhang et al., 
2012). It has been show that different forms of antigens are taken up by different 
types of endocytic receptors (Burgdorf et al.. 2006). In addition, multiple 
pathways for presenting exogenous antigens on MHC-I have been proposed and 
studied. They are discussed below and illustrated in Figure 1-3. 
1.7.2.1 Phagosome-to-cytosol pathway 
In the phagosome-to-cytosol pathway, exogenous antigens are captured into 
phagosomes from the extracellular space and are exported into the cytoplasm for 
processing into peptides for MHC-I presentation (Figure 1-3A). This mechanism 
was first reported by two studies, which demonstrated that exogenous antigens 
can gain access to the cytoplasm and that the proteasomal degradation of 
exogenous antigens, but not lysosomal proteolysis, is essential for presenting 
exogenous antigens (Kovacsovics-Bankowski and Rock, 1995. Norbury et al., 
1995). This mechanism requires active capture of exogenous antigen sources into 
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Figure 1-3| Cross presentation pathways. Peptides originated from external antigens can 
be cross presented onto MHC-I by several possible mechanisms, including the phagosome-
to-cytosol pathway (A), vacuolar pathway (B). cross-dressing of peptide/MHC-l (C). and 
peptide transfer via a gap junction (D). (A) In the phagosome-to-cytosol pathway, antigens 
are captured into phagosomes (1). The captured antigens are translocated into the 
cytoplasm for proteasomal processing (2-3). Peptides generated are then translocated into 
ER (4) or back to the phagosomes (5) for MHC-I binding via TAP. The peptide/MHC-l 
complexes are then presented on the cell surface (6). (B) In vacuolar pathway, the 
proteolytic processing of internalised antigens and the peptide loading onto MHC-I occur 
within the phagosomes e.xclusively. (C) During cross dressing. peptide/MHC-I complexes 
presented on neighbouring cells are transferred to the surface of APCs. (D) Peptides 
generated from the neighbouring cells can also be translocated into APCs via gap junctions 
for MHC-I loading and presentation. 
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the phagosomes (Shen et al.. 1997) and the TAP-mediated transport of processed 
peptides from the cytoplasm into the ER for binding onto MHC-I (Kovacsovics-
Bankowski and Rock. 1995; Ackerman et al.. 2005). In addition to phagocytosis, 
micropinocytosis is also involved in cross presentation, especially for capturing 
soluble antigens (Norbury et al., 1995). 
Degradation of captured antigens within phagosomes is detrimental to this cross 
presentation pathway as suggested by a range of evidence. Antigens susceptible to 
lysosomal proteolysis are less likely to be cross presented via this pathway 
(Delamarre et al., 2005). In addition, the export of phagocytosed antigens to the 
cytoplasm and their cross presentation can be enhanced by treating presenting 
cells with chloroquine or ammonium chloride, which inhibit lysosomal 
acidification and reduce the activity of several lysosomal proteases 
(Accapezzato et al., 2005). This is further supported by findings from Amigorena 
and colleagues (2006; 2009) which showed that DCs have a mechanism to prevent 
over- acidification of their phagosomes, which would otherwise increase 
proteolysis of the captured antigens and lead to a reduced level of cross 
presentation. However, unfolding of exogenous proteins carrying disulfide bonds 
by IFN-y-inducible lysosomal thiolreductase, as well as partial processing of 
antigens within phagosomes by proteases, is necessary for the effective cross 
presentation of the HSV-I glycoprotein B (gB) antigen via the phagosomes-to-
cytosol pathway (Singh and Cresswell, 2010). Overall, these results demonstrate 
that a precise control of the degradation of exogenous antigens is essential for this 
pathway. 
The phagocytosed antigens need to gain access to the cytoplasm for proteasomal 
processing and the ERAD pathway may play an important role here (Ackerman et 
al., 2006). Sec61 protein, an ER-located channel complex required for 
retrotranslocation of proteins from the ER into the cytosol for ERAD (Wiertz et 
a l , 1996), can be found in the phagosomes (Guermonprez et al., 2003; Houde et 
al., 2003). Sec6l , together with ATPase p97 which provides energy for ERAD-
associated retrotranslocation, are required for this cross presentation pathway 
(Ackerman et al., 2006). 
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In addition to the ER. phagosomes can also serve as sites for peptide loading onto 
MHC-1. Phagosomes isolated from DCs and macrophages have been found to 
carry all the required machinery for antigen processing, including MHC-I, TAP 
and peptide-loading complex proteins (Ackerman et al., 2003; Guermonprez et al., 
2003), as well as the proteasomes which are associated with the cytosolic side of 
the phagosomal membrane (Houde et al., 2003). Peptides can be readily 
transported into the lumen of the purified phagosomes via TAP, where they bind 
MHC-I (Ackerman et a l . 2003. Guermonprez et al.. 2003). Burgdorf et al. (2008) 
reported that early endosomes can provide exogenous antigens to the cytosol for 
antigen processing and act as a compartment for MHC-I loading, similar to the 
phagosomes described above. The presence of the ER proteins required for MHC-
I presentation within the phagosomes suggests the existence of ER-phagosome 
fusion, although one report has failed to detect such a process (Touret et al., 
2005). It was later identified that Sec22b. a soluble N-ethylmaleimide-sensitive 
factor attachment protein receptor (SNARE) protein that controls membrane 
fusion, is important for recruiting ER proteins, such as TAP, tapasin and 
calreticulin. to phagosomes (Cebrian et al.. 2011). Knocking down this protein 
with short hairpin ribonucleic acid (RNA) significantly reduced the cross 
presentation of exogenous antigens in DCs (Cebrian et al., 2011). If amino-
terminal-extended peptides are imported into phagsomes, they may be further 
processed into final mature peptides (Saveanu et a l , 2009). 
1.7.2.2 Vacuolar pathway 
Processing and presentation of phagocytosed antigens can occur entirely within 
the phagosomes and this mechanism is known as the vacuolar pathway (Figure 1 -
3B; Rock, 1996). Pfeifer, et al (1993) and Harding and Song (1994) demonstrated 
that MHC-I presentation of antigens expressed from vacuolar bacteria or 
associated with latex beads captured by macrophages did not require newly 
synthesised MHC-I and that peptide binding to MHC-I did not occur in the ER. 
The investigators proposed that antigen processing and peptide binding can 
happen entirely within the vacuolar compartments. It was later reported that 
treating macrophages with proteasomal inhibitors did not affect the presentation 
of these antigens (Song and Harding, 1996) and that this pathway does not require 
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transportation of peptides into the ER (Bachmann et al., 1995). Other exogenous 
antigens can also be presented via this pathway, including those from protozoa 
(Bertholet et al., 2006). lAV (Di Pucchio et al., 2008), measles virus (Gromme et 
al., 1999). inactivated Sendai virus (Liu et al., 1995: Liu et al., 1997), and virus-
like particles (Schirmbeck et al., 1995: Ruedl et al., 2002: Leclerc et al., 2007). 
Out of the possible proteases in the phagosomal and endosomal compartments. 
Shen et al (2004) found that the cysteine protease cathepsin S alone could process 
the full-length model antigen ovalbumin (OVA) into the minimal CD8^ T cell 
epitope peptide (OVA-257; amino acid sequence SlINFEKL: Falk et a l , 1991b; 
Rotzschke et al., 1991) in vitro. They also demonstrated that cathepsin S plays a 
key role in priming CDS* T cell responses against antigens that are cross 
presented via the vacuolar pathway in vivo (Shen et al., 2004). 
1.7.2.3 Cross-dressing: Transfer of peptide/MHC-l complexes 
The transfer of membrane proteins between different immune cells has long been 
observed (Sharrow et al., 1981: reviewed in Davis, 2007). It has been shown that 
DCs can receive membrane components from other DCs, macrophages. B cells 
and even T cells during co-incubation in vitro (Harshyne et al., 2001). More 
importantly, DCs can acquire intact peptide/MHC-l complexes from other cells 
for presentation to CD8* T cells (Russo et al., 2000; Herrera et al., 2004) and this 
route for antigen presentation is known as cross-dressing (Figure 1-3C; Yewdell 
and Haeryfar, 2005). 
The significance of this mechanism for priming was first demonstrated when it 
was shown that peptide/MHC-I complexes transferred to recipient DCs were able 
to sustain CD8^ T cell proliferation in vitro (Smyth et al., 2008). It has been 
suggested that exosomes from donor DCs can facilitate peptide/MHC-I transfer 
(Andre et al., 2004). However, others have demonstrated that direct cell contact is 
essential for this process in vitro (Dolan et al., 2006; Wakim and Bevan. 2011). 
When a large number of donor cells was transferred into recipient mice, host DCs 
could acquire peptide/MHC-I complexes to allow proliferation of naive CD8^ T 
cells and induce their effector functions (Dolan et al., 2006; Smyth et al., 2012) . 
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Using a DNA vaccination strategy in which a DNA construct encoded a single-
chain peptide-MHC-l-P2m molecule, Li et al. (2012) showed that the single-chain 
peptide/MHC-1 molecules expressed on keratinocytes could transfer to DCs and 
allow activation of naive and memory CD8^ T cells in vivo. However, in a more 
physiological setting. Wakim and Bevan (2011) discovered that cross-dressed 
DCs carrying peptide/MHC-1 complexes from parenchymal cells of mice infected 
with VSV could re-stimulate memory, but not prime naive. CDS" T cell 
responses. The difference between these in vivo findings may reflect the number 
of donor cells and the amount of peptide/MHC-1 available for transfer. 
1.7.2.4 Peptide transfer via gap junction 
Gap junctions are intercellular channels that allow molecules to be transferred 
between connected cells (Goodenough and Paul. 2009). Neijssen et al (2005) first 
discovered that expressing connexin 43. a major component of gap junctions, in 
tumour cells allowed antigenic peptides to be transferred from the tumour cells to 
DCs for antigen presentation in vitro (Figure 1-3D). Processed peptides from 
apoptotic tumour cells and antigen-loaded DCs can also be transferred into DCs 
via gap junctions for antigen presentation in vitro (Mendoza-Naranjo et al., 2007; 
Pang et al.. 2009). A recent study showed that immunising mice with SalmoneUa-
infected tumour cells which expressed an increased level of connexin 43 allows an 
induction of a CDS" T cell response to control distal tumour formation (Saccheri 
et al., 2010). Although this presentation mechanism has been examined using 
various tumour models, all these systems involved either transduction of the 
connexin 43 gene or in vitro stimulation to enhance connexin 43 expression in the 
antigen donor cells. Its physiological role in vivo has yet to be demonstrated. 
1.7.3 Contributions of different cross presentation pathways 
The availability of the many possible cross presentation pathways clearly 
demonstrates the importance of this process for inducing CDS" T cell responses in 
the host and contradicts Zinkernagel (2002), who suggested that cross 
presentation and cross priming are not physiologically relevant. The relative 
contribution of the different cross presentation mechanisms to the induction of 
CDS" T cell immunity depends on various factors. Firstly, the nature of the 
3S 
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antigen influences how tiie antigen will be processed. For instance, OVA attached 
to iron oxide particles is only cross presented via the phagosome-to-cytosol 
pathway, while OVA incorporated with poly(lactic-co-glycolic acid) can be 
processed by the vacuolar pathway (Shen et al., 2004). Moreover, the size of the 
captured antigens affects how they are processed (Mant et al.. 2012). Secondly, 
certain presenting cells may favour particular pathways for presenting exogenous 
antigens. For example, an in vitro study has indicated that CD8a' DCs. but not 
CD8« ' dendritic cells, prefer peptide/MHC-I transfer over conventional cross 
presentation (Smyth et al.. 2008). 
It should be noted that only a few studies have analysed their contributions to 
prime CD8^ T cells in vivo. Using TAP-deficient bone marrow chimeric mice, it 
has been demonstrated that in vivo cross priming of CD8^ T cells against antigens 
from tumours and polio virus is completely reliant on TAP expression in the bone 
marrow derived APCs. suggesting the importance of the phagosome-to-cytosol 
pathway (Huang et al.. 1996; Sigal et al., 1999). Shen et al (2004) used a similar 
system with TAP- and cathepsin S-double-deficient bone marrow chimeric mice 
to dissect the contributions of phagosome-to-cytosol and vacuolar pathways for 
cross priming CD8^ T cell immunity. They discovered that although both 
pathways contribute to cross priming of CD8^ T cell against cell-associated 
antigens, the phagosome-to-cytosol pathway seems to be more important for 
particulate antigens and influenza A virus infection in vivo (Shen et al.. 2004). 
1.7.4 Substrates for direct and cross presentation 
Stable proteins available in the cytoplasm can be processed by proteasomes for 
direct presentation (Moore et al.. 1988). However, it is generally accepted that the 
major substrates for generating antigenic peptides are newly-synthesised gene 
products that are rapidly-degraded by proteasomes (Reits et al., 2000; Schubert et 
a l , 2000; Princiotta et al., 2003; Donohue et al., 2006; Qian et al., 2006; Dolan et 
al., 2010; Dolan et al., 2011; Croft et al., 2013). Defective ribosomal products 
(DRiPs) have been demonstrated to be one such substrate form (Yewdell et a l , 
1996; Princiotta et al., 2003; Qian et al., 2006; Dolan et al., 2010; Dolan et al., 
2011). 
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Physiological antigen processing from full-length proteins is relatively inefficient: 
on average only one peptide/MHC-1 complex is formed from 2000 degraded 
proteins (Princiotta et al., 2003). This problem can be overcome experimentally. 
Firstly, the efficiency of direct presentation can be enhanced by increasing the 
degradation of antigens by proteasomes (Townsend et al.. 1988; Princiotta et al.. 
2003). Secondly, minimal peptide sequences, known as minigenes. can be directly 
expressed in the cytosol with a start codon or in the ER with an ER-targeted signal 
sequence at the amino-terminus (Anderson et al.. 1991; Bacik et al.. 1994). These 
minigene constructs minimise the requirement for proteolytic processing and. with 
ER-targeting. bypass TAP translocation, allowing the peptides to be presented 
more efficiently (Bacik et a l . 1994; Anton et al.. 1997; Porgador et al.. 1997). For 
instance, it has been found that APCs infected with VACV expressing full-length 
OVA express around 10-fold fewer OVA-257/H-2K'' complexes on the cell 
surface than APCs infected with VACV expressing OVA-257 minigene (3x10^^ 
compared to 3.5x10'* OVA-257/H-2K'' molecules after a six-hour infection; 
Princiotta et al., 2003). 
In contrast, cross-presented antigens need stability to survive long enough to be 
acquired by antigen-presenting cells. It is proposed that substrates for cross 
priming exist either as (a) processed peptides that are complexed and stabilised by 
chaperones. such as HSPs (Srivastava. 2002), or (b) stable proteins (Yewdell and 
Haeryfar, 2005). Partially-degraded antigens have also been found to be the 
source of cross presentation (Sema et al., 2003; Blachere et al., 2005), but their 
role has not been further examined. 
Multiple HSPs isolated from tumour cells, including ER-resident HSP gp96 (also 
known as GRP94), and cytosolic gp70 and HSP90. have been shown to induce 
anti-tumour immunity in vivo (Srivastava et al., 1986; Ullrich et al., 1986; Udono 
and Srivastava, 1994). It was later found that antigenic peptides complexed with 
HSPs can be cross presented onto MHC-I in vitro by macrophage and DCs (Suto 
and Srivastava, 1995; Basu et al., 2000). In addhion. CD8^ T cell immunity can be 
induced in mice immunised with HSPs either isolated from antigen-expressing 
cells (Arnold et al.. 1995; Suto and Srivastava. 1995; Casey et al.. 2003) or in 
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vitro complexed with peptides (Biachere et al., 1997; Mo et al., 2011). Various 
antigen delivery systems based on this HSP/peptide model have been developed 
and suggested as potential cancer vaccines (Suzue et a!., 1997; Yamazaki et a!., 
1999; Oizumi et al., 2007). 
The role of HSP/peptide complexes for cross presentation under physiological 
conditions has been examined mainly by Srivastava and colleagues. Using lysates 
ot MHC-I-niismatched antigen-expressing cells as immunogens in vivo. Binder 
and Srivastava (2005) showed that cross priming was suppressed when all HSPs 
of interest, but not stable antigens, were depleted. Purified HSPs from antigen-
expressing cells induced CD8^ T cell immunity in the absence of any stable 
antigens (Binder et al., 2007). In addition, the same research group showed that 
antigen-loaded cells lost their cross presentation ability after being treated with 
specific HSP90 inhibitors (Callahan et al.. 2008). Expression of HSP90 and gp96 
within antigen-donor cells can improve cross presentation of a stable antigen, 
although the mechanism responsible was not examined (Basta et al.. 2005). 
Even though these studies support the role of HSP/peptide complexes in cross 
priming, their importance remains highly questionable. The first source of 
uncertainty is the specificity of peptide binding to HSPs. Several studies have 
attempted to isolate and characterise the peptides chaperoned by HSPs. Two 
separate studies showed that an extended antigenic peptide precursor from an 
engineered OVA antigen, but not the final antigenic OVA-257 peptide, could 
associate whh HSP90 and gp96 isolated from antigen-expressing cells (Kunisawa 
and Shastri. 2006; Binder et al.. 2007). Furthermore, viral and tumour antigenic 
fragments associated with HSPs have been identified from virus-infected or 
tumour cells (Nieland et al., 1996; Ishii et al., 1999; Meng et al., 2001; Grossmann 
et al., 2004). However, other studies failed to recover antigenic peptides from 
purified HSP (Paz et al., 1999; Lev et al., 2008). More importantly, short peptides 
diffuse freely within the cytosol and nucleus and are degraded rapidly within 
cells, suggesting that the majority of peptides are not stabilised by chaperones to 
any significant level (Reits et al., 2003). It is estimated that only up to 0.4% of the 
gp96 chaperones are associated with peptides in vivo (Demine and Walden, 
2005). Further, the affinity and stability between gp96 and an examined antigenic 
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peptide derived from VSV nucleoprotein (NP) was found to be weak at 
physiological temperature and pH (Ying and Fiatmark, 2006). These studies 
support the model in which HSPs interact weakly with peptides to help harbour 
them between important antigen processing machineries (Kunisawa and Shastri, 
2006). However. HSP/peptide interactions should not be stable enough for cross 
presentation. 
Several studies have also questioned the role of HSP/peptide complexes in 
eliciting antigen-specific immunity. It has been shown that injecting mice with 
gp96-expressing fibroblasts can induce anti-tumour immunity, independent of the 
antigen availability (Baker-LePain et al.. 2002). This non-specific induction of 
immunity may be due to the adjuvant property of the HSPs (Baker-LePain et al., 
2002; Vabulas et al.. 2002). In support of this hypothesis, an engineered form of 
gp96 can improve the in vivo cross presentation of unchaperoned OVA antigen 
(Oizumi et al., 2007). However, it has also been suggested that the observed 
adjuvant effect could be caused by contamination of the purified HSPs with other 
potent adjuvants, such as lipopolysaccharides (Nicchitta. 2003; Tsan and Gao. 
2004; Yewdell. 2005). 
In contrast to the HSP/peptide model, multiple studies have clearly demonstrated 
that cross-presented antigens are acquired by antigen-presenting cells in the form 
of stable antigens. Firstly, unlike Binder and Srivastava (2005), Shen and Rock 
(2004) showed that removal of the stable OVA proteins from cell lysate resulted 
in a failure to induce a CD8^ T cell response against the dominant OVA-257 
peptide via cross presentation. Secondly, Norbury et al (2004) demonstrated that 
the OVA-257 peptide expressed from a rapidly-degraded antigen or as a short-
lived minigene construct failed to be cross-presented in vivo, in spite of the high 
level of the OVA-257 peptide generated from these unstable antigens (Princiotta 
et al., 2003). They further demonstrated that stable OVA constructs were cross-
presented effectively (Norbury et al., 2004). Thirdly, Wolkers and colleagues 
(2004) found that peptides within the rapidly-cleaved ER-inserting sequence of an 
antigen were significantly less immunogenic than the same peptides derived from 
the stable part of the same protein during cross presentation in vivo, although 
peptides from either position were effectively directly presented in vitro. Fourthly, 
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Janda et al (2004) found that cross presentation of antigens from LM-infected 
ceils by dendritic cells was eniianced by iniiibiting tiie proteasomal-mediated 
antigen degradation pathway in infected cells that no longer expressed new 
antigens. Fifthly, a DNA vaccine encoding a stable antigen induced a better CDS"^  
T cell response in vivo than one encoding a rapidly-degraded antigen when 
examined in a setting where only cross presentation was allowed (Bins et al., 
2007). Although cross presentation of an accumulated stable antigen was 
improved by HSP expression, the rapidly-degraded version of the same antigen 
failed to be cross presented even in the conditions favouring HSP expression 
(Basta et a l , 2005). According to the HSP/peptide theory, one would assume that 
increasing production of peptides would increase the amount of HSP-associated 
substrates for cross presentation. However, the studies mentioned above clearly 
reject this hypothesis and suggest that stable antigens are the natural substrates for 
cross presentation. 
Altogether, these results suggest that cross-presented peptides on MHC-I originate 
from stable antigens. Consistent with these findings, a study has shown that 
minigene constructs of two lAV CD8^ T cell epitopes were not cross-presented to 
prime CD8^ T cells in vivo when expressed from VACV recombinants (Lev et al.. 
2008). Surprisingly, the same study found that another € 0 8 " T cell epitope from 
lAV, known as PA-224 from the acid polymerase (PA), expressed as a minigene 
could be cross-presented from VACV-infected cells. Additional data suggested 
that there was a stable cytosolic PA-224 peptide pool within the infected cells, 
possibly with indirect association with HSP90 (Lev et al., 2008). The effect of this 
HSP on cross priming of the full-length PA antigen was not examined. In contrast 
to the PA-224 peptide, expression of HSP90 has minimal effect on the cross 
presentation of native VACV antigens from VACV-infected cells (Lev et al., 
2008). Similarly, the ER-located gp96 is not involved in cross priming against 
VACV and lAV antigens (Lev et a l , 2009). These results suggest that exceptions 
like PA-224 aside, minimal peptides are not normally protected by HSPs 
extensively and are not used as substrates for cross presentation. 
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1.8 Factors influencing immunogenicity of a particular antigen 
Although many antigens can be expressed from a virus, only a few of them can 
elicit CD8^ T cell responses. Furthermore, the size of the response induced against 
individual peptides varies, with some dominating the overall response while the 
contribution of other is at the limh of detection (Yewdell and Bennink. 1999). 
This phenomenon, known as immunodominance, has been observed in mice 
during DNA immunisations (Rodriguez et al.. 2002; Liu et al.. 2006a; Riedl et al.. 
2009) and infections with various types of pathogens, including large T antigen 
from simian virus 40 (Mylin et a l , 2000), lAV (Chen et al.. 2000; Belz et al.. 
2001). LCMV (van der Most et al., 1996). VACV (Tscharke et al.. 2005; 
Moutaftsi et al., 2006). HSV-1 (St. Leger et al.. 2011). and LM (Busch and Pamer. 
1998). A similar phenomenon has been observed in humans during infections and 
vaccinations (Yu et al.. 2002a; Smith et al.. 2005b; Wu et a l . 2011). During 
immunisation with recombinant vaccines, one would hope that the induced 
immunity can focus on the recombinant antigens that are artificially expressed 
from the vaccines, but not on the vaccine vector itself Thus it is important to 
understand how immunogenicity can be manipulated to favour antigens of 
interest. Factors influencing immunogenicity can be divided into two categories: 
(a) factors related to antigen presentation and (b) factors related to the CDS"^ T 
cell repertoire. 
1.8.1 Factors related to the presented antigen 
1.8.1.1 Expression kinetics of the antigen 
It is generally accepted that antigens expressed early and at high levels during 
infections or immunisations are more immunogenic than those expressed late and 
in lower abundance. During VACV infections, CD8^ T cell immunity tends to 
target native viral proteins that are expressed early during infection (Oseroff et al., 
2005; Tscharke et al., 2005; Moutaftsi et al., 2006; Oseroff et al., 2008; Moutaftsi 
et al., 2010). Similarly, anti-HSV-I immunity is skewed towards early-expressed 
genes (St. Leger et al., 2011). One possible explanation brought forward by these 
studies is that early gene products are more available for presentation by DCs 
(Oseroff et al., 2008; St. Leger et a l , 2011). It should be noted that this correlation 
is not absolute, with some late gene products being immunogenic (Moutaftsi et 
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al., 2006; Oserof fe t al., 2008; St. Leger et al., 2011), implying that other factors 
also contribute to the immunogenicity of antigens. 
Studies that have directly compared the same antigenic constructs expressed by 
promoters with different kinetics also lead to similar conclusions. Recombinant 
antigens expressed from a late promoter are less immunogenic than the same 
antigens expressed from an early promoter when expressed from VACV, as 
shown in two virus strains (Coupar et a!.. 1986; Kastenmuller et a!.. 2007). 
Enhancing expression during early infection is also important to further improve 
the immunogenicity of antigens (Coupar et al.. 1986; Baur et al.. 2010). A similar 
result has been observed for adenovirus immunisation, where modifying an 
immediate-early promoter to enhance expression level improves the 
immunogenicity of the inserted antigen (Sridhar et al.. 2008). 
1.8.1.2 Efficiency of antigen processing and presentation 
As shown in Section 1.7.4. the efficiency of antigen processing during direct 
presentation affects the surface expression level of the peptide/MHC-l complex. 
Therefore, it also influences the immunogenicity of a given peptide when direct 
priming is the main mechanism to induce CD8^ T cell immunity. During VACV 
infection, the efficiency of peptide generation from full-length antigens for direct 
presentation can be influenced by having different flanking sequences and this in 
turn affects the immunogenicity of antigens expressed (Del Val et al.. 1991). 
Further, antigenic constructs that enhance direct presentation, including rapidly-
degraded proteasomal substrates and minigenes (Townsend et al., 1988: Porgador et 
al., 1997; Princiotta et a l , 2003), generally induce better CD8^ T cell responses 
than the full-length proteins when expressed from VACV (Lawson et al., 1994; 
Restifo et al., 1995; Deng et al., 1997; Tobery and Siliciano, 1997). As discussed in 
Section 1.7.4. translocation of a processed peptide into the ER via TAP also affects 
the efficiency of the peptide binding to MHC-I. Minigene constructs tagged with an 
ER-targeting sequence at their amino-termini have been designed to avoid this 
bottleneck to improve immunogenicity of a given antigen (Restifo et al., 1995; Fu 
et al., 1998). These data indicate that efficiently processed antigens are more likely 
to be highly immunogenic. 
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If cross presentation is the preferred pathway for priming CD8^ T cells during a 
particular type of vaccination, rapid degradation of antigens will be detrimental to 
the level of immunogenicity elicited, as discussed in Section 1.7.4. This has been 
demonstrated during intramuscular and intradermal (i.d.) DNA immunisations 
(Wong and Pamer, 2001; Bins et al., 2007; Schliehe et al., 2012), which involves 
cross presentation of antigens sourced from transduced muscle cells (Fu et al., 
1997; Cho et al.. 2001). Increasing the stability of peptide vaccines by extending 
them with three amino acids at the amino-terminus allows for more effective cross 
priming of CD8^ T cells in vivo (Wei and Sherman. 2007). Furthermore, 
modifications to specifically target exogenous antigens to the cross presentation 
pathway have been developed to enhance CDS" T cell cross priming. This mainly 
involves the use of antibodies to specifically target antigens to endocytic receptors 
important for cross presentation, which have been mentioned in Section 1.7.2 
(Bonifaz et al.. 2002: Bonifaz et al.. 2004; He et al., 2007; Caminschi et al., 2008; 
Hesse et al.. 2013). 
It is important to remember that multiple factors influence the presentation pathway 
favoured during a vaccination. For instance, although enhanced degradation of an 
antigen favours its immunogenicity during intramuscular immunisation with a high 
dose of adenovirus (Rouard et al., 2003). stable full-length antigens are more 
favourable when a lower dose of virus is used (Millar et al., 2007). This clearly 
suggests that the dose of an immunogen influences the optimal form of antigens. 
Likewise, increasing instability of antigens to enhance immunogenicity during 
DNA immunisation has also been reported (Rodriguez et al., 1997), clearly 
contradicting the reports discussed above (Wong and Pamer, 2001; Bins et al., 
2007; Schliehe et al., 2012). As the antigen, the dose and the immunisation regime 
used were different amongst these studies, one may conclude that these factors 
affect how an antigen is presented during DNA immunisation. 
1.8.1.3 Peptide binding affinit) to MHC-I 
Once a peptide is processed successfully, its MHC-I binding affinity affects how 
long it is presented on the surface of APCs and could in turn affect 
immunogenicity. Many highly immunogenic peptides have a relatively high 
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MHC-I binding affinity when determined as thie MHC-I association rate (Sette et 
a l , 1994; Kotturi et al., 2008). Furthermore, peptides with too low binding affinity 
fail to present on the cell surface and do not induce any immune responses during 
pept ide immunisat ion (Sette et a l , 1994). indeed, bioinformatic prediction of 
MHC-I binding affini ty has been used as the first step to identify possible epitope 
candidates within a virus (e.g. Zhong et al., 2003; Moutafts i et a!., 2006). 
However , highly immunogenic peptides do not necessarily have the highest 
MHC-I binding affinity. For example, the highly immunogenic CD8^ T cell 
epi tope f rom the lAV NP antigen during lAV infection in BALB/c mice, known 
as NP-147 , has a relatively low MHC-I affinity compared with other lAV peptides 
(Chen et al., 2000). Some investigators have suggested that a slow MHC-I 
dissociation rate is more important because it relates directly to the stability of a 
pept ide /MHC-l complex and its longevity at the cell surface (Ojcius et al., 1993; 
Harndahl et al., 2012). In support of this idea. Burg and colleagues (1996) showed 
that most mapped CD8* T cell epitopes they tested had a low MHC-I dissociation 
rate. 
To enhance affinity and stability of peptide binding to MHC-I , pept ide-MHC-l-
p2m single chain trimers and similar technology have been developed (Mottez et 
al., 1995; Yu et al., 2002b; Palmowski et al., 2009; Li et al., 2012). These 
constructs improve antigen presentation and the ability to induce CD8^ T cell 
responses in vivo. Alternatively, in some experimental models where the natural 
pept ides have a modest MHC-I affinity, immunising mice with modif ied peptides 
with enhanced MHC-I binding affinity or stability can improve the CD8^ T cell 
responses against the natural peptides (Sarobe et al., 1998; van Stipdonk et al., 
2009; Watson et al., 2012). However , one needs to be aware that immunising 
mice with modif ied peptides with too high MHC-1 affinity can resuh in reduced 
quality of CD8^ T cell immunity (McMahan et al., 2006). This may be due to an 
expansion of CD8^ T cells that recognise pept ide/MHC-I poorly or subversion of 
T cells into an anergic state (McMahan et al., 2006). Overall , while peptides need 
to bind onto MHC-I to induce a CD8^ T cell response, this property alone cannot 
account for the immunogenici ty of a given antigen. 
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1.8.2 Factors related to the CD8^ T cell repertoire 
Other than the importance of antigen presentation, several characteristics of CDS"^ 
T cells specific to a given peptide/MHC-l complex also modulate the induced 
CD8^ T cell response. 
1.8.2.1 Naive CD8^ T cell precursor frequency 
The naive CD8^ T cell precursor frequency is the number of CD8^ T cells in a 
non-immune individual that can recognise a given peptide. There is a diverse 
population of naive CDB^ T cells in each individual and only few of them can 
recognise a particular peptide. Previously, only indirect and time-consuming 
methods could estimate a naive CD8^ T cell precursor frequency. One common 
method used was a limiting dilution analysis based on either in vitro cytotoxicity 
assay with naive cells or in vivo proliferation and expansion of transferred T cells 
relative to the host 's endogenous response (Lindahl and Wilson. 1977; Blattman 
et al.. 2002; Choi et al., 2002; Seedhom et al., 2009). Recently, a new strategy that 
allows direct quantification of the naive epitope-specific CD8^ T cell has been 
developed: it involves labelling naive cells from all secondary lymphoid organs 
with peptide/MHC-I tetramers. followed by magnetic enrichment of the labelled 
cells (Kotturi et al., 2008; Obar et al.. 2008). 
With this isolation technique, several studies have shown that peptides recognised 
by more naive CDB^ T cells tend to induce higher responses in several infection 
models (Kotturi et a l , 2008; Obar et al., 2008; Tan et a l , 2011). Similarly, 
lowered immunogenicity of several VACV antigens in C57BI/6 x DBA/2 F1 
progeny mice compared to the parental strains correlates with reduced numbers of 
antigen-specific naive CDB"^  T cells in the F1 mice (Flesch et al., 2010). In 
contrast. La Gruta et al (2010) found that the immunogenicity of individual lAV 
peptides during infection in C57BI/6 mice does not correlate to the naive cell 
precursor frequency. Rather, they demonstrated that effective T cell recruitment 
and expansion are more important in their lAV infection model (La Gruta et al., 
2010). 
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1.8.2.2 TCR binding affinitj for peptidc/MHC-l 
TCR affinity indicates how well a given TCR can bind to the peptide/MHC-1 
complex it recognises. This can either be measured in vitro with purified TCR and 
peptide/MHC-l complexes (Corr et al., 1994) or estimated from the association of 
CD8^ T cells to peptide/MHC-I tetramers ex vivo (Kalergis et al.. 2001). CD8^ T 
cells with low affinity to peptide/MHC-I are less likely to become completely 
activated (Kalergis et al.. 2001). Zehn et al (2009) studied the effects of TCR 
affinity in vivo using I .CMV recombinants to express OVA-257 peptide variants 
which bind equally well to MHC-1 H-2K'' but are recognised by TCR-transgenic 
OT-I CDS" T cells with different affinity. They found that although OT-I cells can 
proliferate during infection with LCMV expressing low affinity TCR ligands. the 
period of expansion is significantly reduced compared to the well-recognised 
peptide variants (Zehn et al.. 2009). During an lAV infection. CDS" T cells 
specific to the dominant NP-366 peptide express TCRs with lower affinity to the 
cognate peptide compared with those specific to the co-dominant PA-244 peptide 
(La Gruta et al.. 2004). This correlates with the inferior ability of the NP-366-
specific C D S ' T cells to produce cytokines (La Gruta et al.. 2004). 
However. CDS" T cell function cannot be further improved once the TCR affinity 
reaches to a certain level, suggesting a ceiling effect (Schmid et al.. 2010). In 
addition. TCRs with too high affinity can be detrimental to T cell function 
(Kalergis et al.. 2001). It is hypothesised that CDS" T cells carrying TCRs whh 
too high affinity are less likely to make serial engagement with peptide/MHC-I on 
APCs, which is essential for ideal T cell activation (Valitutti et a l . 1995: 
Hudrisier et al., 199S; Kalergis et al., 2001). On the other hand. CDS" T cells 
expressing TCRs with a lower affinity can form memory T cells that respond 
during challenge (Zehn et al., 2009). These results indicate that there is a fine 
balance in TCR affinity for a strong immunogenicity. 
1.8.2.3 Functional avidity of CD8" T cells 
Besides the individual affinity of TCR to peptide/MHC-I, other factors also affect 
the overall sensitivity of a CDS" T cell to respond to its cognate epitope, and 
collecdvely this is known as functional avidity (Slifka and Whitton. 2001). 
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Increased functional avidity of CD8^ T cells improves their ability to respond 
when the level of antigen is low (Slifka and Whitton, 2001; Mothe et a l , 2012). 
For instance. HIV-infected patients who successfully control the infection carry 
CDS"^ T cells that have a higher functional avidity than those that fail to control 
the infection, as measured by the ability of T cells to respond to low antigen 
concentration and to various antigenic variants (Mothe et al.. 2012). 
Functional avidity is influenced by the following factors. Firstly, the strength of 
TCR binding will affect how well it can recognise peptide/MHC-1, as discussed in 
Section 1.8.2.2. Secondly, multiple TCR molecules on the cell surface of activated 
CD8^ T cells are organised into clusters, which improves the overall avidity to 
peptide/MHC-1 complexes compared to naive T cells (Fahmy et al., 2001). 
Thirdly, the CD8 co-receptor contributes to the functional avidity as it improves 
the overall avidity of the TCR-peptide/MHC-l interaction, and therefore allows 
CD8" T cells to respond to lower levels of cognate antigens (Cawthon and 
Alexander-Miller. 2002; Holler and Kranz. 2003; Mothe et al., 2012). Finally, 
enhanced expression of TCR signalling adaptor molecules, such as Lck, also 
correlates with better functionality of CD8^ T cells during LCMV and VACV 
infections (Slifka and Whitton. 2001; Amoah et al., 2012). Overall, increasing 
functional avidity improves the outcome of immunity during an infection. 
1.8.2.4 T cell competition 
Competition for presented peptides on APC between naive CDS"^ T cells during 
priming can also affect the responses induced. This model has been used to 
explain how TCR-transgenic CD8^ T cells can negatively influence the host ' s 
endogenous responses specific to the same antigens (Butz and Bevan. 1998; Kedl 
et al., 2000). This could be caused by the down-regulation of peptide/MHC-1 on 
APC after interacting with T cells (Kedl et al., 2002). T cells with different 
specificities can also compete with each other because multiple peptides are 
presented on the same APC during an immunisation (Kedl et al., 2000; Kedl et al., 
2002). The availability of a highly immunogenic peptide in a DNA vaccine affects 
the priming of T cells against a less immunogenic peptide presented on the same 
constructs during the primary response (Rodriguez et a l , 2002; Liu et al., 2006a; 
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Riedl et al.. 2009). Similarly, immunodomination by highly immunogenic 
antigens has been detected during secondary lAV and VACV infections 
(Andreansky et al., 2005; Kastenmuller et a!., 2007). In addition, the presence of a 
high number of T cells specific to a particular peptide can suppress responses 
against other peptides (von Herrath et al.. 1994; Chen et al., 2000; Kedl et al., 
2000; Kedl et al.. 2002; Lin et al.. 2013). Importantly, a high affinity CD8 ' T cell 
specific for one peptide can suppress the priming of a low affinity CD8^ T cell 
with another specificity, probably due to the enhanced activation and proliferation 
ability of the high affinity T cells (Kedl et al.. 2002; Dzutsev et al., 2007). 
Recently. Lin et al (2013) showed that the immunodomination effect is more 
profound during primary peripheral VACV infections than systemic infections, 
probably due to the lower number of APCs available for priming in draining LNs 
and a competition for co-stimulation betweeen CDS" T cells. Thus, systemic 
immunisation enhances the responses against less immunogenic antigens. 
1.9 Vaccinia virus 
VACV is an Orthopoxvirus within the wider Poxviridae family (Moss. 2007). It 
has a linear double-stranded DNA genome (Easterbrook. 1967; McCrea and 
Lipman. 1967). which is approximately 190.000 base pairs (bp) long (Geshelin 
and Bems. 1974; Goebel et a l , 1990; Meyer et al., 1991; Antoine et a l . 1998; 
Meisinger-Henschel et al., 2007). Within the Orthopoxvirus genus, there are other 
closely-related species that cause diseases in animals and humans, including 
ectromelia virus that causes mousepox, variola virus that causes smallpox in 
humans, as well as cowpox and monkeypox viruses which can cause zoonotic 
infections in humans. VACV was used as the vaccine to eradicate smallpox in the 
last century. In addition, VACV is the prototype member of the Poxviridae family 
and is extensively studied to understand the biology of poxviruses. 
The basic form of an infectious VACV mature virion found within infected cells 
contains two lateral bodies and a biconcave-shaped core carrying the DNA 
genome, covered with a lipid membrane to form a brick-shaped particle, 
approximately 200 nm x 300 nm (Peters, 1956; Epstein. 1958; Westwood et al., 
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1964; Hollinshead et a l , 1999). Some mature virions can be wrapped by a double 
layer of lipid membrane originated from the Golgi apparatus (Hiller and Weber, 
1985). The outer membrane of this form of virion can fuse with the cell 
membrane to release the virus onto the cell surface or into the extracellular space 
(Ichihashi et al., 1971). This type of virus particle is known as the enveloped 
virion (Moss, 2006), and has an additional lipid membrane layer compared to the 
mature virion. 
Infectious viruses can enter cells either by direct viral-cell membrane fusion on 
the cell surface (Armstrong et al., 1973; Chang and Metz. 1976; Carter et al., 
2005) or via macropinocytosis where virions are taken up into vesicles followed 
by viral-vesicle membrane fusion (Dales. 1963; Dales and Kajioka. 1964; 
Townsley et al., 2006; Lucas et al., 2008; Mercer and Helenius. 2008; Mercer and 
Helenius. 2009; Mercer et al., 2010). Viral cores are then released into the 
cytoplasm where viral gene transcription and viral replication takes place, using 
viral machinery (Cairns. 1960; Becker and Joklik. 1964; Baroudy and Moss. 
1980; Jones and Moss. 1984; Broyles and Moss. 1986; Earl et al., 1986; Ahn et 
al., 1990). VACV genes can be categorised into early, intermediate and late genes 
based on the time they are expressed after infection (reviewed; Broyles. 2003; 
Yang et al., 2010; Yang et al., 2011). More recently, it has been shown that early 
genes can be separated into two subgroups by cluster analyasis, known as E l . l 
and El .2 , in which E l . l genes are expressed earlier and at an increased level 
compared to El .2 genes (Assarsson et al., 2008; Yang et al., 2010). After four to 
five hours of infection, viral DNA and new virion particles will begin to be 
produced and packed within discrete areas of the cytoplasm known as viral 
factories (Cairns, 1960; Dales, 1963). Mature virions can be seen in infected cells 
six hours after infection (Dales, 1963). 
During VACV infection, multiple host cellular pathways are modulated by viral 
gene products. Firstly, host protein synthesis is inhibited starting from very early 
during infection (Shatkin. 1963; Becker and Joklik. 1964; Moss, 1968). VACV 
also encodes proteins to suppress the various anti-viral responses induced within 
infected cells, which would otherwise inhibit viral gene translation and viral 
replication (Carroll et al., 1993; Davies et al., 1993; Myskiw et al., 2009). This 
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includes interfering with multiple pathways important for inducing an anti-viral 
state within infected cells, including the LFN-1 and NF-KB signalling pathways 
(Gedey et al., 2006; Meng et al.. 2009; Myskiw et al., 2009; Fagan-Garcia and 
Barry. 2011). Although these genes are not all essential for virus growth in 
general, some of them are required for the virus to replicate in certain cell lines in 
vitro and they are known as host range genes (Perkus et al.. 1990; Beattie et al.. 
1991; Wyatt et al., 1998; Shisler et al., 1999; Brandt and .lacobs. 2001). Some 
other non-essential genes, known as immunomodulatory genes, have no apparent 
effect on nomial \iral replication in vitro, but are involved in the modulation of 
immune responses induced during VACV infection and can influence 
pathogenesis (Alcami and Smith. 1992; Symons et al.. 1995; Sroller et al.. 2001). 
1.9.1 VACV as a vaccine to induce immune response.s 
Immunity induced by one Orthopoxvims can provide cross-protective immunity 
against infections with another Orthopoxvirus species, and this is the basis for 
using VACV as a smallpox vaccine. Live cowpox virus was shown by .lenner 
(1798) to be an effective vaccine against smallpox and was subsequently used in 
local vaccination programs in the 19''^  century. However, h was found that the 
VACV used as the smallpox vaccine in later immunisation programs was different 
from natural cowpox virus isolated from infected cattle or cattle farmers (Downie. 
1939a; Downie, 1939b: Fenner et al.. 1988; pp258-271). During the global 
smallpox eradication program in the mid 20"' century, muhiple live VACV strains 
were used throughout the world as smallpox vaccines, including strain New York 
City Board of Health in the US. strain Lister in Europe. Africa. Asia, as well as 
strain Tian Tan in China (Fenner et al., 1988; pp581-587). There are differences 
amongst VACV strains in terms of pathogenicity, but these vaccine strains were 
considered to be immunogenic as a smallpox vaccine at that time (Fenner et al., 
1988;pp581-587). 
After VACV immunisation, various adaptive immune responses are induced and 
immunological memory is maintained. Primary VACV immunisation in humans 
results in the activation and expansion of VACV-specific CD8^ T cell immunity 
which peaks at two to four weeks after vaccination, followed by a period of 
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contraction to form memory CD8^ T cells (Terajima et al., 2003; Rock et al., 
2005). The activated CD8^ T cells isolated during the peak of primary response 
are poly-functional as they are able to produce multiple effector molecules, 
including granzymes, IFN-y, TNF-a, and IL-2 (Amara et al., 2004; Rock et a l , 
2005; Precopio et al., 2007). CD4^ T cells follow a sirnilar trend of expansion, 
contraction and memory maintenance (Amara et al., 2004). Antibody responses 
peak at around one month after vaccination in humans and reduce gradually 
afterwards (Crotty et al., 2003; Frey et al., 2003). More importantly, VACV-
specific cellular and humoral immunity from vaccinated people is detectable and 
significantly higher than in non-immunised people, in some cases even 70 years 
after a single vaccination (Crotty et al.. 2003; Hammarlund et al.. 2003). 
In order to dissect how individual arms of immunity contribute to controlling 
VACV infection, animal models are required. The strain of VACV that is w idely 
used in experimental settings is the strain Western Reserve (WR). WR was 
derived from 18 passages of VACV strain New York City Board of Health in 
mouse brains (Bronson and Parker. 1941; Parker et al., 1941). This virus is 
neuropathogenic and more virulent than many other VACV strains, including 
those used as smallpox vaccines (Parker et al., 1941; Tartaglia et al., 1992; Fang 
et al., 2005; Hayasaka et al., 2007; Zhang et al., 2010). As a result, this virus has 
not been used as a smallpox vaccine in humans, but as an experimental tool. Both 
innate and adaptive immunity are important in controlling WR infection, although 
their contribution varies depending on the dose and site of infection. During 
intraperitoneal (i.p.) infection. NK cells are needed to control early viral 
replication (Bukowski et al., 1983; Martinez et al., 2010b). Monocytes have also 
been shown to help control virus growth at the inoculation site and virus 
dissemination to other sites during WR infection (Barbalat et al.. 2009; Fischer et 
al.. 2011; Hickman et al., 2013). A new population of innate immune cells, which 
express neutrophil phenotypic markers (Ly6C^Ly6G^) but have a morphology 
similar to monocytes, have been described recently and are important for 
controlling VACV replication and preventing extensive tissue damage during 
dermal WR infection (Fischer et al., 2011; Hickman et al., 2013). 
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Adaptive immunity is also critical for the control of WR infection. RAG-deficient 
mice, which do not have B or J cells (Mombaerts et al., 1992; Shinkai et al., 
1992), do not control WR growth and fail to recover during i.n., i.p. or skin 
scarification infection (Xu et al., 2004; Mota et a!., 2011; Goulding et al., 2012). 
However, the contribution for each division of adaptive immunity depends on the 
infection route. CD4' T ceils and B cells are necessary to control primary i.p. WR 
infection while CDS" T cells play a minor role, preventing further virus 
dissemination in mice deficient for CD4" f and B cells (Xu et al.. 2004). On the 
other hand, mice require an early CDS" T cell response to protect them from an 
i.n. infection with a sub-lethal dose of WR (Goulding et al., 2012). Ahhough 
transfer of serum from WR-immunised mice allows quicker recovery from i.n. 
infection, depletion or deficiency of CD4" T cells and B cells does not affect the 
outcome of pathogenesis compared to wildtype mice (Goulding et al., 2012). 
Using a different mouse strain and the i.n. model, it has been reported that CD4" 
and CDS" T cells are required synergistically to control WR (Belyakov et al., 
2003). For local infection routes, one report failed to identify any significant role 
of CDS" T cells in influencing the formation of viral lesions after VACV infection 
via skin scarification (Spriggs et al., 1992). However, with the use of mutant mice 
with various degrees of immunodeficiency, a recent report demonstrated that both 
B and T cells are essential to provide protection against viral replication at the 
infection site and viral spread into internal organs during skin scarification 
infection (Mota et al., 2011). In a similar dermal infection model in ear pinnae, 
Hickman et al (2013) used intravital microscopy and observed that antigen-
specific CDS" T cells eliminate infected monocytes that are moving out from the 
viral lesions, and they worked cooperatively with Ly6G" innate immune cells 
(mentioned above) to resolve lesions. 
B cell and T cell memory induced by immunisation with a low dose of WR or 
attenuated VACV strains is necessary to provide potent protection against 
challenge with a lethal dose of WR (Belyakov et a l , 2003; Wyatt et al., 2004; Liu 
et al., 2010; Jiang et al., 2012). Furthermore, immunising mice with synthetic 
VACV CDS" T cell epitope peptides in the presence of adjuvants or transfer of 
memory VACV-specific CDS" T cells into naive mice can improve recovery and 
survival from VACV challenge (Snyder et al., 2004; Salek-Ardakani et al., 200S; 
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Moutaftsi et a l , 2009; Salek-Ardakani et al., 2011a). These studies demonstrate 
an important role for CDS"^ T cell memory in controlling VACV infection. 
However, it should be noted that vaccination route, the nature of peptides for 
immunisation and challenge routes all affect the protection outcome (Moutaftsi et 
al., 2009; Liu et al., 2010; Jiang et a l , 2012 and studies discussed above). 
Therefore, the immunity generated by VACV and the requirement of individual 
arms of immunity in different challenge models are not always the same. 
The data discussed above indicate that both innate and adaptive immunity work 
together to control VACV infection. The potent immune response induced during 
VACV immunisation attracts medical researchers to explore whether this virus 
can be used to make recombinant vaccines. 
1.9.2 VACV as a recombinant vaccine vector 
Following the eradication of smallpox, the focus was switched to investigate 
whether VACV can be used as a vector for vaccines against other diseases. Large 
DNA fragments can be inserted into VACV stably using a homologous 
recombination strategy which is relatively straightforward (Mackett et al., 1982: 
Panicali and Paoletti. 1982: Smith and Moss. 1983). Many experimental vaccines 
have since been developed and used in animal models (Panicali et al., 1983: Smith 
et al., 1983a; Smith et al., 1983b: Smith et al., 1984: Schneider et a l , 1998; 
Goonetilleke et al., 2003: Verreck et al., 2009). The first VACV used as a 
recombinant vaccine on a large scale expresses the rabies virus glycoprotein 
(Wiktor et al., 1984; Blancou et al., 1986). It is used as a vaccine bait to control 
rabies in wildlife in Europe and North America (Brochier et al., 1991; Brochier et 
al., 1995; Hanlon et al., 1998). In addition, some other recombinant VACV are 
being examined in clinical trials as recombinant vaccines against HIV, 
tuberculosis and malaria, or as an immunotherapy strategy against cancers 
(McConkey et al., 2003; McShane et al., 2004; Moorthy et al., 2004; Mwau et al., 
2004; Smith et al.. 2005a; Webster et al., 2005; Adamina et al., 2010; Currier et 
al., 2010; Kantoff et al., 2010; Breitbach et al., 2011; Heo et al., 2013; Tameris et 
a l , 2013). These vaccines show different levels of success in clinical trials. 
C h a p t e r I 
As stated above, VACV strain WR is commonly used in animal models and it is 
also used widely to generate experimental VACV-based vaccines for examination 
in mice. However, because of its high virulence, it is not safe for clinical use in 
humans. In addition, the pathogenicity and potential complications caused by the 
smallpox vaccines used in the global smallpox eradication program are deemed to 
constitute a high risk by today's vaccine standards (Fenner et al., 1988: pp58l-
587). To overcome this problem, attenuated strains of VACV are used as 
recombinant vaccine vectors. Two commonly used attenuated strains are NYVAC 
and modified VACV Ankara (MVA). NYVAC was generated by targeted deletion 
of 18 non-essential genes, including host range and immunomodulatory genes, 
from VACV strain Copenhagen (Tartaglia et al., 1992). NYVAC has a reduced 
ability to replicate in many mammalian cell lines and shows low pathogenicity in 
animal models, including in immunocompromised models (Tartaglia et al.. 1992; 
Edghill-Smith et al. .2003). 
MVA was generated by more than 500 serial passages on chicken embryo 
fibroblasts of a VACV strain originating in Turkey, chorioallantois VACV 
Ankara (CVA) (Mayr et al.. 1975). As a result. MVA has lost its ability to grow-
on most mammalian cell lines and is completely non-pathogenic and does not 
replicate in immunocompromised mice and monkeys (Werner et al., 1980; Meyer 
et al., 1991; Carroll and Moss. 1997; Drexler et al., 1998; Stittelaar et al.. 2001; 
Wyatt et al., 2004). However, this virus remains able to replicate well in chicken 
embryo fibroblasts and the baby hamster kidney (BHK-21) cell line (Drexler et 
al., 1998), allowing a high titres of virus to be grown relatively easily. Through 
genomic mapping and sequencing, it was found that there are six major deletions 
in the MVA genome, with many other mutations along the genome (Altenburger 
et al., 1989; Meyer et al., 1991; Antoine et a l , 1998; Meisinger-Henschel et al., 
2007). Importantly, many host range and immunomodulatory genes are lost in 
MVA, compared to WR and CVA (Meyer et al., 1991; Antoine et al.. 1998; 
Meisinger-Henschel et al., 2007). These include host range genes C12L and KIL 
(Gillard et al., 1986; Perkus et al., 1990; Oguiura et a l , 1993; Shisler et al., 1999), 
C3L, which encodes the complement control protein (Kotwal et al., 1990; Isaacs 
et al., 1992), A52R, M2L and NIL , which inhibit NF-KB activation (Bartlett et a l , 
2002; Harte et al., 2003; DiPerna et al., 2004; Cooray et al., 2007; Hinthong et al., 
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2008), B13R. which inhibits apoptosis (Dobbelstein and Shenk, 1996; Kettle et 
al., 1997), as well as B8R and B19R which code for the soluble IFN-y and 
interferon-! receptors respectively (Alcami and Smith. 1995; Symons et al., 1995; 
Alcami et al., 2000; Symons et al., 2002). Some of these deleted genes have 
multiple functions. For instance, the host range gene K I L prevents NF-KB 
activation and inhibits the IFN-l-induced antiviral signalling pathway (Shisler and 
Jin. 2004; Meng et a!., 2009) while N I L has an anti-apoptotic property within 
infected cells, in addition to its role in inhibiting NF-KB (Aoyagi et al., 2007; 
Cooray et al., 2007) . 
Two recent studies have examined the importance of the large deletions by 
generating recombinants from CVA and strain Lister with targeted deletions of 
these genomic regions (Meisinger-Henschel et al.. 2010; Dimier et al., 2011). 
They showed that these deletions only result in moderate virus attenuation 
(Meisinger-Henschel et al., 2010; Dimier et al., 2011). Importantly, recombinants 
carrying all of the major deletions can still replicate and cause mild illness in 
infected mice, especially in those that are immunodeficient (Meisinger-Henschel 
et al., 2010; Dimier et al., 2011). This clearly indicates that mutated genes outside 
the major deletions are essential for the complete loss of replicative ability and 
virulence of MVA in vivo. Indeed, even small in-frame deletions found in some 
genes from MVA can result in loss of function and can contribute to the 
avirulence of MVA (McCoy et al., 2010). 
Ahhough MVA is highly attenuated, h is able to induce humoral and cellular 
memory in animals and humans against subsequent challenge with pathogenic 
poxviruses (Earl et al., 2004; Wyatt et al., 2004; Coulibaly et al., 2005; Parrino et 
al., 2007; Seaman et a l , 2010; Wilck et a l , 2010). In addition, M V A has been 
examined as a recombinant vaccine vector and it has been found that recombinant 
antigens expressed from MVA are immunogenic and can provide protective 
immunity (Sutter et al., 1994; Ramirez et al., 2000; Goonetilleke et al., 2003; 
Ramlau et al., 2008). Some of these vaccines are designed to induce CD8^ T cell 
immunity (McConkey et al., 2003; Smith et al., 2005a; Webster et al., 2005). As a 
CD8^ T cell response is also required to control infection of the virulent strain 
Chapter 1 
WR. it is important to dissect and compare how tiie CDS ' T cell response is 
elicited during immunisat ion witi: V A C V strains WR and MVA. 
1.9.3 CD8^ T cell pr iming during immunisat ion with V A C V 
The mechanism involved in eliciting CD8^ T cell immunity during V A C V 
infection has mainly been studied using strain WR. Using bone marrow chimeric 
models . Sigal et al (1999) and Lenz et al (2000) independently showed that bone-
marrow derived cells are important for priming ant i -VACV CD8^ T cells. Within 
these cells, macrophages and DCs are the two main cell types that are infected 
during W R infection in vitro and in vivo (Norbury et al.. 2002; Sanchez-Puig et 
al., 2004: Hickman et al.. 2008: Abadie et al.. 2009; Hickman et al.. 2011b). 
However , only DCs are responsible for C D S ' T cell priming. Using confocal and 
mult iphoton microscopy to study the draining lymph nodes excised from mice 
infected with WR in footpads. Norbury et al (2002) found that CD8^ T cells 
preferentially interact with and form clusters around WR-infected DCs in an 
antigen-specific manner , but not with infected macrophages. With two photon 
intravital microscopy to study live mice infected subcutaneously, it was later 
shown that this clustering of naive CDS* T cells with DCs infected with W R 
expressing cognate antigen results in T cell activation (Hickman et al.. 2008). In 
contrast to the stable contacts formed with infected DCs. CDS^ T cells only 
transiently interact with infected macrophages in the draining lymph nodes 
(Hickman et al.. 201 lb) . Al though this interaction with infected macrophages can 
be improved by depleting DCs. it does not sustain effective CDS"^ T cell priming 
(Hickman et al., 201 lb) . Similarly, depleting DCs completely abrogates C D S ' T 
cell immunity during i.p. M V A infection (Liu et al., 2008). These studies clearly 
demonstrate that CD8^ T cells are primed by DCs but not macrophages during 
V A C V infection. 
To understand which DC subsets are needed for priming ant i -VACV CDS^ T cell 
immunity, most studies have used an in vitro priming assay in which the 
proliferation level of naive T C R transgenic CDS"^ T cells is measured after co-
culture with individual DC subsets isolated from infected mice (e.g. Belz et al., 
2004). LN-resident CDSa"' DCs were found to be mainly responsible for CDS"^ T 
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cell priming when mice were infected with WR subcutaneously in the footpads or 
through the i.v. route (Belz et al.. 2004; He et a l , 2006). A study using i.v. 
infection also found that CD8a^ DCs play a more important role than CD8a" DCs 
for priming one day after infection, although they seem to share a similar CDS"^ T 
cell priming capability at an earlier time point (six hours) post infection 
(Yammani et al., 2008). On the other hand, it has recently been reported that 
CD 103^ DCs which migrate from the infected lung, but not tissue-resident CD8a^ 
DCs. are involved in priming an anti-VACV CDS" T cell response during i.n. 
infection (Beauchamp et al.. 2010). The importance of different subsets of 
priming DCs between various infection routes might be influenced by a 
differential ability of the virus to infect individual DC subsets after different 
routes of infection are used. 
Dermal infection of MVA in mice has been studied by Combaddiere and 
colleagues (Abadie et al., 2009; Duffy et a l , 2012; Liard et al., 2012). They firstly 
found that macrophages and DCs from the draining lymph nodes can present 
antigens to activate CDS"^ T cells (Abadie et al., 2009). Interestingly, purified 
CD8a" DCs fail to simulate naive polyclonal CD8" T cells ex vivo to produce 
IFN-y (Abadie et al., 2009). One problem with this assay with polyclonal T cells 
is that it does not guarantee that the stimulation is antigen-specific and truly 
represents T cell priming. Liard et al (2012) later showed that infected epidermal 
Langerhans cells can migrate to draining LNs after mice are immunised with 
MVA via the dermal route. They also showed that Langerhans cells are involved 
in CD8" T cell priming in vivo by using a Langerin-diphtheria toxin receptor 
transgenic mouse model. As Langerin is not only expressed by Langerhans cells, 
but also by some dermal DCs, the investigators had made sure that only 
Langerhans cells were depleted in their experiments (Liard et al., 2012). However, 
whether CD8" T cells are directly primed by infected Langerhans cells or via 
cross priming by other DCs was not determined in the study. More recently, it has 
been found that the bone marrow can be a priming site for CDS" T cells and that 
myeloid DCs in the bone marrow can stimulate polyclonal CDS" T cells (Duffy et 
al., 2012). The priming in bone marrow requires transfer of MVA from the 
inoculation site to the bone marrow by neutrophils (Duffy et al., 2012). Priming 
activity in the bone marrow seems to be lower than in draining LNs and their 
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relative contribution to the overall CD8" T cell response has yet to be directly 
compared. In addition, further research is needed to determine whether infectious 
virions or expressed viral proteins are transported by neutrophils for priming in 
the bone marrow. Therefore, the DC subsets for CD8^ T cell priming during 
VACV infection have yet to be identified conclusively. 
1.9.4 Differences in MHC-1 antigen presentation pathways between VACV 
WR and MVA 
Direct presentation is thought to be the key pathway for inducing CDS"^  T cell 
responses during VACV infection (Yewdell and Haeryfar. 2005). This is 
supported by several studies, although they mainly focused on strain WR only. 
Some of the evidence for this has been mentioned in various sections in this 
chapter and they are summarised here. Firstly, many antigens expressed as 
minigenes or rapidly degraded constructs, which favour direct priming, have 
similar immunogenicity or are even more immunogenic than stable full-length 
proteins when expressed by WR (Minev et al.. 1994: Restifo et al.. 1995: Tobery 
and Siliciano. 1997). Secondly, two studies have used TAP-deficient mouse 
models to suggest that direct infection of bone marow-derived APC is important 
for CD8^ T cell priming (Sigal et al., 1999: Norbury et al.. 2001). Thirdly, there is 
direct visual evidence of naive CD8^ T cells interacting with WR-infected DCs in 
the draining LNs of infected mice in an antigen-specific manner, leading to T cell 
activation (Norbury et al.. 2002: Hickman et al.. 2008; Hickman et al., 2011b). 
Fourthly, pre-treating mice with a synthetic oligonucleotide containing 
unmethylated cytosine-guanine dinucleotide motif (CpG). which has been 
reported to inhibit cross presentation exclusively (Wilson et al., 2006), does not 
inhibit priming of CD8^ T cell responses during i.p. or subcutaneous WR 
infections (Xu et al., 2010). These studies support the hypothesis that direct 
presentation can prime anti-VACV CD8^ T cell immunity. 
In some scenarios, responses against VACV antigens may be cross primed. For 
instance, viral antigens from WR-infected MHC-I-mismatched cells can be cross-
primed relatively well in vivo (Larsson et al., 2001; Norbury et al., 2004; Lev et 
al., 2009). It has also been suggested that cross presentation may be the preferred 
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pathway for T cell priming during local VACV infection (Shen et a l , 2002). In 
addition, induction of CDS"^ T cell responses against some VACV antigens is 
resistant to direct presentation blockage and responses against these antigens can 
be effectively cross-primed from infected MHC-1 mismatched cells (Basta et a!., 
2002). It has also been speculated that antigens expressed by late VACV 
promoters should be exclusively cross presented because infection of DCs is 
abortive and does not generate late gene products (Bronte et al., 1997; 
Engelmayer et al.. 1999; Subklewe et al., 1999; Chahroudi et al., 2006). 
Importantly, the ability for a late gene product to be cross presented is reduced if 
the antigen is not released from viral factories in infected cells, suggesting a role 
of VACV to modulate cross presentation of late antigens (Tewalt et al.. 2009). 
While it might seem reasonable to assume that the biology of different VACV 
strains would be similar, a study has shown that that MVA may differ from WR in 
the way it elicits CD8^ T cell responses (Gasteiger et al., 2007). Specifically, 
Gasteiger et al (2007) argued that CD8^ T cells are largely cross-primed during 
MVA infection. Firstly, infecting DCs in vitro with MVA expressing tyrosinase 
(Tyr) as a rapidly-degraded antigen enhances the direct presentation ability of its 
CD8^ T cell epitope, Tyr-369. However, the immunogenicity of this antigen in 
mice is significantly lower than its stable unmodified counterpart. Similarly, the 
OVA-257 minigene, which allows better direct presentation, is also less able to 
prime CD8^ T cell in vivo when expressed from MVA, compared with full-length 
OVA (Gasteiger et al., 2007). Gasteiger et al (2007) further found that that CpG 
pre-treatment of mice can significantly inhibit responses against all MVA-
expressed antigens, contradicting findings for WR (Xu et al., 2010). With these 
resuhs, Gasteiger et al (2007) concluded that anti-MVA CD8^ T cell immunity is 
mainly cross-primed. It was reasoned that the reduced level of maturation and 
early apoptosis of infected DCs may prevent direct priming in vivo, but favour 
cross-priming by uninfected DCs (Drillien et al., 2004; Chahroudi et a l , 2006; 
Kastenmuller et al., 2006; Guerra et al., 2007; Pascutti et al., 2011). Another study 
also suggested an involvement of cross presentation of antigens from infected 
DCs to induce anti-MVA responses (Liu et a l , 2008). Contrary to these studies, 
interactions between naive CD8^ T cells and MVA-infected DCs have been 
observed in vivo using intravital microscopy, clearly demonstrating a role of 
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direct presenta t ion (Kas tenmii l le r et al. , 2013) . Further , reduct ion o f maturat ion of 
D C s fo l lowing W R infec t ion in vi t ro ha s been observed in mul t ip le studies and 
m a n y o f them c la imed that c ross p resen ta t ion may be important for pr iming anti-
W R responses ( E n g e l m a y e r et al.. 1999; S u b k l e w e et al., 1999; .lenne et al.. 2000; 
Bonin i et al., 2001 ; Yates and Alexander -Mi l l e r . 2007) . Despi te these a rguments , 
the weight of ev idence m a k e s it c lear that direct presentat ion is more important . 
In s u m m a r y , direct p r iming by W R is n o w well establ ished as the main 
m e c h a n i s m in vivo. For M V A . the p r iming pa thway remains controversial and it 
requi res fur ther examina t ion . 
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1.10 Aims of this thesis 
Our understanding of the presentation pathway for priming CD8^ T cell responses 
during MVA infection lags behind that of WR substantially. In addition, no direct 
comparison of CD8^ T cell priming between VACV strains WR and MVA has 
been reported. Due to the importance of MVA as a recombinant vaccine vector, 
more in-depth studies are required. Any further information generated would help 
to improve the design of recombinant MVA vaccines. 
This thesis investigates the presentation pathways involved in priming CD8^ T 
cell responses against antigens expressed from VACV strains WR and MVA 
through four aims: 
a) to dissect the presentation mechanisms involved in CDS^ T cell priming 
against individual VACV antigens (Chapter 3); 
b) to examine the immunogenicity of recombinant antigens that are targeted for 
direct presentation when expressed from VACV strains WR and MVA 
(Chapter 4); 
c) to investigate why enhancing direct presentation reduces the immunogenicity 
of a well-characterised lAV antigen expressed from VACV (Chapter 5); and 
d) to characterise CD8^ T ceil responses elicited against recombinant antigens 
fused to VACV virion core proteins (Chapter 6). 
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2.1 Materials 
2.1.1 Media, buffers and solvents 
2.1.1.1 Media 
Dulbecco's Modified Eagle Medium (DMEM) 
DMEM with iiigh glucose and phenol red (Life Technologies), supplemented 
with 2 niM L-glutamine (Life Technologies). For some uses. DMEM was 
further supplemented with 2% (volume/volume (v/v)) or 10% of heat 
inactivated foetal bovine serum (FBS; Serana. Australia). There were called 
D2 and DIO respectively. DMEM without FBS was called DO. 
FBS. heat inactivated, from Serana, Australia. 
Agarose plaque media 
1% (weight/volume (w/v)) low melting point agarose (Life Technologies) in 
D2 media. 
Agarose overlay media with 0.04% X-gal 
1% (w/v) low melting point agarose in D2 rnedia. supplemented with 0.04% 
(w/v) 5-bromo-4-chloro-3-indolyl-P-D-galactopyranoside (X-gal; BioVectra. 
Canada). 
Carboxymethyl cellulose (CMC) plaque media 
0.4% (w/v) of medium viscosity CMC (Sigma-Aldrich) in D2 media. 
DC media 
DIO media with 10 ng/ml recombinant mouse granulocyte macrophage 
colony-stimulating factor (GM-CSF; R&D Systems) and 50 ^M 2-
Mercaptoethanol. 
Phenol red-free CMC plaque media 
0.4% (w/v) of medium viscosity CMC in DMEM (without phenol red; Life 
Technologies), supplemented with 2mM L-glutamine and 2% FBS (v/v). 
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T cell media 
DIO media with 50 ^M 2-mercaptoethanol (Life Technologies) and 10 m M 
N-2-hydroxyethylpiperazine-N-2-ethane sulfonic acid (HEPES) buffer (Life 
Technologies). 
Luria-Bertani (LB) media 
10 g/L tryptone (Bacto), 5 g/L yeast extract (Bacto), 10 g/L sodium chloride 
(Sigma-Aldrich) in deionised water. It was supplemented with 100 mg/ml 
ampicillin (Sigma-Aldrich) or 50 mg/ml kanamycin (Sigma-Aldrich) before 
use. 
LB-agar plates 
10 g/L tryptone. 5 g/L yeast extract. 10 g/L sodium chloride and 15 g/L of 
Bacto-agar (Bacto) in deionised water. Before pouring into plates, ampicillin 
or kanamycin was added to warm liquefied LB-agar media to final 
concentration of 100 ng/ml or 50 ng/ml respectively. 
Super optimal broth with catabolite repression (SOC) medium 
20 g/L tryptone. 5 g/L yeast extract. 0.5 g/L sodium chloride, 2.5 mM 
potassium chloride (Sigma-Aldrich), 20 mM glucose (AnalaR) and 10 mM 
magnesium chloride (Sigma-Aldrich) in deionised water. 
2.1.1.2 Buffer 
0.5 M Ethylenediaminetetraacetic acid (EDTA), pH 8 
0.5 M EDTA in sterile water. pH was adjusted to 8.0 with sodium hydroxide 
pellets (Sigma-Aldrich). 
Magnetic-activated cell sorting (MACS) buffer 
0.5% BSA (Sigma-Aldrich) and 2 mM EDTA (pH 8) in PBS. 
Phosphate-Buffered Saline (PBS; Ix or lOx) 
Obtained from the John Curtin School of Medical Research, the Australian 
National University, Australia. Ix PBS contains 210 mg/L monopotassium 
phosphate monobasic, 9 g/L sodium chloride and 726 mg/L disodium 
phosphate in sterile water. 
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PBS+2%FBS 
1 xPBS supplemented with 2% FBS. 
Red cell lysis buffer 
0.14 M ammonium chloride (Sigma-Aldrich) and 19 mM Tris-Cl in sterile 
water. pH was adjusted 7.2. 
10 mM Tris Buffer. pH 9 
10 mM Tris base (Sigma-Aldrich) in sterile water. pH was adjusted to 9.0 
with 36% hydrochloric acid (Univar). 
1X Tris-acetate-EDTA (TAE) buffer 
40 mM Tris base. 20 mM glacial acetic acid (Univar) and 1 mM EDTA (pH 
8) in deionised water. 
2.1.1.3 solvents 
Acetone, from Merck. 
Dimethyl sulfoxide (DMSO). from Sigma-Aldrich. 
Ethanol. from Merck. 
Methanol, from Merck. 
Sterile water, from Baxter Healthcare. 
2.1.2 Chemicals and Reagents 
2.1.2.1 Reagents for molecular biolog> 
100 bp and 1,000 bp DNA markers, from New England Biolabs. 
1 % agarose for DNA gel electrophoresis 
1% (w/v) UltraPure Agarose (Life Technologies) in 1 x TAE buffer. 
Axyprep Plasmid MiniPrep Kit. from Axygen. 
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BigDye terminator for DNA sequencing (Life Technologies) 
Obtained from the Biomoiecular Resource Facility, John Curtin School of 
Medical Research, the Australian National University. 
Bromophenol blue, from Merck. 
Competent Escherichia coli for plasmid transformation 
Competent a-select (Gold Efficiency) E.coli cells were obtained from 
Bioline. Competent E. coli strains DH5a and XLlO-gold competent cells 
were also used. These cells were prepared in the Tscharke lab. 
Deoxyribonucleotide triphosphate (dNTP) mix. 10 mM. from Bioline 
6x DNA gel loading buffer 
50% (v/v) glycerol (Sigma-Aldrich), 0.25% (w/v) bromophenol blue and 
0.25% (w/v) xylene cyanol (Sigma-Aldrich) in deionised water. Aternatively 
6x DNA gel loading buffer were obtained from New England Biolabs. 
DNA staining solution 
SYBR Safe DNA gel stain solution (Invitrogen), 1 in 10.000 diluted in 
deionised water. 
Geneclean spin kit, from MP Biomedicals. 
In-Fusion HD Cloning Kit, from Clontech. 
LigaFast rapid DNA ligation kit, from Promega. 
Phusion and Taq DNA polymerases, from New England Biolabs. 
Potassium chloride, from Sigma-Aldrich, IM in sterile water. 
Restriction enzymes, from New England Biolabs. 
Sodium acetate, from AnalaR. 2.4M in sterile water. 
Sodium hydroxide, from Sigma-Aldrich, 5M in sterile water. 
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20% Sodium N-lauroylsarcosinate solution, f rom Sigma-Aldrich. 
Sucrose, f rom Amresco. 
Supercoiled DNA ladder, from Life Technologies. 
lOx Thermopol reaction buffer 
Obtained from New England Biolabs. 1 x Thermopol reaction buffer was used 
in various reactions. 
2.1.2.2 Reagents for cell culture and virologj 
10 mg/ml blasticidin S in HEPES buffer, from InvivoGen. 
Crystal violet solution 
0.1% (w/v) of crystal violet (Sigma-Aldrich) and 15% (v/v) ethanol in sterile 
water. 
DAB substrate solution 
It was prepared by dissolving tablets from SIGMAFAST DAB With Metal 
Enhancer Tablet Set (Sigma-Aldrich) in sterile water. The solution contains 
0.5 mg/ml of 3.3'-Diaminobenzidine tetrahydrochloride (DAB), 0.2 mg/ml 
cobalt chloride, 0.3m g/ml urea hydrogen peroxide. 0.05 M Tris and 0.15 M 
sodium chloride. 
Lipofectamine 2000, from Life Technologies. 
36% Sucrose solution 
36% (w/v) sucrose (Amresco) in 10 mM Tris buffer pH 9. 
10 |ig/ml Proteinase K 
10|ag/ml of proteinase K (Roche) in 50|iM Tris buffer (pH 8). 
0 .4% trypan blue solution, from Life Technologies. 
Trypsin 
0 .05% (w/v) trypsin with 0.53mM EDTA (Life Technologies) in PBS. 
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2.1.2.3 Reagents for iinmunolog> 
4'-Aminomethyltrioxsalen hydrochloride (AMT) 
1 mg/ml AMT (Sigma-Aldrich) dissolved in sterile water. The solution was 
further diluted in PBS before use. 
4.5.8-Trimethylpsoralen (TMP) 
2.5 mg/ml TMP (Sigma-Aldrich) dissolved in DMSO. The solution was 
further diluted in PBS before use. 
5(6)-carboxytluorescein diacetate N-succinimidyl ester (CFSE) 
1 mg/ml CFSE (1.79mM; Sigma-Aldrich) dissolved in DMSO. It was further 
diluted in DO before use. 
Brefeldin A 
5 mg/ml brefeldin A (Sigma-Aldrich) dissolved in methanol. It was further 
diluted in DIO before use. 
CD8^ T cell isolation kit II (mouse), from Mihenyi Biotec. 
DimerX H-2K'':lg fusion protein, obtained from BD Biosciences. 
Horse cytochrome c (cytc) 
100 mg/ml horse cytc resuspended in sterile water. It was diluted in PBS to a 
concentration of 25 mg/ml before injection into mice. 
Isoflurane. Inhalation Anaesthetic, from Pharmachem. 
Paraformaldehyde, 16% in H2O, from Electron Microscopy Sciences. 
Recombinant mouse IL-2 
I ng/ml recombinant mouse lL-2 (R&D Systems) resuspended in DIO. 
Saponin 
5% (w/v) saponin (Fluka) dissolved in sterile water. It was further diluted in 
PBS-2%FBS before use. 
Vybrant DiD cell-labelling dye. from Life Technologies. 
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2.1.3 Plasmids 
Pla smids used in this thesis were pur i f ied as descr ibed in Sect ion 2.2.9. They were 
used as D N A templa te s for P C R or D N A sequenc ing react ions (Sect ions 2.2.1 and 
2 .2 .11) or as a t rans fe r p lasmids for genera t ion of V A C V recombinan t s (Sect ions 
2 .2 .13 and 2 .2 .14) . Tab le 2-1 shows the p lasmids that were avai lable for use in 
th is thes is whi le Tab le 2-2 i l lustrates the p lasmids genera ted in this thesis. Please 
note that s o m e of the p lasmids were genera ted with the ass is tance o f S.A. Smith. 
Table 2-11 Information of plasmids that were available for this thesis 
Name Description Reference 
This plasmid expresses a green fluorescent 
protein/blasticidin resistant (GFP/bsd) fusion protein 
under the control of the VACV strong synthetic 
pSCl 1GB promoter from the HiiuM\ site of plasmid pSCl 1-
SBAKN (Chakrabarti et al.. 1985). With this 
plasmid. transgenes can be inserted into the 
thymidine kinase (TK) gene in the VACV genome. 
Wong et al. 
(2013) 
pSCl IGB-ES 
P7.5GB-ins 
pSSmCB 
It contains a GFP/bsd fusion gene under the control 
of the VACV strong synthetic promoter in the 
Hmd\\\ site of plasmid pSCl 1-ES (Eisenlohr et al., 
1992a). This plasmid contained a multiple cloning 
site at the 3' end of the DNA sequencing encoding 
the ER-targeted signal peptide from the adenovirus 
E3/19K protein (amino acid sequence 
MRYMILGLLAL-AAVCSA). With this plasmid. 
transgenes canying an ER-targeted sequence can be 
inserted into the TK gene in the VACV genome. 
This plasmid allows gene insertion into the 
intergenic region between the A11R and A12L genes 
in the VACV genome using a transient dominant 
selection with the GFP/bsd selection marker. 
A modification version of plasmid p7.5GB (Wong et 
al., 2011). It contains a DNA cassette encoding a 
mCherry fluorescent protein-blasticidin resistant 
(mCheny/bsd) fusion protein under the control of 
the VACV strong synthetic promoter. 
H. Korres and 
D.C. Tscharke 
(Unpublished) 
Wong et al. 
(2011) 
E. Spierings, 
S.A. Smith and 
D.C. Tscharke 
(Unpublished) 
Chapter 2 
Table 2-1 (Continued)] Information of plasniids that were available for this thesis 
Name Description Reference 
pSC l lGB-
FullgB 
A DNA fragment encoding the full-length HSV-I H. Korres and 
glycoprotein B (gB) antigen was inserted into the D.C. Tscharke 
plasmid pSCl IGB (Unpublished) 
pUC57-GIP 
A plasinid that contains a DNA fragment encoding T. Stefanovic 
the eOFP-STS recombinant antigen, which consists and D.C. 
of enhanced GFP (eGFP). OVA-257. B8-20 and gB- Tscharke 
498 peptides. It was synthetised by GenScript. (Unpublished) 
Table 2-2| Information of plasmids that were generated in this thesis 
Name Description 
pSCl IGB-
ESminigB 
pSCI IGB-
FullPBIF2 
pSCI IGB-
ESminiPBIF2 
pSCI IGB-
FullOVA 
pSCI IGB-mini 
OVA 
P7.5GB-
insp7.50VA 
This plasmid contains an ER-targeted HSV gB-498 minigene under 
the control of the VACV p7.5 promoter. This plasmid was used to 
generate the recombinant virus MVA-ESmini-gB. 
This plasmid carries a full-length lAV basic polymerase I frame shift 
2 (PBIF2) antigen under the control of the V A C V p7.5 promoter. 
This plasmid was used to generate MVA-Full-PB IF2. 
This plasmid contains an ER-targeted lAV PBIF2-62 minigene 
under the control of the VACV p7.5 promoter. This plasmid was 
used to generate the recombinant virus MVA-ESmini-PBI F2. 
A DNA fragment encoding the full-length OVA antigen was inserted 
into the plasmid pSCI IGB. This plasmid was used to generate the 
recombinant virus MVA-TK-OVA. 
This plasmid contains a cytosolic OVA-257 minigene under the 
control of the VACV p7.5 promoter. This plasmid was used to 
generate the recombinant virus MVA-TK-SIIN. 
A DNA cassette encoding the full-length O V A antigen under the 
control of a VACV p7.5 promoter was cloned into plasmid 
p7.5GB_ins. This plasmid was used to generate the recombinant 
v i rusMVA-AI I /A I2-0VA. 
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Table 2-2 (Continued)] Information of plasmids that are generated in this thesis 
N a m e Descr ip t ion 
A DNA cassette encoding the cytosolic OVA-257 minigene under 
the control of the VACV p7.5 promoter was cloned into the plasmid 
p7.5GB_ins. This plasinid was used to generate the recombinant 
virus MVA-Al 1/A12-SI1N. 
P7.5GB-
insp7.5miniOVA 
pSSmCB -WR -A3 
pSSmCB-WR-
EGFP-STS-A3 
pSSmCB-WR-
eGFP-SKS-A4 
pSSmCB-MVA-
eGFP-SKS-A4 
This plasmid contains a DNA fragment spanning the 5' upstream of 
A3L gene to part of the A3L encoding sequence from the WR 
genome. 
A DNA fragment encoding the eGFP-STS recombinant antigen, 
which was amplified from pUC57-GIP. was cloned into the plasmid 
pSSmCB-WR-A3 in a way that the inserted DNA sequence was 
placed directly after the start codon of A3L gene. This plasmid was 
used to generate the recombinant virus WR-eGFP-STS-A3. 
A pSSmCB plasmid carrying a DNA sequence spanning the 5" 
upstream of A4L gene to part of the A4L encoding sequence from 
the WR genome. In addition, a sequence encoding a recombinant 
eGFP-SKS antigen, consisting of an eGFP. followed by the OVA-
257. D3E-128 and gB-498 peptides, was placed directly after the 
start codon of A4L gene. This plasmid was used to generate the 
recombinant virus WR-eGFP-STS-A3. 
This plasmid is similar to that of plasmid pSSmCB-WR-eGFP-SKS-
A4. However, the upstream sequence of A4L and the A4L encoding 
sequence was amplified from the MVA genome. 
2 .1 .4 O l i g o n u c l e o t i d e s 
All o l i g o n u c l e o t i d e s used w e r e syn thes i sed by S i g m a - A l d r i c h and are listed in 
T a b l e s 2 - 3 and 2 -4 . T h e concen t ra t ion of the w o r k i n g s tock o f each 
o l i g o n u c l e o t i d e u sed w a s 10 p m o l / n l in s ter i le wa te r . 
O l i g o n u c l e o t i d e s s h o w n in T a b l e 2 -3 w e r e u sed to gene ra t e short doub le - s t r anded 
D N A inse r t s e n c o d i n g pep t ide m i n g e n e s for c lon ing . T h i s w a s d o n e by annea l ing 
t w o c o m p l e m e n t a r y o l i gonuc l eo t i de s t oge the r (Sec t ion 2 .2 .6) . O l i g o n u c l e o t i d e s 
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shown in Table 2-4 were used as primers in PCR (Section 2.2.1) or DNA 
sequencing reactions (Section 2.2.11). 
Synthetic phosphorothioated CpG1668 oligonucleotide, with the sequence 
TCCATGACGTTCCTGATGCT, was resuspended in 1 nmol/^l in sterile water. 
It was diluted to 0.1 nmol/nl in PBS before injection into mice (Section 2.2.23). 
Table 2-3| Oligonucleotides used for the generation 
of short double-stranded DNA inserts 
Name Sequence Encoded niinigene 
pSC 11GB- GTGCACCATGTCTATAATAAACTTT 
miniOVAfor GAGAAGTTATAGTGA 
OVA-257 minigene 
pSC 11G B- GGCCTC ACTATAACTTCTCAA AGTT 
miniOVArev TATTATAGACATGGTGCACGGCC 
pSC 11ESGB- GGCCCTTTCCTTGAGGAATCCCATC 
ESitiiniPBlF2for CTGGTATGATAGGATATC 
OVA-257 ininigene 
(complementary to 
pSCllGB-miiiiOVAfor) 
PB1F2-62 minigene 
pSC 11 ESGB- GGCCG ATATCCTATCATACCAGG A 
ESminiPBlF2rev TGGGATTCCTCAAGGAAAG 
MiniGeneNotl/NotIF GGCCTCCTCCATCGAGTTCGCCCG 
pSClIES GCTGTGATAGGATATC 
PB1F2-62 minigene 
(complementar\ to 
pSCllESGB-
ESminiPBIF2rev) 
HSV gB-498 minigene 
pSCGB- GGCCGATATCCTATCACAGCCGGG 
ESHSVgB498-bot CGAACTCGATGGAGGA 
HSV gB-498 minigene 
(complementary to 
pSCllESGB-
ESminiPBlF2rev) 
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Table 2-4| Oligonucleotides used as primers for PCR or DNA sequencing reactions 
N a m e Sequence Use 
pSCl 1GB-
fullPBlF2for 
GTACAGATCTGTACGG 
TGCACCATGGGACAG 
GAAC 
To amplify full-length PB1F2 gene 
from the recombinant virus WR-
Full-PBIF2 
pSCl 1GB-
fullPBlF2rev 
TAGTTAGCTGCGGCCT 
CACTACTCGTGTTTGC 
TG 
To amplify full-length PBIF2 gene 
from the recombinant virus WR-
Full-PB1F2 
pSC l l FullOVA 
for 
GTACAGATCTGTACGG 
ACCATGGGCTCCAT 
To amplify the DNA sequence 
encoding full-length OVA antigen 
from MVA-dellll-OVA 
pSCI l _Fu l lOVA 
rev 
TAGTTAGCTGCGGCCT 
TTCTAGATTAAGCT 
To amplify the DNA sequence 
encoding full-length OVA antigen 
from MVA-dellll-OVA 
i n f u s f o r pSC 11 
TGCAGATATCACTAGC 
GTAGCATCGCTTCT 
i n f u s r evpSC 11 
infusion_A3L_for 
infusion_A3L_328 
rev 
before A3L start 
GAATGTATTAACTAGC 
CCTATAGTGTCACC 
To amplify fragments encoding full-
length OVA and OVA-257 
miningene OVA from plasmids 
pSCllGB-FullOVA and pSCl lGB-
miniOVA respectively 
To amplify fragments encoding full-
length OVA and OVA-257 
miningene OVA from plasmids 
pSCllGB-FullOVA and pSCllGB-
miniOVA respectively 
CAGTGTGCTGGAATTT To amplify part of the A3L gene 
CCTATTGTGGCCAC sequence from the VACV genome 
GATATCTGCAGAATTC 
AATTGCATTCCCAT 
TATTTATATTCGTAGT 
TTTTACTCG 
To amplify part of the A3L gene 
sequence from the VACV genome 
To amplify the whole plasmid 
pSSmCB-A3-328 
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Table 2-4 (Continucd)l Oligonucleotides used as primers for PCR and DNA sequencing 
reactions 
N a m e Sequence Use 
after A3L start 
i n f u s f o r G F P -
STS 
GAAGCCGTGGTCAATA To amplify the whole plasmid 
GC pSSmCB-A3-328 
CTACGAATATAAATAA 
TGGTGAGCAAGGGC 
To amplify the sequence encoding 
the eGFP-STS recombinant antigen 
from plasmid pUC57-GIP 
i n f u s r e v G F P -
STS 
ATTGACCACGGCTTCG 
GCCTTCAGCCGGGCGA 
ACTC 
To amplify the sequence encoding 
the eGFP-STS recombinant antigen 
from the plasmid pUC57-GIP 
CAGTGTGCTGGAATTC 
A4Lup fwd TCGTTGAAGCAAGTTA 
TAG 
To amplify the upstream region of 
the A4L gene from the VACV 
genome 
A4Lup_rev 
TTAAGGCTTTAAAATT 
GAATTGC 
To amplify the upstream region of 
the A4L gene from theVACV 
genome 
AGTTCGCCCGGCTGAA 
A4L_f\vd GGCCGACTTCTTTAAC 
AAGTTCTCAC 
To amplify part of the A4L gene 
sequence from the VACV genome 
GATATCTGCAGAATTG 
A4L_rev ACATATCAGATGATGT 
ATTAG 
To amplify' part of the A4L gene 
sequence from the VACV genome 
A4Lup eGFP fwd 
GCAATTCAATTTTAAA 
GCCTTAAATGGTGAGC 
AAGGGC 
Primer to amplify part of the DNA 
sequence encoding the eGFP-STS 
antigen for the generation of a DNA 
fragment encoding a new eGFP-SKS 
antigen 
eGFP-SKS rev 
GGCCTTCAGCCGGGCG 
AACTCGATGGAGCTGG 
CCTTGAGGTTCTCATA 
TTGCACCACTTTGGCC 
TTCAGTTTTTCAAAG 
Primer to ainplify part of the DNA 
sequence encoding the eGFP-STS 
antigen for the generation of a DNA 
fragment encoding a new eGFP-SKS 
antigen 
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Table 2-4 (Continued)] Oligonucleotides used as primers for P C R and DNA sequencing 
reactions 
Name Sequence Use 
VACV092fvvd 
GGATGACAACTCAAA 
CATCTGC 
Diagnostic PCR primer for VACV 
recombinants with inserts in the 
VACV TK gene 
laczpSC 11 rev 
AGGCACATGGCTGAAT 
ATCG 
Diagnostic PCR primer for VACV 
recombinants with inserts in the 
VACV TK gene 
SP6 
GATTTAGGTGACACTA 
TAG 
Diagnostic PCR primer for VACV 
recombinants witii inserts in the 
VACV TK gene 
TKLrevl 
GTCAGTCTCATGTTCT 
CACCG 
Diagnostic PCR primer for VACV 
recombinants with inserts in the 
VACV TK gene 
FwdHSV-gBend 
A C A C A A G G C C A A G A A 
G A A G G 
Diagnostic PCR primer for the 
recombinant virus MVA-Full-gB 
SeqGFPbsd600For 
CAACTAGCAGACCATT 
ATC 
Diagnostic PCR primer for VACV 
recombinants with inserts in the 
VACV TK gene 
revGFPbsdend 
CCTCCCACACATAACC 
AGA 
Diagnostic PCR primer for VACV 
recombinants with inserts in the 
VACV TK gene 
VACV095rev 
ACGGACGATCTTATTA 
AGGTA 
Diagnostic PCR primer for VACV 
recombinants with inserts in the 
VACV TK gene 
WRBOfvvd 
GGTAAGACTCCGTATA 
AATCAA 
Diagnostic PCR primer for VACV 
recombinants with inserts in the 
A11R/A12L intergenic region 
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Table 2-4 (Continued)] Oligonucleotides used as primers for PCR and DNA sequencing 
reactions 
Name Sequence Use 
SeqGbFll 
CGTCACTGTTCTTTAT 
GATTCTA 
Diagnostic PCR primer for VACV 
recombinants with inserts in the 
A11R/A12L intergenic region 
WR131rev 
CTAGCGCAAATCGGTG 
GA 
Diagnostic PCR primer for VACV 
recombinants with inserts in the 
A11R/A12L intergenic region 
before_A3L_seq GATCAAAAGACGACG 
ACACC 
Diagnostic PCR primer for the 
recombinant virus WR-eGFP-STS-
A3 
reveGFPseq 
CTCGACCAGGATGGGC 
AC 
Diagnostic PCR primer for the 
recombinant virus WR-eGFP-STS-
A3 
for_eGFP_524seq 
CCACAACATCGAGGA 
CGG 
Diagnostic PCR primer for the 
recombinant virus WR-eGFP-STS-
A3 
rev_A3_454seq CATGGGTAAGGAGTTG 
AAATAG 
Diagnostic PCR primer for the 
recombinant virus WR-eGFP-STS-
A3 
for_eGFP_524seq 
revWRI23seq 
CCACAACATCGAGGA 
CGG 
ACGTCTGAGAAGGTTG 
GG 
Diagnostic PCR primer for 
recombinant viruses WR-eGFP-
SKS-A4 and MVA-eGFP-SKS-A4 
a) Diagnostic PCR primer for 
recombinant viruses WR-eGFP-
SKS-A4 and MVA-eGFP-SKS-
A4 
b) Sequencing primer for the A4L 
gene 
SeqRevpEGFPNl 
CTCGACCAGGATGGGC 
AC 
Diagnostic PCR primer for 
recombinant viruses WR-eGFP-
SKS-A4 and MVA-eGFP-SKS-A4 
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Table 2-4 (Continued)] Oligonucleotides used as primers for PCR and DNA sequencing 
reactions 
Name 
fwdWR124seq 
Sequence Use 
CTTTGTCAAAATCGTT 
TACCGAC 
Sequencing primer for the A4L gene 
SeqpSCl lp7.5 
Sequencing primer for inserts in the 
CACTAATTCCAAACCC transfer plasmids p S C l l G B and 
ACCC pSCl IGB-ES and in the VACV TK 
gene from the VACV genome 
SeqpSCl ITK-R 
Sequencing primer for inserts in the 
TGAAATGTCCCATCGA transfer plasmids pSCl 1GB and 
GTGC pSCl lGB-ES and in the VACV TK 
gene from the VACV genome 
pSCl l lacZseq 
GTGCTGCAAGGCGATT 
AAGT 
Sequencing primer for the inserts in 
the VACV TK gene from the VACV 
genome 
Sequence SP6 rev 
CTATAGTGTCACCTAA 
ATC 
Sequencing primers for inserts in the 
transfer plasmids p s C l l G B and 
pSCl lGB-ES 
HSVgB p2(235) 
CGCTACTCCCAGTTTA 
TGGGGAT 
Sequencing primer for the full-length 
HSV gB antigen 
HSVgB p4(237) 
GAGTACGGCGGCTCCT 
TCCGAT 
Sequencing primer for the full-length 
HSV gB antigen 
HSVgB p6(239) 
CGAGCTACAGAATCAC 
GAGCTGAC 
Sequencing primer for the full-length 
HSV gB antigen 
OvaSeqForl 
TCCTTCAGCCAAGCTC 
CGTG 
Sequencing primer for the full-length 
OVA gene 
Frd_seq_PCR_blu 
ntll MCS 
TACGCCAAGCTATTTA 
GGTG 
Sequencing primer for inserts in 
plasmids p7.5GB, p7.5GB-ins, and 
pSSmCB 
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Table 2-4 (Continued)] Oligonucleotides used as primers for PCR and DNA sequencing 
reactions 
Name Sequence Use 
Rev_seq_PCR_ 
bluntlI_MCS 
CGATTAAGTTGGGTAA 
CGCC 
Sequencing primer for inserts in 
p7.5GB. p7.5GB-ins, and pSSniCB 
WR130-Fi 
TATGCATCAAGCTTGC 
ATTATCGAGCAAGCAT 
TGC 
Sequencing primer for inserts in 
A1IR/A12L intergenic region from 
VACV genome 
WR131-Fi 
GCCAGTGTGATGGATT 
AGAGACGGCCAATTA 
GAAG 
Sequencing primer for inserts in 
A11R/A12L intergenic region from 
VACV genome 
2.1.5 Mice 
Female specific pathogen-free C57BI/6. B6.SJL. and F5 TCR transgenic mice 
(Mamalaki et a l , 1992; Mamalaki et al.. 1993) were obtained from the Animal 
Resources Centre (Perth. Australia) or the Australian Phenomics Facility 
(Canberra, Australia). Mice were housed and used for experiments at 7-14 weeks 
old. All experiments were done according to the relevant ethical requirements and 
were approved by the Australian National University Animal Ethics and 
Experimentation Committee (protocol numbers: F.BMB.38.08, A201I .00I and 
A2011.038). C57BI/6 mice were used unless otherwise stated. 
2.1.6 Cell lines 
Cell lines used are listed in Table 2-5. They were maintained in DIO media at 
37°C with 5% CO2 in culture flasks and were subcultured twice a week. Cells 
were maintained as described in Section 2.2.12. 
Chapter 2 
Table 2-5| Cell lines used in this thesis 
Cell line 
293A 
2 9 3 - 0 " -
293-K'' 
BHK-21 
BSC-1 
DC2.4 
Origin Use 
Primary human embrvonic 
kidney cells 
(transformed with human 
adenovirus 5 DNA) 
293A cells that stably 
express H-2D'' under the 
control of the strong 
cy tomegalovirus promoter 
293A cells that stably 
express H-2K'' under the 
control of the strong 
cytomegalovirus promoter 
Sy rian golden Hamster 
kidneN fibroblast 
African green monkey 
kidney epithelial cells 
DC-like cell line generated 
from C57B1/6 mouse. It 
expresses H-2K'' and H-2D'' 
a) For generating recombinant viruses with 
VACV strain WR background 
b) As antigen donor cells for in vivo cross 
priming experiments 
a) As stimulators used in the in vitro 
presentation experiments 
a) As stimulators used in the in vitro 
presentation assays 
b) As APCs for measuring OVA-257/H-2K' ' 
presentation after infection w ith VACVs 
expressing OVA constructs 
a) For MVA titration 
b) For generation and plaque purification of 
recombinant VACVs with MVA 
background 
c) For growing VACV stocks 
a) For VACV strain WR titration 
b) For plaque purification of recombinant 
VACVs with WR background 
a) As stimulators used in the in vitro direct 
presentation assays 
b) As APCs for measuring OVA-257/H-2K' ' 
presentation after infection with VACVs 
expressing OVA constructs 
1 Refer to the American Type Culture Collection (ATCC; www.atcc.ori;). USA. 
2 Tscharke et al. (2005). 
3 Shenetal .(1997). 
2 .1 .7 S y n t h e t i c P e p t i d e s 
Syn the t i c p e p t i d e s w i t h the min ima l a m i n o ac id s e q u e n c e s o f C D 4 ^ or C D 8 ^ T 
cell e p i t o p e s w e r e u sed fo r ex v ivo s t imula t ion o f sp len ic C D 8 ^ T ce l l s i so la ted 
f r o m i m m u n i s e d m i c e (Sec t ion 2 .2 .29) , pep t ide load ing o f D i m e r X (Sec t ion 
2 .2 .31 ) , o r p u l s i n g b o n e m a r r o w - d e r i v e d D C s ( B M D C s ) in v i t ro (2 .2 .34) . T h e 
p e p t i d e s w e r e s y n t h e s i s e d by G e n S c r i p t un le s s o the rwi se s ta ted . T h e p e p t i d e s 
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used are listed in Table 2-6. Master stock of peptides were prepared at a 
concentration of 1 or 10 mg/ml in DMSO and stored in a -80°C freezer. Peptides 
were diluted with DO media or PBS before use. 
Table 2-6| Synthetic peptides used in this thesis 
Peptide 
name ' 
Amino acid 
sequence 
Origin of peptide ^ 
MHC-1 
Restriction 
Reference 
A42-88 YAPVSPIVI VACV, A42. 88-96 H-2D'' 
Tscharke et al. 
(2005) 
A8-70 IHYLFRCV VACV, A8. 70-77 H-2K'' 
Moutaftsi et al. 
(2006) 
J3-289 SIFRFLNI VACV, J3. 289-296 H-2K'' 
Moutaftsi et al. 
(2006) 
C4-125 LNFRFENV VACV, C4. 125-132 H-2K'' 
Moutaftsi et al. 
(2006) 
A3-191 YSPSNHHIL VACV, A3. 191-199 H-2K'' 
Moutaftsi et al. 
(2006) 
A47-171 ^ YAHINALEYI VACV. A47, 171-180 H-2K'' 
Yuen et al. 
(2010) 
L2-53 VIYIFTVRL VACV, L2, 53-61 H-2K'' 
Moutaftsi et al. 
(2006) 
A47-138 AAFEFINSL VACV, A47, 138-146 H-2K'' 
Tscharke et al. 
(2005) 
B2-54 YSQVNKRYI VACV, B2. 54-62 H-2D'' 
Moutaftsi et al. 
(2006) 
K3-6 YSLPNAGDVI VACV, K3,6-15 H-2D'' 
Tscharke et al. 
(2005) 
A23-297 IGMFNLTFl VACV, A23, 297-305 H-2D'' 
Moutaftsi et al. 
(2006) 
A3-270 K S Y N Y M L L VACV, A3, 270-277 H-2K'' 
Moutaftsi et al. 
(2006) 
A8- I89 ITYRFYLI VACV, A8, 189-196 H-2K'' Moutaftsi et al. 
(2006) 
B8-20 TSYKFESV VACV, B8, 20-27 H-2K'' Tscharke et al. 
(2005) 
OVA-257 SIINFEKL Chicken. OVA. 257-264 H-2K'' 
Falk et al. 
( 1991b)and 
Rotzschke et 
a l . ( 1991) 
T a b l e 2 - 6 ( C o n t i n u e d ) l Synthe t i c pept ides used in this thesis 
C h a p t e r ; 
P e p t i d e 
n a m e ' 
g B - 4 9 8 
P B 1 F 2 - 6 2 
P A - 2 2 4 
N S 2 - 1 1 4 
P R 8 N P -
3 6 6 
N T 6 0 N P -
3 6 6 
P R 8 N P -
3 6 6 - p S 
D 3 E - 1 2 8 
E l A - 3 2 4 
H B c A g -
128 
A m i n o ac id 
s e q u e n c e 
S S I E F A R L 
P B l - 7 0 3 ^ S S Y R R P V G I 
Orig in o f pept ide ^ M H C - I 
Restr ict ion 
L S L R N P I L V 
S S L E N F R A Y V 
R T F S F Q L I 
A S N E N M E T M 
A S N E N M D A M 
A p ( S ) N E N M E T M 
K V V Q Y E N L 
S G P S N T P P E I 
T P P A Y R P P N A P I L 
H S V - 1 , g lycopro te in B 
(gB) . 4 9 8 - 5 0 5 
l A V strain A/Pue r to 
R ico /8 /1934 (PR8) . 
bas ic po lymerase 1 ( P B l ) . 
703-711 
lAV strain PR8. 
PBl f r a m e shift 2 
(PB1F2) . 6 2 - 7 0 
l A V strain PR8. 
acid po lymerase (PA) . 
2 2 4 - 2 3 3 
lAV strain PR8. 
non-s t ructural 2 (NS2) . 
114-121 
lAV strain PR8. 
n u c l e o p r o t e i n ( P R 8 N P ) . 
366 -374 
l A V strain A/Nor the rn 
Ter r i to ry /60 /1968 
( N T 6 0 ) . nucleoprote in 
( N T 6 0 N P ) . 366-374 
S a m e sequence as 
P R 8 N P 3 6 6 . wi th ser ine at 
pos i t ion 2 p h o s p h o r j lated 
D e n g u e virus type 3. 
enve lope protein , 128-135 
A d e n o v i r u s ty pe 5, 
ear ly 1A protein, 234 -243 
Hepat i t i s B virus, 
core an t igen . 128-140 
H-2K' ' 
H-2K' ' 
H-2D' ' 
H-2D' ' 
H-2K' ' 
H-2D' ' 
H-2D' 
H-2D' ' 
( A s s u m e d ) 
H-2D' ' 
(Pred ic ted) 
H-2D' 
H-2I -A 
R e f e r e n c e 
Bonneau et al. 
( 1993) 
B e l z e t a l , 
(2001) 
Chen et al. 
( 2 0 0 1 a ) 
Belz et al. 
(2000) 
Vitiel lo et al. 
( 1996) 
Ro tzschke et 
al. ( 1 9 9 0 ) 
t Ro tzschke et 
al. ( 1990) 
B. Q u i n a n and 
D.C. T s c h a r k e 
( U n p u b l i s h e d ) 
Kast and 
M e l i e f ( 1 9 9 1 ) 
Mil ich et al. 
b ( 1 9 8 8 ) a n d 
A l e x a n d e r et 
al. ( 1 9 9 4 ) 
1 The name for each peptide is based on the name of the protein that contains the particular sequence. 
2 The origin, the name of the protein that contained the peptide sequence, followed by the residue 
number of the peptide within the protein is shown for each peptide. 
3 The A47-171 peptide was synthesised by Mimotopes. The PBl-703 peptide was provided by the 
laboratory of Professor S. Turner (University of Melbourne, Australia). 
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2.1.8 Viruses 
Viruses used in this s tudy that were a l ready avai lable are listed in Tab le 2 .7 . T h e 
major i ty o f these v i ruses were obta ined f r o m Dr. J .R. Bennink and Dr. J .W. 
Yewdel l (Nat ional Insti tute of Al lergy and Infec t ious Diseases , U S A ) , un l e s s 
o therwise stated. V A C V recombinan t s genera ted in this thes is are listed in T a b l e 
2.8. S o m e viruses were genera ted wi th the ass is tance of S.A. Smi th . It should be 
noted that for most r ecombinan t viruses wh ich express t r ansgenes f r o m the T K 
locus, a kicZ gene under the control of the late V A C V p l l p romote r w a s a l so 
inserted into the T K locus, except for WR-Fu l l -PA and WR-Fu l I -NS2 . In addi t ion , 
the ER-targeted sequence used in some recombinant v i ruses is the ER- ta rge ted 
signal pept ide f r o m the adenovi rus E3/19K protein (Eisenlohr et al. , 1992a) . 
unless o therwise stated. Please also note that tables showing the v i ruses used in 
each chapter are reproduced in the Append ix for the ease of re ference . 
Table 2-7| Viruses that were already available for this thesis 
Virus Descript ion R e f e r e n c e 
Parker et al. 
WR ' Wildtype VACV strain WR 
(1941)and 
Bronson and 
Parker (1941) 
WR-delTK WR with the TK locus knocked out 
Chakrabarti et 
a l . (1985) 
WR-TK-OVA 
WR expressing full-length OVA by the VACV p7.5 
promoter from the TK locus 
Restifo et al. 
(1995) 
WR-TK-SIIN 
WR expressing a cytosolic OVA-257 minigene by 
the VACV p7.5 promoter from the TK locus 
Baclk et al. 
(1994) 
WR-Full-gB -
WR expressing full-length HSV gB antigen by the 
p7.5 promoter from the TK locus 
Lin et al. 
(2013) 
WR-ESmini-gB ' 
WR expressing an ER-targeted gB-498 minigene by 
the p7.5 promoter from the TK locus 
Blaney et al. 
(1998) 
WR-Full-PBl 
WR expressing full-length PBl from lAV strain 
PR8 by the p7.5 promoter from the TK locus 
Chen et al. 
(2001a) 
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Table 2-7 (Continued)] Viruses that were already available for this thesis 
Virus Description Reference 
WR-ESmini -PBl 
WR-Full-PB1F2 
WR-ESmini-
PB1F2 
WR-Full-PA 
WR-ESmini-PA 
WR-Full-NS2 
WR-ESmini-NS2 
WR-Full-PR8NP 
WR-ESmini-
PR8NP 
WR-mini -PR8NP 
WR-Ful l -T60NP 
WR-ESniini-
NT60NP 
WR expressing an ER-targeted PB1-703 minigene 
by the p7.5 promoter from the TK locus 
WR expressing full-length PB1F2 from lAV strain 
PR8 by the p7.5 promoter from the TK locus 
WR expressing an ER-targeted PB1F2-62 minigene 
bv- the p7,5 promoter from the TK locus 
WR expressing a full-length PA from lAV strain 
PR8 by the p7.5 promoter from the TK locus 
WR expressing an ER-targeted PA-224 minigene 
by the p7.5 promoter from the TK locus 
WR expressing a full-length NS2 antigen from lAV 
strain A/Udorn/1972 by the p7.5 promoter from the 
TK locus 
WR expressing an ER-targeted NS2-114 minigene 
by the p7.5 promoter from the TK locus 
WR expressing a full-length PR8NP antigen by the 
p7.5 promoter from the TK locus 
WR expressing an ER-targeted PR8NP-366 
minigene by the p7.5 promoter from the TK locus 
WR expressing a cytosolic PR8NP-366 minigene 
by the p7.5 promoter from the TK locus 
WR expressing a full-length NT60NP antigen by 
the p7.5 promoter from the TK locus 
WR expressing an ER-targeted NT60NP-366 
minigene by the p7.5 promoter from the TK locus. 
The ER-targeted sequence was the signal sequence 
of the hemagglutinin protein from lAV strain PR8. 
Unpublished 
Chen et al. 
(2001a) 
Lev et al. 
(2009) 
Smith et al. 
(1987) 
Lev et al. 
(2009) 
Smith et al. 
(1987) 
Unpublished 
Restifo et al. 
(1995) 
Lev et al. 
(2009) 
Lev et al. 
(2009) 
Tovvnsend et 
a l . (1988) 
Elliott et al. 
(1995) 
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Table 2-7 (Continued)l Viruses that were already available for this thesis 
Virus Descr ipt ion R e f e r e n c e 
WR expressing a recombinant NP-S-GFP antigen 
WR-NP-S-GFP consisting of PR8NP, OVA-257 peptide and eGFP 
by the p7.5 promoter from the TK locus 
Anton et al. 
(1999) 
WR expressing the NP-S-GFP antigen tagged with 
WR-UbR-NP-S- an ubiquitin protein and an arginine residue at the Princiotta et al. 
GFP amino-terminus. The transgene was driven by the (2003) 
p7.5 promoter from the TK locus. 
WR expressing the amino acid residues of 13-498 
WR-cyto-PR8NP of PR8NP under the control of p7.5 promoter from 
the TK locus 
Golovina et al. 
(2002) 
WR-ES-PR8NP 
WR e.xpressing a recombinant antigen consisting of 
the amino acid residues of 13-498 of PR8NP tagged 
with an ER-targeted sequence under the control of Golovina et al. 
p7.5 promoter from the TK locus. The ER-targeted (2002) 
sequence was the leader sequence of the 
hemagglutinin protein from lAV strain A/WSN/33. 
WR-delB8 WR with B8R deleted 
WR-delB8- WR with the B8R gene replaced by a cytosolic B8-
miniB8 * 20 minigene 
MVA Wildtype VACV strain MVA 
Symons et al. 
(2002) 
Wong et al. 
(2011) 
Mayr et al. 
(1975) 
MVA-dellll- MVA expressing full-length OVA by the VACV Gasteiger et al. 
O V A ' 
MVA-dellll-
S l I N ' 
p7.5 promoter from the deletion III (dellll) region (2007) 
MVA expressing a cytosolic OVA-257 minigene by Gasteiger et al. 
the VACV p7.5 promoter from the dellll region 
MVA-delB8 ' MVA with B8R deleted 
MVA-delB8- MVA with the B8R gene replaced by a cytosolic 
miniB8 ^ B8-20 minigene 
(2007) 
Kastenmuller 
e ta l . (2007) 
Y.C. Wong 
and D.C. 
Tscharke 
(unpublished) 
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Table 2-7 (Cont inued)] V iruses that w e r e already available for this thesis 
Virus Description Reference 
lAV strain 
PRS*^ 
Wild type lAV strain PR8 
-
S.A. Smith. T. 
IAV-B8 ' 
lAV strain PR8 with B8-20 peptide inserted into the Cukalac and 
neuramin idase stalk D.C. Tscharke 
(Unpubl ished) 
HSV strain K O S Wildtype H S V strain K O S 
Rawls et al. 
(1968) 
1 The virus was provided by Dr. B. Moss (National Institute of Allergy and Infectious Diseases. 
U.S.A.). 
2 The viruses were generated in the Tscharke lab (Australia National University. Australia). 
3 The virus was provided by Professor S.S. Tevethia (Pennsylvania State University. U.S.A.) 
4 The virus was provided by Professor G.L. Smith (University of Cambridge. UK). 
5 They were provided by Professor 1. Drexler (Heinrich-Heine-Universitat. Gennany) 
6 The virus was obtained from the laboratory of Professor C. Goodnow (Australia Nation 
University. Australia). 
7 The virus was generated in the laboratory of Professor S. Turner (University of Melbourne. 
Australia). 
8 The virus was provided by Professor F. Carbone (University of Melbourne. Australia). 
Table 2-8| V A C V recombinants generated in this thesis 
Virus Comment 
M V A - d e l T K 
M V A - F u l l - g B 
M V A - E S m i n i - g B 
M V A - F u l l - P B 1 F 2 
M V A - E S m i n i - P B I F 2 
M V A - T K - O V A 
M V A with the TK locus knocked out 
M V A e.xpressing ful l- length gB antigen by the p7.5 promoter 
f rom the TK locus 
M V A express ing an ER-targeted gB-498 minigene by the p7.5 
p romoter f rom the TK locus 
M V A express ing a ful l- length PB1F2 antigen by the p7.5 
p romoter f rom the T K locus 
M V A express ing an ER-targeted PB1F2-62 minigene by the 
p7.5 p romoter f rom the TK locus 
M V A express ing ful l- length O V A by the V A C V p7.5 promoter 
f rom the TK locus 
Chapter 2 
Table 2-8 (Continued) | VACV recombinants generated in this thesis 
V irus C o m m e n t 
MVA-TK-SIIN 
MVA-A11/A12-OVA 
MVA-A11/A12-S1IN 
MVA-dellll-OVA-
delTK. 
MVA-dellll-SIIN-
delTK 
WR-eGFP-STS-A3 
WR-eGFP-SKS-A4 
MVA-eGFP-SKS-A4 
MVA expressing a cytosolic OVA-257 minigene by the VACV 
p7.5 promoter frotn the TK locus 
MVA expressing full-length OVA by the VACV p7.5 promoter 
from the VACV A11R/A12L intergenic region 
MVA expressing a cytosolic OVA-257 minigene by the VACV 
p7.5 promoter from the VACV A11R/A12L intergenic region 
MVA expressing full-length OVA by the VACV p7.5 promoter 
from the dellll region, with TK gene knockout 
MVA expressing a cytosolic OVA-257 minigene VACV p7.5 
promoter from the dellll region, with TK gene knockout 
WR with A3 antigen tagged with a recombinant antigen 
consisting of eOPP. OVA-257. B8-20 and gB-498 peptides 
(eGFP-STS recombinant antigen) at the amino-terminus. 
WR with A4 antigen tagged with a recombinant antigen 
consisting of cGFP. OVA-257, D3E-128. and gB-498 peptides 
(eGFP-SKS recombinant antigen) at the amino-terminus 
MVA with A4 antigen tagged with the eGFP-SKS recombinant 
antigen at the amino-terminus 
2.1.9 Ant ibodies and a n t i - V A C V h y p e r i m m u n e serum 
Comtnerc ia l ly avai lable an t ibodies used in this thesis are listed in Table 2.7. M o s t 
of the ant ibodies were used to label cei ls for f low cytometr ic analysis . Ant i - rabbi t -
IgG-peroxidase w a s used as the secondary ant ibody for immunos ta in ing of M V A -
infected cell mono laye r s dur ing titration of M V A (Sect ion 2.2.17.2). 
In addi t ion to the commerc ia l ly avai lable ant ibodies , rabbit a n t i - V A C V 
h y p e r i m m u n e serum w a s used as the pr imary ant ibody for i m m u n o s t a i n i n g o f 
M V A - i n f e c t e d cell mono laye r s for M V A titration (Sect ion 2.2.17.2) . It w a s 
genera ted by four immunisa t ions of a rabbit at three weekly intervals wi th V A C V 
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strain M V A ( I x i o ' P F U ) and s e r u m w a s col lected two weeks af ter the last 
immuni sa t ion (Inst i tute o f Medica l and Veter inary Science, Austral ia) . 
W h e n indicated, cul ture superna tan t f r o m the 2 .4G2 hybr idoma. which expresses 
a n t i - m o u s e - C D 16 /CD32 an t ibody , w a s use to block receptors specif ic for the 
f r agmen t crys ta l l i sable reg ion (Fc) of ant ibody expressed on cells before fur ther 
an t ibody labell ing. 
Table 2-9| Commercially available antibodies used in this thesis 
A n t i b o d y ( -conjugate ) Species Clone Source 
Anti-mouse IFN-y-APC ' 
Anti-niouse-CD8a-PE" 
Anti-mouse-CD8a-PE-Cy7 ^ 
anti-OVA-257/H-2K''-APC 
Rat 
Rat 
Rat 
mouse 
XMG1.2 
53-6.7 
53-6.7 
25D1.16 
Biolegend 
Biolegend 
Biolegend 
Biolegend / 
eBioscience 
Anti-mouse-TNF-a-PE-Cy7 rat MP6-XT22 
BD 
Pharmingen 
Anti-mouse-IL-2-a-PE-Cy5 ^ 
Anti-mouse-CD45.2-APC 
Anti-mouse-CD69-PE-Cy7 
rat 
mouse 
Annenian 
Hamster 
JES6-5H4 
104 
H1.2F3 
Biolegend 
Biolegend 
Biolegend 
Anti-mouse-CD25-PE 
Anti-mouse-CD 11 c-APC 
Rat 
Armenian 
Hamster 
PC61 
N418 
Biolegend 
Biolegend 
Anti-mouse-IgGl-PE Rat A85-1 
BD 
Phanningen 
Anti-rabbit-lgG-peroxidase' Goat Polyclonal Sigma-Aldrich 
1 APC: allophycocyanin 
2 PE: phycoerythrin 
3 PE-Cy7: phycoerythrin-cyanine 7 
4 P E - C y 5 : phycoery th r in -cyan ine 5 
5 The antibody is conjugated to horseradish peroxidase 
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2.2 Methods 
2.2.1 Polymerase chain reaction (PCR) 
PCR was performed with either Phusion DNA polymerase (New England 
Biolabs) or Tcicj DNA Polymerase (New England Biolabs). 
Phusion DNA polymerase has high fidelity to reduce the rate of errors in the PCR 
product sequence. This enzyme was used wherever the product was to be 
incorporated into a recombinant virus. In a PCR with Phusion DNA polymerase. 
0.2 ml tubes were set up with a final reaction volume of 50 [il in sterile water, 
including 1 x Phusion HF Buffer. 200 |.iM dNTPs. 0.5 ^M of each forward and 
reverse primer. 2 |.d DNA template (either purified plasmids (Section 2.2.9) or 
viral genomic DNA (Section 2.2.15)) and 1 unit of Phusion DNA polymerase. 
The samples were then run in a thermocycler (a Veriti 96-well Thermal Cycler 
(Life Technologies) or a Mastercycler (Eppendorf)). Sample thermal cycling 
conditions are shown below: 
a. 98°C for 30 seconds (sec) (Initial denaturation) 
b. 30 cycles of: 
- 9 8 ° C f o r l 0 s e c (Denaturation) 
- 45-72°C for 30 sec (Annealing temperature was 
determined from the primers used) 
- 72°C for 15 sec/l.OOObp (Extension) 
c. 72°C for 10 minutes (min) (Final extension) 
d. Holda t4°C. 
Taq DNA Polymerase has lower fidelity and was used for the diagnostic PCRs to 
screen recombinant viruses (Section 2.2.14). It was also used to produce DNA 
fragments from the recombinant viruses for DNA sequencing (Section 2.2.11). In 
a PCR with Taq DNA polymerase, 0.2 ml tubes were set up with a final reaction 
volume of 25 in sterile water, including Ix ThermoPol reaction buffer, 200 |iM 
of dNTPs, 0.35 |iM of each forward and reverse primer. 1 of prepared viral 
genomic DNA from isolated plaques (Section 2.2.15) and 0.5 unit Taq DNA 
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polymerase. The samples were then run in a thermocycler as above. Sample 
thermal cycling conditions are shown below: 
a. 9 5 ° C f o r 3 0 s e c (Initial denaturation) 
b. 30 cycles of: 
- 95°C for 30 sec (Denaturation) 
- 45-65°C for 30 sec (Annealing temperature was determined 
from the primer pairs used) 
- 68°C for 1 min/kb (Extension) 
c. 6 8 ° C f o r l 0 m i n (Final extension) 
d. Ho lda t4°C 
2.2.2 Restriction enzyme digestion 
Purified plasmids were digested with different restriction endonucleases. This was 
to either produce linearised plasmids for cloning (Section 2.2.7) or for restriction 
digestion analysis of recombinant plasmids cloned with DNA inserts (Section 
2.2.9). In general, each restriction digestion reaction (20-50 |il) contained Ix 
NEBuffer provided. 5-100 ng/^l purified plasmids. 0.1-0.4 unit/^il restriction 
enzymes in sterile water. When required. 1 x bovine serum albumin solution was 
added. The reactions were then incubated at 37°C for 2-4 hours (h). When the 
Apa\ restriction enzyme was used, the reaction was carried out at 25°C. 
2.2.3 Agarose gel electrophoresis 
To visualise the PCR products or restriction-digest fragments of plasmids, 
samples were run on a 1% agarose gel in IX TAE by gel electrophoresis which 
separates DNA fragments according to their lengths. Horizontal electrophoresis 
apparatuses (Bio-Rad) were used. Firstly, a 1% agarose gel was casted. Samples 
were mixed with appropriate volumes of 6x DNA loading dye. 6-15 nl of the 
solution was loaded into wells of the agarose gel. DNA ladder was loaded into the 
gels and used as a molecular size and mass standard. Gel electrophoresis was then 
performed at 90 to 120V for 30 min to 1 h in an electrophoresis chamber. The gel 
was stained with DNA staining solution for at least 15 min, followed by de-
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staining in water. The gel was visualised with a UV transilluminator system 
(Vilber Lourmat). 
2.2.4 Determination of DNA concentration 
The concentration of purified plasmids or PCR products was determined based on 
the absorbance of light at 260 nm wavelength using a NanoDrop UV/Vis 
spectrophotometer (Thermo Scientific). 
2.2.5 Purification of PCR products and linearised plasmids obtained from 
restriction enzyme digestion 
Two different approaches were used. The first approach involved purification of 
DNA samples directly from reaction solutions while the second approach required 
gel purification. In both cases, the Geneclean spin kit (MP Biomedicals) was used 
according to the manufacturer's instructions. 
2.2.6 Annealing of single-stranded synthetic oligonucleotides 
Oligonucleotides shown in Table 2-3 were annealed with their complementary 
oligonucleotides to generate short double-stranded DNA inserts encoding peptide 
minigenes for cloning into transfer plasmids (Section 2.2.7.1). Briefly, two 
complementary single-stranded oligonucleotides at concentrations of 10 pmol/|il 
were mixed in a molar ratio of 1:1. The annealing reaction was then performed in 
a thermocycler with the following reaction conditions: 
a. 9 5 ° C f o r 5 m i n 
b. 70 cycles of 1 min incubation starting at 95°C, with the incubation 
temperature decreased by l°C per cycle, until a temperature of 25°C 
was reached. 
The reaction mix was then stored at 4°C before use. 
2.2.7 Cloning of DNA inserts into plasmids 
Two different methods were used to insert DNA fragments into plasmids: ligation 
with T4 DNA ligase or In-Fusion cloning (Clontech). 
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2.2.7.1 DNA ligation 
The LigaFast rapid DNA ligation system (Promega) was used to ligate restriction-
linearised plasmid with double-stranded oligonucleotides (Section 2.2.6) that 
carried the same restriction-overhangs. DNA ligation was performed in different 
molar ratio of plasmids to inserts. In general, a 10 nl ligation reaction contained 
0.01-0.02 pmol of linearised plasmid. 0.1-10 pmol of DNA inserts. Ix rapid 
ligation buffer, and 2 units of T4 DNA ligase. The reaction was incubated at room 
temperature for 15 min and was then stored on ice. The product was then used for 
transformation (Section 2.2.8). The plasmids shown in Table 2-10 were created 
with this method. 
Table 2-10| Plasmids generated using the DNA ligation strategy 
Plasmid Parental Restriction Annealed Antigen encoded 
produced plasmid enzymes ' oligonucleotides by the Insert 
1. p S C l l G B -
p S C l l G B -
miniOVA 
p S C l l G B 
Apa\ and 
Nol\ 
miniOVAfor 
2. p S C l l G B -
miniOVArev 
1. MiniGeneNotl/Notl 
Cytosolic OVA-
257 minigene 
p S C l l G B -
ESminigB 
p S C l l G B 
-ES 
Nol] 
FpSCIIES 
2. pSCGB-
ESHSVgB498-bot 
ER-targeted gB-
498 minigene 
p S C l l G B -
ESmin iPBlF2 
p S C l l G B 
-ES 
Noll 
1. p S C l l E S G B -
ESminiPBlF2for 
2. p S C l l E S G B -
ESminiPBlF2rev 
ER-targeted 
PBIF2-62 
mingene 
1 Restriction enzymes used to linearise parental plasmids 
2.2.7.2 In-Fusion cloning strategy 
In-Fusion cloning (Clontech) uses homologous recombination to insert PCR 
products into linearised plasmids. The PCR products used as inserts for In-Fusion 
cloning were amplified with primers containing 15 bp-long extensions at their 5" 
ends homologous to the sequences flanking the insertion sites of the plasmids of 
choice. This allowed homologous recombination catalysed by the In-Fusion 
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enzyme to occur between the ends of the digested plasmids and the ends of PCR 
products. In general, each 10 In-Fusion reaction contained Ix In-Fusion 
Reaction buffer. 1 (il In-Fusion enzyme, a PCR insert, a linearised plasmid (in a 
2;1 molar ratio of insert : plasmid) and sterile water. The cloning reaction was 
performed by incubating the reaction at 37°C for 15 min, followed by 50°C for 15 
min in a PCR machine. The cloning reaction mix was diluted with 40 nl TE buffer 
and was used for transformation (Section 2.2.8). 
The plasmids listed in Table 2-11 were generated with this approach. The 
generation of plasmids pSSmCB-WR-eGFP-SKS-A4 and pSSmCB-MVA-eGFP-
SKS-A4 are described separately. 
Table 2-111 Plasmids generated using the In-Fusion Cloning strategy 
Plasmid Parental 
produced plasmid 
Restriction f e n e r a t i o n of the insert fragment 
information DNA template primers 
p S C l l G B - pSCl l Apa\ and 
FullPBlF2 GB Nol\ 
Genomic DNA 
from virus WR-
Full-PB1F2 
1. p S C l l G B -
fullPBlF2for 
2. pSCl lGB-
fullPBlF2rev 
Full-length 
PB1F2 
p S C l l G B - pSCl l 
FullOVA GB 
pSSGB-
insp7.5 
OVA 
p7.5GB^ 
ins 
Apa\ and 
Nol\ 
Spe\ 
Genomic DNA 
from virus MVA-
dellll-OVA 
Plasmid 
p S C l l G B -
FullOVA 
1. pSCl l Full 
OVAfor 
2. pSC]l_Full 
OVArev 
1. infus for pSC 
II 
2. infus_rev_pSC 
11 
Full-length OVA 
Full-length OVA 
pSSGB-
insp7.5 
miniOVA 
p7.5GB_ 
ins 
Spe\ 
Plasmid 
p S C l l G B -
miniOVA 
1. infus_for_pSC 
11 
2. infus rev pSC 
11 
Cytosolic OVA-
257 minigene 
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Table 2-11 (Continued)] P lasmids generated us ing the In-Fusion Cloning strategy 
Plasniid 
produced 
Parental Restrict ion Generat ion of the insert fragment 
plasmid e n z y m e s ' p ^ A template primers information 
pSSmCB-
WR-A3 
pSSmCB-
WR-eGFP-
STS-A3 
pSSmCB 
pSSniCB 
-WR-A3 
1. infusion_A3L_ 
Genomic DNA for 
from VACV WR 2. infusion A3L 
328 rev 
326bp upstream 
to the first 328bp 
o f t h e A 3 L g e n e 
pUC57-GIP 
1. infus_for_GFP 
-STS 
2. infus rev GFP 
-STS 
DNA fragment 
encoding eGFP-
STS was inserted 
into the 5' end of 
the A3L gene 
1 Restriction enzymes used to linearise parental plasmids 
2 A linearised DNA fragment of plasmid pSSmCB-WR-A3 was created by PCR with primers 
before_A3L start and after A3L start. 
Plasmid pSSmCB-WR-eGFP-SKS-A4 
A DNA sequence spanning from -323 bp to -1 bp upstream of the start of the WR 
A4L gene was amphfied from the WR genome using primers A4Lup_fwd and 
A4Lup_rev (Fragment 1). A second DNA fragment corresponding to the sequence 
o f + 3 bp to +341 bp of the WR A4L gene was amplified with primers A4L_fwd 
and A4L_rev from the WR genome (fragment 2). A third DNA fragment, which 
encoded the eGFP-SKS recombinant antigen, was generated by PCR using 
pritners A4Lup_eGFP fwd and eOFP-SKS rev. with plasmid pUC57-GIP as the 
DNA template (fragment 3). An overlap extension PCR was then performed with 
fragments 1, 2, and 3 as templates, together with primers A4Lup_fwd and 
A4L_rev. This created a PCR product containing the upstream region of the A4L 
gene, following by the DNA fragment encoding the eGFP-SKS antigen which was 
inserted directly after the start codon of A4L gene, and the DNA sequence 
spanning from +3 bp to +341 bp of the WR A4L gene. This fragment was cloned 
into the ^coRI-digested pSSmCB using In-Fusion cloning strategy to create the 
plasmid pSSmCB-WR-eGFP-SKS-A4. 
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Plasmid pSSmCB-MVA-eGFP-SKS-A4 
Plasmid pSSmCB-MVA-eGFP-SKS-A4 was created using the same strategy as 
the plasmid pSSmCB-WR-eGFP-SKS-A4. Here the upstream fragment and the 
A4L fragment were amplified from MVA genomic DNA. The primer sets used 
were identical to those used for generation of pSSniCB-WR-eGFP-SKS-A4. 
2.2.8 Transformation 
For each transformation. 5 |il DNA ligation product or diluted In-Fusion reaction 
product was mixed with 50-100 of competent E.coli cells and incubated on ice 
for 30 min. followed by heat shock at 42°C for 30 sec and then incubated on ice 
for 2 min. The transformed cells were incubated at 37°C for I h in 900 ni SOC 
medium with shaking. 100 |.il of the transfomiants was then plated on LB-agar 
plates with either 100 ng/ml ampicillin (Sigma-Aldrich) or 50 ng/ml kanamycin 
(Sigma-Aldrich). depending on the antibiotic resistance genes in the plasmids. 
The plates were then incubated at 37°C overnight. Plasmids from colonies were 
then purified (Section 2.2.9). 
2.2.9 Plasmid purification 
To purify plasmids from transformed bacterial cells, the AxyPrep plasmid 
miniprep kit (Axygen) was used. Colonies on LB-agar plates with transformed 
bacterial cells were picked and allowed to grow in LB media containing the 
appropriate antibiotic at 37°C overnight (100 ng/ml ampicillin or 50 |ig/ml 
kanamycin). One day later, plasmids from the bacterial cells were isolated 
according to the manufacturer's instructions. 
2.2.10 Colony cracking for plasmid screening 
Colony cracking strategy was used occasionally as a method to screen a large 
number of bacterial colonies transformed with newly generated plasmids. Briefly, 
bacterial colonies grown on LB-agar plates were picked. Some of the material was 
transferred to a new LB-agar plate supplemented with the appropriate antibiotics 
while the remaining bacterial cells were transferred to new microcentrifuge tubes. 
Each sample was resuspended in 40 |il of 10 mM EDTA (pH 8). 50 |il of cracking 
buffer containing 10 mg sucrose, 0.5% sodium N-lauroylsarcosinate and 200 mM 
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sodium hydroxide was mixed with the resuspended bacteria. The solution was 
incubated at room temperature for 5 min. 10 nl marker solution containing 8 mM 
EDTA (pH 8), 0.48 mM potassium chloride, and 0.03% bromophenol blue was 
added. The solution was then incubated on ice for 5 min. followed by 
centrifugation at 14.000g for 3 min. The supernatant was then used as the sample 
for agarose gel electrophoresis (Section 2.2.3). Supercoiled DNA ladder was used 
as the molecular size standard. 
2.2.11 DNA sequencing 
DNA sequencing was used to check the sequence of the DNA inserts in plasmids 
or recombinant viruses. To sequence an insert from a recombinant virus, viral 
DNA was first extracted from a virus seed stock (Section 2.2.16.1) and the insert 
region was amplified by PCR with Taq DNA polymerase to produce a DNA 
template for sequencing. 
Each DNA sequencing reaction mix contained 1 |.il of BigDye terminator (Life 
Technologies). 3.2 pmol primer. 3.5 |il of 5x sequencing buffer and a DNA 
template (10-40 ng for PCR products or 150-300 ng for purfied plasmids) in a 
final volume of 20 in sterile water. The extension reaction was then performed 
in a PCR machine with the following reaction conditions: 
a. 94°C for 5 min (Initial denaturation) 
b. 30 cycles of: 
- 96°C for 10 sec (Denaturation) 
- 50°C for 5 sec (Annealing temperature) 
- 60°C for 4 min (Extension) 
c. Ho lda t4°C 
Sequencing reaction products were purified according to the instructions provided 
by the Biomolecular Resource Facility (.lohn Curtin School of Medical Research, 
the Australian National University). In brief, for each 20 i^l sequencing reaction, 
the DNA product was precipitated by mixing with 80 nl of solution containing 75 
mM sodium acetate (pH4.6), 3.125 mM EDTA (pH 8), 75% ethanol. The solution 
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was incubated at room temperature for 15 min. followed by centrifugation at 
14.000 g for 20 min. The supernatant were removed and the 250 nl of 70% 
ethanol was added. The solution was centrifuged at 14,000 g for 5 min. The 
product was dried by air and sent to Biomolecular Resource Facility (John Curtin 
School of Medical Research, the Australian National University) for DNA 
sequencing. VectorNTl software (Life Technologies) was used to analysed the 
obtained results. 
2.2.12 Maintenance and preparation of mammalian cell lines 
To prepare mammalian cell lines from a culturing flask, media were removed, 
followed by washing with PBS. The cells were then treated with 0.05% trypsin 
(Life Technologies) in PBS at 37°C until cells detached. The cells were then 
diluted with DIO media accordingly. Cells were transferred into new culturing 
flasks (Nunc) or plated into wells in 6-well or 96-well tlat-bottom tissue-culture 
plates (Coming). The flasks and plates were incubated at 37°C with 5% COi. The 
flasks and plates were used when the cells had grown into a confluent monolayer. 
In some experiments, a single cell suspension was prepared. Viable cells were 
counted after staining with trypan blue solution using a haemocytometer or a 
Countess automated cell counter (Life Technologies). 
2.2.13 Generation of recombinant viruses 
Homologous DNA recombination between the transfer plasmid that carried the 
gene of interest and the viral genome within VACV-infected cells was used to 
generate VACV recombinants. After a DNA sequence of interest was cloned into 
a transfer plasmid (Section 2.2.7), the plasmid was transfected into VACV-
infected cells to generate VACV recombinants. Briefly, confluent 293A or BHK-
21 cell monolayers in 6-well plates were infected with WR or MVA respectively 
at a muhiplicity of infection (m.o.i.) of 0.05 in D2 media. The cells were 
incubated at 37°C with 5% CO2 for 1 h. During this incubation, a transfection mix 
was prepared by mixing 5 ng/|il of plasmid in DO with 1% (v/v) Lipofectamine 
2000 (Life Technologies) in DO in equal volume by gently mixing The 
transfection mix was incubated at room temperature for 30 min. After 1 h of 
infection, the infectious inoculum on each cell monolayer was aspirated and 
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replaced with 600 nl of DO. Transfection mix in a volume of 400 was then 
added to each well drop-wise. The plate was incubated for 2 h at 37°C in 5% CO2 
for the transfection mix to be taken up by the VACV-infected cells. The 
transfection mix was then aspirated and 2 ml D2 was added. The cells were 
incubated for two days at 37°C in 5% CO.. During the infection/transfection 
process, plasmids carrying sequences homologous to the insertion sites of choice 
in the viral genome were expected to incorporate into the insertion sites by 
homologous recombination. After two days of incubation, the infected/transfected 
cells were harvested. The cells were frozen at -80°C and thawed in a 37°C water 
bath three times to lyse the infected cells and release the viruses. The cell lysate 
was then sonicated for 20 sec three times. The cell lysate was expected to contain 
both wildtype and recombinant viruses. The samples were ready to be used for 
plaque puritication (Section 2.2.14). When not used, the samples were stored at 
-80°C. 
2.2.14 Isolation of recombinant viruses via transient dominant selection 
After the generation of VACV recombinants (Section 2.2.13), they needed to be 
isolated from wildtype viruses via serial steps of plaque purification. BSC-I and 
BHK-21 cells were used for plaque purification of recombinant viruses from 
VACV W R and MVA backgrounds, respectively. Transient dominant selection 
was employed here, such that intermediate recombinants were selected first, 
followed by screening of final recombinants (Falkner and Moss. 1990). Two 
related selection markers were used. The first one is the GFP/bsd fusion protein 
(Wong et al., 2011) and the other one is the mCherry/bsd fusion protein (E. 
Spierings, S.A. Smith and D.C. Tscharke, unpublished). Both markers allow 
selection of intermediate recombinant viruses with antibiotic blasticidin S. The 
expression of GFP or mCherry fluorescent protein allowed a visual screening for 
intermediate recombinant viruses with fluorescence microscopy (Olympus 
microscope CKX41. equipped with reflected fluorescence illuminator CKX-
RFA). 
Briefly, cell lysates from infection/transfection process (Section 2.2.13) were 
serially diluted in 5-fold steps with D2 and added to confluent monolayers of 
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BSC-1 (for WR) or BHK-21 (for MVA) cells in 6-well plates. After 2 h of 
incubation at 37°C with 5% CO2, the inoculum in each well was replaced with 
phenol red-free CMC plaque media containing 15 ng/ml antibiotic blasticidin S. 
Phenol red-free media were used to avoid auto-fluorescence associated with the 
pH indicator. The infected plates were incubated for two days at 37°C with 5% 
CO2. Blasticidin S kills cells that do not express the blasticidin S resistance gene 
by inhibiting protein synthesis (Izumi et al., 1991). Two days later, the plates were 
observed with fluorescence microscopy. If the GFP/bsd selection marker was 
used, green fluorescent plaques were marked with a pen on the bottom of the 
plates. Alternatively, if the mCherry/bsd selection marker was used, red 
fluorescent plaques were marked. The plaques were collected by scraping the 
plaques off from the cell monolayer with pipette tips, followed by aspirating them 
into the tips. The isolated samples were then transferred into 500 nl D2. The 
isolated plaques were subjected to three rounds of freeze/thawing, followed by 
sonication for 20 sec three times. The isolated plaques were used to infect new 
plates with BSC-1 or BHK-21 cells in 5-fold serial dilutions for one more round 
of plaque purification in the presence of blasticidin S. 
After two rounds of plaque purification with blasticidin S. the plaque purification 
was performed as above but in a non-selective CMC plaque media without 
blasticidin S. Here non-fluorescent plaques were marked and isolated. It should be 
noted that after each round of plaque purification, the isolated plaques were 
analysed by diagnostic PCRs using primers that amplified the insertion regions. 
This was to check for the presence of final recombinants and any unwanted 
wildtype or intermediate recombinant viruses. Plaque purification was repeated 
until all the isolated plaques contained final recombinants only. The PCR products 
amplified from the inserted transgenes from the final recombinant viruses were 
analysed by DNA sequencing to confirm the inserted sequence (Secfion 2.2.11). 
The plaques were then used to grow up a recombinant virus stock. 
Using this transient dominant selecfion strategy, multiple VACV recombinants 
were generated. The more detailed procedures for generating each virus are 
described below. 
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2.2.14.1 Isolation of MVA recombinants with transgenes inserted into the 
VACV TK gene 
This method was used to generate MVA recombinants with transgenes inserted 
into the VACV TK gene region. Transfer plasmids and parental viruses used to 
generate these recombinant viruses are listed in Table 2-12. All the transfer 
plasmids used here contain transgenes encoding the minigenes or full-length 
antigens of interest which were placed under the control of the early/late VACV 
p7.5 promoter. The transfer plasmids also have a lacZ gene encoding P-
galactosidase under the control of the late VACV p l l promoter. These DNA 
sequences are flanked by sequences homologous to the VACV TK gene. There is 
also a GFP/bsd-encoding sequence in these transfer plasmids, allowing transient 
dominant selection using blasticidin S to generate tlnal recombinants with 
transgenes inserted into the VACV TK gene. 
Table 2-12| V A C V recombinants with transgenes inserted into 
the V A C V TK locus that were generated in this thesis 
Recombinant virus generated Parental virus Transfer plasmid used 
MVA-delTK 
MVA-TK-SIIN 
MVA-TK-OVA 
MVA-Full-PB1F2 
MVA-ESiTiini-PBlF2 
MVA-Full-gB 
MVA-ESmini-gB 
MVA-dellll-OVA-delTK 
MVA-dellll-SIIN-delTK 
MVA 
MVA 
MVA 
MVA 
MVA 
MVA 
MVA 
MVA-dellll-OVA 
MVA-dellll-SlIN 
pSCllGB 
pSCl IGB-miniOVA 
pSCllGB-FuilOVA 
pSCllGB-FullPBlF2 
pSCl lGB-ESminiPBlF2 
pSCllGB-FuilgB 
pSCllGB-ESminigB 
pSCHGB 
pSCllGB 
During the selection process, the first two rounds of plaque purification in the 
presence of blasticidin S were performed as stated above. However, during the 
plaque purification process without the selection pressure, agarose plaque media 
was used instead of CMC plaque media. In brief, confluent BHK-21 cells in 6-
well plates were infected with viruses isolated from a previous round of 
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purification at 37°C with 5% CO2. After 2 h incubation, tiie inoculum in each well 
was replaced with 2 ml agarose plaque media. The plates were incubated for a day 
at 3TC with 5% CO2. One day later. 1 ml agarose overlay media with 0.04% X-
gal was laid on top of the agarose plaque media. The plates were incubated for 
one more day. Non-fluorescent plaques that were blue in colour, indicating the 
existence of (i-galactosidase-expressing recombinant viruses, were collected. The 
insertion sites were verified by diagnostic PCRs during the plaque purification 
process. The conditions of the PCRs were shown in Table 2-13. 
Table 2-13] The conditions of the diagnostic PCRs performed during the 
isolation of recombinant VACVs with insertions in the TK region 
Amplified viral Primer pair ' genome region 
1. VACV092fvvd 
Wild type TK region V A C V 0 9 5 r e v 
GFP/bsd selection marker in the 1. S e q G F P b s d 6 0 0 F o r 
in termediate recombinant V A C V s 2 r e v G F P b s d e n d 
Lef t arm of the insertion site in the TK locus 1. V A C V 0 9 2 f w d 
in the final recombinant V A C V s 2, l aczpSCI I rev 
Right a n n of the insertion site in the TK locus 1. SP6 
in the final recombinant V A C V s 2, T K L r e v I ' 
Size of the 
PCR product^ 
1892 bp 
568 bp 
1 0 1 5 b p 
1 0 1 9 b p 
1 Sequences of the primers are shown in Table 2-4. 
2 PCRs were perfonned with Taq DNA polymerase as described in Section 2.2.1. During the 
extension cycles, the annealing temperature was 55°C and the extension time was 2 min. 
3 For MVA-Full-gB, primer FwdHSV-gBend was used instead of the primer SP6 (a 1167 bp 
product was expected to be produced irom MVA-Full-gB). 
2.2.14.2 Isolation of MVA recombinants with transgenes inserted into the 
intergenic region between A l l R and A12L genes 
This method was used to generate MVA-Al 1/A12-SIIN and MVA-A11/A12-
OVA from wildtype MVA using transfer plasmids P7.5GB-insp7.5miniOVA and 
P7.5GB-insp7.50VA respectively. The two transfer plasmids used contain DNA 
fragments encoding either OVA-257 minigene or full-length OVA under the 
control of VACV p7.5 promoter, which are flanked by sequences homologous to 
the VACV A1IR and AI2L regions. There is a GFP/bsd-encoding sequence in the 
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transfer plasmids, allowing transient dominant selection of the final recombinants 
with blasticidin S. The plaque purification process was performed as stated in 
Section 2.2.14. Diagnostic PCRs were performed to verify the insertion during the 
plaque purification process (Table 2-14). 
Table 2-14 | The condi t ions o f the diagnostic PCRs performed during the isolation 
o f r ecombinant V A C V s with insertions in the A 1 1 R / A 1 2 L intergenic region egu 
A m p l i f i e d v ira l 
g e n o m e reg ion 
P r i m e r pa ir S ize o f the P G R p r o d u c t ' 
A1 1R/A12L intergenic region 
GFP/bsd selection marker in 
the in termedia te recombinant 
V A C V s 
Left arm of the inserts in the 
A1 1 R / A 1 2 L region in the final 
r ecombinan t V A C V s 
1. W R O O f w d 
2, W R I 3 1 r e v 
Wildtype virus: 898 bp 
M V A - A n / A ] 2 - S I I N : 1313 bp 
M V A - A l l / A 1 2 - O V A : 2 5 6 1 bp 
1. SeqGFPbsd600For 
2. revGFPbsdend 
1. WR130fvvd 
2. S e q O b F l l 
Right a n n o f the inserts in the 
1. o r u 
A ] I R / A 1 2 L region in the final , 
2. W R I 3 l r e v 
recombinant V A C V s 
568 bp 
718 bp 
499 
i PCRs were perfonned with Taq DNA polymerase as described in Section 2.2.1. During the 
extension cycles, the annealing temperatures was 51°C and the extension time was 1 min. 
2 . 2 . 1 4 . 3 I s o l a t i o n o f W R - e G F P - S T S - A 3 
WR-eGFP-STS-A3 was generated from wildtype WR with the transfer plasmid 
pSSmCB-WR-EGFP-STS-A3. This plasmid allowed the insertion of DNA 
sequence encoding the eOFP-STS recombinant antigen directly after the start 
codon of A3L gene. The selection marker on this plasmid is the mCherry/bsd 
fusion protein. 
The procedures of plaque purification stated in Section 2.2.14 were followed with 
some modifications. During the first two rounds of plaque purification with 
blasticidin S selection, plaques that fluoresced both red and green were selected. 
This ensured that the selected intermediate viruses contained DNA sequences 
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encoding the eGFP-STS antigen and the mCherry/bsd marker within their viral 
genomes. During the purification process without blasticidin S, only green 
fluorescent plaques were selected for further testing and purification. Diagnostic 
PCRs were performed to verify the insertion and the conditions were illustrated in 
Table 2-15. 
Table 2-15| The conditions of the diagnostic PCRs 
performed during the isolation of WR-eGFP-STS-A3 
Ampliried viral 
genome region 
Primer pair 
PCR 
conditions ' 
Size of the PCR 
product 
A3L locus 
1. before_A3L_seq 
2. rev_A3_454seq 
54°C 
2 min 
Wildtype virus: 902 bp 
WR-eGFP-STS-A3: 
1706 bp 
Left arm of the insert from 
the final recombinant 
1. for eGFP_524seq 
2. rev_A3_454seq 
STC 
2min 
752 bp 
Right arm of the insert 
from the final recombinant 
1. before_A3L_seq 
2. rev eGFP seq 
54°C 
2 min 
502 bp 
1 PCRs were performed Taq DNA polymerase as described in Section 2.2.1. The annealing 
temperatures for the primers to the DNA templates and the extension times were shown. 
2.2.14.4 Isolation of WR-eGFP-SKS-A4 and MVA-eGFP-SKS-A4 
Recombinant viruses WR-eGFP-SKS-A4 and MVA-eGFP-SKS-A4 were 
generated from wildtype WR or MVA with transfer plasmids pSSmCB-WR-
eGFP-SKS-A4 and pSSmCB-MVA-eGFP-SKS-A4 respectively. These plasmids 
allowed the insertion of DNA sequence encoding the eGFP-SKS antigen at the 5' 
end of the A4L gene of WR or MVA. The selection marker encoded by these two 
plasmids is the mCherry/bsd protein. As such, the procedures of plaque 
purification stated in Section 2.2.14.3 were followed. Diagnostic PCRs were 
performed to verify whether the DNA sequence encoding the eGFP-SKS antigen 
was successfully inserted into the 5' end of A4L gene. The PCR conditions were 
shown in Table 2-16. 
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Tabic 2-161 The conditions of the diagnostic PCRs performed during 
the isolation of WR-eGFP-SKS-A4 and lVlVA-eGFP-SKS-A4 
Amplified viral PCR Size of the PGR 
Primer pair 
genome region conditions' product 
A4L locus 
1. revWR123seq 54°C 
Wildtype virus: 966 bp 
2. fvvdWR124seq 2 min 
WR-eGFP-STS-A4: 
1770 bp 
Left arm o f the insert from 
the final recombinant 
1. for_eGFP_524seq 
2. revWR123seq 
54°C 
2 min 
794 bp 
Right arm o f the insert 1. SeqRevpEGFPNl 57°C 
524 bp 
from the final recombinant 2. fvvdWR124seq 2niin 
1 PCRs were pertbrmed as described in Section 2.2.1. Tlie annealing temperatures for the primers to 
the DNA teinplates and the extension times were shown. 
2 DNA fragments in slightly different sizes were produced during the generation of MVA-eGFP-
SKS-A4. The first primer set produced PCR products in size of 939 bp (wildtype MVA) or 1743 
bp (MVA-eGFP-SKS-A4). The second and the third primer sets produced DNA fragments in sizes 
of 767 and 524 bp respectively. 
2.2.15 Viral DNA preparation from virus stocks or from isolated plaques 
Viral DNA prepared from pure virus stocks was used as the template for PCR for 
amplifying viral sequences of interest (Section 2.2.1). 10 jti of virus stoci< was 
mixed with 10 ng/ml proteinase K (Sigma-Aldrich) diluted in Ix PCR ThermoPol 
buffer (New England Biolabs) in a final volume of 200 |4l. The virus solution was 
incubated at 56°C for 20 min. Proteinase K was then heat inactivated at 85°C for 
10 min. The sample was then used as a DNA template for PCR. 
Viral DNA were also prepared from the plaques isolated during the process of 
recombinant virus generation for diagnostic PCRs. Briefly, 96-well plates of 
confluent BSC-1 or BHK-21 cells were incubated with 20-40 nl viral solution 
from individual isolated plaques. 100 nl of fresh DIO was added on top. Plates 
were incubated at 37°C in 5% CO2 for two days. Media were then removed and 
the infected cell monolayers were washed with 150 |il of PBS. 100 |il of 10 ng/ml 
proteinase K solution in 1 x PCR ThermoPol buffer was added to each well. The 
plates were frozen at -80°C and then thawed at room temperature to lyse the cell 
membranes to release viruses. The plates were incubated at 56°C for 20 min and 
then 85°C for 10 min. The supernatants were used as DNA templates for PCR. 
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2.2.16 Preparation of virus stock 
2.2.16.1 Preparation of a virus seed stock 
To prepare a virus seed stock, a 25cm^ flask of confluent BHK-21 cells was 
inoculated with 5ml of D2 containing 200-300 of an isolated plaque, which had 
been confirmed to contain the final recombinant virus. After three days of 
incubation at 37°C in 5% COi. the infected cells were scraped from the flask with 
a cell lifter (Corning). Infected cells were collected by centrifugation at 2.000 
revolutions per minute (rpm) for 10 min (Beckman Coulter AllegraX-l5R). The 
supernatant was removed and the cell pellet was resuspended in 500 of 10 mM 
Tris (pH 9). The resuspended solution was subjected to three rounds of 
freeze/thawing, followed by sonication for 20 sec three times. This crude viral 
seed stock was titrated as in Section 2.2.17. 
2.2.16.2 Preparation of a crude virus stock 
To prepare a crude virus working stock, one or two 175cm^ flasks of confluent 
BHK-21 cells were each inoculated with 30 ml of D2 media containing the master 
virus stock (Section 2.2.16.3) at an m.o.i. of 0.1 and incubated at 37°C in 5% CO2 
for three days. Infected cells were harvested by scraping the flasks with cell 
lifters, followed by centrifugation at 2.000 rpm and 4°C for 10 min (AllegraX-
15R). Cell pellets were resuspended in 1-2 ml of 10 mM Tris buffer (pH 9). The 
resuspended infected cells were subjected to three rounds of freeze/thawing, 
followed by sonication for 20 sec three times. This crude viral stock was titrated 
as in Section 2.2.17. 
2.2.16.3 Preparation of a semi-purified virus working stock via sucrose 
cushion centrifugation 
To prepare a semi-purified working virus stock from a newly prepared seed stock, 
5-10 175cm^ flasks of confluent BHK-21 cells were each inoculated with 30 ml of 
D2 media containing the crude virus stock at an m.o.i. of 0.1 at 37°C in 5% CO2 
for three days. The infected cells were then harvested by scraping the flasks with 
cell lifters, followed by centrifugation at 2,000 rpm and 4°C for 10 min 
(AllegraX-15R). Cell pellets were resuspended in 5-10 ml of 10 mM Tris buffer 
(pH 9.0). The cells were homogenised in a Dounce homogeniser (Wheaton) with 
no 
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60 strokes to lyse the cell membrane to release viruses. The homogenates were 
cemrifuged at 800 rpm at 4°C for 5 min (AllegraX-15R) to remove nuclei. 
Supernatants were collected. The nuclei pellets were resuspended in 5-10 ml of 10 
mM Tris (pH 9) and were re-homogenised and centrifuged again to release more 
viruses. The supernatants were pooled. To prepare the sucrose cushion. 17 ml of 
36% sucrose in 10 mM Tris (pH 9) was first added to ultracentrifuge tubes 
(Beckman Coulter). 5 ml of the virus supernatant was layered evenly on top of 
each sucrose cushion solution, and then topped up with 10 mM Tris (pH 9). In 
general, two to four sucrose cushions were prepared for each virus stock. The 
samples were then centrifuged at 13.500 rpm for 80 min at 4°C in a Beckman 
Coulter Optima LE-80K Ultracentrifuge with a SW-32Ti rotor. Supernatants were 
aspirated and the pellets, which contained mostly purified viruses, were 
resuspended in 1-2 ml of 10 mM Tris (pH 9). The resuspended solution was used 
as a working virus stock and was titrated before use (Section 2.2.17). 
2.2.16.4 Preparation of a purified virus working stock via sucrose gradient 
centrifugation 
To prepare a purified working virus stock, sucrose gradient centrifugation was 
used. In brief, two sets of 24% to 40% continuous sucrose gradient were prepared 
in sterile ultracentrifuge tubes by layering 6 ml each of 40%, 36%. 32%. 28% and 
24% sucrose in 10 mM Tris (pH 9). The tubes were stored at 4°C overnight. One 
day later, a semi-purified virus stock was prepared by sucrose cushion purification 
(Section 2.2.16.3) and was resuspended in 10 mM Tris (pH 9). The virus solution 
was sonicated twice for 30 sec and was layered on top of a sucrose gradient. The 
sample was then centrifuged at 12,000 rpm for 50 min at 4°C in the Optima LE-
80K Ultracentrifuge. After centrifugation. the milky layer, which contained 
purified VACV, near the middle of the tubes was collected with careful pipetting 
and was transferred to a sterile 50 ml tube (BD Biosciences). The remaining 
supernatant was discarded. The pellet at the bottom of the sucrose gradient 
contained aggregated viruses. It was resuspended in 10 mM Tris (pH 9), sonicated 
twice for 30 sec, and layered on top of the remaining sucrose gradient. The 
samples were centrifuged at 12,000 rpm for 50 min at 4°C again in the Optima 
LE-80K Ultracentrifuge. After the centrifugation. the milky VACV layer was 
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collected and pooled with the purified virus collected before. The virus solution 
was transferred into two sterile ultracentrifuge tubes in equal volume. The tubes 
were topped up with 10 mM Tris (pH 9) and were then centrifuged at 13,500 rpm 
for 60 min at 4°C (Optima LE-80K Ultracentrifuge). The purified virus pellets 
were resuspended in 1 -2 ml of 10 mM Tris (pH 9). The sample was titrated before 
use (Section 2.2.17). 
2.2.17 Virus titration 
Titration of VACV was performed by plaque assay to ensure that a known amount 
of virus was used in each experiment. For viruses on the VACV WR background, 
their titers were determined with confluent BSC-1 cell monolayers in 6-well 
plates. For viruses on the strain MVA background, their titers were determined 
with confluent BHK-21 cell monolayers grown in 6-well plates. 
2.2.17.1 Titration of VACV strain W R 
Duplicate 10-fold serial dilutions of virus stock were prepared in DO media. 
Media was removed from two 6-well plates with confluent BSC-1 cell 
monolayers and 0.5 ml of the virus dilutions were added to wells and incubated 
for 90 min at 37°C with 5% CO2. During the incubation, plates were rocked every 
10-15 min. After 90 min of incubation, the virus inocula were aspirated, and the 
cells were overlaid with warm CMC plaque media. The cells were incubated at 
37°C and 5% CO2 for three days. Three days later, the media were aspirated and 
the plaques were visualized by staining with crystal violet staining solution. The 
number of plaques was counted and the titer in plaque-forming unit (PFU)/ml was 
calculated according to the virus dilution used and was averaged from the 
duplicate. 
2.2.17.2 Titration of VACV strain MVA 
Duplicate 10-fold serial dilutions of a MVA stock were prepared and used to 
inoculate confluent BHK-21 cell monolayers in 6-well plates, as in the titration of 
WR described in Section 2.2.17.1. After 90 min of inoculation with virus 
dilutions, inocula were removed and replaced with warm D2 media. The plates 
were incubated at 37°C with 5% CO2 for one day. Cell monolayers were then 
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fixed with a 1:1 solution of methanol:acetone for 5 min. The fixing solution was 
removed and the monolayers were washed with 2 mi PBS-2%FBS twice, and then 
incubated for 1 h at room temperature with 1 ml rabbit polyclonal anti-MVA 
antiserum (diluted in 1 in 1.000 in PBS-2%FBS). The cell monolayers were then 
washed with 2 ml PBS-2%FBS twice and were incubated with 1 ml anti-rabbit-
IgG-peroxidase (diluted in 1 in 500 in PBS-2%FBS). Cell monolayers were washed 
twice with PBS-2%FBS and incubated with 0.8 ml DAB substrate solution. Areas 
of blue-black colour were formed on cell monolayers, indicating foci of cells 
infected w ith MVA. The number of stained foci was counted. The titer in PFU/ml 
was calculated according to the virus dilution used and was averaged from the 
duplicate. 
2.2.17.3 V A C V titration from isolated organs 
Organs were taken from mice immunised with WR or WR recombinants (Section 
2.2.18) at times indicated. The organs were stored at -80°C before use. Samples 
were thawed, and homogenised with 1ml tissue grinders (Wheaton). The 
homogenates were resuspended in a final volume of 1 ml in DO media. The 
samples were frozen and thawed three times, followed by sonication for 20 sec 
three times. VACV titers were determined by plaque assays on BSC-1 cells as 
described in Section 2.2.17.1. 
2.2.18 Immunisat ion of mice 
2.2.18.1 i.d. immunisation 
Mice were anesthetised by isoflurane inhalation (4%, in oxygen with a flow rate 
of 800 ml/min) using an anaesthetic machine (Advanced Anaesthesia Specialists) 
(Lin et al., 2012). The anesthetised mice were injected with 10 nl virus inocula 
diluted in PBS into ear pinnae using 100 |il Gastight glass syringes (Hamiton) and 
27-gauge needles (BD Biosciences). For in vivo cross presentation experiments. 
2x10^ cells resuspended in 20 nl PBS were injected into ear pinnae of the 
anesthetised mice. In some experiments, lesions formed on the infected ear pinnae 
were measured with a vernier calliper (Trojan). 
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2.2.18.2 i.p. immunisation 
Mice were injected with 200 |il of virus or cell inocula resuspended in PBS using 
1 ml tuberculin syringes (BD Biosciences) and 27-gauge needles into the 
peritoneal cavity of the mice. 
2.2.19 Preparation of splenocytes from mice 
Naive or immunised mice were culled and spleens were collected. The spleens 
were homogenised using plungers from 1 ml tuberculin syringes and the 
splenocytes were filtered through 70 nm cell strainers (BD Biosciences) by 
washing with PBS. Single cell suspensions of splenocytes from each mouse were 
centrifuged at 1,500 rpm at 4°C for 5 min (AllegraX-15R) and were resuspended 
in 5 ml red cell lysis buffer for 3 min. 30 ml PBS was added to each sample, 
mixed well, and centrifuged at 1.500 rpm at 4°C for 5 min (AllegraX-l5R). The 
splenocytes were resuspended in 5 ml D10. Viable splenocytes were counted after 
staining with trypan blue solution using a haemocytometer or a Countess 
automated cell counter (Life Technologies). 
2.2.20 Isolation of purified F5 TCR transgenic CDS"^  T cells 
The CD8a^ T cell isolation kit II (Miltenyi Biotec) was used to isolate CD8^ T 
cells from F5 TCR transgenic mice by selective depletion of other cell types. The 
manufacturer's instructions were followed. Briefly, splenocytes from naive F5 
mice were resuspended in MACS buffer. The cells were centrifuged at 1,500 rpm 
at 4°C for 10 min (AllegraX-15R). The supernatant was aspirated and the cells 
were labelled with the biotin-antibody cocktail provided in a ratio of 10 n l / i o ' 
cells. The solution was mixed and incubated at 4°C for 10 min. The anti-biotin 
microbead solution provided was then added to the sample in a ratio of 20 )il/10' 
cells. The solution was incubated at 4°C for 15 min. The labelled cells were then 
washed with MACS buffer and were resuspended in 1 ml fresh MACS buffer. The 
labelled cells were passed over a magnetised LS column (Miltenyi Biotec). The 
column was washed three times with MACS buffer. All the flow-through 
solutions containing untouched CD8^ T cells were collected and pooled together. 
The pooled solution was then centrifuged at 1,500 rpm at 4°C for 5 min 
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(AllegraX-15R) and the cell pellet was resuspended in PBS. The cells collected 
were untouched purified CD8^ T cells (at around 95% purity). 
2.2.21 Generation of BM DCs 
BMDCs from C57B1/6 mice were prepared as described by Lutz et al. (1999) with 
some modifications. In brief mice were culled and femurs and tibiae were 
collected. Both ends of the bones were cut and the bone marrow was flushed out 
with DO media using 23 gauge needles (BD Biosciences) attached to 10 ml 
syringes (BD Biosciences). The bone marrow was centrifuged at 1.500 rpm at 4°C 
for 5 min (AllegraX-15R) and resuspended in DIO media. Cell aggregates were 
broken up by pipetting. Cells were counted and resuspended at IxlO** cells/ml in 
the DC media. 5x 10" cells were placed into individual wells of 6-well plates. The 
cells were incubated at 37°C with 5% CO: for 9 days. On days 3. 6. and 8. 2.5 ml 
of the media from each well were collected and centrifuged at 1.500 rpm at 4°C 
for 5 min (AllegraX-l5R). Cell pellets were resuspended in fresh DC media (2.5 
ml for each well), and added back to the 6-well plates. At day 9. non-adherent and 
easily-dislodged cells were resuspended in the 6 well-plates by gentle pipetting. 
The cells were collected and resuspended in DIO media. The cells were counted 
and stored on ice before use. 
2.2.22 Adoptive transfer of immune cells into mice 
Cells for adoptive transfer were resuspended in 200 jil PBS at concentrations as 
stated below. Mice were placed under an infrared lamp for 2 min and were then 
put inside in a restraining device with tails out. 200 ^l of cells were injected into 
lateral tail veins with 0.5 ml insulin syringes (with 27-gauge needles, Terumo). 
For CDS"^ T cell transfer, 5x10^ or 1 xlO" cells were injected into each mouse. For 
immunisation with peptide-pulsed BMDCs, mice were injected with 2x l0" 
BMDCs. For in vivo cytotoxicity assays, 1 x 1 o" peptide-pulsed splenocytes were 
adoptively transferred into mice. 
2.2.23 CpG and cytc treatments 
Mice were placed under an infrared lamp for 2 min and were then put inside in a 
restraining device with tails out. Mice were then injected i.v. via tail veins with 20 
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nmol synthetic phosphorothioated CpG1668 oligonucleotide diluted in 200 |il 
PBS one day before immunisation with 0.5 ml insulin syringes (27-gauge 
needles). For cytc treatment, mice were injected i.v. with 5 mg horse cytc in 200 
PBS for five consecutive days starting one day before immunization. Control 
mice were injected with 200 PBS. 
2.2.24 VACV infection of cells in vitro 
2.2.24.1 Generation of antigen donor cells for in vivo cross priming assays 
293A cells in single cell suspension were incubated with viruses indicated at an 
m.o.i. of 5 for 1 h at 37°C in a shaking incubator (shaking at 200 rpm) in a volume 
of 0.5-2 ml of DO. depending on the number of cells used. Infected cells were then 
transferred to wann 40 ml D2 media in 50 ml tubes and the infection were 
continued for another 5 h at 37°C with gentle rotation (4 rpm. MACSmix tube 
rotator (Miltenyi Biotec) in a 37°C incubator). 
2.2.24.2 Infection of cells for in vitro antigen presentation 
293-D^ 293-K\ DC2.4 or BMDCs (generated as described in Section 2.2.21) in 
single cell suspension were mixed with viruses indicated at an m.o.i. of 5 in a 
volume of 0.5 ml in DO media. The cells were then incubated at 37°C with 
shaking at 200 rpm in a shaking incubator for 1 h. Infected cells were then 
transferred to 10 ml warm D2 media in 15 ml tubes and the incubation was 
continued for another 5 h at 37°C. During the infection period, the cells were 
either rotated at 4 rpm using the MACSmix tube rotator or were gently mixed 
every 20 min. Aliquots of cells were taken at times indicated and were stored on 
ice before further use. 
2.2.24.3 In vitro growth analysis of VACV recombinants 
Confluent BSC-1 cell monolayers in 6-well plates were infected with viruses 
indicated at an m.o.i. of 0.01 in 1ml D2 media. Plates were incubated for 1 h at 
37°C with 5% CO2. Infectious inocula were aspirated, cells were washed with 1 
ml D2, and 2 ml D2 were added. The plates were incubated at 37°C with 5% CO2 
for the time indicated. To harvest infectious viruses from the infected cells, cell 
monolayers were scraped, followed by centrifugation at 2,000 rpm for 10 min. 
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Supernatant was removed and cells were resuspended in 1 ml D2 media. Cells 
were then subjected to three rounds of freeze/thawing cycle to release viruses. The 
amount of infectious viruses was determined by plaque assay (Section 2.2.17). 
2.2.25 TMP/UV and AMT/LIV treatment of VACV or VACV-infected cells 
Two psoralen derivatives, namely TMP and AMT. were tested for their ability to 
inhibit VACV replication and viral gene expression. Solutions of VACV or 
VACV-infected cells containing 10 (ig/ml TMP or 100 ng/ml AMT in PBS were 
prepared. The samples were transferred to small plastic weighing trays that had 
been wrapped with parafilm (Pechiney plastic packaging). The whole setup was 
put on top of ice. The samples were irradiated 10 mm below a 365 nm UV-A 
lamp (Vilber Lourmat) for up to 60 min. The samples were mixed by pipetting 
every 8-10 min. Aliquots of samples were taken at times indicated. 
To block VACV replication but still allow early virus gene expression. VACV 
inocula containing 1 ng/ml TMP in PBS were prepared. The samples were 
irradiated 10 mm below a 365 nm UV-A lamp for 3 min. The samples were mixed 
every 30 sec during the irradiation. 
2.2.26 Heat inactivation of VACV or VACV-infected cells 
Heat inactivation was used to inhibit virus replication and viral gene expression of 
VACV inocula or of residual viruses on VACV-infected cells. In brief, VACV or 
VACV-infected cells were resuspended in PBS (maximum volume: 1 ml). The 
solutions were then heat-treated in a 60°C heat block for 60 min. 
2.2.27 In vitro activation of F5 TCR transgenic CDS"^  T cells 
Half of the splenocytes prepared from naive F5 TCR transgenic mice were taken, 
centrifuged at 1.500 rpm at 4°C for 5 min (AllegraX-l 5R). and resuspended in 2.5 
ml of 0.1 nM synthetic NT60NP-366 peptide diluted in DO media. The cells were 
incubated at 37°C for 1 h in a shaking incubator (shaking at 200 rpm) for peptide-
pulsing. The peptide-pulsed cells were washed twice with DIO media and mixed 
with the unpulsed cells. The mixed cells were counted, centrifuged at 1.500 rpm at 
4°C for 5 min (AllegraX-15R), and resuspended in 2.5x10'' cells/ml in T cell 
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media supplemented with 1.25 ng/ml recombinant mouse lL-2 (R&D System). 
Cells were incubated in 75 cm^ culture flasks at 37°C with 5% CO2. One day 
later, cells were pelleted by centrifugation at 1.500 rpm for 5 min at 4°C 
(AllegraX-15R). The cells were resuspended at 2.5x10^ cells/ml in T cell media 
supplemented with 2.5 ng/ml recombinant mouse lL-2. The cells were incubated 
at 37°C with 5% CO2 overnight, and an equal volume of fresh T cell media with 
2.5 ng/ml recombinant mouse IL-2 was added to the cells. The cells were further 
incubated at 37°C with 5% CO2 for another day before use. 
2.2.28 Detection of OVA-257/H-2K'' presentation on APCs 
0.2-1x10'' cells were resuspended in 20 |.il of the culture supernatant of hybridoma 
2.4G2 (to block Fc receptors) for 20 min at 4°C. Cells were washed with PBS-2% 
FBS. and then resuspended in 50 |il 25D1.16-APC antibody (1 in 150 dilution) in 
PBS-2%FBS. The cells were incubated at 4°C for 30 min. The antibody-labelled 
cells were washed once with PBS-2%FBS, followed by a wash with PBS. Cells 
were then fixed with 50 |il 1% paraformaldehyde in PBS at room temperature for 
20 min. Cells were washed twice with PBS-2%FBS. The cells were resuspended 
in 50-100 nl PBS-2%FBS and were ready for tlow cytometric analysis. 
2.2.29 Re-stimulation of activated CDS"^  T cells 
2.2.29.1 Re-stimulation with synthetic peptides 
Splenocytes from immunised mice (Sections 2.2.18 and 2.2.19) or in vitro-
activated CD8^ T cells (Section 2.2.20) were isolated and were adjusted to I x 10^ 
cell/ml in DIO media. 100 nl of the cells were transferred to wells of 96-well 
plates (U-bottom. BD Biosciences). Unless otherwise stated. 100 |xl of 0.2 (iM 
synthetic peptides in DO media were added to individual wells. Therefore, cells 
were generally co-cultured with 0.1 nM synthetic peptides. After 1 h of incubation 
at 37°C with 5% CO2, 20 nl of 50 |ig/ml brefeldin A diluted in DIO media was 
added to each well. The cells were further incubated for another 3 h. 
In some cases, synthetic peptides were titrated against splenocytes isolated from 
immunised mice. Here, 10-fold serial dilutions of peptides were prepared with DO 
media. The peptide dilutions were then added to the splenocytes as stated above. 
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2.2.29.2 Re-stimulation with infected APCs 
Instead of synthetic peptides used in Section 2.2.29,1, infected cells (as prepared 
in Section 2.2.24.2) were used as stimulators here. In brief, 1x10^ splenocytes or 
activated CDS" T cells in 100 |il DIO media were co-cultured with infected cells 
resuspended in 100 nl D2 media in wells of 96-well plates (U-bottom). A 
stimulator: effector ratio of 1:5 was normally used, unless otherwise stated. The 
cells were incubated at 37°C with 5% CO2 for 1 h. 20 |il of 50 ng/ml brefeldin A 
in DIO was then added to the cells. The cells were incubated for another 3 h. 
2.2.30 Intracel lular cytokine staining ( ICS) 
In most experiments, only intracellular IFN-y staining was performed. Brielly. 
after re-stimulation o f splenocytes or activated CDS" T cells as staled in Section 
2.2.29. the cells were centrifuged at 2.100 rpm at 4°C for 3 min (AllegraX-15R). 
Media were removed and cells were resuspended in 40 anti-CDSa-PE (I in 150 
dilution in PBS-2%FBS). Cells were incubated at 4°C in the dark for 30 min. 
Cells were washed with PBS-2%FBS, followed by an additional wash with PBS. 
The cells were fixed in 40 |il 1% paraformaldehyde in PBS at room temperature 
for 20 min. Cells were washed with PBS-2%FBS three times and then stained 
with 40 |il anti-IFN-y-APC antibody (1 in 200 dilution) in 0.25% saponin diluted 
in PBS-2%FBS at 4°C overnight in the dark. The next day, cells were washed 
three times with PBS-2%FBS and were resuspended in 50 nl of PBS-2%FBS. The 
cells were ready for analysis by flow cytometry. 
There were two variations to the standard ICS described above. The first variation 
involved co-labelling o f IL-2, TNF-a and IFN-y simultaneously. Here, anti-IL-2-
PE-Cy5 and anti-TNF-a-PE-Cy7 antibodies were used in addition to anti-IFN-y-
APC during the intracellular cytokine staining. The second variation involved 
tracking responses induced by the transferred CD45.2" CDS" F5 cells. Here, anti-
CD45.2-FITC antibody was added in addition to anti-CDS-PE during the cell 
surface antibody staining step. 
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2.2.31 DimerX labelling 
DimerX staining was performed according to the manufacturer's instructions. In 
brief, 2 |ig of H-2Kb:lg fusion protein was incubated overnight at 37°C with a 160 
molar excess of a synthetic peptide in PBS. The peptide-loaded dimers were then 
incubated with 0.8 ng of the secondary anti-mouse-lgGl-PE antibody at room 
temperature for 1 h in the dark. This allowed the binding of two peptide-loaded 
DimerXTg fusion proteins with one bivalent secondary antibody. IxlO** 
splenocytes were first incubated with 20 |al of the culture supernatant of 
hybridoma 2.4G2 for 15-20 min at 4°C to block Fc receptors on the cells. Cells 
were then washed with PBS-2% FBS and were labelled with the peptide-loaded 
dimers and anti-CD8a-APC (I in 150 dilution) in 50 PBS-2%FBS for I h on 
ice. The labelled cells were washed twice with PBS-2%FBS. Cells were 
reuspended in 50-100 PBS-2%FBS and were ready for flow cytometric 
analysis. 
2.2.32 CFSE labelling 
CFSE labelling of cells was required for in vivo CD8^ T cell proliferation (Section 
2.2.33.2) and in vivo cytotoxicity assays (Section 2.2.35). Cells were resuspended 
in 2 ml DO media containing CFSE at the concentrations stated below. The cells 
were incubated in a 37°C water bath for 10 min with gentle shaking every 2-3 
min. After the incubation, cold DIO was added to stop the labelling reaction. Cells 
were then washed with DIO media three times. After the last wash, cells were 
resuspended in PBS at the appropriate concentration. 
For an in vivo proliferation assay (Section 2.2.33.2), purified TCR transgenic 
CDS^ T cells were labelled with 5 |iM CFSE. For an in vivo cytotoxicity assay 
(Section 2.2.35), peptide-pulsed splenocytes were labelled with 0.25 [jM CFSE 
while unpulsed splenocytes were labelled with 2 |iM CFSE. 
2.2.33 In vivo early activation and proliferation assay 
2.2.33.1 Early activation assay based on CD69 expression 
B6.SJL mice were adoptively transferred with |xl0' F5 CD8^ T cells via i.v. 
injection. One day later, mice were immunised with recombinant viruses as 
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indicated. One day post immunisation, spienocytes were isolated. 1-2x10'' 
splenocytes were stained with 50 ni PBS-2%FBS containing anti-CD8a-PE, anti-
CD45.2-APC and anti-CD69-PE-Cy7 antibodies (each in 1: 150 dilution) for 30 
min at 4°C. The cells were then washed once with PBS-2%FBS. followed by a 
wash with PBS. Cells were fixed with 50 nl 1% paraformaldehyde in PBS at room 
temperature for 20 min. Cells were washed twice with 150 nl PBS-2%FBS and 
resuspended in 80-100 |al PBS-2%FBS. The cells were ready for How cytometric 
analysis. 
2.2.33.2 In vivo CFSE-based proliferation assay with CD25 straining 
B6.SJL mice were adoptively transferred with IxlO*" F5 CDS^ T cells labelled 
with 5 nM CFSE. One day later, mice were immunised with recombinant viruses 
as indicated. Two days post immunisation, splenocytes were isolated. 1-2x10'' 
splenocytes were stained with 50 |J1 PBS-2%FBS containing anti-CD8a-APC-
Cy7, anti-CD45.2-APC and anti-CD25-PE antibodies (each in I; 150 dilution) for 
30 min at 4°C. The cells were then washed once with 150 |il PBS-2%FBS and 
were resuspended in 50 of PBS+2%FBS containing 0.04 ng/|il 7-amino 
actinomycin D (7AAD: Life Technologies). 7AAD binds to the DNA of dead 
cells and fluoresces, allowing discrimination of live and dead cells during flow 
cytometric analysis. Cells were incubated at 4°C for 30 min. Cells were then 
washed once with PBS+2%FBS. followed by a wash with PBS. Cells were fixed 
with 50 nl 1% paraformaldehyde in PBS containing 5 |ig/ml actinomycin D 
(Sigma-Aldrich) at room temperature for 20 min. Cells were washed twice with 
PBS-2%FBS and resuspended in 80-100 nl PBS-2%FBS. The cells were ready for 
f low cytometric analysis. 
2.2.34 Peptide-pulsing of BMDCs 
5x10'' BMDCs (Section 2.2.21) were collected and centrifuged at 1.500 rpm at 
4°C for 5 min (AllegraX-15R). Cells were resuspended in 2.5 ml DO with 1 |aM 
synthetic HBcAg-128 peptide, together with either 1 nM PR8NP-366 or A47-171 
peptides. Cells were incubated at 37°C for 60 min in a shaking incubator (shaking 
at 200 rpm). After the incubation, cells were centrifuged at 1,500 rpm at 4°C for 5 
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min (AllegraX-15R), and resuspended in 500 |il PBS. The peptide-pulsed cells 
were used for i.v. injection into mice (Section 2.2.22). 
2.2.35 CFSE-based in vivo c> totoxicitj 
A single cell suspension of splenocytes was divided into two populations. One 
population was pulsed with 0.1 nM synthetic gB-498 peptide in the presence of 
Vybrant DiD cell-labelling dye (in 1 in 200 dilution; Life Technologies) in DO 
media at 37°C for 1 h in a shaking incubator (200 rpm shaking). The second 
population was left unpulsed but was also stained with 1 in 200 diluted Vybrant 
DiD dye in DO media. The two populations were then washed twice with DIO, 
followed by a wash with DO. The peptide-pulsed and unpulsed populations were 
labelled with 0.25 |iM and 2 |iM CFSE in DO as stated in Section 2.2.24. The cell 
numbers were counted and the two populations were mixed together in a 1:1 ratio. 
Cells were resuspended in 5xlO' cells/ml in PBS. Ix lO ' mixed cells were i.v. 
injected into naive or immunised mice via the tail vein (Section 2.2.19). Four 
hours after cell transfer, the spleens from the mice were collected and single 
splenocyte suspensions were prepared. The samples were subjected to flow 
cytometric analysis. The transferred cell population, which is DiD"^, was identified 
from the collected events during flow cytometric analysis. Within this population, 
the percentages of CFSE''' (unpulsed) and CFSE'" (gB-498-pulsed) populations 
were measured. The equation below was used to calculate the specific lysis of the 
gB-498-pulsed cells: 
% specific lysis = < 1 -
/percentage of CFSe'''\ 
Ipercentage of CFSe'o/^ .^^ ,^ 
/percentage of CFSe'''\ 
^percentage of ^^^^^ 
X 100 
2.2.36 Data acquisition with flow cytometry 
Flow cytometry discriminates individual cells into separated populations based on 
fluorescence intensities. Here, cells were firstly labelled with fluorescent dyes or 
with fluorescent-labelled antibodies that bind to proteins of interest as described 
above. Flow cytometry was then used to determine the percentages of cells 
expressing proteins of interest and the level of protein expression in individual 
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cells. Cells labelled with fluorescent dyes were detected similarly. In this study, a 
LSR-II Flow Cytometer (BD Biosciences) was used for data acquisition. 
Adequate numbers of events were collected. For instance. 100.000 CD8^ events 
were collected from each ICS samples in general. 
2.2.37 Data analysis 
2.2.37.1 Measurement of plaque sizes 
Images of plaques from cell monolayers infected with VACV were acquired by 
the Olympus DP20 digital microscope camera mounted on the O h m p u s 
microscope CKX41. The diameters of the plaques were measured from the images 
using Image.I 1.47 software (Schneider et al.. 2012). The images were then 
prepared using Photoshop CS2 or CS4 softwares (Adobe). 
2.2.37.2 Flow cytometric analysis 
Flow cytometry data (Section 2.2.36) were analysed with FlowJo 8.8.4 software 
(Tree Star). To analyse the data, appropriate gates were applied to the samples as 
stated below. 
(1) ICS (Section 2.2.30) 
Events were first gated on a side scatter and forward scatter (SSCxFSC) plot. In 
this population, the CD8^ population was gated on a SSC x CDS plot, then the 
percentage of CD8^ events that were IFN-y"^ was determined on an IFN-y x CD8 
plot. Backgrounds were determined using controls that were cultured with media 
only, without any synthetic peptides. The gating scheme is illustrated on Figure 
2-1. The final data for each sample was calculated by subtracting the background. 
The total number of CDS"^. IFN-y"^ T cells was calculated as below: 
Total number of C D 8 ^ I F N - / T cells 
= % I F N Y of CD8^ cells x % CD8^ of all lymphocytes x total splenocyte count 
There are two variations on how the events were gated. Firstly, to identify the 
CD45.2' ' adoptively transferred cells that produced IFN-y after ex vivo peptide 
stimulation from splenocytes of the B6.SJL recipients, CDS"^ events that were 
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Figure 2-11 The gating strategy for identifying CD8* IFN-y^ cells from splenocytes of 
immunised mice after ex vivo stimulation with peptides, followed by ICS. 
Representative flow cytometric plots of splenocytes, from a mouse immunised with VACV 
WR for seven days, after mock stimulation with media only (without any peptide; A) or ex 
vivo stimulation with K3-6 peptide (B), followed by ICS. Cells were first gated on SSC x 
FSC plots. The CDS events were then gated from the lymphocyte populations on SSC x 
CDS plots. The IFN-y' cells were identified form the CDS populations on IFN-y x CDS 
plots. The number in each plot represents the percentage of events of the gated population 
relative to the population shown in the plot. 
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CD45.2" and I FN- / were determined. This allowed the detection of the frequency 
of CD45.2" I F N Y c e i l s relative to the overall CD8" population. The percentage of 
I F N Y cells within the CD8" CD45.2" events was also determined. Secondly, 
when ICS with IL-2. TNF-a and IFN-y was performed, the CD8" events that were 
positive for individual cytokines were first gated separately. Boolean gating 
analysis was then conducted to determine the frequency of events that were 
positive for each of the possible cytokine combination. It should be noted that 
events that were negative for all cytokines were not included during analysis. 
Here. SPICE 5.22 software (Roederer et al.. 2011) was also used in conjunction 
with FI0W.I0 for data analysis. 
(2) DimerX labelling (Section 2.2.31) 
A similar gating method as the one used for ICS (refer to Figure 2-1) was used to 
identify the CDS* populations from the samples. In brief, cells were first gated on 
a SSC X FSC plot, followed by gating on a SSC x CD8 plot to identify the CD8^ 
population. The percentage of CD8^ events that were DimerX^ was determined on 
a DimerX x CDS plot (refer to Figure 5-2C). Backgrounds were detemiined using 
DimerX pulsed with an irrelevant peptide. The final data for each sample was 
calculated by subtracting the background. 
(3) 25D1.16 antibody labelling (Section 2.2.28) and GFP expression 
Events were first gated on a SSC x FSC plot. From this population, the mean 
fluorescence intensity (MFI) o f the fiuorophore-conjugated 25D1.16 antibody on 
the gated events was determined. A similar gating scheme used for 25D1.16 
antibody labelling analysis was used here, except the MFI o f GFP in cells was 
determined. 
(5) CD69 expression (Section 2.2.33.1) 
Figure 2-2 illustrates the gating scheme for identifying the transferred CD45.2^ 
CD8^ F5 T cells from the B6.SJL recipients. Briefly, cells were first gated on a 
SSC X FSC plot. From this population, the CD8^ population was gated on a SSC 
X CDS plot. The transferred F5 CDS^ T cell population was identified as CD45.2^ 
from the CDS"^ population on a CD45.2 x CDS plot. From the CD45.2^ 
population, a histogram was used to illustrate the level of anti-CD69 labelling on 
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Figure 2-2| The gating scheme for identifying the 0045.2"^ CDS"^ F5 ceils that were 
adoptively transferred into B6.SJL recipients for the early activation assay based on 
CD69 expression. A B6.SJL ( 0 0 4 5 . 1 ) mouse was adoptively transferred with purified 
I x i o " CD45.2 CD8 F5 cells a day before immunised with a WR recombinant. WR-
delTK. One day post immunisation, splenocytes from the mouse were prepared and 
labelled with anti-CD8a-PE. anti-CD45.2-APC and anti-CD69-PE-Cy7 antibodies by 
following the procedures shown in Section 2.2.33.1. To identify the transferred CD8 F5 
cells, cells were first gated on a SSC x FSC plot. The CDS events were then gated from 
the on a SSC x CDS plot. The CD45.2^ cells were identified fonn the CDS population on 
a CD45.2 x CDS plot. This CD45.2^CDS population represented the transferred F5 CDS 
T cells. A histogram was then used to illustrate the CD69 expression on the transferred cell 
population (refer to Figure 5-10). The number in each plot represents the percentage of 
events of the gated population relative to the population shown in the plot. 
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the gated events (refer to Figure 5-10). The MFI of CD69 labelling and the 
percentage of CD69^ events relative to the CD8"CD45.2 ' events was determined. 
(6) CFSE-based in vivo proliferation and CD25 expression (Section 2.2.33.2) 
A slightly different strategy was used to identify the transferred CD45.2''CD8'^ F5 
T cells from the B6.SJL recipients here. First, cells were gated on a SSC x FSC 
plot. The singlet population was then gated on a plot of width signal of FSC x 
area signal of FSC. From this singlet population, live events (7AAD") were 
identified on a SSC x 7AAD plot. The CD8^ population was then gated from the 
live events on a SSC x CD8 plot. The transferred F5 CD8^ T cell population 
(CD45.2^) was identified from the CD8'' population on a CD45.2 x CD8 plot 
(Figure 2-3). A CD25 x CFSE plot showing the level of CFSE and anti-CD25 
labelling on the events of the CD8" CD45.2^ population were used to determine 
the percentages of CD25^ events and CFSE'" events relative to the CD8^CD45.2^ 
events (refer to Figure 5-11 A). The division index, representing the number of cell 
division for a transfen'ed cell, was also determined from the transfen-ed CD45.2^ 
population. 
(7) In vivo cytotoxicity assay (Section 2.2.35) 
Events were gated on a SSC x FSC plot. From this population, the DiD^ 
population was identified and gated on a SSC x DiD plot (Figure 2-4). From the 
DiD^ population, a histogram was used to illustrate the level of CFSE labelling on 
the gated events. From this histogram, percentages of CFSE'" and CFSE'" cells 
were determined and the information was used to calculate the percentage of 
specific lysis (refer to Section 2.2.35, Figure 6-1 OA). 
2.2.37.3 Statistical analysis 
Statistical analysis was performed in Microsoft Excel 2007 software and 
GraphPad Prism 5 software. In general, when two groups of samples were 
compared, the two-tailed, unpaired student's T test was performed. One-way 
analysis of variance with the Tukey post test was performed if more sample 
groups were compared. The difference between the two tested samples is 
considered to be statistical significant w h e n p < 0.05. 
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Figure 2-3| Gating strategy for identifying 01)45.2"^ CDS"^ F5 cells that were 
adoptively transferred into B6.SJL recipients for the in vivo CFSE-based 
proliferation assay with CD25 straining. A B6.SJL (CD45.1 ) mouse was adoptively 
transferred with purified I x lO" CD45.2 ' CD8 F5 cells a day before immunised with a WR 
recombinant, WR-delTK. Two day after immunisation, splenocytes from the mouse were 
prepared and were subjected to the procedures described in Section 2.2.33.2. To identify 
the transferred CD8 F5 cell population, cells were first gated on a SSC x FSC plot (A). 
Singlets were gated on a plot of FSC (width signal)x FSC (area signal) (B). Live C D 8 
cells were identified on a SSC x 7AAD plot (C), followed by gating on a SSC x CDS plot 
(D). The transferred CD45.2^ CDS F5 cells were identified from the CDS ' population on a 
CD45.2 X CDS plot (E). A CD25 x CFSE plot was then used to illustrate the CD25 
expression level and CFSE level in the transferred cell population (refer to Figure 5-11). 
The number in each plot represents the percentage of events of the gated population 
relative to the population shown in the plot. 
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Figure 2-4| Gating scheme to identify transferred splenocytes that were stained with 
Vybrant DiD labelling solution in the in vivo cytotoxicity assay. A naive C57B1/6 
mouse was i.v. injected with I x l O ' cells that contained 1:1 ratio of DiD CFSE'" 
splenocytes that was pulsed with gB-498 peptide and DID CFSE'" splenocytes that was 
left unpulsed (as described in Section 2.2.35). Four hours later, splenocytes were prepared 
from the mouse and were analysed with flow cytometry. To identify the transferred 
splenocyte population, which was DiD . cells were first gated on a SSC x FSC plot, 
followed by gating on SSC x DiD plot. The percentages of CFSE'" and CFSE''' cells were 
determined within this population and used to determine the percentage of specific lysis of 
gB-498-presenting cells (refer to Figure 6-1 OA and Section 2.2.35). The number in each 
plot represents the percentage of events of the gated population relative to the population 
shown in the plot. 
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C h a p t e r s Anti-vaccinia virus CD8^ T cell priming 
pathways cannot be dissected with systemic 
Toll-like receptor 9 ligation or selective killing 
of dendritic cell subsets with cytochrome c 
Chapter 3 
Chapter 3 
3.1 Introduction 
Understanding how CD8^ T cells are primed during immunisation with VACV, 
especially the highly attenuated strains such as MVA, has practical relevance for 
designing better VACV-based recombinant vaccines. In addition, the lack of 
consistency in the literature about priming mechanisms across the VACV strains 
indicates that further research is needed to dissect priming pathways for anti-viral 
CDS" T cells. 
Most studies on antigen presentation during VACV immunisation focused on a 
few model antigens expressed from recombinant WR, such as OVA (Norbury et 
al., 2001; Norbur>' et al.. 2004; Ma et al.. 2009; Xu et al., 2010) and P-
galactosidase (Shen et al.. 2002; Tewalt et al.. 2009). These data were important 
for establishing how CDS" T cell responses can be induced during VACV 
immunisation, but more information is necessary before generalising these 
findings. More importantly, only one study directly addressed the priming 
pathway used by MVA and suggested that antigens expressed from MVA are 
mainly cross presented to induce CDS" T cell immunity in vivo (Gasteiger et al., 
2007). This study mainly focused on a tumor model antigen. Tyr, and OVA 
expressed as various constructs from recombinant MVA. Clearly, further research 
with more antigens is required to examine the conclusion of this study. 
Here, for the purpose of this thesis, the word 'antigen' is used to describe full-
length proteins where the antigenic peptides, which bind onto MHC-I, are 
processed from. 'CDS" T cell epitopes' is used to describe MHC-bound peptides 
that are known to be recognised by CDS" T cells isolated from animals or humans 
that have been immunised or infected. 
Presentation of peptides from native VACV antigens to CDS" T cells in vivo has 
only been examined in one study. Basta et al. (2002) immunised mice with a 
recombinant WR expressing the human cytomegalovirus proteins US2 or USl I. 
which down-regulate MHC-I and prevent direct presentation on the infected cells 
(Jones et al., 1995; Jones and Sun, 1997). When mice were immunised with these 
recombinant viruses, CDS" T cell responses against some VACV CDS" T cell 
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epitopes were selectively suppressed while a subset of VACV peptides remained 
immunogenic (Basta et al., 2002). Further, CD8^ T cells against the latter group of 
VACV peptides could be cross-primed from the lysates of MHC-I mismatched 
cells that were infected with WR (Basta et al., 2002). These data suggest that 
some VACV antigens can be cross presented in vivo. However, this study focused 
on antigenic peptides fractionated from APCs infected with VACV in vitro with 
the use of reverse-phase high-performance liquid chromatography, and the 
identities of the presented peptides were not determined. Moreover, the effects of 
US2 and US l l on the in vitro expression of H-2D'' and H-2K'' molecules 
contradicted the effects of these proteins on the in vivo presentation of antigens on 
these two MHC-I alleles (Basta et al., 2002). This further complicates the 
interpretation. More recently, numerous immunogenic VACV CD8^ T cell 
epitopes have been mapped in C57B1/6 mice (Tscharke et al., 2005; Moutaftsi et 
al., 2006; Yuen et a l , 2010). Although it has been shown that responses against 
some of these mapped epitopes can be elicited via cross presentation from VACV-
infected cells (Lev et al., 2009), it remains unknown how CD8^ T cells against 
most of these epitopes are primed during natural VACV immunisation. 
Examining the MHC-I presentation pathways of this large panel of VACV CDS^ 
T cell epitopes in vivo would improve our understanding of CDS^ T cell priming 
by VACV in general. 
Several strategies can be used to examine how individual antigens are presented 
from a virus. As discussed above, recombinant viruses expressing proteins to 
down regulate MHC-I presentation pathway can be used in vivo (Basta et al., 
2002; Shen et al., 2002). APCs infected with such recombinant viruses will not 
present peptides via direct presentation and in vivo direct priming will be 
suppressed. However, cross priming should not be affected as the cross presenting 
APCs are not infected. Thus, a reduction in the CD8^ T cell response against a 
given peptide induced by the recombinant viruses, compared to the control virus, 
indicates the contribution of direct priming. Alternatively, an unaffected immune 
response suggests a role for cross priming. Several proteins have been used to 
inhibit the direct presentation pathway in this context, such as the human 
cytomegalovirus proteins US2 or USl 1 described above (Basta et al., 2002- Shen 
et al., 2002), the HSV ICP47 protein which inhibits translocation of peptides via 
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TAP (Hill et al., 1995; Berger et a!., 2000), or the cowpox virus CPXV12 and 
CPXV203 proteins which inhibit TAP ability to transport peptides and suppress 
MHC-I export to the cell surface respectively (Byun et al., 2007; Alzhanova et al., 
2009; Byun et al., 2009; Gainey et a l , 2012; Lin, 2013). For this strategy, it is 
essential to use inhibitory proteins that can completely block direct presentation 
because even a highly reduced level of peptides presented on cells infected with 
the recombinant virus may still allow effective direct priming (Lin. 2013), 
A second method involves mutant mouse models which do not express 
components essential for the antigen presentation pathway. TAP-deficient mice 
have been used to study how different constructs of O V A and lAV NP antigen 
expressed from VACV W R are presented in vivo (Norbury el al., 2001). In 
another study, Xu et al. (2010) generated bone marrow chimeric mice by 
reconstituting lethally-irradiated wildtype mice with the bone marrow from MHC-
1-deficient mice (MHC-l-deficient^wildtype chimera). By immunising these 
mice with a recombinant W R expressing the MHC-I H-2K'' molecule, they found 
that direct presentation by bone marrow-derived APCs is essential for priming a 
CD8^ T cell response against the immunodominant VACV peptide B8-20 (Xu et 
al., 2010). The importance of a particular cross presentation mechanism can also 
be examined with transgenic mouse models, such as the cathepsin S-deficient 
mice, which are defective in the vacuolar cross presentation pathway (Shen et al., 
2004). 
The two strategies mentioned above require mutant mice and/or recombinant 
viruses. Recently, two new methods that inhibit cross presentation by DCs in 
wildtype mice have been reported. The first method requires pre-treatment of 
mice with CpG (Wilson et al., 2006), a toll-like receptor (TLR)-9 agonist (Hemmi 
et al., 2000). CpG is internalised by the DEC-205 receptor on the surface of DCs 
(Lahoud et al., 2012) and is then translocated into lysosomes where it binds to 
TLR-9 (Takeshita et al., 2001; Ahmad-Nejad et al., 2002). Binding of TLR-9 
leads to activation of the myeloid differentiation marker (MyD) 88 adapter 
molecule which ultimately leads to DC maturation (Hacker et al., 2000; Schnare 
et al., 2000; Kaisho and Akira, 2001; Kaisho et al., 2001; Hemmi et al., 2003). 
CpG can be further classified into three different classes (class A. B and C) 
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depending on the nucleotide sequences (Vollmer et al., 2004). The three classes of 
CpG have different immmunostimulatory effects and the inhibitory effect of CpG 
class B on cross presentation is discussed here. Injecting mice i.v. with this class 
of CpG causes systemic maturation of DCs resulting in their loss of ability to 
cross present antigens, but direct presentation is apparently not affected (Wilson et 
al., 2006). It should be noted that the timing of CpG injection dictates the outcome 
of the treatment. It has been shown that immunisation of mice with soluble 
antigens together with CpG or with CpG-conjugated soluble antigens leads to 
cross priming of antigen-specific CDS" T cells (Sparwasser et al., 2000; Maurer et 
al., 2002). In this chapter, on the other hand, the reported feature of CpG pre-
treatment to suppress cross presentation in vivo was exploited. 
Secondly, systemic administration of horse cytc before immunisation selectively 
triggers apoptosis in cross-presenting CD8a" DCs and CD 103" DCs and results in 
the inhibition of cross presentation (Lin et al., 2008; Qiu et al.. 2009). This 
targeted killing is a result of the unique ability of these DCs to translocate 
extracellular proteins into their cytoplasm (Lin et al., 2008). In this case, any 
captured cytc available in the cytoplasm binds to the apoptotic protease activating 
factor-1 to trigger apoptosis (Zou et al., 1997; Lin et al., 2008). Both CpG and 
cytc methods have been used in studies of cross presentation mechanisms 
(Farrand et al., 2009; Imai et al., 2011) and of CD8" T cell priming pathways in 
various models, including HSV-1 infection (Allan et al., 2003; Wilson et al., 
2006), Plasmodium infection (Chakravarty et a l , 2007; Cockbum et a l , 2011), 
and allograft transplantation (Sutherland et al., 2011). 
Importantly, CpG treatment has been applied in two separate studies to VACV 
WR and MVA. Xu et al (2010) demonstrated that this treatment does not reduce 
CD8" T cell responses to a directly presented OVA-257 construct and the native 
VACV B8-20 peptide expressed from WR. In contrast. Gasteiger et al (2007) 
showed the opposite when mice were immunised with MVA. In this latter study, 
CpG treatment suppressed CD8" T cell responses against all tested peptides 
expressed from MVA. Based on the reported inhibitory effect of CpG on cross 
priming, these contradictory results were used as evidence to support the 
arguments that antigens expressed from WR are directly presented while antigens 
136 
Chapter 3 
f rom M V A are cross presented for C D 8 ' T cell priming. However, there has not 
been a direct comparison of cross and direct priming with these two VACV 
strains. Further, no single study has used both the CpG and cytc methods to see 
whether these two methods give similar results for any model system. 
In this chapter, the antigen presentation mechanisms for individual native antigens 
expressed from VACV WR and MVA were investigated. Firstly, an assay for 
examining cross presentation from VACV-infected cells in vivo was established. 
Using this assay, several VACV antigens were shown to be cross presented from 
VACV-infected cells to prime CD8^ T cells. The CpG (class B) and cytc pre-
treatments were then used with the aim of dissecting how native antigens from 
WR and MVA prime CDS* T cells during VACV immunisation. Contrary to 
previous reports, results here demonstrate that these two commonly used methods 
do not separate priming pathways of VACV antigens. 
3.2 Results 
3.2.1 CD8^ T cell immunity against a panel of 14 VACV peptides is induced 
during dermal immunisation with VACV WR or MVA 
(For the ease of reference, the viruses used in this chapter are listed in Table 
A-1 in the Appendix) 
Most studies on MHC-I presentation of VACV-expressed antigens focused on 
CD8^ T cell responses induced during systemic immunisations, such as through 
the i.p. or i.v. routes (Norbury et al., 2001; Gasteiger et al., 2007; Xu et al., 2010). 
In these cases, VACV spreads to multiple internal organs and secondary lymphoid 
organs (Buller et al., 1985; Rodriguez et al., 1988; Ramirez et a l , 2000; Benning 
and Hassett, 2004; Naik et a l , 2006; Gomez et a l , 2007; Lin et al., 2013). 
However, during vaccination with VACV in humans, dermal immunisation is 
used as discussed in Section 1.9.1. The CD8^ T cell immune responses induced 
during a peripheral route of immunisation may be different to the better studied 
systemic routes. Therefore, we focused on i.d. immunisation with VACV in ear 
pinnae (Tscharke and Smith, 1999; Lin et al., 2012). Here the virus is restricted to 
the infected ears and draining LNs even after injection with a high dose (lO*" PFU) 
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of VACV WR (Tscharke and Smith. 1999; Fischer et al., 2011: Lin et al., 2013), 
suggesting that this VACV infection is controlled locally. 
To examine the CD8^ T cell responses to a large panel of 14 VACV CD8^ T cell 
epitopes mapped based on i.p. VACV immunisation. C57B1/6 mice were injected 
i.d. with VACV strains WR or MVA. Seven days after immunisation at the peak 
of an CD8^ T cell response (Hassett et al.. 2000; Harrington et al., 2002), single 
cell suspensions of splenocytes from immunised mice were prepared and 
stimulated with synthetic peptides ex vivo. The responding CD8^ T cells were 
then identified by ICS of IFN-y. This assay allows a robust and precise 
quantification of antigen-specific CD8'^ T cells during acute VACV and HSV-1 
infections, comparable to peptide/MHC-l tetramer staining and other similar 
technologies (Flesch et al.. 2012). 
Fig 3-1A shows representative flow cytometric plots of splenic CD8^ T cells from 
WR or MVA-immunised mice which produced IFN-y after stimulation with the 
peptides indicated. The gate of the IFN-y^ population was set from a media-only 
control for each individual experiment and was applied to all samples of each 
individual experiment. In some rare scenarios, for example when splenocytes 
from WR-infected mice were stimulated with the B8-20 peptide as shown in Fig 
3-1 A. the IFN-y" population within the CD8^ population showed a marked 
increase in the MFl of IFN-y staining. This situation occurred only when there 
was a large population of CD8^ T cells responding to a given peptide. A likely 
explanation is that not all the IFN-y was blocked from secretion from the large 
population of responding cells during ex vivo peptide stimulation even in the 
presence of BFA. Some of the released IFN-y might become associated with other 
cells in the culture, and therefore might increase the background IFN-y staining. 
To overcome this problem, the IFN-y^ gate was adjusted upward slightly in these 
rare cases to more accurately separate the IFN-y^ and IFN-y" events, which were 
clearly two distinct populations. 
As seen in Figure 3-1B & C, mice immunised with WR via the i.d. route elicited 
CDS"^ T cell responses against multiple CD8^ T cell epitopes, which can be ranked 
into a hierarchy based on their immunogenicity. Around 10% of the CDS"^ T cells 
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Figure 3 - l | CD8^ T cell responses against 14 native VACV peptides elicited after i.d. 
immunisation with V A C V WR or MVA in C57BI/6 mice. C57B1/6 mice were 
immunised i.d. with 2x10" PFU of WR (A-C) and or MVA (A, D and E). CD8^ T cell 
responses to the peptides indicated were measured in spleens 7 days later by ex vivo 
peptide stimulation, followed by ICS. (A) Representative flow cytometry (IFN-y x CDS) 
plots gated on C D S ' events are shown. The numbers indicate the percentage of CDS 
events which were IFN-y . Percentages (B and D) and absolute numbers (C and E) of 
CDS* T cells producing IFN-y are shown as mean ± standard error of mean (SEM). Data 
represent results compiled from three independent experiments (n = 9). Please note that 
graphs B to E are shown on the following page. 
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were B8-20-speciric. which was equivalent to approximately 2.5x10'' B8-20-
specific CD8^ T cells. It was followed by a large group of subdominant VACV 
peptides, each of which was recognised by around 1-2% of CD8^ T cells (2.0-
5.5x10' specific CD8" T cells). This group of peptides included A8-189, A3-270, 
A23-297, K3-6, B2-54, A47-138, L2-53, A47-171, A3-191. C4-125 and J3-289. 
Furthennore. about 0.2% of CD8^ T cells, or around 7xl0' CD8^ T cells, from 
WR-immunised mice were specific to A8-70 or A42-88. This immunodominance 
hierarchy of individual native VACV epitopes induced during i.d. immunisation is 
similar to that induced by i.p. immunisation (Moutaftsi et al., 2006). 
Similar to WR. 88-20 remained as the immunodominant peptide during MVA 
immunisation (Figure 3-1D & E). MVA induced a B8-20-specific CD8^ T cell 
response which made up around 8% of the total CD8'^ T cell population. However, 
the immunodominance hierarchy of the subdominant peptides induced by MVA is 
different to that of WR. A47-17I is clearly the second most immunogenic peptide 
while A3-270 ranked third, recognised by around 1% and 0.8% of CDS" T cell 
respectively. The immunogenicity of the rest of the peptides was less than 0.5% 
each. Notably, the B2-54 and C4-I25 peptides are not expressed by MVA 
(Antoine et al., 1998) and as expected no responses to these peptides were 
detected. Further. MVA primed much smaller CDS"^  T cell responses against the 
examined peptides than WR. as measured by absolute numbers of responding 
CDS"^ T cells. For example, only 5.5xl0' CD8^ T cells were found to be specific 
to the immunodominant 88-20 peptide in MVA-immunised mice, a response 
approximately 80% smaller than the antigen-specific population induced by WR. 
This suggests that MVA provides less co-stimulation for CD8" T cell priming 
than WR. as has been suggested for other less virulent strains of VACV (Salek-
Ardakani et al., 201 la). MVA may also provide a lower antigen dose compared to 
WR as it does not replicate in vivo. In spite of these differences between the two 
VACV strains in inducing CDS"^ T cell immunity, both are capable of inducing 
responses against multiple native VACV peptides. 
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3.2.2 The use of heat treatment to inactivate residual VACV on infected 
antigen donor cells in an in vivo cross priming assay 
After establishing that many peptides from native VACV antigens are 
immunogenic when mice were immunised with VACV WR or MVA via the i.d. 
route, we were interested in the presentation pathways involved in priming their 
responses. Firstly, we examined if CDS"^  T cells against any of these peptides can 
be cross primed. For this purpose, an in vivo cross priming assay was required. 
Cells deficient in MHC-I or expressing mismatched MHC-I have been used as 
antigen donor cells in many studies to examine cross priming (Norbury et a l , 
2004: Shen and Rock. 2004: Wolkers et al.. 2004: Basta et al.. 2005). In this 
assay. CD8^ T cells from the immunised mice cannot directly recognise peptides 
presented on the surface of antigen donor cells. In this thesis, human 293A cells 
infected with VACV were used as antigen donor cells. These cells express human 
MHC-I which cannot be recognised by murine CD8^ T cells and they have been 
used in cross presentation assays in mice in various studies (Norbury et al.. 2004: 
Donohue et al., 2006: Lev et al., 2009). 
Because VACV-infected cells were used to induce cross priming in vivo, residual 
viral particles associated with the infected cells must be completely inactivated to 
abolish their infectivity. Complete viral inactivation eliminates the possibility of 
infection of APCs in the host and resulting direct presentation. Several methods 
have been used to inactivate viruses, including psoralen/UV treatment to crosslink 
viral DNA (Hearst and Thiry, 1977: Hanson et al., 1978), and heat inactivation to 
denature viral proteins (Kaplan, 1958: Woodroofe, I960: Madeley, 1968). 
Firstly, the ability of psoralen derivatives, namely TMP and AMT, to inhibit viral 
replication and viral gene expression were tested. Psoralen and its derivatives 
covalently attach to pyrimidines on RNA and DNA and form crosslinks between 
the opposite strands of DNA in the presence of UV irradiation (Musajo et al., 
1967; Song and Tapley, 1979). This treatment has been used to inactivate 
different viruses, including those with large DNA genomes such as VACV and 
HSV (Hearst and Thiry, 1977; Hanson et a l , 1978; Hanson, 1992; Tsung et al., 
1996; Fischer et al., 2007). To test their efficiency at inhibiting VACV replication 
and gene expression, a WR recombinant, namely WR-TK-SIIN (Restifo et al., 
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1995), was chosen as the model virus. This recombinant virus expresses the 
dominant CDS" T cell epitope in OVA. OVA-257, as a cytosoiic minigene 
(MSI INFEKL) under the control of the VACV p7.5 early/late promoter f rom the 
V A C V TK locus. Because of the short length of the minigene (27 bp long), 
suppression of its expression from V A C V with psoralen requires extended UV 
exposure compared to the full-length OVA antigen (Fischer et al., 2007). More 
importantly, the O V A - 2 5 7 minigene expressed from WR can only be directly 
presented but not cross presented (Serna et al.. 2003; Norbury et al., 2004). 
Therefore, a CDS" T cell response induced against the OVA-257 minigene from 
WR-TK-SlIN- infec ted cells that were treated with an inactivation method would 
imply an incomplete inactivation of the virus. With this virus, we could 
stringently examine V A C V inactivation. 
T M P was first examined. WR-TK-SIIN was treated with 10 ng/ml of T M P and 
irradiated with UV light at 365 nm. This concentration of TMP has been used in 
previous studies to inactivate V A C V (Norburj ' et al., 2004; Fischer et al., 2007). 
After irradiation with UV for 20 min. the replicative ability of the TMP-treated 
virus was reduced to below the detection limit of the standard plaque assay 
(Figure 3-2A). To examine if this treatment also inhibited VACV gene expression 
and antigen presentation, we took advantage of 293-K'' cells and 25D1.16 
antibody. 293-K' ' cells are human 293A cells stably expressing mouse MHC-1 H-
2K'' (Tscharke et al., 2005), the restricting MHC-I of OVA-257 (Carbone and 
Bevan, 19S9; Falk et al., 1991b; Rotzschke et a l , 1991). 25D1.16 antibody 
recognises the OVA-257/H-2K' ' complex (Porgador et al., 1997), and so this 
reagent al lows a direct measurement of MHC-1 presentation of OVA-257. Here 
the surface expression level of OVA-257/H-2K' ' was measured with 25D1.16 
antibody on 293-K' ' cells that had been incubated with the treated viruses for six 
hours. The results on Figure 3-2B show that T M P treatment of WR-TK-Sl lN 
fol lowed by up to an hour of UV irradiation only moderately reduced surface 
OVA-257/H-2K' ' expression on the inoculated 293-K' ' cells, suggesting that 
T M P / U V treatment did not completely inactivate VACV. 
Another psoralen derivative, AMT, was also examined. It has been reported that 
A M T can completely inhibit V A C V viral gene transcription (Tsung et a l , 1996). 
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Figure 3-2| Psoralen/UV treatment does not completely stop the O V A - 2 5 7 minigene 
expression from residual V A C V used during infection o f cells in vitro. (A-D) IxlO** 
PFU of WR-TK-SIIN was treated with 10 ng/ml TIMP (A and B) or 100 ng/ml A M T (C 
and D) in PBS in a final volume o f 500 (il. The solutions were irradiated with UV-A 
light (365 nm). At times indicated. 100 jil o f virus solution was taken for further 
experiments. (A and C) Residual viral infectivity was determined by standard plaque 
assay. (B and D) OVA-257 minigene expression and MHC-I presentation was 
determined by infecting 293A-K' ' cells with the treated virus at an m.o.i. o f 5. followed 
by 25D1.16 antibody staining 6 h later. (A-D) Results represent data from a single 
experiment. (E) 293A cells were infected with WR-TK-SIIN at an m.o.i. o f 5 for 6 h. 
These infected cells were then treated with 100 ng/ml A M T and 60 min UV irradiation 
( 4 x 1 0 ' cells in 2 ml). A group o f three mice were then immunised i.p. with I x i o ' 
infected AMT/UV-treated cells. CDS T cell responses to OVA-257 and V A C V B 8 - 2 0 
were measured in spleens 7 days later via ICS. The percentages of CDS T cells 
producing IFN-y are shown as mean ± SEM (n = 3; from a single experiment). 
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In c o m p a r i s o n to T M P used above , a h igher concentrat ion of A M T w a s applied 
here to ensure bet ter viral inhibi t ion. Similar to T M P . WR-TK-SI IN treated with 
100 ^g /ml o f T M P and irradiated with U V light at 365 nm for 20 min abol ished 
the viral repl icat ion abili ty as detected by standard plaque assay (Figure 3-2C) . 
Cont ra ry to T M P . as little as 20 min of U V irradiation greatly reduced the level of 
O V A - 2 5 7 / H - 2 K ' ' presenta t ion on the sur face of 293-K' ' cells inoculated with 
A M T - t r e a t e d v i rus (Figure 3-2D) . However , a closer examinat ion revealed that 
the inhibi t ion of the O V A - 2 5 7 min igene presentat ion f rom AMT-t rea ted W R - T K -
SIIN might not be comple te even af ter an hour of UV irradiation. This was 
sugges ted by the slightl> h igher MFI of the 2 5 D - 1 . I 6 ant ibody staining on the 
cel ls inoculated with the AMT- t rea ted virus, compared to the mock- infec ted cells 
(F igure 3-2D) . T o empir ical ly demonst ra te whether A M T / U V treatment could be 
used to comple te ly inact ivate residual vi rus on infected cells in a cross pr iming 
assay . 2 9 3 A cells that had been infected with W R - T K - S I I N for 6 h were treated 
wi th 100 | jg/ml A M T and irradiated with UV for 60 min. Mice were then 
immun i sed with these treated cells. Seven days af ter immunisa t ion . O V A - 2 5 7 -
speci f ic CD8^ T cell immuni ty w a s induced by the AMT/UV- t rea ted W R - T K -
SIIN- infec ted cells (Figure 3-2E) . This result demonst ra tes that A M T / U V 
t rea tment did not comple te ly inhibit viral gene express ion f rom residual V A C V 
associa ted with the infected cells. 
The use fu lness o f heat inact ivat ion w a s then investigated. Heat ing V A C V to 55-
6 5 ° C has been used to suppress its infectivi ty (Kaplan . 1958; Woodroo fe . I960 ; 
Made l ey . 1968). Un l ike psora len /UV treatment which targets V A C V D N A 
g e n o m e , heat t rea tment dena tures V A C V viral prote ins and ablates their func t ions 
even at 4 5 ° C ( B e m s et al. , 1969). Here W R - T K - S I I N w a s heat-treated at 60°C for 
60 min . Th is t rea tment inhibited the replicat ive ability of the virus to be low the 
de tec t ion limit (F igure 3 -3A) . Heat t rea tment also complete ly inhibited growth of 
w i ld type W R and o ther V A C V recombinan t s as de termined by standard p laque 
assay (data not shown) . Fur thermore , 293-K' ' cel ls inoculated with the heat-
inact ivated W R - T K - S I I N did not present the O V A - 2 5 7 min igene as measured by 
su r face O V A - 2 5 7 / H - 2 K ' ' express ion with 2 5 D 1 . 1 6 ant ibody labell ing (Figure 3-
3B) . An independen t exper iment wi th W R recombinan t express ing an ER-targeted 
O V A - 2 5 7 min igene con f i rmed this finding (data not shown) . Finally, mice 
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Figure 3-3 | Heat ing VACV- in fec ted cells to 60°C for 60 min completely inhibits the 
O V A - 2 5 7 minigene express ion from residual V A C V . (A) 8 x l 0 ' PFU of W R - T K - S I I N 
in 400 of PBS w a s either incubated on ice or at 60°C for 60 min. The replicat ive ability 
of the treated virus was de tenn ined by standard plaque assay. (B) 293-K' ' cells mock-
inoculated or inoculated with WR-TK-SI IN that was either put on ice or heat-treated at 
60°C for 60 min at an m.o.i . of 5 for 6 h. OVA-257 /H-2K ' ' complex express ion on cell 
surface was measured with 25D1.16 ant ibody. (C) 293A cells were infected with ei ther 
W R - T K - O V A or WR-TK-SI IN at an m.o.i. of 5 for 6 hours. Cel ls were then heat treated 
at 60°C for 60 min in PBS in a vo lume of 500 (il ( 4 x l 0 ' cells). G roups of three mice were 
then immunised i.p. with I x l O ' infected heat-treated cells. CD8^ T cell responses to the 
O V A - 2 5 7 and V A C V B8-20 peptides were measured in spleens 7 days later via ICS. The 
percentage of CDS T cells producing IFN-y are shown as means ± SEM. (A and B) 
Results represent data f rom one exper iment . (C) Resul ts shown are compi led f rom two 
independent exper iments ( W R - T K - O V A : n = 5; W R - T K - S I I N : n = 6). 
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immunised with 293A cells infected with WR-TK-SIIN followed by heat 
inactivation did not show any OVA-257-specitic CD8" T cell response (Figure 3-
3C). This was not due to the inability of the infected heat-treated cells to provide 
antigens for cross presentation because a B8-20-specific response was detected in 
these mice. Also, cells infected with WR-TK-OVA, a WR recombinant 
expressing full-length OVA that is known to be cross presented from VACV-
infected cells (Sema et al., 2003; Norbury et al., 2004; Lev et al., 2009). elicited a 
measurable OVA-257-specific CDS" T cells response (Figure 3-3C). The failure 
of the OVA-257 minigene. but not full-length OVA. to induce an OVA-257-
specitlc CD8" T cell response from the VACV-infected cells indicates that the 
minigene is completely inactivated from residual virus on the infected cells after 
heat treatment. Therefore, this method was chosen to inactivate the VACV-
infected cells used for our cross priming assay. To ensure that no active virus was 
associated with the infected cells for our cross priming experiments after heat 
treatment, the infected cells were routinely checked for their lack of replicative 
ability and their inability to infect fresh APCs for direct presentation in vitro (data 
not shown). 
3.2.3 Some V A C V antigens can be cross presented from VACV-infected cells 
to prime CD8" T cells 
Next, we examined whether any of the CDS" T cell responses against the native 
VACV peptides tested in Figure 3-1 could be cross primed using the newly 
established cross priming assay. 293A cells were infected with WR or MVA for 6 
h. followed by heat inactivation at 60°C for 60 min. Six hours of infection should 
allow expression of all VACV antigens tested in this thesis (Assarsson et al., 
2008; Yang et al., 2010). Mice were then immunised i.p. with 1x10^ of these heat-
treated VACV-infected cells. Seven days after immunisation, responses against 
several of the VACV antigens were detected directly ex vivo (Figure 3-4). Even 
under conditions where only cross presentation was allowed. B8-20 remained the 
most immunogenic peptide for WR and MVA, representing 2 and 3% of CD8" T 
cell response respectively (Figure 3-4A and C). For WR. the next most 
immunogenic peptide was A3-270, which induced a response of a similar size to 
BS-20. Several other native VACV peptides from WR were also immunogenic in 
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Figure 3-4| CD8^ T cell responses against some VACV antigens can be elicited in 
mice by cross presentation from VACV-infected, heat-treated cells. 293A cells were 
infected with WR (A and B) or MVA (C and D) for 6 h at an m.o.i. of 5 at 37°C, 
followed by heat treatment at 60°C for 60 min to inactivate the residual virus. Mice were 
immunised i.p. with I x l O ' of these infected, heat-treated cells. CDS* T cell responses 
were measured in spleens 7 days later, after ex vivo peptide stimulation followed by ICS. 
Data are shown as percentages (A and C) or absolute numbers (B and D) of CDS* T cells 
against the indicated peptides (mean ± SEM). Data represent results compiled from two 
independent experiments (n = 6). 
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this context, including A42-88. L2-53, J3-289 and A3-191, eaci: of which was 
recognised by 0.1-0.3% of CD8^ T cells (Figure 3-4A). A similar group of VACV 
antigens were shown to be cross presented in a previous study in which mice were 
immunised with 293A cells infected with WR-TK-OVA followed by irradiation 
with 254 nm UV light (Lev et al.. 2009). This suggests that heat treatment is 
comparable to the germicidal UV treatment used to inactivate residual virus on 
antigen donor cells. In mice immunised with MVA-infected cells. A3-270 was 
also the second most immunogenic peptide, similar to that observed in mice 
immunised with WR-infected cell (Figure 3-4C and D). However, the 
immunogenicity of the rest of the peptides induced via cross priming was much 
lower from MVA-infected cells, compared with WR-infected cells. This will be 
discussed in Section 3.3 (p. 175). 
Dermal immunisation with VACV-infected cells was then examined to study if it 
would produce comparable results. Similar to the result shown in Fig 3-3C in 
which mice were immunised with WR-TK-SllN-infected cells via the i.p. route, 
the OVA-257 minigene did not cross prime an OVA-specific CD8^ T cell 
response after i.d. immunisation with 2x10"^  WR-TK-SllN-infected cells (Figure 
3-5). This indicates that the OVA-257 minigene was also not cross presented from 
infected cells during dermal immunisation. The responses against native VACV 
peptides were then studied. Seven days after an i.d. immunisation with 2x10'' cells 
infected with VACV WR or MVA. the overall immunogenicity hierarchies were 
similar to those of the i.p. route (Figure 3-6, compared with Figure 3-4). It should 
be noted that the B8-20-specific response induced by MVA-infected cells was 
significantly higher than that of WR-infected cells (p < 0.05 when percentages or 
total numbers of B8-20-specific CD8^ T cells were compared). This was not 
observed for other VACV peptides (p > 0.05). This might be due to a difference 
between the amounts of the B8 antigen expressed within cells infected with WR 
or MVA. In addition, we noticed that the size of the CD8^ T cell immune 
response, measured as absolute numbers of peptide-specific CD8^ T cells, induced 
from WR-infected cells seemed to be lower when the i.d. injection route was used, 
compared with i.p. immunisation (refer to Figure 3-4). However, this is likely to 
be a dosage effect, not a route-specific effect. As shown in Figure 3-7 below, i.p. 
immunisation of mice (treated with PBS) with Ixio''cells induced a similar 
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Figure 3-5| Dermal immunisation with WR-TK-SIIN- infectcd does not cross prime 
CD8^ T cells against the OVA-257 minigene. 293A cells were infected with WR-TK-
SIIN for 6 h at an m.o.i. of 5 at 37°C. followed by heat inactivation at 60°C for 60 min. 
Mice were immunised i.d. with 2x10' ' of these infected, heat-treated cells. CD8 T cell 
responses in the spleens were analysed 7 days later, after ex vivo peptide stimulation and 
ICS. Data are shown as percentages (A) or absolute numbers (B) of CDS ' T cells 
responding to peptides indicated (mean ± SEM; n = 3). This experiment was repeated but 
the repeated experiments were designed to compare the cross priming ability of cells 
infected with WR-TK-OVA and WR-TK-SIIN, The results are shown in Figure 4-12. 
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Figure 3-6| Similar to i.p. immunisation, dermal immunisation with VACV-infected 
can cross prime CDS"^ T cell immunity against some VACV antigens. Mice were 
immunised i.d. with 2x10" 293A cells, previously infected with WR (A and B) or MVA 
(C and D) for 6 hours at an m.o.i. of 5 at 37°C, followed by heat inactivation as described 
in Figure 3-4. CD8^ T ceil responses were measured in spleens 7 days later with ex vivo 
peptide stimulation and ICS. Data are shown as percentages (A and C) or absolute 
numbers (B and D) of CDS' T cells against the indicated peptides. Data (mean ± SEM) 
represent results compiled from two independent experiments (n = 6). 
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magnitude of responses as those produced following i.d. immunisation with 2x10 
infected cells. 
Overall, the results presented here demonstrate that out of all the VACV CDS"^ T 
cell epitopes tested, several of them can be cross presented from VACV-infected 
cells for CDS"^ T cell priming. However, these results do not predict if these 
peptides are also cross presented during the standard VACV immunisation. 
3.2.4 CpG inhibits cross presentation of VACV antigens from VACV-infected 
cells 
To dissect the priming pathways of the native VACV antigens during 
immunisations with VACV WR and MVA, CpG pre-treatment was chosen, on the 
basis that it should only inhibit cross priming. To establish that CpG inhibits cross 
presentation of VACV antigens, mice were pre-treated with 20 nmol CpG or PBS 
(as a control). The treated mice were immunised i.p. with 1x10^ heat-treated. WR-
TK-OVA-infected 293A cells one day later. CD8^ T cell responses to OVA and 
the large panel of VACV peptides were measured 7 days post immunisation 
(Figure 3-7 A and B). Confirming our previous in vivo cross priming experiments 
(Figure 3-4 and 3-6). responses against a similar set of VACV peptides, as well as 
OVA-257. were induced in control mice. In contrast, responses against all these 
peptides were significantly reduced in CpG-treated mice by at least 80% (Figure 
3-7C and D). The results here confirm and extend the range of VACV peptides for 
which cross presentation is inhibited by CpG treatment (Xu et al., 2010). 
3.2.5 CpG inhibits direct presentation after dermal immunisation with VACV 
After confirming that CpG treatment inhibited cross priming of VACV antigens in 
vivo, this method was applied to dissect the presentation pathway of VACV 
antigens after VACV immunisation via the i.d. route. CpG- and PBS-treated mice 
were i.d. immunised with 2x10'' PFU of WR or MVA. Seven days later. CD8^ T 
cell responses were measured. For MVA. CDS"^ T cell responses against B8-20, 
L2-53 and J3-289 were significantly inhibited by CpG treatment, irrespective of 
the percentages or absolute numbers of responding CD8^ T cells (left of Figure 3-
8C and D). Percentages of CD8^ T cell recognising A3-270 and A47-138 were 
Chapter 3 
i.p. 1x10® heat-treated WR-TK-OVA-infected cells 
A 
B 
Peptide 
V 1 . 5 
S 1.0 
g 0.5 
" 0.0 
• PBS 
• CpG 
Pept ide 
Peptlda PepMe 
Figure 3-7| CpG treatment inhibits cross presentation. Mice were pre-treated with 10 
nM CpG or PBS (control). These mice were then immunised i.p. with IxiO" WR-TK-
OVA-infected and heat inactivated 293A cells one day later. CD8 T cell responses to the 
peptides shown were measured in spleens 7 days post immunisation. The percentages (A) 
and absolute numbers (B) of responding CD8^ T cells for peptides indicated are shown as 
mean ± SEM. (C and D) Extent to which responses to OVA-257. B8-20. and the sum of 
13 other VACV epitopes (others) were suppressed in CpG compared with control treated 
mice are shown, based on data in (A) and (B) respectively. * denotes statistical 
significance (p < 0.05). Data are compiled from 3 independent experiments (n = 12). 
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Figure 3-8| CpG treatment suppresses anti -VACV CD8^ T cell immunity after i.d. 
immunisation. CpG- or PBS-treated mice were immunised i.d. with 2x10' ' PFU V A C V 
strains WR (A and B) or MVA (C and D) and CD8* T cell responses to the peptides 
shown were measured in spleens 7 days later. Percentages (A and C) and absolute 
numbers (B and D) of CD8^ T cells that made IFN-y after short stimulation with peptides 
indicated are shown as mean ± SEM on left. Extent to which responses to B8-20 or the 
sum of other epitopes (others) were suppressed in CpG compared with control mice based 
on percentages or absolute numbers are shown on right. Data are compiled from two 
independent experiments (n = 6). * denotes statistical significance {p < 0.05). 
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significantly reduced after CpG treatment. However, the decreases were not 
reflected by the absolute numbers of CD8" T cells that recognised these two 
peptides, due to the variation in the numbers of CD8^ T cells induced in individual 
mice. Responses against A3-191 were reduced by CpG treatment, but the 
difference was not significant when compared with mock-treated mice. We also 
noticed that there were few exceptions in which responses against K3-6 and A47-
171 were not affected by CpG treatment. Overall, CpG treatment suppressed at 
least 50% of the CDS* T cell responses induced against native VACV peptides 
expressed from MVA (right of Figure 3-8C and D). This is in agreement with 
suggestions that MVA relies on cross priming (Gasteiger et al., 2007). 
However, unexpected results were found when CD8^ T cell responses were 
measured in CpG-treated mice after WR immunisation. In contrast to published 
data (Xu et al., 2010). priming of CD8^ T cell responses to nearly all examined 
VACV peptides of WR were significantly inhibited by CpG treatment (left of 
Figure 3-8A and B). Inhibition by CpG treatment was more than 70% for all 
epitopes and in some cases more than 80% (right of Figure 3-8A and B). One 
could interpret the results here as suggesting that cross priming is the dominant 
pathway both for MVA and WR after i.d. immunisation. This conclusion for WR 
after i.d. immunisation has been suggested by one study (Shen et al., 2002). 
However, observations from intravital microscopy using this route and 
subcutaneous immunisation, another peripheral route, favour direct priming for 
WR. as well as MVA (Norbury et al., 2002; Hickman et al., 2008; Hickman et al., 
201 lb; Kastenmuller et al., 2013). It is possible that CpG treatment may influence 
other functions of the immune system, in addition to its inhibitory effect on cross 
priming. This could complicate the interpretation of the results here. 
To test directly whether CpG treatment genuinely dissects direct and cross 
priming after i.d. immunisation, WR-TK-SIIN was used again. As shown in 
Figure 3-5 previously, the OVA-257 minigene expressed from this virus does not 
cross prime CD8^ T cells from WR-TK-SIIN-infected cells via i.d. immunisation. 
When PBS-treated mice were i.d. immunised with 2x10^ PFU of WR-TK-SIIN, 
nearly 2% of splenic CD8^ T cells recognised the OVA-257 peptide seven days 
post immunisation (left of Figure 3-9A), which was similar to the response 
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Figure 3-9| CpG treatment suppresses direct priming after i.d. immunisation. CpG-
or PBS-treated mice were immunised i.d. with 2x10'' PFU of WR-TK-SllN (A and B) or 
MVA-TK-SIIN (C and D), CD8' T cell responses to OVA and B8-20 were measured by 
ex vivo peptide stimulation and ICS 7 days later. Results are shown as percentage of 
CD8 T cells (left of A and C) or absolute numbers of CDS' T cells (left of B and D) 
producing IFN-y as mean ± SEM. Graphs on the right show the extent to which responses 
to OVA-257 and B8-20 were suppressed in CpG compared with control treated mice, 
based on data on the left. Data are compiled from two independent experiments (n = 6). * 
denotes statistical significance (j) < 0.05). 
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induced by this recombinant virus after i.p. immunisation (see Figure 3-10 and 
Norbury et al., 2004). This suggests that direct priming is efficient after i.d. 
immunisation with VACV WR. Moreover, the CD8^ T cell response against this 
directly-presented OVA-257 construct was inhibited by 80% in mice pre-treated 
with CpG (right of Figure 3-9A and B). This is similar to the inhibition detected 
for the immunodominant VACV B8-20 epitope (Figure 3-9A and B). To extend 
this finding to MVA. a new MVA recombinant which expressed the cytosolic 
OVA-257 minigene under the VACV p7.5 promoter from the VACV TK insertion 
site was generated. This virus was specifically made to match WR-TK-SllN and 
was named MVA-TK-SIIN. An OVA-257-specific CD8^ T cell response of 
around 1.5% of CD8^ T cells was induced when mice were immunised with 
MVA-TK-SllN via the i.d. route, similar to WR-TK-SIIN (left of Figure 3-9C). 
This suggests efficient direct priming by MVA. However, the OVA-257-specific 
response induced by this MVA recombinant was again inhibited by more than 
80% in mice treated with CpG. when the response was measured as percentages 
or absolute numbers of responding CD8^ T cells (right Figure 3-9C and D). 
Results here indicate that CpG treatment reduces CD8^ T cell responses against 
antigens expressed from WR and MVA after i.d. immunisation, even if the 
antigens are exclusively targeted for direct presentation and cannot be cross 
presented. 
3.2.6 The effect of CpG treatment on CDS"^  T cell priming depends on antigen, 
immunisation route and virus replication 
To determine whether the results above were specific to i.d. immunisation, the 
effect of CpG on CD8^ T cell responses induced after systemic i.p. immunisation 
with WR-TK-SllN and MVA-TK-SllN was studied. This also allowed a direct 
comparison with the published work with CpG, which mainly use systemic routes 
for immunisation. Unlike the i.d. route, CpG treatment did not reduce OVA-257-
and B8-20-specific responses after i.p. injection with WR-TK-SIIN when 
measured as the percentages of responding CD8'^ T cells (Figure 3-lOA left). 
Surprisingly, CpG significantly lowered the responses against most of the other 
VACV peptides by 60%, suggesting that the effect of this treatment was epitope-
specific (Figure 3-1 OA). When the absolute numbers of responding CD8^ T cells 
were measured, we found that the size of responses against OVA-257 and B8-20 
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Figure 3-10| CpG treatment shows inconsistent influences on CD8^ T cell responses 
induced during MVA and WR immunisation via the i.p. route. CpG-treated or control 
mice (PBS) were immunised i.p. with 2x10" PFU of WR-TK-SIIN (A and B) or MVA-
TK-SIIN (C, D). CD8 T cell responses to the peptides shown were measured in spleens 7 
days later. Percentages (A, C) and absolute numbers (B, D) of responding CDS"^ T cells 
are shown on graphs on the left as mean ± SEM. Extent to which responses to OVA-257, 
B8-20. or the sum of other VACV peptides (others) were suppressed in CpG compared 
with control treated mice after immunisations are shown on graphs on right, based on the 
data on left. N.S.: not significant. * denotes statistical significance (p < 0.05). Results are 
compiled from three independent experiments (n = 9). 
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were also reduced by CpG (Figure 3-1 OB). This implies that CpG might repress 
the overall magnitude of the ant i -WR CD8" T cell response. However, this 
phenomenon was not observed by Xu et al. (2010). After i.p. immunisation with 
M V A - T K - S I I N . CpG treatment significantly inhibited responses to all peptides 
examined, including B8-20 and the directly-presented OVA-257 minigene. by 
nearly 9 0 % (Figure 3-10 C and D). Overall, these results confirm published data 
for WR (Xu et a l , 2010) and MVA (Gasteiger et al.. 2007) when a systemic 
immunisat ion route is used. However, results f rom the additional VACV peptides 
for WR and the directly-presented OVA-257 minigene for MVA demonstrate that 
CpG treatment could not be used to analyse antigen presentation pathways. 
The reasons responsible for the differential effect of CpG treatment on CD8^ T 
cell priming between WR and M V A after i.p. immunisation were examined. 
While the M V A genome contains several large deletions and multiple smaller 
mutat ion regions compared to that of WR (Antoine et al., 1998), the most obvious 
phenotypic differences between WR and M V A is the inability of MVA to 
replicate in vivo (Ramirez et al., 2000; Stittelaar et al., 2001; Wyatt et al., 2004). 
To examine the relationship between V A C V replication and the effect of CpG 
treatment, a new V A C V inactivation method was developed to abolish viral 
replication ability, but allow early virus gene expression. A method based on the 
T M P / U V treatment of V A C V tested in Section 3.2.2 was used. This treatment has 
been shown to inhibit replication of the treated WR-TK-SIIN while a relatively 
normal OVA-257/H-2K' ' presentation on cells infected with the treated WR-TK-
SIIN was detected (refer to Figure 3-2). The amount of T M P and UV exposure 
t ime was re-titrated such that it only effectively stops viral replication but does not 
affect the antigen expression level f rom WR. Here a WR recombinant, namely 
WR-NP-S-GFP. was used. This virus expresses a recombinant antigen, namely 
NP-S-GFP. This antigen consists of the N P antigen from lAV strain PR8. with its 
carboxyl- terminus fused to the OVA-257 peptide (SIINFEKL) and a GFP 
(Norbury et al., 2002; Princiotta et al., 2003). This protein is 752 amino acid 
residues in length, which is longer than 9 5 % of the native V A C V proteins. This 
antigen al lowed us to examine how the T M P / U V treatment would affect the 
expression level of a relatively long antigen expressed from VACV. WR-NP-S-
G F P was mixed with I | ig/ml of T M P and exposed to UV for various lengths of 
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time. Samples were tested for replicative ability by standard plaque assay and the 
expression level of NP-S-GFP by measuring GFP fluorescence level in 293A cells 
inoculated with the treated virus. From the results shown in Figure 3-11 A, the 
TMP-treated virus lost its ability to form plaques after 3 min of UV irradiation. In 
addhion. more than 95% of cells inoculated with WR-NP-S-GFP that had been 
treated with 1 ng/ml TMP and 3 min UV irradiation expressed GFP (Figure 3-
11B). Ahhough the GFP expression level decreased after the treatment, it was still 
much higher than the mock infected cells (Figure 3-1IC). This suggests that long 
proteins encoded by VACV can be expressed relatively well after the TMP/UV 
treatment. Thus, treating virus with 1 ng/ml TMP followed by 3 min UV exposure 
inhibits VACV replication but still allows early viral gene expression. 
To test whether replication ability plays a role in determining the outcome of CpG 
experiments. WR-TK-SllN was treated with the TMP/UV method as stated above 
and was injected i.p. into CpG- or PBS-treated mice. The inability of the treated 
virus to replicate was confirmed by standard plaque assay (data not shown). Seven 
days after immunisation with the non-replicating WR-TK-SIIN, CD8^ T cell 
responses against the examined peptides, including OVA-257 and 88-20. were 
reduced by around 70-90% in CpG-treated mice (Figure 3-12). These results 
closely resembled the findings using MVA-TK-SIIN (compare to Figure 3-lOC 
and D). Because the response against the directly-presented OVA-257 minigene 
was suppressed when WR-TK-SllN was rendered non-replicative, it clearly 
demonstrates that virus replication, but not priming pathway, influences the 
outcome of CpG treatment. 
3.2.7 CpG treatment reduces virus loads, but this does not explain its impact 
on CDS"^  T cell priming 
It remained puzzling why CpG affected priming of CD8"^ T cell responses against 
B8-20 and the OVA-257 minigene more strongly after WR immunisation via i.d. 
than i.p. injection. As shown in the previous section, the outcome of CpG 
treatment was sensitive to VACV replication after i.p. immunisation. It is possible 
that the amounts of antigens from WR available for priming between 
immunisations via the i.d. and i.p. routes are different which in turn influence the 
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Figure 3-11| T M P treatment with brief IIV irradiation inhibits V A C V replication, 
but still allows early viral gene expression. 2x10'* PFU/ml of WR-NP-S-GFP treated 
with 1 (ig/ml of TMP in PBS (480 |.il) was irradiated with UV Mght at 365 nm wavelength. 
At times indicated. 50 |il virus solution was taken for further experiments. (A) The 
replicative ability of the treated virus was examined by standard plaque assay. (B and C) 
The GFP expression of the treated virus in 293A cells at an m.o.i. of 5 after 6 h of 
infection was determined by flow cytometric analysis. (B) Percentages of cells expressing 
GFP after infection. (C) A histogram showing the level of GFP expression in the infected 
cells. This experiinent was repeated twice; representative results from one experiment are 
shown. 
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Figure 3-12| Viral replication ability dictates the inhibitory effect of CpG treatment 
on CD8^ T cell responses after i.p. immunisation. Mice were treated with CpG or PBS 
and one day later they were immunised i.p. with 2x10' ' PFU WR-TK-SIIN that was treated 
with 1 ng/ml TMP and 3 inin UV irradiation. The percentage (A) or absolute numbers (B) 
of CDS" T cell responses to the peptides indicated were measured in spleens 7 days later 
and are shown as means ± SEM on graphs on the left. Graphs on the right show the extent 
of suppression based on the data from the left. * denotes statistical significance (p < 0.05). 
Results are compiled from three independent experiments (n = 9). 
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inhibition effect o f CpG. Previous studies have shown that W R repHcation and 
spread is relatively limited after i.d. injection into the ear pinnae compared with 
systemic routes (Tscharke and Smith. 1999; Fischer et al., 2011; Lin et a!., 2013). 
Furthermore. CpG treatment can induce a robust innate immune responses to 
prevent the replication and dissemination o f VACV in vivo (Rees et al.. 2005; 
Belyakov et al., 2006). It was possible that these two factors together decrease the 
amount o f viral antigens expressed in vivo and in turn compromise the CD8 ' T 
cell priming after immunisation o f CpG-treated mice with W R via the i.d. route. 
To test this hypothesis, the amount of infectious W R in various organs, including 
the known priming LNs, were examined after i.d. or i.p. immunisation of CpG-
treated and control mice. Because priming occurs early after VACV immunisation 
(Norbury et al.. 2002), one and three days post immunisation were chosen as the 
examination time points. After i.d. immunisation, there was no difference between 
the amount of infectious virus isolated from the infected ears of CpG-treated and 
control mice (Figure 3-13A). However, there was significantly lower amount of 
infectious virus (around 1.5 logio-fold reduction) in the draining cervical LNs. 
After i.p. immunisation with WR-TK-SIIN. although the averaged virus titres 
seemed to be lower in CpG-treated mice in the examined organs, the difference 
was only statistically significant in the spleen on day 3 (Figure 3-138). These data 
imply that CpG treatment prevented the spread of W R and might compromise 
antigen loads in priming sites early after i.d. immunisation, but to a lesser extent 
for i.p. immunisation. 
To investigate whether the reduction of the amount o f W R alone might prevent an 
optimal priming of CD8^ T cell responses after i.d. immunisation, a low dose of 
W R was used for immunisation. Mice were immunised with 2x10^ PFU of WR , a 
1000-fold reduction on the dose used in previous experiments. At the first day 
post immunisation, less than 2 PFU of virus was isolated from the draining 
cervical LNs (Figure 3-13C). This was much lower than that detected on day 1 in 
CpG-treated mice immunised with a high dose of virus (Figure 3-13 A). The virus 
load in cervical LNs became more typical three days after immunisation with a 
low dose of WR . Despite the reduced virus levels in draining LNs on the first day, 
mice immunised with the low dose of W R had strong CD8^ T cell responses to all 
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Figure 3-13| CpG treatment reduces VACV loads, but lower virus doses prime typical 
CD8^ T cell responses. (A and B) CpG- or PBS-treated mice were immunised with 2x10'* 
PFU VACV WR via the i.d route (A) or WR-TK-SIIN via i.p. route (B). Virus titers from 
organs as shown were determined by standard plaque assay 1 and 3 days post-
immunisation. (C-E) Mice were immunised i.d. with 2 x l o ' PFU WR. (C) Virus titres in LN 
and ear were measured 1 and 3 days after immunisation. Percentage (D) and absolute 
numbers (E) of splenic CDS' T cells producing IFN-y after ex vivo stimulation with peptide 
indicated were measured 7 days after immunisation and are shown as mean ± SEM. (A and 
B) Data are combined from two independent experiments (n = 6). Data in (C-E) represent 
results from two independent experiments (n = 6). * denotes statistical significance {p < 
0.05). 
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VACV epitopes, similar to those injected with 1000-fold more virus (Figure 3-
I3D and E, compared with control mice in Figure 3-8A and B). This experiment 
was not ideal because virus was available in the draining LNs at day 3 after low 
dose immunisation. This might contribute to CD8^ T cell priming. Nevertheless, it 
has been suggested that the first 24 hours after immunisation is the most important 
time for priming CD8^ T cells by VACV (Norbury et al., 2002). Also, by three 
days after immunisation. CpG significantly reduced the amount of virus in the 
spleens of mice immunised WR-TK-SIIN with via the i.p. route (Figure 3-I3B). 
However, this did not affect the percentages of CD8^ T cells that were specific to 
B8-20 and OVA-257 (Figure 3-1 OA). These arguments suggested that differences 
in virus levels at day 3 post immunisation might not be as relevant as those at 
earlier time points. 
Collectively, CpG treatment reduced virus loads in the priming LNs and this 
might contribute to the reduced CD8^ T cell priming after i.d. immunisation with 
WR. However, it seemed unlikely that this effect solely responsible for the strong 
inhibition of anti-WR CD8^ T cell responses by CpG in this route. 
3.2.8 Increased antigen dose partially overcomes the inhibition of €08"^ T cell 
priming by CpG 
The relationship between virus replication and CpG-induced inhibition of CD8^ T 
cell responses explored in the previous sections suggests a role for antigen dose in 
influencing the outcome of CpG treatment. Therefore, it seemed likely that the 
inhibition of CD8^ T cell responses by CpG treatment could be rescued simply by 
increasing the dose of antigen. This theory was tested by immunisation with a 
high dose of MVA. Here, CpG-treated and control mice were immunised twice 
with MVA-TK-SIIN, two days apart with 2x |0^ PFU via the i.p. route. This 
increased the MVA inoculum by 100-fold for each individual dose, as well as 
doubled the vaccination dose given as the dose used in Figure 3-10. From the 
result, the B8-20-specific response was still significantly suppressed by CpG 
treatment after this high-dose immunisation with MVA. However, the extent of 
the reduction decreased to around 45% (Figure 3-14A and B). In comparison, 
nearly 80% of B8-20-specific response was suppressed by CpG when the normal 
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Figure 3-14| Immunisation with a higher dose of M V A overcomes the inhibitory 
effect of CpG treatment on CD8^ T cell responses. Mice were immunised i.p. witli 
2x10" PFU of MVA-TK-SIIN on day 0 and day 2, starting from a day after CpG or PBS 
treatments. Percentages (A) and absolute numbers (B) of the CD8^ T cells recognising 
OVA-257 and B8-20 were measured in spleens 7 days after immunisation. Results are 
shown as mean ± SEM on graphs on the left. Graphs on the right show the extent to 
which responses were suppressed in CpG compared with control treated mice, based on 
the data presented on the left. Results are compiled from two independent experiments (n 
= 6). * denotes statistical significance ( p < 0 .05). 
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dose of MVA was used (refer to Fig 3-lOC and D). In addition, the OVA-257-
specific response induced by tiie directly-presented OVA-257 minigene was no 
longer significantly lower in CpG-treated mice compared with control mice 
(Figure 3-14A and B). The apparent reduction of this response was around 40%, 
compared with 90% for the usual dose (refer to Fig 3-IOC and D). 
The ability of a high antigen dose to overcome the inhibition of cross priming by 
CpG treatment was then investigated. Here CpG-treated and control mice were 
immunised i.p. with 2.5x10' heat-inactivated WR-TK-OVA-infected cells, which 
was 25 times more than the dose used in the original experiments shown in Figure 
3-7. A significantly lower response was observed for B8-20- but not OVA-257-
specific CDS"^ T cells in CpG-treated mice compared with control mice (Figure 3-
15). Furthermore, the suppression of CD8^ T cell responses by the CpG treatment 
was reduced for both epitopes when mice were immunised with 2.5x10' infected 
cells (40-70%; right of Figure 3-15 A and B), as compared with experiments using 
a dose of I^IO*" cells (more than 80%; Figure 3-7C and D). This finding with a 
high dose of antigen donor cells is similar to that using a dose of MVA inoculum 
(refer to Figure 3-14). Results in Figure 3-14 and 3-15 demonstrate that the extent 
to which CpG treatment inhibited CD8^ T cell responses was sensitive to the 
antigen dose administered. 
3.2.9 Cytc treatment fails to differentiate between direct and cross priming 
The studies above indicate that CpG treatment only reflected antigen dose used, 
but not the CD8^ T cell priming pathways. Therefore, a different strategy was 
needed for the original aim of this chapter, which was to dissect MHC-I 
presentation pathways for individual native VACV peptides. Cytc treatment was 
chosen as the alternative method because it has been published as an approach to 
selectively inhibit cross presentation (Lin et al., 2008). 
The original report indicated that pre-treating mice once with 5 mg cytc one day 
before immunisation was enough to suppress cross priming in vivo (Lin et al., 
2008). Here the length of cytc treatment was extended, in which mice were 
injected i.v. with 5 mg cytc for five consecutive days starting one day before 
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Figure 3-15| Increasing antigen dose partially overcomes the inhibitory effect of CpG 
treatment on cross priming. CpG- and PBS-treated mice were immunised i.p. with 
2.5x10' heat-inactivated. WR-TK-OVA-infected 293A cells. Percentages (A) and absolute 
numbers (B) of the OVA-257- and B8-20-specific CDS' T cell responses were measured in 
spleens 7 days after immunisation and are shown as mean ± SEM on graphs on the left. 
Graphs on the right show the extent to which responses were suppressed in CpG compared 
with control treated mice, based on the data presented on the left. Results are combined 
from two independent experiments (n = 6). * denotes statistical significance (p < 0.05). 
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immunisation. 1 his was to prolong its possible inhibitory effect on cross priming 
over the whole course of immunisation. Because cytc treatment has not been 
applied to the study of VACV before, its ability to stop cross presentation of 
VACV antigens in vivo was first examined. Figure 3-16 shows that cytc reduced 
CD8^ T cell responses against multiple peptides elicited by VACV-infected cells. 
However, the inhibition seemed to be less than we observed for CpG treatment 
and most apparent reductions were not statistically significant. 
Next, the effect of cytc on priming CD8^ T cell responses during VACV 
immunisation was analysed. The VACV recombinants expressing the directly-
presented OVA-257 minigene were used again here. This allowed us to determine 
if the treatment would affect direct priming. Results from Figure 3-17A show that 
CDS" T cell responses against OVA-257 and B8-20 induced by WR-TK-SIIN 
were enhanced by cytc treatment while other responses were not affected. This 
result contradicts the experiments whh CpG as shown on Figure 3-10. For MVA-
TK-SIIN, cytc caused a reduction in CDS"^  T cell responses against many peptides 
tested, including OVA-257 and 88-20 (Figure 3-178). It was noticed that the 
A47-171-specific response was not affected by cytc here. To determine whether 
the outcomes of cytc treatment for WR and MVA were also dictated by their 
replicative ability, TMPAJV treatment (Section 3.2.6) was used again to stop WR-
TK-SIIN from replicating in vivo. Similarly to the CpG experiment shown in 
Figure 3-12, priming of CDS"^  T cell responses by the non-replicating WR-TK-
SIIN was suppressed by cytc for most peptides tested (Figure 3-17C), in a manner 
most similar to MVA, but not WR. It should be noted that in this experiment, the 
OVA-257-specific response was reduced by cytc, but the difference was not 
significant. Interestingly, the response to A47-171 was also inhibited here, 
different from MVA-TK-SIIN. 
Overall, cytc clearly impairs direct priming of CDS" T cell responses during 
immunisation with non-replicating VACV. One possibility is that cytc may 
eliminate APCs that would normally be infected with VACV, which will 
compromise direct priming in vivo. In addition, the effects of CpG and cytc 
treatments on the CDS" T cell responses induced during WR immunisation were 
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Figure 3-16 | Cytc treatment reduces cross pr iming o f CDS"^ T cell responses from 
V A C V - i n f e c t e d cells. Cytc- or PBS-treated mice were immunised i.p. with Ix lO' ' heat-
inactivated W R - T K - O V A - i n f e c t e d 293A cells. Percentages (A) and absolute number s 
(B) of CD8^ T ceil responses to pept ides indicated were measured in sp leens 7 days post 
immunisa t ion by ex vivo peptide stimulation and ICS. Data are shown as m e a n s ± S E M 
and are combined f rom two independent exper iments (n = 2 and 5 fo r PBS and cytc 
respect ively) . * denotes statistical s ignif icance (p < 0.05). 
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Figure 3-17| Cytc treatment does not dissect CDS"^ T cell priming pathway for 
V A C V W R and MVA. Cytc-treated or control (PBS) mice were immunised i.p. witli 
2x10' ' PFU of WR-TK-SIIN (A), MVA-TK-Sl lN (B) or WR-TK-SIIN treated with 
TMP/UV inactivation method as described in Figure 3-12 (C). Percentages (left) and 
absolute numbers (right) of CDS' T cell responses to the peptides indicated were 
measured in spleens 7 days later and are shown as means ± SEM. Results are combined 
from three (A) and two (B, C) independent experiments (A: n = 9; B and C: n = 6). * 
denotes statistical significance (p < 0.05). 
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not consistent. Therefore, cytc treatment does not provide insight into the 
pathways involved in priming anti-VACV CD8^ T ceils. 
3.3 Discussion 
The original focus of this chapter was to examine the MHC-i presentation 
pathways used by a large panel of native VACV antigenic peptides to prime CD8^ 
T cells during immunisation with VACV WR and MVA. CpG and cytc pre-
treatments. two well-published strategies, were chosen for this purpose. However, 
both failed to dissect CD8^ T cell priming pathways. 
Results in this chapter first demonstrate that dermal immunisation of mice with 
WR and MVA induced CD8^ T cell responses against multiple VACV peptides 
which were first identified to be immunogenic from mice i.p. immunised with WR 
(Tscharke et al., 2005; Moutaftsi et a l , 2006). The overall immunodominance 
hierarchy induced by WR via the i.d. route was similar to the published study by 
Moutaftsi et al. (2006) in which the i.p. route was used. This confirms the findings 
which showed that the overall hierarchy of the immunogenicity of individual 
VACV peptides is not altered by the choice of routes (Oseroff et al., 2008; Lin et 
al., 2013). Compared to WR. the immunogenicity of VACV peptides expressed 
from MVA were generally lower. For instance, although the percentage of CD8'^ 
T cells specific to B8-20 is similar between WR- and MVA-immunised mice, a 
closer examination of the total number of B8-20-specific T cells showed that the 
magnitude of the response induced by MVA was smaller. This reduced level of 
immunogenicity was more apparent for the subdominant antigens. A decreased 
overall anti-VACV CD8^ T cell response induced during MVA immunisation 
compared to WR has been noted previously (Ramirez et al., 2000). 
For two peptides, namely B2-54 and C4-125, the lack of responses can be 
explained by the absence of these two peptides from MVA. The B2 protein from 
MVA is truncated and it loses the carboxyl-terminal sequence, including the B2-
54 peptide, when compared with WR (Antoine et al., 1998). It should be noted 
that a putative polypeptide, containing the B2-54 peptide, could be expressed 
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from the remanent o f the M V A B2R gene (Antoine et al., 1998). However, the 
lack of B2-54-speciric response implies that this protein might not be expressed 
from M V A . The entire C4L gene, which encodes the C4 antigen, is lost from the 
M V A genome as it is within one of the six large deletion regions (Antoine et al.. 
1998). Because no responses to B2-54 and C4-I25 were induced by M V A , it 
implies that M V A does not encode cross-reactive mimitopes for these two 
peptides. For other antigens, one may argue that the level of expression and 
stability o f the antigens may vary between W R and M V A due to small variations 
within the genes or promoter sequences (refer to Table A-2 in the Appendix). This 
is possible as M V A contains many small mutations within its genome, in addition 
to the six major deletions compared to WR. Thus, the efficiency of antigen 
processing and presentation may be affected. However, it is unlikely to explain all 
the differences. For instance, both the promoter sequence and the A8 amino acid 
sequence encoded by the VACV A8R gene from M V A and W R are identical 
(Table A-2 in Appendix) and so it is hard to explain the observed differences in its 
immunogenicity between W R and M V A with the antigen-intrinsic reason 
suggested above. Further, there are broad differences in the genetics between 
these two V A C V antigens as a whole, which in turn dictates their virulence. Viral 
virulence is involved in modulating the magnitude of CD8^ T cell responses. For 
instance, the B18R gene from VACV strain W R encodes a soluble and cell 
surface-associated IFN-I binding protein which is not functional in M V A 
(Symons et al., 1995; Alcami et al., 2000; Waibler et al., 2009). When B18R is 
deleted from W R . it does not alter the replication ability of the virus in vitro, but 
the mutant is less pathogenic in vivo and induces a lower anti-VACV CD8^ T cell 
response compared with the wildtype virus (Symons et al., 1995; Salek-Ardakani 
et al., 201 lb). It has been shown that mice deficient in IFN-a/p receptor are more 
susceptible to infection with wildtype VACV strain W R (Muller et al., 1994). The 
CD8^ T cell response in these mice against this VACV strain has not been 
reported, probably due to the high virulence of the virus in this mutant strain. 
Recently, a study shows that M V A can induce a functional CD8^ T cell response 
in IFN-a/p receptor-deficient mice (Volz et al., 2014). However, a direct 
comparison between wildtype and the transgenic mice has yet to be reported. It 
should be noted that, as discussed in section 1.5.3, direct IFN-I signalling is 
essential for the expansion of CD8^ T cells after priming (Thompson et al., 2006). 
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In addition. WR induced a stronger anti-viral CD8^ T cell response than VACV 
strains that are less virulent (Ramirez et al., 2000; Salek-Ardakani et al., 201 la)., 
It has been shown that the less virulent strains are less able to fully activate 
multiple co-stimulatory signalling pathways (Salek-Ardakani et al., 201 lb). These 
antigen-extrinsic factors which are defined by the interaction between the virus 
and host are clearly important in dictating how well a CD8^ T cell response is 
primed during VACV immunisation. 
We have developed an in vivo cross priming assay here based on immunisation 
with VACV-infected cells. We found that heat inactivation is a suitable method 
for inhibiting residual virus on infected cells for use in a cross priming assay. 
Psoralen/UV treatment, which crosslinks the DNA genome of VACV after UV 
irradiation, inhibited viral replication in our studies, but failed to completely 
inactivate OVA-257 minigene gene expression from WR-TK-SIIN. It has been 
shown that antigen presentation from a VACV-expressed minigene is not as 
severely affected by this treatment as a full-length antigen (Fischer et al., 2007). 
This is most likely because of a lower probability of crosslink formation within 
shorter, compared to longer, genes. Our results confirmed that it is difficuh to 
eliminate the minigene expression and presentation from WR-TK-SIIN with 
psoralen/UV treatment. We were concerned that this treatment might not be 
reliable and therefore it was not chosen for use in our cross presentation assay. 
Heat inactivation. on the other hand, causes denaturation of VACV antigens. It 
has been shown that when VACV was heated to 60°C, there was a rapid 
inacfivation of most virus particles within 10 min of treatment, followed by a 
gradual decline of infectivity of residual virus particles that seemed to be less 
thermosensitive (Kaplan. 1958). More importantly, after 60°C heat treatment, 
infectivity of VACV was reduced by more than lO'-fold as shown in multiple 
studies (Kaplan. 1958; Woodroofe, 1960; Madeley, 1968). In addition, this 
treatment abrogates the ability of VACV to transcribe and translate viral genes 
within cells (Harper et al., 1978). Our studies with WR-TK-SIIN, which show that 
headng VACV to 60°C for 60 min sufficiently abolishes both virus replication 
and MHC-I presentation of the OVA-257 minigene, confirm these early reports. 
Indeed, heat-treated cells that had been infected with WR-TK-OVA. but not WR-
TK-SIIN, primed an OVA-257-specific response in vivo, in accordance with a 
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previous finding which utihsed germicidal UV irradiation to inactivate VACV-
infected cells (Norbury et al., 2004). In addition, the specificity of CD8^ T cell 
responses induced by heat-inactivated WR-infected cells was similar to the 
responses elicited with germicidal UV-inactivated cells infected with WR-TK-
O V A (Lev et al., 2009). It should be noted that heating antigens could result in 
antigen aggregation (Speidel et al., 1997; Cho et al., 2003). This could influence 
how an antigen is cross presented. To test this possibility, a 293A cell line stably 
expressing V A C V B8 protein could be treated with heat inactivation. These 
treated cells could then be used to immunise mice. Any differences in the B8-20-
specific CD8^ T cell response induced by the heat-treated cells compared to the 
untreated cells will indicate that the inactivation treatment affects how an antigen 
is processed for cross priming. Transgenic mice lacking components essential for 
certain cross presentation pathways (such as cathepsin S-deficient mice) could 
also be used to determine the processing pathway involved. Overall, data 
presented in this chapter support the validity of the use of heat treatment to 
eliminate residual virus on the infected cells used in our cross priming 
experiments. 
When we examined which antigens are cross presented from VACV-infected 
cells, we found that peptides originating from the early (J2-289, L2-53, K3-6, 
A47-171 and B8-20), intermediate (A3-191 and A3-270) and late (A42-88) 
classes of V A C V gene products are all immunogenic in this context. Interestingly, 
although both CD8^ T cell epitopes from A47 (A47-138 and A47-171) are 
immunogenic during W R immunisation, only A47-171, but not A47-138. can be 
cross presented from infected cells to prime CDS"^ T cells. In contrast, CD8^ T 
cells that recognised the A3-191 and A3-270 peptides originating from the A3 
antigen can be primed via cross presentation from VACV-infected cells. This 
implies that cross presentation o f a peptide is not only influenced by the nature of 
the cross-presented antigen, but also affected by either the characteristic of the 
presented peptide or the processing of the peptide from the surrounding amino 
acid sequences of the antigen. It is also noticed that responses against 
subdominant peptides induced by cross priming from MVA-infected cells were 
lower than those o f WR-infected cells after i.p. immunisation. Although many 
mammalian cell lines, including the human 293A cell line used as antigen donor 
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cells here, are not peirnissive for MVA replication, late genes from MVA are still 
expressed efficiently within these cells (Sutter and Moss, 1992; Carroll and Moss, 
1997; Ludwig et al., 2005). In addition, it has been shown that MVA expressed a 
similar level of (i-galactosidase antigen when driven by a VACV late promoter in 
infected 293A cells, compared to WR (Sutter and Moss. 1992). This suggested 
that a similar level of antigens can be expressed by WR and MVA in the antigen 
donor cells used here. However, we could not rule out that native VACV antigens, 
which are the focus of this study, might be expressed differentially by these two 
VACV strains. 
This cross priming assay successfully demonstrated that some, but not all, 
antigens can be cross presented from VACV-infected cells. However, there are 
several limitations related to this cross priming assay. Firstly, our cross priming 
assay is different from the naturally-occurring cross priming during virus 
immunisation. This is because the infected antigen donor cells were heat-treated 
and so no further antigen expression was allowed in our assay. Secondly, there 
may be unmapped VACV CD8^ T cell epitopes that are exclusively cross 
presented. CDS"^ T cell responses against these peptides might have been missed. 
Thirdly, VACV antigens may be available in various forms for cross presentation, 
not only associated with infected cells. For instance, secreted VACV antigens 
may be cross presented as soluble antigens. VACV B8 antigen, a secreted IFN-y 
receptor (Alcami and Smith. 1995; Sroller et al.. 2001; Verardi et al., 2001; 
Symons et al., 2002), may be able to be cross-presented in this form. Interestingly, 
several of the antigens that are cross presented from VACV-infected cells are 
found within virion particles, including A3, A42, and J3 antigens (Jensen et al., 
1996; Chung et al., 2006; Yoder et al., 2006; Resch et al., 2007). The hypothesis 
that these antigens can be cross presented from inactivated virions to prime CD8^ 
T cell responses are examined in Chapter 6. 
After finding that some VACV antigens could be cross presented from infected 
cells, the next question was how native VACV antigens are presented during 
VACV immunisation. Here the CpG and cytc treatments were used. However, 
both methods failed to determine the priming mechanisms for anti-VACV CD8^ T 
cells in mice. Firstly, studies here show that CpG treatment inhibits direct priming 
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by V A C V when the dose of antigen is hmited, especially during immunisation via 
the local dermal route or with non-replicating VACV. Secondly, the extent o f 
CpG inhibition o f cross priming from virus-infected cells is not absolute. Rather it 
depends on the quantity o f antigen donor cells used. These findings highlight the 
difficulty in examining direct and cross priming during a viral infection with this 
method. When infectious virus is used, replication occurs and the antigen dose 
produced can be very high. This effect would be even more prominent i f the 
infection can spread to other organs, which is exactly what occurred during i.p. 
immunisation with V A C V W R (Bulleret al., 1985; Lin et al.. 2013). Disruption of 
the V A C V TK gene by insertion of foreign antigen-expressing constructs into the 
genome of W R decreases the virulence of the resulting recombinants (Buller et 
al.. 1985). However, these recombinants, such as WR-TK-SllN used in this study, 
can still spread to multiple internal organs after i.p. injection (Buller et al.. 1985; 
Ramirez et al., 2000; Benning and Hassett. 2004; Gomez et al.. 2007). In contrast, 
non-replicating viruses, such as MVA . provide relatively lower amounts o f 
antigen in vivo (Ramirez et al., 2000; Gomez et al., 2007). Similarly, the in vivo 
cross priming assay used in this thesis can also be considered to provide a low 
antigen dose for priming. This is because a finite number of antigen donor cells 
were used and no antigens were expressed further within the cells after heat 
treatment. Methods such as the CpG treatment, which is sensitive to antigen levels 
as shown in Sections 3.2.6 and 3.2.8, might suppress CD8^ T cell responses 
induced by low antigen doses to a greater extent than those associated with high 
antigen doses. This might explain the results of experiments using CpG which at 
first glance imply priming by M V A by any route and W R by i.d. injection in the 
ear requires cross presentation. 
Our data do not reveal how CpG treatment influences anti-VACV CD8^ T cell 
priming. Extensive systemic CpG injection results in a significant change in the 
host's immune system. This includes splenomegaly and a change of the 
composhion of lymphocytes in the spleen (Sparwasser et al., 1999; Heikenwalder 
et al., 2004). Importantly, the organisation of secondary lymphoid organs is 
disrupted in mice treated with CpG (Heikenwalder et al., 2004). In addition, CpG 
treatment affect the migration of DCs in vivo (Behboudi et al., 2000; Yang et al., 
2005; Constabel et al., 2009). The latter two effects might negatively influence 
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how well DCs can be infected by virus in vivo. They might also prevent cell-to-
cell contacts between CD8^ T cells and antigen-presenting DCs in vivo, which are 
required for priming. Furthermore, it has been shown that CpG treatment 
increases expression of indoleamine 2,3-dioxygenase and activation of regulatory 
T cells, which results in a suppression of CD8^ T cell immunity (Wingender et al., 
2006; Baban et a!.. 2011). Finally, because CpG treatment reduces VACV loads, 
it might decrease the antigen dose available for priming, especially at sites where 
VACV spread is restricted, such as i.d. immunisation. 
Results in Figure 3-8 and 3-10 show that CpG caused a differential suppression of 
CD8^ T cell responses across different VACV peptides. The mechanism behind 
this was not further pursued. Interestingly. CD8^ T cell epitope-specific effects 
have been observed during co-administration of TLR ligands with LCMV 
(Siddiqui and Basta. 2011), suggesting this phenomenon is unlikely to be specific 
to VACV, It is possible that DCs matured by CpG in vivo might have a different 
functionality and this might result in an alteration of their ability to express, 
process and present individual antigens via direct presentation pathway. The high 
level of MHC-I presentation of the immunodominant B8-20 peptide and the 
OVA-257 minigene (Princiotta et al., 2003; Croft et al., 2013) might also partially 
compensate for the general reduction of CDS"^ T cell priming caused by CpG 
treatment, allowing CD8^ T cell responses to these two peptides to be induced. 
Further, the relatively high frequency of B8-20-specific CD8^ T cells in the naive 
repertoire might play a role as well (Flesch et al., 2010). However, it should be 
noted that CpG reduced the overall anti-VACV CD8^ T cell immunity when the 
total number of responding CD8^ T cells was measured, demonstrating its 
inhibition effect on CD8'^ T cell priming in general. Indeed. Wilson et al. (2006) 
demonstrated that CpG inhibits the CD8^ T cell response after HSV infection in 
mice although this outcome was attributed solely to the ability of CpG to inhibit 
cross presentation by the authors. 
Wilson et al. (2006) showed that direct priming of CD8^ T cells against OVA 
expressed endogenously in DCs was not affected by CpG in CDl lc-OVA 
transgenic mice, where the OVA expression (as a membrane-bound antigen) is 
under the control of the C D l l c promoter. In this model. OVA-257 should be 
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continuously presented by MHC-I on the DC surface. Maturation of DCs by CpG 
might simply enhance the stability of this established presentation (Chow et al.. 
2002; Ackerman and Cresswell. 2003). In addition. CpG might further enhance 
expression of co-stimulatory molecules on these presenting DCs (Hemmi et al., 
2000; Sparwasser et al., 2000), resulting in better CD8^ T cell activation. This is 
different from the situation o f the immunisation of mice after CpG treatment, 
where a virus must infect and have its antigens expressed, processed and 
presented by mature DCs. Moreover, the CDI l c-OVA transgenic mice used by 
Wilson et al. (2006) are not well characterised. In addition to DCs. other C D l Ic"^ 
cells would also be expected to express the OVA antigen in these mice. This 
could complicate the interpretation of the results. Furthermore, there are in vitro 
studies suggesting that presentation pathways cannot be separated simply based 
on DC maturation status. For instance, mature DCs generated from in vitro 
culturing with CpG could still cross present soluble or cell-associated antigens 
(Datta et al., 2003; de Brito et al., 2011). In addition, it has been shown that in 
vivo CpG pre-treatment does not affect cross priming of CD8^ T cell responses 
against soluble antigens (Drutman and Trombetta. 2010). This would further 
complicate the interpretation o f data even i f direct presentation was not affected. 
This demonstrates the complexity of models for dissecting antigen presentation 
that are based on the DC maturation states. 
Experiments with a different strategy, the cytc treatment, demonstrate that this 
treatment was also unable to show any insight into the priming mechanisms of 
anti-VACV CD8^ T cell responses. In vivo cytc treatment causes a depletion o f a 
subset o f CD8a^ DCs that are responsible for phagocytosing exogenous antigens 
for cross presentation (Lin et al.. 2008: Qiu et al., 2009). The CD8a" DC subset 
has also been implicated in CDS" T cell priming by W R (Belz et al., 2004; He et 
al., 2006). Together with the intravital observation of direct priming of CD8" T 
cells by WR-infected DC (Norbury et al., 2002; Hickman et al., 2008). it is 
reasonable to assume that the CDSa" DC subset is required for direct priming of 
anti-WR CD8" T cells. Therefore, it was unexpected when it was found that CDS"^ 
T cell responses to B8-20 and the directly-presented OVA-257 minigene induced 
by WR-TK-SIIN were enhanced after cytc treatment. It could be that the 
induction of DC apoptosis by cytc might disturb the organisation of secondary 
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lymphoid organs, similar to the CpG treatment, h is also possible that unknown 
signals might be generated after the elimination of DCs, which might modulate 
CD8^ T cell responses. However, it should be noted that the effect is peptide-
specific as responses against other tested VACV peptides were not affected. More 
importantly, cytc treatment, similar to CpG, impairs direct presentation. This is 
demonstrated by its inhibition on the direct priming of CD8^ T cells specific to the 
OVA-257 minigene expressed from MVA-TK-SIIN and the non-replicating 
TMP/UV-inactivated WR-TK-SIIN. A recent report by Kastenmiiller et al. (2013) 
used in vivo imaging and found evidence for direct CD8^ T cell priming by 
MVA-infected DCs in draining LNs. If priming of CD8^ T cells specific to 
antigens expressed from MVA and TMP/UV-inactivated WR requires CD8a^ 
DCs (as for WR). an elimination of these cells by cytc might result in poor direct 
priming. Although we showed that cytc suppressed cross presentation of VACV-
infected cells in vivo, we did not directly demonstrate whether cytc could deplete 
cross-priming CD8a^ DCs. It is possible that the effects observed could be a side 
effect. This could be easily tested by measuring the numbers of CD8a^ DCs in 
mice with and without cytc treatment and by determining the cross priming ability 
of the remaining CD8a^ DCs in cytc-treated mice ex vivo. Overall, results in this 
chapter show that the CpG and cytc treatments altered the CD8^ T cell priming in 
a way that was independent of the presentation pathways. This is probably 
because these treatments do not simply act on the presentation pathway directly, 
but via modifications of the overall immune system. 
The results presented here have several implications on antigen presentation in 
general. Firstly, our findings may not simply be limited to treatments with CpG 
and cytc, but may also be applicable to other TLR ligands that have been 
suggested to inhibit cross presentation in vivo, such as lipopolysaccharide (a TLR-
4 ligand) and synthetic dsRNA polyinosinic: polycytidylic acid (poly(I:C); a TLR-
3 ligand; Wilson et al., 2006; Bouvier et al., 2011). Recently, it has been shown 
that pre-treating DCs with pure LPS actually enhances in vitro cross presentation 
and peptidoglycan. a contaminant found during normal LPS preparation, is the 
chemical responsible for inhibiting cross presentation after DC maturation 
(Wagner and Cresswell, 2012). Secondly, we also believe that the findings shown 
in this chapter are not specific for VACV, but can apply to other viruses. As such, 
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experiments in which cross presentation is targeted by these methods should be 
analysed with caution. 
Interestingly, data in Figures 3-9 and 3-10 show that strong OVA-257-specific 
responses were induced in control mice after i.d. and i.p. immunisation with WR-
TK-SIIN and MVA-TK-SIIN. These results demonstrate that antigens expressed 
from these two V A C V strains can be directly presented effectively for CD8^ T 
cell priming in vivo. This confirms reports for W R (Lawson et al.. 1994; Restifo 
et al., 1995; Deng et al., 1997; Tobery and Siliciano, 1997; Norbury et al.. 2004; 
Tewalt et al., 2009). but contradicts that of Gasteiger et al. (2007), which 
suggested that CD8^ T cell responses against antigens expressed from M V A are 
induced by cross priming. Further comparisons of minigenes versus full-length 
antigens expressed from W R and M V A are examined in Chapter 4. 
In conclusion, the presentation mechanism for individual native VACV peptides 
expressed from V A C V strains W R and M V A were not successfully determined 
with CpG and cytc treatments in this chapter. This is mainly due to the complex 
effects of these treatments in vivo independent of antigen presentation pathways. 
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4.1 Introduction 
In the previous chapter, we attempted to dissect how native VACV peptides are 
presented using CpG and cytc treatments. Although these two strategies failed to 
provide any insights into the presentation pathways involved in priming anti-
V A C V CD8^ T cells, it was noted that OVA-257-specific CD8^ T cell responses 
were induced by the directly-primed OVA-257 minigene expressed from V A C V 
W R and MVA. The effect ive direct priming of the OVA-257 minigene expressed 
f rom M V A is surprising because it contradicts the study of Gasteiger et al. (2007). 
As discussed in Section 1.7.4. it is generally accepted that rapidly-degraded 
antigens and cytosolic or ER targeted minigene constructs facilitate direct 
presentation. Increasing the rate of proteasomal degradation of an antigen 
enhances the efficiency of direct presentation (Townsend et al.. 1988; Rodriguez 
et al.. 1997; Princiotta et al., 2003). Another strategy to enhance direct 
presentation is to bypass the requirement for protolytic processing entirely. As 
discussed in Section 1.7.4, peptides expressed as cytosolic minigenes require 
minimal antigen processing (to remove the methionine at the amino-terminus 
encoded by the start codon) while ER-targeted minigenes can even bypass the 
need for TAP translocation to bind to MHC-1 (Eisenlohr et al., 1992b; Bacik et a l , 
1994; Anton et al., 1997; Porgador et al., 1997; Fu et al., 1998; Princiotta et al., 
2003; Lev et al., 2008). 
Most of the above methods to enhance the efficiency of direct presentation 
originated f rom studies with VACV, mainly with strain WR. Foreign antigens 
expressed f rom WR in forms designed to facilitate direct presentation allow 
effect ive priming of CD8^ T cells in vivo. In many cases they are found to be 
more immunogenic than the full-length stable antigens (Irvine et a l , 1995; Restifo 
et al., 1995; Tobery and Siliciano. 1997; Fu et al., 1998; Tobery and Siliciano, 
1999; Norbury et al., 2004). In these studies, the in vitro direct presentation rate 
and the in vivo CDS'" T cell priming ability are clearly correlated. However, the 
study by Gasteiger et al. (2007) demonstrated that there was an opposite 
correlation for antigens expressed f rom MVA. The cytosolic OVA-257 minigene 
expressed f rom M V A induced a significantly lower OVA-257-specif ic CD8^ T 
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cell response compared to the full-length antigen, in spite of its more efficient 
direct presentation in vitro (Gasteiger et al., 2007). The investigators also noticed 
a similar result when they looked at the model tumor antigen Tyr, which 
contained a human MHC-I HLA-A*0201-restricted Tyr-369 epitope (Wolfel et al., 
1994; Mosse et a!., 1998). Gasteiger et al. (2007) found that enhancing the 
degradation of Tyr by fusing it to ubiquitin increased the in vitro direct 
presentation efficiency. However, this modification reduced the ability of the 
antigen to prime Tyr-369-specific CD8^ T cell response in transgenic HHD mice 
expressing HLA-A*0201. 
These findings by Gasteiger et al. (2007) suggest that constructs that facilitate 
direct priming do not allow effective priming in vivo when expressed from MVA. 
However, there are several caveats in their studies. Firstly there was no direct 
comparison with the relevant WR recombinants. WR recombinants expressing 
Tyr ehher as a minigene or as a full-length antigen have been generated and both 
allow induction of a Tyr-369-specific CDS"^ T cell response in mice (Bullock et 
al., 2000; Palmowski et al., 2002). However, different techniques were used to 
measure the CDS"^ T cell responses and so the relative immunogenicity between 
the Tyr-369 minigene and the full-length Tyr antigen could not be compared. 
Secondly, Gasteiger et al. (2007) focused on MVA recombinants that express 
foreign antigens from an insertion site that is not available in the WR genome. For 
most WR recombinants, including those used to examine the immunogenicity of 
minigenes and rapidly-degraded constructs as discussed above, the transgenes are 
commonly inserted into the J2R gene, which encodes the VACV TK protein. This 
gene locus is chosen as the insertion site because there is a well-established 
method to allow the selection of final recombinants that are TK" (Chakrabarti et 
al., 1985). This involves the use of 5-bromodeoxyuridine (BUdR) to suppress the 
replication of TK^ wildtype virus during the generation of recombinant virus with 
a TK" phenotype (Mackett et a l , 1982; Mackett et al., 1984; Chakrabarti et al., 
1985). On the other hand. Gasteiger et al. (2007) generated their MVA 
recombinants by inserting foreign antigens into the dellll region, one of the six 
large deletions in the MVA genome compared to those of other VACV strains 
(Section 1.9.2). The dellll region of MVA corresponds to a genomic segment 
encoding four functional proteins in WR and as such cannot be used as an 
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insertion site for WR. A previous report found tiiat the expression level of a given 
transgene from WR depends on the insertion site used (Coupar et a!., 2000). Thus, 
results from Gasteiger et al. (2007) should not be directly compared with studies 
that used WR recombinants. Thirdly, only two model antigens were examined for 
MVA in one single study. More examples are needed to test whether the findings 
of Gasteiger et al. (2007) can be generalised to other antigens. 
In this chapter, the immunogenicity of a number of recombinant antigens 
expressed as minigenes from VACV WR and MVA were compared with the full-
length antigens. For each set of recombinants used, the inserted antigen was 
expressed by the same promoter from the same insertion site. This allowed a 
direct comparison between the two VACV strains. We found that minigenes of 
these antigens expressed from WR and MVA allowed effective in vitro direct 
presentation. Importantly, minigenes expressed from both VACV strains were as 
immunogenic as. if not better than, full-length antigens in inducing CD8^ T cell 
immunity in vivo. Further investigations were conducted to understand the 
disparity between our results and those published. Studies with the OVA-
expressing MVA recombinants generated by Gasteiger et al. (2007) and the 
related OVA-expressing MVA recombinants demonstrated that the insertion site 
and the function of VACV TK play a role in dictating the immunogenicity of the 
foreign antigen. 
4.2 Results 
4.2.1 The immunogenicity of the immunodominant HSV gB-498 epitope when 
expressed as a minigene from VACV WR and MVA 
(Viruses used in this chapter are listed in Table A-3 in the Appendix) 
The immunodominant CD8^ T cell epitope from HSV-1 was chosen for the first 
set of experiments. The peptide is known as gB-498 and it is processed from the 
HSV gB antigen, whh the amino acid sequence SSIEFARL (Hanke et al.. 1991; 
Bonneau et al., 1993). This peptide is presented by MHC-1 H-2K^ The gB antigen 
is localised to the HSV-1 virion envelope and is important for virus entry into 
cells (Sarmiento et al., 1979; Sarmiento and Spear, 1979; Cai et al.. 1988). During 
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an acute HSV-1 infection in C57BI/6 mice, around 5-10% of total splenic CD8^ T 
cells recognise gB-498. representing at least 45% of the total anti-HSV-1 CD8^ T 
cell response (Wallace et al., 1999; St. Leger et al., 2011). HSV-2 also expresses 
this peptide and it is recognised by the CD8^ T cells induced during HSV-2 
infection (Bonneau et a l , 1993; Tang and Rosenthal, 2010). 
WR recombinants expressing the full-length HSV gB protein or an ER-targeted 
gB-498 minigene. namely WR-Full-gB and WR-ESmini-gB respectively, were 
available (Blaney et al.. 1998; Lin et al., 2013). The gB constructs of both 
recombinants are expressed under the control of the early/late VACV p7.5 
promoter (Cochran et al., 1985) from the VACV TK. locus. The immunogenicity 
of the constructs expressed from these WR recombinants has been studied in 
mice. Compared with the full-length gB. the ER-targeted minigene induces a 
significantly higher gB-498-specific CD8^ T cell response when expressed from 
WR (Lin et al., 2013). In addition, the response induced by the minigene is at a 
level similar to that of the immunodominant VACV B8-20 epitope (Lin et a l , 
2013). We were interested in the immunogenicity of this highly immunogenic 
HSV antigen when expressed from MVA. In order to allow a direct comparison of 
the results between WR and MVA. two new MVA recombinants were designed 
and generated. They express either a full-length gB protein or an ER-targeted gB-
498 minigene by the same p7.5 promoter and from the same insertion site (VACV 
TK locus) as the set of WR recombinants mentioned above. The MVA 
recombinants are called MVA-Full-gB and MVA-ESmini-gB respectively. 
4.2.1.1 Direct presentation of gB-498 is enhanced when it is expressed as an 
ER-targeted minigene from VACV WR and MVA 
It is generally accepted that minigenes allow better direct presentation in vitro 
than full-length antigens when expressed from VACV, but it has not been 
empirically demonstrated for the HSV gB antigen. Therefore, this question was 
first examined using the gB-expressing WR recombinants and the newly-made 
MVA recombinants. Because there is no available reagent for direct measurement 
of gB-498/H-2K'' complexes, we set up an in vitro direct presentation assay using 
re-stimulation of splenocytes from a mouse infected with HSV-1 strain KOS as a 
readout. In brief, DC2.4 cells, a DC-like cell line generated from C57BI/6 mice 
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(Shen et al.. 1997), were used as stimulators. These cells were infected with the 
gB-expressing V A C V recombinants. The infected cells were then used to induce 
IFN-y production in CD8^ T ceils from a HSV-immunised mouse during co-
culturing in the presence of BFA. Standard ICS was then performed to measure 
the percentage of CDS ' T cells expressing IFN-y after stimulation. 
The percentage of HSV-immune CDS ' T cells activated reflects the direct 
presentation level o f the gB-49S peptide on the infected DC2.4 cells. Although 
this assay has the possibility of detecting the presentation of other antigenic 
epitopes available in the full-length gB protein, the MHC-I binding affinities of 
the other known epitopes from gB are much lower than the immunodominant gB-
49S epitope (St. Leger et al.. 2011). More importantly, these minor epitopes only 
constitute a very small proportion of the anti-HSV CDS ' T cell response induced 
in HSV-immunised mice (St. Leger et al.. 2011). Also, these CDS ' T cells would 
favour recognition o f the full-length gB only, but not the gB-49S minigene. 
Therefore, they should not affect the analysis of this assay. 
Results o f this in vitro direct presentation assay are shown in Figure 4-1. Firstly. 
DC2.4 cells infected with WR-delTK and MVA-delTK. two control recombinants 
which do not express any gB constructs, did not stimulate the HSV-specific CDS ' 
T cells (Figure 4-1A and C). This demonstrates that there is no cross-reactivity of 
HSV-specific CDS ' T cells to VACV antigens. Secondly. DC2.4 cells infected 
with V A C V expressing the gB-498 constructs were able to re-stimulate the HSV-
immune CDS ' T cells in vitro, in spite o f the differences in the re-stimulation 
levels between different constructs. Kinetically, the re-stimulation of HSV-
immune CDS ' T cells by DC2.4 cells infected whh WR-ESmini-gB and MVA-
ESmini-gB reached the maximal level after two hours of infection and remained 
at this high level for the following four hours (Figure 4-1A and C). In comparison, 
the stimulation level by DC2.4 cells infected with WR-Full-gB and MVA-Full-gB 
increased gradually in the first four hours and then levelled o f f However, even at 
the maximal level, DC2.4 cells infected with V A C V expressing the full-length gB 
protein only stimulated around 50-60% of the HSV-immune CDS ' T cells 
compared to those infected with VACV expressing the gB-49S minigene. As a 
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Figure 4-11 HSV gB-498 expressed as an ER-targeted niinigene is directly 
presented more effectively than as a full-length antigen when expressed from W R 
and MVA. DC2.4 cells (simulators) were infected with the indicated recombinant WR 
(A and B) or MVA (C and D) for 5 h. They were then co-cultured with splenocytes 
(effectors) from mice immunised with either HSV-1 strain KOS (A and C) or V A C V 
WR (B and D) seven days earlier. A stimulator:effector ratio of 1:5 was used. BFA was 
added I h after cells were mixed, followed by another 3 h of co-culture. ICS was then 
performed to measure the percentage of CD8 T cells that produced IFN-y. Standard 
ICS assay with a synthetic gB-498 peptide was also performed in parallel to measure 
the maximum possible gB-498-specific T cell response. (A and C) Data show the level 
of gB-498-specific CD8^ T cell activation by the infected DC2.4 cells, standardised to 
the percentage of maximal activation induced by the synthetic gB-498 peptide. ( 8 and 
D) Data show the percentages of splenic CD8 T cells from a WR-immunised mouse 
activated by the indicated infected DC2.4 cells. Data for the gB-expressing 
recombinants represent mean ± SEM from triplicate samples while data for the control 
viruses represent single measurements. Data are representative of two independent 
experiments. 
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control, these infected DC2.4 cells stimulated VACV-specific CD8^ T cells 
adequately, suggesting that the cells are infected comparably (Figure 4-IB and D). 
This experiment demonstrates that gB-498 expressed as an ER-targeted minigene 
allows better direct presentation on infected cells than as a full-length antigen. 
This phenomenon is irrespective of virus background. 
4.2.1.2 Full-length gB, but not the gB-498 minigene, can be cross presented 
from recombinant VACV-infccted cells. 
The ability of the gB-498 peptide expressed as various forms from VACV for 
CD8^ T cell cross priming was examined. Here the in vivo cross priming assay 
using VACV-infected antigen donor cells established in Section 3.2.3 was used 
again. MHC-l-mismatched human 293A cells were infected with the gB-
expressing VACV recombinants for six hours, followed by heat inactivation at 
60°C for 60 min. Mice were then immunised with these infected cells via the i.d. 
route in the ear pinnae. Responding CD8^ T cells against the gB-498 and various 
VACV epitopes were measured seven days later. 
The data in Figure 4-2A shows that 293A cells infected with WR-Full-gB induced 
a response of approximately 0.2% of CD8'^ T cells that were specific to gB-498. 
This was equivalent to around I xlO^ gB-498-specific CD8^ T cells (Figure 4-2B). 
On the other hand. 293A cells expressing the ER-targeted gB-498 minigene from 
WR-ESmini-gB did not prime any detectable gB-498-specific CD8^ T cells. As a 
control. 293A cells infected with WR-Full-gB or WR-ESmini-gB elicited 
comparable levels of CD8'^ T cells against the VACV epitopes examined. A 
similar result was detected when 293A cells infected with the two gB-expressing 
MVA recombinants were used for immunisation (Figure 4-2C and D), in which 
full-length gB, but not the ER-targeted minigene, induced a gB-498-specific CD8^ 
T cell response when cross presented from recombinant MVA-infected cells. In 
summary, the ER-targeted gB-498 minigene cannot be cross presented from WR-
or MVA-infected cells to prime CD8^ T cells in vivo. 
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Figure 4-2| Full-length gB, but not the ER-targeted gB-498 minigene, expressed in 
VACV-infected cells can prime CD8^ T cells in vivo via cross presentation. 293A 
cells were infected with the indicated recombinant WR (A and B) or MVA (C and D) at 
an m.o.i. of 5 for 6 h, followed by heat treatment at 60°C for 60 min. Groups of three 
mice were then immunised i.d. with 2x10' ' infected heat-treated cells. Seven days later, 
antigen-specific CD8 T cell responses were determined by ex vivo peptide stimulation 
and ICS. Percentages (A and C) and absolute numbers (B and D) of CD8 T cells 
responding to the indicated peptides are shown as mean ± SEM. Data represent results 
pooled from two independent experiments (n = 6). * denotes statistical significance (j> < 
0.05). 
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4.2.1.3 gB-498 co-dominates with VACV B8-20 when expressed as a minigene 
from VACV W R and MVA 
To compare the immunogenicity of the two gB constructs expressed from VACV 
WR and MVA. groups of mice were i.d. immunised with the gB-expressing 
VACV recombinants. Seven days after immunisation, primary CD8^ T cell 
responses against gB-498 and a group of 10 VACV epitopes were measured. 
Confirming tlie published data (Lin et al.. 2013), the ER-targeted gB-498 
minigene elicited a very strong anti-gB-498 CD8^ T cell response, at around 7% 
of total splenic CDS"^ T cells, which was significantly higher than the 1.5% of 
CD8^ T cells specific to gB-498 induced by WR-Full-gB (Figure 4-3A). A similar 
observation was detected when the absolute number of gB-498-specific CD8^ T 
cells was measured (Figure 4-3B). Intriguingly, MVA-ESinini-gB also induced a 
significantly larger gB-498-specific CD8^ T cell response than MVA-Full-gB, 
demonstrating that the ER-targeted gB-498 minigene was more immunogenic 
than the full-length gB antigen when expressed from MVA (Figure 4-3C and D). 
This data is completely opposite to the findings from Gasteiger et al. (2007) with 
the OVA-257 minigene. 
In these experiments, we made an interesting secondary observation that the 
magnitude of the gB-498-specific responses induced by WR-ESmini-gB and 
MVA-ESmini-gB were comparable to that of the immunodominant VACV B8-20 
epitope (Figure 4-3). In addition, responses against B8-20 and some other 
subdominant VACV epitopes, such as A47-17I and L2-53, were significantly 
reduced when mice were immunised with a VACV recombinant that expresses the 
gB-498 minigene. This immunodomination, while interesting, was not pursued 
further in this thesis. 
In summary, the ER-targeted gB-498 minigene allows better priming of CD8^ T 
cells than the full-length gB antigen when expressed from VACV WR and MVA. 
This directly correlates with the enhanced direct presentation efficiency of the 
ER-targeted minigene. 
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Figure 4-3| The ER-targeted gB-498 minigene is more immunogenic than the full-
length gB for priming CD8^ T cell responses when expressed from WR and MVA. 
Groups of three mice were immunised i.d. with 2x10'' PFU of recombinant WR (A and 
B) or MVA (C and D) as indicated. Seven days later, percentages (A and C) and 
absolute numbers (B and D) of CD8^ T cells responding to the indicated peptides were 
measured by ex vivo peptide stimulation followed by ICS. Results are shown as mean ± 
SEM and represent data compiled from two independent experiments (n = 6). * denotes 
statistical significance (j? < 0.05). 
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4.2.2 Comparison of the immunogenicity of an lAV antigen expressed either 
as a full-length antigen or as an ER-targeted minigene from VACV 
The experiments above focused on the highly immunogenic gB-498 peptide. One 
could argue that the immunodominant nature of this CDS"^ T cell epitope is not 
representative of other epitopes in general. Thus we decided to identify a foreign 
antigen that could be recognised by a similar level of CD8^ T cells as the native 
subdominant VACV antigens. Here we focused on five lAV antigens, including 
PA. PBl . PBIF2. NS2. and PR8NP (NP from lAV strain PR8). Each of these 
antigens contains an immunogenic peptide that is recognised by CD8^ T cells in 
C57B1/6 mice infected with lAV, namely PA-224 (Belz et al., 2000), PBl-703 
(Belz et al., 2001). PBIF2-62 (Chen et al., 2001a), NS2-114 (Vitiello et al., 1996), 
and PR8NP-366 respectively (Rotzschke et al., 1990). 
4.2.2.1 lAV antigens expressed as minigenes from WR are generally more 
immunogenic than the full-length antigens, but with some exceptions 
A pilot experiment was performed to identify a suitable lAV epitope as our new 
model CD8'^ T cell epitope for examining the effect of CD8^ T cell priming 
against a less immunogenic epitope expressed from VACV. Five sets of WR 
recombinants, each expressing an lAV epitope either as an ER-targeted minigene 
or as a full- length protein, were examined. The minigene-expressing 
recombinants were WR-ESmini-PA. WR-ESmini-PBl. WR-ESmini-PBIF2, WR-
ESmini-NS2 and WR-ESmini-PR8NP. The corresponding WR recombinants 
expressing the full-length antigens were WR-Full-PA, WR-Full-PBl, WR-Full-
PB1F2, WR-Full-NS2 and WR-Full-PR8NP respectively. Similar to the WR 
recombinants used in Section 4.2.1, the transgenes encoding the lAV antigens 
were under the control of the VACV p7.5 promoter and were inserted into the 
VACV TK locus. Mice were immunised i.p. with these WR recombinants and 
CD8'^ T cell responses were measured seven days later. 
We found that ER-targeted minigenes were more immunogenic than full-length 
antigens for three of the five lAV epitopes tested. They were PA-224, PBl-703, 
and PB1F2-62 (Figure 4-4A, B and C). Importantly, the responses induced by the 
minigenes of these three antigens were within the range of responses specific to 
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A 4 2 - 8 8 and K3-6 , the two subdominan t V A C V epi topes examined , i rrespective of 
w h e t h e r the pe rcen tages or absolu te number s of responding CD8^ T cells were 
e x a m i n e d . Dur ing the statistical analysis , several observat ions were made . Firstly, 
the P B l - 7 0 3 - s p e c i r i c CD8^ T cell response induced by WR-Fu l l -PBl was be low 
the de tec t ion limit o f this assay and so it was not possible to pe r fo rm statistical 
ana lys i s (F igure 4 -4B) . For the PBlF2 -exp re s s ing viruses, there w a s a variation in 
the abso lu te n u m b e r of CD8^ T cells induced in individual mice. Therefore , 
a l t h o u g h the pe rcen tage of the PBl F2-62-specif ic CD8^ T cells induced in mice 
i m m u n i s e d wi th W R - E S m i n i - P B l F 2 was signif icantly higher than that of W R -
F u l l - P B 1 F 2 (Figure 4 -4C left) , the d i f fe rence in the total n u m b e r of PB1F2-62-
spec i f i c CD8 ' ' T cells w a s not significant (Figure 4 -4C right). This w a s also the 
case for expe r imen t s wi th the PA-express ing viruses (Figure 4 - 4 A right). 
T h e r e w e r e t w o except ions to the observat ion descr ibed above. The first was NS2-
114. N o NS2-114- spec i f i c €08"^ T cell response was detected when N S 2 - 1 4 4 w a s 
expres sed as an ER-targeted minigene or as a ful l - length ant igen f rom W R (Figure 
4 - 4 D ) . Th i s da ta sugges ts that NS2-114 is not immunogen i c w h e n expressed f rom 
W R in the cons t ruc t s examined . This observat ion w a s not fur ther investigated. 
T h e second w a s P R 8 N P - 3 6 6 . The ful l- length P R 8 N P ant igen expressed f rom W R 
w a s i m m u n o g e n i c , inducing around 0 .7% of CD8^ T cel ls specif ic to P R 8 N P - 3 6 6 
(F igure 4-4E) . H o w e v e r , to our surprise, the ER-targe ted P R 8 N P - 3 6 6 min igene 
bare ly p r imed any detectable T cell response . Th is contradicts the 
es tab l i shed pa r ad igm which is that ER-targeted min igenes are at least as 
i m m u n o g e n i c as, if not m o r e than, ful l - length ant igens w h e n expressed f rom W R 
( R e s t i f o et al., 1995). This interesting phenomenon is fur ther investigated in 
C h a p t e r 5. Overal l , the results here conf i rm the findings f r o m the previous section 
us ing the g B 4 9 8 pept ide that min igenes are general ly more immunogen ic than 
fu l l - l eng th an t igens w h e n expressed f rom W R in general . 
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Figure 4-4| CD8^ T cell epitopes from lAV expressed from W R as minigenes are 
generally more immunogenic than full-length antigens. Mice were immunised i.p. 
with 2x10" PFU of the WR recombinants expressing lAV CD8^ T cell epitopes either as 
ER-targeted minigenes or as full-length antigens. The epitopes tested were PA-224 (A). 
PBl -703 (B). PB1F2-62 (C). N S 2 - 1 1 4 ( D ) and PR8NP-366 (E). C D 8 T c e l l responses to 
the peptides indicated were measured in spleens 7 days later by ex vivo peptide 
stimulation, followed by ICS. Percentages and absolute numbers of CDS T cells 
producing IFN-y are shown as mean ± SEM on graphs on the left and right respectively. 
(A) Data compiled from two independent experiments, each with groups of three mice (n 
= 6). (B-E) Data represent one experiment with groups of three mice. * denotes statistical 
significance (j? < 0.05). 
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4.2.2.2 PB1F2-62 as an ER-targeted minigene is more immunogenic than the 
full-length PB1F2 antigen when expressed from WR and MVA 
lAV PBIF2 is a virulence factor that promotes apoptosis in lAV-infected cells 
and contributes to the pathogenesis during lAV infection in vivo (Chen et al., 
2001a; Zamarin et a!., 2006). The PB1F2-62 peptide has an amino acid sequence 
LSLRNPILV and binds to murine MHC-1 H-2D'' (Chen et al., 2001a). As shown 
in Figure 4-4C, the ER-targeted PB1F2-62 minigene allowed effective priming of 
CDS" T cells compared to full-length PB1-F2 when expressed from WR. We 
decided to further test the PB1F2-62 peptide in the context of MVA. Two MVA 
recombinants expressing either an ER-targeted PBIF2-62 minigene or a full-
length PBIF2 antigen were generated with the transgenes expressed under the 
control of the VACV p7.5 promoter from the TK locus. The recombinants are 
named MVA-ESmini-PBlF2 and MVA-Full-PB1F2 respectively. Similar to the 
set of gB-expressing VACV recombinants used in Section 4.2.1, these MVA 
recombinants directly matched the corresponding WR recombinants, WR-ESmini-
PB1F2 and WR-Full-PB1F2. 
We first tested how efficiently the PB1F2-62 peptide could be directly presented 
on infected DC2.4 cells when expressed as an ER-targeted minigene or a full-
length antigen from VACV WR and MVA. Although a phage antibody fragment 
specific to PB1F2-62/H-2D'' complexes has been generated (Lev et al., 2008). this 
reagent is not sensitive enough to measure PB IF2-62/H-2D'' expression on cells 
that express full-length PB1F2 antigen (J.W. Yewdell, personal communication). 
Therefore, the in vitro direct presentation assay used in the previous section was 
employed again to measure the direct presentation of the PBIF2-62 epitope. Here, 
DC2.4 cells infected with the PBlF2-expressing VACV recombinants were used 
as stimulators while splenocytes isolated from a mouse infected with the lAV 
strain PR8 were used as effectors. 
As shown in Figure 4-5A, WR-ESmini-PBlF2-infected DC2.4 cells re-stimulated 
more lAV-immune CDS" T cells than those infected with WR-Full-PB1F2. 
Similarly, DC2.4 cells infected with MVA-ESmini-PBlF2 showed a better ability 
to re-stimulate lAV-immune CDS" T cells than those infected with MVA-Full-
PB1F2 (Figure 4-5C). Compared with the data from experiments with the WR 
200 
Chapter 4 
recombinants, the difference in the antigenicity between the two forms of the 
PB1F2 antigen seemed to be greater when expressed from MVA. However, this 
observation was not consistent across ail independent repeats (data not shown). 
DC2.4 cells infected with the two control viruses. MVA-delTK and WR-delTK. 
failed to stimulate any CD8^ T cells from the lAV-immunised mouse, suggesting 
that anti-lAV CDS"^ T cells did not recognise VACV antigens. Finally. DC2.4 
cells infected with the PBlF2-expressing VACV recombinants stimulated VACV-
specific CD8^ T cells comparably (Figure 4-5B and D). This indicates that the 
difference in the level o f re-stimulation of the lAV-specific CDS' T cells is not 
simply due to any obvious differences in the level of infection. These data show 
that the ER-targeted PBIF2-62 minigene allows better direct presentation than the 
full-length PB1F2 when expressed from VACV W R or MVA . 
The cross priming ability of the PB1 F2-expressing VACV recombinants from 
V A C V infected cells were examined. Immunisation of mice with 293A cells 
infected with WR-ESmini-PBlF2 or WR-Full-PB1F2 induced CD8^ T cell 
responses against multiple VACV peptides tested (Figure 4-6). However, we did 
not detect any cross priming of PB I F2-62-specific CD8^ T cells by either the full-
length PB1F2 antigen or the ER-targeted PB1F2-62 minigene available within the 
infected antigen donor cells. Likewise, a PBIF2-62-specific CD8^ T cell response 
was not induced by 293A cells infected with MVA-ESmini-PBlF2 or MVA-Full-
PB1F2. These results suggest that PB1F2 might not be cross presented, even when 
expressed as a full-length antigen from VACV-infected cells. Full-length PBIF2 
antigen has been found to be unstable and has a half-life of 30 min (Chen et al., 
2001a). This may contribute to its inability to prime CD8^ T cells via cross 
presentation. 
We then compared the immunogenicity of ER-targeted PB1F2-62 minigene with 
its full-length counterpart upon VACV immunisation. Seven days after 
immunising mice with the V A C V recombinants expressing PB IF2 constructs via 
the i.d. route, the ER-targeted minigene induced a significantly larger PBIF2-62-
specific CD8'^ T cell population than the full-length antigen, independent of the 
V A C V strains (Figure 4-7). Around 0.4% of CD8^ T cells were specific to 
PBIF2-62 in mice immunised with WR-ESmini-PB!F2 (Figure 4-7A). In 
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Figure 4-5| l A V PB1F2-62 is dircetly presented more effectively when expressed as 
an ER-targeted minigene than as a full-length antigen when expressed from V A C V 
W R and MVA. DC2.4 cells were infected with the indicated recombinant WR (A and 
B) or M V A (C and D) for 5 h. They were then mixed with splenocytes from mice 
immunised with either lAV strain PR8 (left) or VACV WR (left) seven days earlier at a 
s t imulatoneffector ratio of 1:5. After 1 h of incubation. BFA was added, followed by 
another 3 h of co-ciilturing. ICS was then performed to measure the percentage of CD8 
T cell that produced IFN-y. Standard ICS assay with synthetic PB1F2 peptide was 
performed in parallel to measure the maximum possible PBlF2-62-spec i f ic T cell 
response. (A and C) Data show the level of PBlF2-62-specif ic CD8 T cell activation by 
the infected DC2.4 cells, after normalisation to the percentage of maximal activation 
induced by the synthetic PB1F2-62 peptide. (B and D) Data show the percentages of 
splenic CDS' T cells from a WR-immunised mouse activated by the infected DC2.4 
cells. Data for the PB1 F2-expressing VACV represent mean ± SEM from triplicate 
samples while data for the control viruses represent single measurements . Data are 
representative of three independent experiments. 
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Figure 4-6| PB1F2 expressed in VACV- infected cells does not cross prime CDS"^ T 
cells in vivo. 293A cells were infected with the indicated recombinant WR (A and B) or 
MVA (C and D) at a m.o.i. of 5 for 6 h, followed by heat treatment at 60°C for 60 min. 
Groups of three mice were then immunised i.d. with 2x10'" infected heat-treated cells. 
Seven days later, antigen-specific C D S ' T cell responses were detennined by ex vivo 
peptide stimulation and ICS. Percentages (A and C) and absolute numbers (B and D) of 
CDS' T cells responding to the indicated peptides are shown (mean ± SEM). Data 
represent results compiled from three independent experiments (n = 9). 
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Figure 4-7| The PB1F2-62 niinigene is more immunogenic than the full-length 
PB1F2 antigen for CDS"^  T cell priming when expressed from VACV WR and 
MVA. Groups of three mice were immunised i.d. with IxlO*" PFU of the indicated 
recombinant WR (A and B) or MVA (C and D). Seven days later, percentages (A and 
C) and absolute numbers (B and D) of peptide-specific CDS' T cells were measured in 
spleens by ex vivo peptide stimulation followed by ICS. Data are shown as mean ± 
SEM and represent results compiled from three independent experiments (n = 9). * 
denotes statistical significance (p < 0.05). 
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comparison, only 0.1% of CD8^ T cells recognised the PB1F2-62 peptide in mice 
immunised with WR-Full-PB1F2, representing a four-fold reduction in the 
immunogenicity. A similar difference was detected when responses were analysed 
as absolute numbers of CD8^ T cells recognising PB1F2-62 (Figure 4-7B). 
Likewise. MVA-ESmini-PBlF2 was capable of inducing a stronger PB1F2-62-
specific CD8^ T cell response than MVA-Full-PBIF2 (Figure 4-7C and D). 
However, the PB1F2-62 responses elicited by the MVA recombinants were much 
lower than those of the corresponding WR recombinants. The inserted PB1F2 
constructs are identical in the WR and MVA recombinants, so this finding 
suggests a role of the VACV strain in dictating the immunogenicity of some 
foreign antigens. 
Overall, the results here suggest that PBIF2-62. a subdominant epitope from lAV, 
was more immunogenic when expressed as an ER-targeted minigene from VACV 
WR and MVA, compared to the full-length antigen. This supports our previous 
findings with the highly immunogenic gB-498 epitope from HSV. 
4.2.3 VACV 88-20 remains immunodominant when expressed as a minigene 
under the control of the B8R promoter from the B8R locus 
The previous two studies in this chapter demonstrate that expressing a foreign 
epitope as a minigene from VACV WR and MVA. which facilitates direct 
presentation, results in an improvement of CD8^ T cell priming in vivo. This 
phenomenon was detected for the highly immunogenic gB-498 and the less 
immunogenic PB1F2-62 epitopes, suggesting that this is independent of the 
immunogenicity of a given antigen. However, only foreign antigens were 
examined. In addition, they are all expressed by the same promoter from the same 
insertion site (i.e. by p7.5 promoter from the VACV TK locus). 
To address whether the above findings were only applicable to this specific 
expression setting, we examined WR and MVA recombinants, namely WR-
delB8-miniB8 and MVA-delB8-miniB8, which express the VACV B8-20 epitope 
as a cytosolic minigene from the original B8R locus, under the control of the 
native B8 promoter (Wong et al.. 2011; Y.C. Wong and D.C. Tscharke, 
unpublished data). The B8 protein expressed by WR is a soluble IFN-y receptor 
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expressed from the B8R gene locus (Alcami and Smith. 1995). This protein can 
bind IFN-y expressed from human and many other species effectively, but has a 
low affinity for murine IFN-y (Alcami and Smith. 1995; Sroller et a l , 2001). 
Knocking out the B8R gene from VACV WR does not affect the in vitro 
replication of the virus or virulence in C57B1/6 mice (Symons et al., 2002). The 
amino acid sequence of the B8-20 epitope is TSYKFESV and it is restricted to 
MHC-I H-2K'' (Tscharke et al.. 2005). The B8 antigen from MVA is truncated 
and non-functional (Antoine et al.. 1998). but its amino-terminus is expressed and 
this includes the B8-20 epitope (Tscharke et al.. 2005; Kremer et al., 2012). Only 
the cytosolic version of the B8-20 minigene was tested here because our previous 
results suggested that expressing B8-20 as a cytosolic or as an ER-targeted 
minigene from the TK locus of WR are similarly immunogenic (Y.C. Wong and 
D.C. Tscharke. unpublished data). The immunodominant nature of the B8-20 
epitope should not affect the outcome here based on the similar findings between 
gB-498 and PB1F2-62 as discussed above. 
To determine whether B8-20 expressed as a cytosolic minigene is directly 
presented more efficiently than the full-length B8 antigen, the in vitro direct 
presentation assay used in Figure 4-1 was employed again. Here the effectors 
were splenocytes from a mouse that had been infected with IAV-B8, a 
recombinant lAV strain PR8 expressing the VACV B8-20 peptide from the stalk 
region of the lAV neuraminidase protein (S.A. Smith. T. Cukalac and D.C. 
Tscharke, unpublished data). The CD8^ T cells from this IAV-B8-immunised 
mouse allowed us to determine the MHC-I presentation of B8-20 on the infected 
cells. This is indicated by the fact that DC2.4 cells infected with VACV that do 
not express the B8 antigen (WR-delB8 and MVA-delB8; Symons et al., 2002; 
Kastenmuller et al., 2007) could not stimulate IFN-y production in the CD8'^ T 
cells from the IAV-B8-infected mouse (Figure 4-8A and C). DC2.4 cells infected 
with WR-delB8-miniB8. MVA-delB8-miniB8, wildtype WR. or wildtype MVA 
were also tested (Figure 4-8A and C). The ability of DC2.4 infected with WR-
delB8-miniB8 and MVA-delB8-miniB8 to re-stimulate B8-20-specific CD8" T 
cells in vitro was maximal after the first two hours of infection and it decreased 
over time. On the other hand, the ability of the DC2.4 cells to re-stimulate lAV-
B8-immune CD8^ T cells increased steadily in the first four hours of 
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Figure 4-8| V A C V B8 expressed as a minigene is directly presented more effectively 
than as a full-length antigen when expressed from V A C V W R and M V A . DC2.4 
cells were infected with the indicated wildtype or recombinant WR (A and B) or M V A (C 
and D) for 5 h. They were then co-cultiired with splenocytes from mice immunised with 
either with IAV-B8 (A and C) or WR-delB8 (B and D) seven days earlier. A 
stimulator:effector ratio of 1:5 was used. After I h of incubation. BFA was added. It was 
followed by another 3 h of co-culture. ICS was then perfomied to measure the percentage 
of CD8 T cells that produced IFN-y. A standard ICS assay with a synthetic B8-20 
peptide was perfonned in parallel with splenocytes from the IAV-B8-immunised mouse 
to measure the total B8-20-specitlc CDS T cell response. (A and C) Data show the level 
of B8-20-specific C D 8 ' T cell activation by the infected DC2.4 cells, after standardisation 
to the percentage of maximal potential activation induced by the synthetic B8-20 peptide. 
(B and D) Data show the percentages of splenic CD8* T cells from a WR-delB8-
immunised mouse that were activated by the infected DC2.4 cells. Data for the B8-
expressing VACV represent mean ± SEM from triplicate samples while data for the 
control viruses represent single measurements. Data are representative of f ive 
independent experiments. 
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infection witli wildtype WR and wildtype MVA. It plateaued for cells infected 
with WR while it decreased when ceils were infected with MVA. Importantly, 
expression of B8-20 as a cytosolic minigene from WR or MVA resulted in an 
enhanced capability of the infected cells to re-stimulate B8-20-specific CD8^ T 
cells compared with cells infected with the wildtype viruses expressing full-length 
B8 proteins. By comparison. DC2.4 cells infected with the B8-20-expressing 
VACV recombinants had a similar ability to re-stimulate CD8^ T cells from mice 
immunised with WR-delB8 (Figure 4-8B and D), indicating that the cells were 
comparably infected. Interestingly, the presentation of the B8-20 minigene 
expressed from MVA-delB8-miniB8 seemed to decline over time (Figure 4-8C). 
Similarly, presentation of other VACV peptides expressed by the tested MVA 
recombinants reduced from 4 to 6 hours post infection (Figure 4-8D), suggesting 
that this is not an epitope-specific effect. As discussed in section 1.9.4, MVA 
infection can lead to early apoptosis of DCs (Chahroudi et al.. 2006). The assay 
here requires presentation of peptides on viable DC2.4 cells to induce IFN-y 
expression by the effector CD8^ T cells. It is possible that the number of viable 
DC2.4 cells infected with the MVA recombinants decreased over the course of the 
experiment, therefore decreasing presentation of all VACV peptides. Overall, the 
B8-20 minigene allows better B8-20/MHC-I presentation compared with the full-
length B8 antigen when expressed from WR and MVA. 
The cross presentation ability of the B8 constructs were also studied. By 
immunising mice whh 293A cells infected with wildtype VACV or recombinants 
that express the B8-20 minigene, we found that only the full-length B8 antigen 
expressed from wildtype WR or MVA was cross presented from infected cells 
(Figure 4-9), as seen in Section 3.2.3. However, the B8-20 minigene failed to 
cross prime any measurable B8-20-specific CD8^ T cell response from cells 
infected with either WR-delB8-miniB8 or MVA-delB8-miniB8. This resuh is in 
agreement with our previous data which showed that full-length antigens, but not 
minigenes, can be cross presented. We noticed that A3-270 expressed from MVA-
delB8-miniB8 induced a significantly lower response than the wildtype MVA in 
this cross priming assay (Figure 4-9C and D). However, this did not occur for the 
L2-53-specific response, suggesting that the antigen donor cells were indeed 
infected with the recombinant virus to allow VACV antigen expression In 
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Figure 4-9 | Ful l - length B8, but not the B8-20 minigene, expressed in VACV-infec ted 
cells cross pr imes B8-20-speci f ic CDS"^ T cells. 293A cells were infected with the 
indicated recombinant W R (A and B) or M V A (C and D) at an ni.o.i. of 5 for 6 h. 
fo l lowed by heat t rea tment as shown in Figure 4-1. Groups of three mice were then i.d. 
immunised with 2x10"^ of these heat-treated cells. Seven days later, antigen-specific C D 8 
T cell responses were de termined by ex v ivo peptide stimulation and ICS. Percentages (A 
and C ) and absolute number s (B and D) of CDS"^ T cells responding to the indicated 
pept ides are shown. Data represent results compiled f rom two independent exper iments 
(mean ± S E M ; n = 6). * denotes statistical s ignif icance (j> < 0.05). 
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addition, a CDS"^ T cell response against A3-270 was detected in mice immunised 
directly with MVA-delB8-miniB8 (refer to Figure 4-lOD and E). This indicates 
that the A3-270 peptide can be generated and presented in vivo and that it is not 
mutated during the generation of MVA-delB8-miniB8. Also, we did not detect 
any changes of the A3-270-specific CD8^ T cell response induced by cells 
infected with WR-delB8-niiniB8 (Figure 4-9A and B), implying that an 
expression of the B8-20 minigene should not affect the immunogenicity of A3-
270 in the cross priming assay. The reason of the lack of cross priming ability of 
A3-270 expressed from MVA-delB8-miniB8 remains undetermined. 
To test how expressing B8-20 as a minigene from WR and MVA affected its 
immunogenicity in vivo, mice were immunised i.d. with the recombinant VACV 
strains expressing the cytosolic B8-20 minigene or with the wildtype viruses. B8-
20 remained the immunodominant epitope in mice immunised with WR-delB8-
miniB8 and MVA-delB8-miniB8 (Figure 4-10). However, there were some 
differences between the results from WR and MVA. WR-delB8-miniB8 induced a 
lower B8-20-specific response than WR when the response was measured as the 
percentage of CD8^ T cells (Figure 4-1 OA). This reduction was more prominent 
when the absolute number of B8-20-specific CD8^ T cells was determined (Figure 
4-1 OB). Moreover, responses against other VACV epitopes were also significantly 
lower in mice immunised with WR-delB8-miniB8, compared to those with WR 
(Figure 4-lOB). This implies that WR-delB8-miniB8 has a lower capability to 
prime an anti-VACV CD8^ T cell response in general. To nonnalise the difference 
in the magnitude of the overall anti-VACV response, the ratio of the B8-20-
specific response to the sum of responses specific for all VACV epitopes was 
examined (Figure 4-IOC). From this analysis, we found that WR-delB8-miniB8 
and WR both induced a similar level of anti-B8-20 response relative to the overall 
anti-VACV responses (around 60%). For MVA, expression of B8-20 as a 
cytosolic minigene enhanced its immunogenicity, as measured by the percentage 
of CD8^ T cells or by the absolute number of B8-20-specific CD8^ T cells (Figure 
4-1OD and E). In contrast to WR-delB8-miniB8, we did not detect any reduction 
of the numbers of VACV-speeific CDS"^ T cells induced by MVA-delB8-miniB8. 
This suggests that expression of the B8-20 minigene does not affect the level of 
anti-VACV CD8^ T cell priming in general. We found that MVA-delB8-miniB8 
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Figure 4-10| Despite some variations in the B8-20-specific response induced, B8-20 
epitope remains immunodominant when expressed as a minigene from VACV WR 
and MVA. Groups of three mice were immunised i.d. with 2x10'^ PFU of recombinant 
WR (A and B) or MVA (D and E) as indicated. Seven days later, the percentage (A and 
D) and absolute number (B and E) of CDS' T cells responding to the indicated peptides 
were measured by ex vivo peptide stimulation followed by ICS. (C) The level of anti-
B8-20 CDS T cell responses induced by the two WR recombinants relative to sums of 
responses induced against all VACV epitopes examined is shown. The result was 
calculated based on data from (B). (A. B. D and E) Data represent results compiled from 
five independent experiments (mean ± SEM: n = 15). * denotes statistical significance 
( p < 0 . 0 5 ) . 
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induced a larger L2-53-specific CD8^ T cell response, but this effect was not 
observed for other epitopes. In summary. B8-20 as a cytosolic minigene remains 
highly immunogenic when expressed from VACV WR or MVA. 
4.2.4 The OVA-257 minigene is less immunogenic than full-length OVA when 
expressed from the del l l l region of MVA 
The studies above clearly demonstrate that antigens expressed as minigenes from 
MVA allow effective CDS"^ T cell priming in vivo. This contradicts the previous 
published results by Gasteiger et al. (2007) as discussed in the introduction 
section of this chapter (Section 4.1). We re-examined their claims directly using 
their MVA recombinants. MVA-dellll-SlIN and MVA-dellll-OVA. These two 
viruses express OVA-257 either as a cytosolic minigene or as a full-length OVA 
protein under the control of p7.5 promoter (Gasteiger et a l . 2007). Unlike the 
viruses used earlier in this chapter, the transgenes were inserted into the dellll 
region of the MVA genome. Two WR recombinants. WR-TK-SIIN and WR-TK-
OVA. were also included here (Restifo et al., 1995). These two viruses have been 
used in Chapter 3 and they express the cytosolic OVA-257 minigene and the full-
length OVA protein respectively. The transgenes are under the control of the 
VACV p7.5 promoter and are expressed from the VACV TK locus (Restifo el a l , 
1995). 
The direct presentation ability of OVA-257 on H-2K'' when expressed as the 
cytosolic minigene or full-length OVA antigen from these VACV recombinants 
was measured directly from infected DC2.4 cells with the 25DI.16 antibody. The 
expression of the OVA-257 minigene in the DC2.4 cells infected with WR-TK-
SIIN or MVA-dellll-SIIN allowed better OVA-257/MHC-I presentation on the 
cell surface than those infected with WR-TK-OVA and MVA-dellll-OVA 
respectively, over the period of 6 hours of infection (Figure 4-11). The 
presentation level of OVA-257 when expressed as a cytosolic minigene from WR 
and MVA reached its maximum level at around 4 hours post infection. In 
comparison, presentation of OVA-257 from the full-length OVA antigen 
increased more slowly over time until 4 hours post-infection, but the presentation 
level of OVA-257 remained much lower than that of the OVA-257 minigene. Our 
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Figure 4-11| Tiie cytosoiic OVA-257 minigene is better at direct presentation tlian 
tiie fuii-lengtli OVA antigen wlien expressed from the TK locus of VACV WR or 
from tlie del l l l region of MVA. DC2.4 cells were infected with the indicated wildtype 
or recombinant WR (A) or MVA (B) at an m.o.i. of 5. At times indicated, aliquots of 
infected cells were collected and labelled with APC-conjugated 25D1.16 antibody prior 
to flow cytometric analysis to measure the mean fluorescence intensity of APC of the 
labelled cells. Data are representative of four independent experiments. 
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results here confirm the previous studies using these recombinants (Porgador et 
al., 1997; Princiotta et a l , 2003; Gasteiger et al., 2007). 
We next demonstrated that the cytosolic OVA-257 minigene did not induce any 
detectable OVA-257-speciric CD8^ T cell response in mice via cross presentation 
from 293A cells infected with WR-TK-SIIN or MVA-dellll-SIIN (Figure 4-12). 
This is in contrast to WR-TK-OVA and MVA-dellll-OVA. in which the full-
length OVA antigen expressed in the infected 293A cells allowed priming of anti-
OVA-257 CD8^ T cell responses. This confirms the findings in Section 3.2.2 and 
by Norbury et al. (2004), in which only full-length OVA can be cross presented 
when expressed from WR (Section 3.2.2). Here this finding is extended to MVA. 
The in vivo immunogenicity of various OVA constructs expressed from VACV 
was studied. Seven days after i.d. immunisation in mice, WR-TK-SllN induced an 
OVA-257-speciflc response of around 2.5% of CD8^ T cells, significantly higher 
than the response induced by WR-TK-OVA (Figure 4-13A). In contrast, the 
opposite result was detected for MVA. The OVA-257 minigene expressed from 
MVA-dellll-OVA elicited a smaller percentage of anti-OVA-257 CD8^ T cells 
than the full-length OVA antigen expressed from MVA-dellll-OVA (Figure 4-
13C). Similar trends were observed when the absolute numbers of OVA-257-
specific CD8^ T cells were measured, but the differences were not statistically 
significant (Figure 4-13B and D). The main reason for this was the variation in the 
absolute number of 008"" T cells induced across the immunised mice. Overall, 
these results are in agreement with those published previously using these OVA-
expressing recombinants (Restifo et al., 1995; Gasteiger et al., 2007). However, 
the lower immunogenicity of the OVA-257 minigene expressed from MVA 
disagrees with our previous results with MVA recombinants expressing gB-498, 
PBlF2-62and 88-20. 
4.2.5 The insertion site in the MVA genome influences the relative 
immunogenicity of the OVA-257 minigene compared to full-length OVA 
The major difference between the MVA recombinants generated in this chapter 
and those in Gasteiger et al. (2007) is the insertion site of the transgenes encoding 
the foreign antigens within the MVA genome. Therefore, we examined whether 
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Figure 4-12 | OVA-lST-spec i f i c CD8* T cells cannot be cross primed by the O V A - 2 5 7 
min igene expressed within VACV- in fec ted cells. 293A cells were infected with the 
indicated recombinant WR (A and B) or M V A (C and D) for 6 h, followed by heat 
t rea tment as described in Figure 4-2. Mice were then immunised i.d. with 2 x 1 0 ' of these 
infected, heat-treated cells. Seven days later, peptide-specif lc C D 8 T cell responses were 
determined by ex v ivo pept ide st imulation and ICS. Percentages (A and C) and absolute 
number s (B and D) of C D 8 T cells responding to the indicated peptides were shown. 
Data represent results compiled f rom groups of three mice from two independent 
exper iments (n = 6). * denotes statistical s ignif icance (p < 0.05). 
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Figure 4-13| The OVA-257 minigene is more immunogenic than the full-length OVA 
when expressed from the TK locus of WR while the opposite result was observed 
when the OVA constructs were expressed from the dell l l region of MVA. Groups of 
three mice were immunised i.d. with 2x10'' PFU of recombinant WR (A and B) or MVA 
(C and D) as indicated. Seven days later, percentages (A and C) and absolute numbers (B 
and D) of CD8 T cells responding to the indicated peptides were measured in spleens by 
ex vivo peptide stimulation followed by ICS. Data represent results compiled from three 
independent experiments (n= 9). * denotes statistical significance (p < 0.05). 
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the choice of insertion site would affect the immunogenicity of the OVA-257 
minigene relative to the full-length OVA antigen. 
Firstly, two M V A recombinants, namely MVA-TK-SIIN and MVA-TK-OVA, 
were examined. The first M V A recombinant has been introduced in Chapter 3 and 
it expresses a cytosolic OVA-257 minigene under the control of the p7.5 promoter 
from the M V A TK locus. As shown in Chapter 3. this virus can effectively prime 
an OVA-257-specific CDS" T cell response in vivo. Here this virus was directly 
compared with MVA-TK-OVA, a M V A recombinant expressing full-length OVA 
by the p7.5 promoter inserted into the M V A TK locus. The OVA-257 minigene 
expressed by MVA-TK-SIIN is directly presented more effectively than the full-
length O V A expressed by MVA-TK-OVA on infected DC2.4 cells as measured 
by 25D1.16 antibody staining (Figure 4-14A). This finding is similar to those 
observed in Figure 4-1 IB which used the M V A recombinants that express OVA 
constructs from the deletion III region. The in vivo immunogenicity of MVA-TK-
SIIN and MVA-TK-OVA was then studied. When mice were immunised i.d. with 
MVA-TK-SIIN, around 2.5% of CDS" T cells specific to OVA-257 were elicited 
seven days later (Figure 4-14B). This is significantly higher than that found in 
mice immunised with MVA-TK-OVA. When the absolute numbers of anti-OVA-
247 CDS" T cells were compared, a similar trend was observed although the 
difference was not significant (Figure 4-14C). These data from this set of M V A 
recombinants, which directly matched the W R recombinants used in Figure 4.13, 
demonstrate that OVA-257 as a cytosolic minigene can be more immunogenic 
than a full-length OVA when expressed from MVA . 
Next, another set o f M V A recombinants were examined. They express the 
cytosolic OVA-257 minigene or the full-length OVA antigen under the control of 
the V A C V p7.5 promoter from the intergenic region between two essential genes, 
A l l R and A12L (Wong et al., 2011). These two viruses are called MVA-
A11/AI2-SIIN and MVA-AI I /A I2-OVA respectively. Similar to the previous in 
vitro studies with other sets of OVA-expressing recombinants, direct presentation 
o f OVA-257 on the surface of infected DC2.4 cells was enhanced when the 
epitope was expressed as a minigene from MVA-Al 1/A12-SIIN compared to the 
full-length O V A expressed from MVA-Al 1/A 12-OVA (Figure 4-15A). Despite 
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Figure 4-15| The OVA-257 minigene and the full-length OVA are similarly 
immunogenic when expressed from the A n / A 1 2 intergenic region of MVA. (A) 
DC2.4 cells were infected with the MVA as indicated. Aliquots of infected cells were 
collected every hour for six hours and were labelled with APC-conjugated 25D1.16 
antibody prior to flow cytometric analysis to measure the MFI of APC on the labelled 
cells. (B and C) Groups of 3-4 mice were immunised i.d. with 2x10*' PFU of MVA-
Al I/AI2-S1IN or MVA-AII /AI2-SIIN. Seven days later, peptide-specific CD8^ T cell 
responses were measured by ex vivo peptide stimulation followed by ICS. Results are 
shown as percentages (B) and absolute numbers (C) of responding CD8 T cells. (A) Data 
are representative of three independent experiments. (B and C) Data are compiled from 
four independent experiments (n = 13). 
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this in vitro difference, these two viruses induced similar levels of OVA-257-
specific CD8^ T cell response in mice immunised via the i.d. route (Figure 4-15B 
and C). The results in Figures 4-13, 4-14 and 4-15 suggest that the choice of an 
insertion site can determine whether a minigene or a full-length antigen is more 
immunogenic when expressed from MVA. 
4.2.6 A functional TK influences the relative immunogenicity of the OVA-257 
minigene when compared with full-length OVA 
By comparing the results with the MVA recombinants expressing OVA constructs 
from various separated loci, it seemed that a functional TK gene might reduce the 
immunogenicity of the OVA-257 minigene. relative to full-length OVA. This is 
because MVA-TK-SIIN, which has a disrupted TK gene due to the foreign gene 
insertion, was more immunogenic than the full-length OVA antigen expressed 
from the same region. On the other hand. MVA-dellll-SIlN and MVA-Al 1/A12-
SllN. which express a functional VACV TK. were less immunogenic than or 
similarly immunogenic as MVA-dellll-OVA and MVA-Al 1/A 12-OVA 
respectively. This hypothesis was directly tested by making two new MVA 
recombinants based on MVA-dellll-SIIN and MVA-delll l-OVA from Gasteiger 
et al. (2007). An empty construct from transfer plasmid p S C l l G B was inserted 
into the TK locus in the genome of these two recombinants to create MVA-dellll-
SIIN-delTK and MVA-dellll-OVA-delTK. These two recombinants express the 
OVA-257 minigene or full-length OVA from the dellll region respectively, but do 
not express functional TK. 
DC2.4 cells infected with MVA-dellll-SIIN-delTK showed a more effective 
OVA-257/H-2K'' presentation on the cell surface than those infected with MVA-
dellll-OVA-delTK (Figure 4-16A). This indicated that deletion of the VACV TK 
gene does not alter the enhanced ability of the OVA-257 minigene in direct 
presentation. When mice were immunised with these two viruses, a similar level 
of anti-OVA-257 CD8^ T cell responses were induced (Figure 4-16B and C). This 
result was in between what we observed with the MVA recombinants expressing 
OVA constructs from dellll region (refer to Figure 4-13) and those expressing 
OVA constructs from VACV TK locus (refer to Figure 4-14). As a side note 
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Figure 4-16| The OVA niinigene expressed from del l l l region of MVA becomes 
similarly immunogenic as the full-length OVA when the VACV TK gene is knocked 
out. (A) DC2.4 cells were infected with the indicated wildtype MVA or MVA 
recombinants. At time indicated, aliquots of infected cells were collected and labelled 
with APC-conjugated 25D1.16 antibody. MFl of APC on the labelled cells was 
determined by flow cytometric analysis. (B-C) Groups of three mice were immunised i.d. 
with 2x10" PFU of the MVA-dellll-SllN-delTK or MVA-dellll-OVA-delTK. Seven days 
after immunisation, splenocytes from the immunised mice were stimulated with the 
indicated peptides ex vivo, followed by ICS. Results are shown as percentages (B) or 
absolute numbers (C) of the responding CDS' T cells. (A) Data are representative of three 
independent experiments. (B and C) Data are compiled from five independent 
experiments (n = 1 5 ) . * denotes statistical significance (j) < 0.05). 
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smaller CD8^ T cell responses against L2-53 and A3-270 were induced in mice 
immunised with MVA-dellll-SIIN-delTK compared to those immunised with 
MVA-dellll-OVA-delTK (Figure 4-16C). However, responses against B8-20 or 
A47-171 were not affected. The cause of this difference remains undetermined. 
To exclude the possibility that the similar ability of MVA-dellll-SlIN-delTK and 
MVA-dellll-OVA-delTK to prime OVA-257-specific CD8^ T cells is because of 
a random effect during the selection of the recombinants, a second independent 
lineage of MVA-dellll-SlIN-delTK was examined. This virus, namely MVA-
dellll-SIlN-delTK-2. also elicited a similar level of anti-OVA-257 CD8^ T cell 
response as MVA-dellll-OVA-delTK (Figure 4-17). These data suggests that a 
functional TK protein plays a role in the reduced immunogenicity of the OVA-
257 minigene compared to the full-length OVA antigen. Interestingly, there were 
no statistical differences in the induced L2-54- and A3-270-specific responses 
amongst the recombinant viruses tested in this experiment (which was detected in 
Figure 4-16C). This suggests variations of CDS"^ T cell responses induced 
between experiments, even with the use of identical viruses. 
4.3 Discussion 
The studies in this chapter clearly demonstrate that peptides as minigenes can be 
more immunogenic than full-length antigens when expressed from MVA. but 
there are some exceptions. Importantly, the choice of an insertion site influences 
the immunogenicity of a given antigen expressed as a minigene from MVA. 
Further, these data suggest that WR and MVA expressing foreign antigens from 
the TK locus allow effective direct priming. One study has demonstrated that 
expressing human cytomegalovirus proteins as rapidly-degraded constructs from 
the deletion II region of MVA could induce CD8^ T cell responses against the 
antigens tested in mice (Wang et al., 2004). It should be noted that CDS"^ T cell 
responses were measured using a cytotoxicity assay after in vitro CDS"^ T cell 
expansion (Wang et al., 2004). Despite some limitations, the study by Wang et al. 
(2004) and the studies shown in this chapter demonstrate that 008"^ T cell 
responses against antigens expressed from MVA can be induced via direct 
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Figure 4-17| A second independent lineage of MVA-del l l l -SIIN-delTK confirms that 
a functional V A C V TK protein influences the immunogenicit>' of the OVA-257 
minigene expressed from the de l l l l region. Groups of three mice were i.d. immunised 
with 2x10" PFU of the recombinant MVA indicated. After seven days, percentages (A) 
and absolute numbers (B) of CDS' T cells responding to the indicated peptides were 
determined with ex vivo peptide stimulation, followed by ICS. Data represent results 
from three independent experiments (n = 9). 
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presentation effectively and are not dissimilar from WR in general. This finding is 
further supported by the observation that MVA-infected DCs interact with naive 
CD8^ T cells in the draining LNs in infected mice, suggesting a role of direct 
CD8^ T cell priming (Kastenmiiller et al., 2013). As an extension of our findings, 
it has been reported that minigenes expressed from avipoxvirus, another species of 
poxvirus that does not replicate in mammals, could prime CD8^ T cell responses 
in mice and in humans (Rosenberg et al.. 2003; Tine et al., 2005). These reports 
are further discussed in Chapter 7. 
So far, studies about the relationship between the effect of the insertion site within 
the VACV genome and the immunogenicity of the inserted foreign antigens have 
been limited. Historically, the VACV TK gene has been used as one of the first 
insertion sites for WR (Panicali and Paoletti. 1982; Flexner et al., 1987). This is 
because there is a well-established selection method based on the use of BUdR to 
select against wildtype VACV that is TK^ phenotype (Mackett et al., 1982; 
Mackett et al., 1984; Chakrabarti et al., 1985). Other insertion sites have been 
used, but they are less common. On the other hand, large deletion regions in the 
MVA genome are commonly used as the insertion site for generating MVA 
recombinants (Sutter and Moss. 1992; Sutter et al., 1995). A previous study 
reported that it was difficult to generate MVA recombinants expressing antigens 
from the MVA TK locus, and the authors suggested that knocking out TK from 
MVA may reduce its in vitro replication ability (Scheifiinger et al., 1996). 
However, multiple reports, including this study, have successfully generated 
recombinant MVA using TK as the insertion site and some have been used in 
human clinical trials (Sanchez-Puig et al., 2004, Kovacs et al., 2003, Cottingham 
et al., 2008, Hanke and McMichael, 2000. Letourneau et al., 2007, Hanke et al., 
1998). These support the idea that MVA carrying transgenes inserted in the 
VACV TK locus are indeed viable. Further, our study here implies that this locus 
may be a better insertion site for minigene constructs. 
Studies in this chapter indicate a role of insertion site on determining the 
immunogenicity of a given minigene construct when expressed from MVA. One 
obvious explanation is that the expression level of a transgene might be different 
when expressed from different insertion sites. Several studies have examined if 
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the insertion site influences the expression level of the transgenes from VACV. 
Expression of a murine MHC-I heavy chain H-2K'' gene inserted into the VACV 
TK locus of VACV WR was comparable to that expressed from the HincRW F 
insertion site, a less common insertion site used in constructing WR recombinants 
(Coupar et a l , 1988). In another study, three independent WR recombinants were 
generated, each expressing the human IL-2 gene from a different insertion loci, 
namely the Hiium C region. VACV TK locus or VACV haemagglutinin locus 
(Flexner et al.. 1987). All three recombinants were attenuated in mice to a similar 
level due to the IL-2 expression (Fle.xner et al.. 1987). Kunke et al. (1993) 
generated a recombinant VACV using strain Praha by inserting the surface and 
core antigens from hepatitis B virus into the VACV TK and the K1L (a host range 
gene) loci respectively. The investigators found that the expression level of these 
two antigens was not influenced if their insertion sites in the VACV genome were 
switched (Kunke et al.. 1993). A separate study demonstrated that insertion of 
foreign genes into VACV TK locus allow higher transgene expression than genes 
inserted into the serpin 2 gene (B13R) locus (Bennett et al., 1999). Interestingly, 
expression of a firefly luciferase gene inserted in the VACV TK locus of VACV 
WR was significantly reduced when a functional TK gene from HSV-1 was 
inserted into the HindW F site (Coupar et al., 2000). One could interpret this 
result as showing that a functional TK in general may negatively affect the 
expression of the inserted antigen in WR. However, whether it is due to the 
insertion into the HindWl F site was not formally ruled out by Coupar et al. 
(2000). Studies relating insertion sites to the immunogenicity of a given antigen 
are far more limited. In a study by Manuel et al. (2010). the immunogenicity of a 
human cytomegalovirus antigen expressed by the VACV early/late H5 promoter 
from two different insertion sites in MVA was examined. In brief, two viruses 
were compared: one expresses the foreign antigen from the intergenic region 
between I3L and I4L genes while the other expresses the antigen from the 
deletion II region. Although both viruses allowed a similar level of foreign 
antigen expression, the antigen expressed from the I3L/I4L intergenic region 
induce a more potent CD8^ T cell response than that expressed from the deletion 
II region (Manuel et al., 2010). This study indicates that an insertion site can 
affect the immunogenicity of the inserted foreign antigen, independent of the 
presentation level. Understanding the mechanism responsible might lead to an 
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identification of better insertion sites for inducing potent CD8^ T ceil immunity 
against foreign antigens. 
Our results also suggest that the functional TK expressed from MVA-dellll-SIlN 
may negatively influence the immunogenicity of the OVA-257 minigene 
expressed from the dellll region. By deleting the VACV TK from MVA-dellll-
SIIN, the OVA-257 minigene induced a similar OVA-257-specific CDS' T cell 
response as MVA-dellll-OVA-delTK. the corresponding MVA expressing full-
length OVA. VACV TK phosphorylates thymidine to form thymidine 
monophosphate which is then further processed to create thymidine triphosphate 
for DNA synthesis (Dubbs and Kit. 1964; Hruby and Ball. 1982; Hruby et al.. 
1983; Hruby. 1985). This protein is not essential for in vitro VACV replication. 
However, deletion of TK from WR results in an attenuation of the virus, probably 
because of the reduced ability for the TK-deleted virus to replicate in non-dividing 
cells (Buller et al.. 1985). A study has demonstrated that a disruption of the TK 
gene in VACV strain Praha reduced the antibody response elicited against a 
foreign antigen expressed from the VACV haemagglutinin gene (Kutinova et al., 
1999). The decreased antibody response correlated with the reduction of the 
virulence of the recombinant virus in vivo (Kutinova et al., 1999). In this thesis, 
the examination of the influence of the TK gene on CD8^ T cell immunity was 
performed using MVA-based recombinant viruses. It should be noted that MVA 
does not replicate in vivo and therefore loss of TK would not be predicted to have 
a change in phenotype in this strain. More importantly, our studies point to a 
specific effect of TK on the immunogenicity of the inserted minigene constructs, 
but not that of the native VACV antigens. 
One possible explanation of the enhanced immunogenicity of the minigene 
expressed from a TK-deficient MVA is that deletion of TK may affect VACV 
gene expression cascade in vivo. Without a functional TK. VACV may not be 
able to replicate the VACV genome effectively in resting cells in vivo. It has been 
shown that expression of VACV intermediate and late genes relies on VACV 
genome replication (Vos and Stunnenberg. 1988; Keck et al., 1990; Baldick and 
Moss, 1993). Thus, it is possible that the decreased VACV genome replication 
ability in cells infected with TK-deficient VACV reduces VACV intermediate and 
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late gene expression and alters the VACV gene expression cascade. This may 
subsequent ly lead to an enhanced expression level of transgenes and allow better 
CDS" T cell priming. However, this correlation between the gene expression 
cascade and the immunogenici ty of the inserted antigen is not likely. Firstly, as 
the inserted transgenes were all controlled by the same p7.5 promoter, any 
changes of the expression level should affect both the minigene and full-length 
constructs. This should be reflected in the immunogenicity of both constructs, not 
only that of minigene as observed in our study. Secondly, it has been shown that 
inhibition of V A C V genome replication in vitro with cytosine arabinoside. a DNA 
replication inhibitor, resulted in decreased expression level of transgenes driven 
by the V A C V p7.5 promoter (Mackett et al., 1984; Cochran et al., 1985). 
Therefore , any possible changes of expression level resulting from a loss of a 
functional TK would be detrimental, not beneficial, to the foreign antigens. 
Thirdly, viral DNA replication does not occur in DCs infected with M V A in vitro 
(Chahroudi et al.. 2006). Therefore, the VACV gene expression cascade may be 
interrupted in the MVA-infected DCs, independent of the TK. expression. Overall, 
it is unlikely that alteration of VACV gene expression cascade in APCs infected 
with TK-deficient M V A is responsible for the enhanced immunogenicity of a 
minigene construct. 
An alternative explanation is that the V A C V TK protein may have other unknown 
funct ions. Many V A C V proteins have multiple functions and this could include 
the V A C V TK protein. We have examined whether expression of TK from MVA 
might af fec t the survival of the infected cells in vitro (data not shown). Our 
hypothesis was that if V A C V TK had a pro-apoptotic property, removing this 
protein might extend the survival of the infected APC to allow better direct 
pr iming of CDS"^ T cell in vivo. However, we failed to detect any obvious changes 
in the viability or the expression of an apoptotic marker (detection of 
phosphat idylser ine via staining with t luorophore-conjugated Annexin V) between 
B M D C s infected with MVA-del l l l -SIIN and MVA-del l l l -SIIN-delTK (data not 
shown) . This suggests that expression of TK does not affect the cell viability 
dur ing M V A infection. Alternatively, we might have chosen the wrong type of 
A P C for testing this hypothesis. DCs isolated f rom mice could be used in future 
studies. 
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The experiments with the gB-498-expressing VACV showed that the ER-targeted 
gB-498 minigene reduced CD8^ T cell responses against several native VACV 
epitopes. This might be due to the competition for MHC-1 binding in the infected 
cells. We have performed an experiment in which DC2.4 cells were co-infected 
with WR-TK-SIIN together with WR-ESmini-gB, WR-Full-gB or WR-delTK as a 
control (data not shown). Co-infection of cells with either of the gB-expressing 
recombinants reduced the OVA-257/MHC-I presentation compared with cells co-
infected with WR-TK-SIIN and WR-delTK. However, there was no difference in 
the OVA-257 presentation level between cells co-infected with WR-ESmini-gB or 
with WR-Full-gB. This experiment implies that enhanced presentation of gB-498 
by the ER-targeted minigene did not significantly influence the MHC-I 
presentation of peptides from other origins, compared with that processed from 
the full-length gB antigen. Rather, it is likely that expression of a foreign gene by 
the VACV p7.5 promoter might suppress the expression of other antigens and 
thus affect their presentation measured in the in vitro experiment. Another 
possible reason for the immunodomination effect for the gB-498 minigene is that 
there is a greater competition between naive CD8^ T cells with different 
specificities in vivo for their cognate epitopes on APC for priming. A previous 
study has shown that there are around 500 and 1000 gB-498- and B8-20-specific 
naive CD8^ T cells in a naive mouse respectively (Haluszczak et al., 2009). These 
numbers are relative high compared to other naive CD8^ T cell populations that 
have been examined (Kotturi et al., 2008; Obar et a l , 2008; Flesch et al., 2010; La 
Gruta et al., 2010). Thus, expressing gB-498 as an ER-targeted minigene to 
facilitate direct presentation may allow more naive gB-498-specific CD8^ T cells 
to interact with the infected APCs in vivo and they may out-compete the naive 
CD8^ T cells specific to the native VACV peptides. One way to examine this 
immunodomination effect is to generate a recombinant virus that co-expresses gB-
498 and OVA-257 as two separate minigenes. With this virus, we could study the 
effect of T cell competition by adoptively transferring different ratios of gB-I and 
OT-I CD8^ T cells which are specific to gB-498 and OVA-257 peptides 
respectively (Hogquist et al.. 1994; Mueller et al., 2002). 
In section 4.2.3, we noticed a decrease of CD8^ T cell priming in general in WR-
delB8-miniB8 as determined by the total number of antigen-specific CD8^ T cells 
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induced. It has been shown that WR-delB8. a W R with B8R gene deleted 
(Symons et al., 2002), does not show any attenuation in vivo in C57B1/6 mice. 
The investigators o f this study (Symons et al., 2002) generated a revertant virus 
based on WR-delB8, by inserting the B8R gene back, to control any possible 
attenuation caused by secondary unwanted mutations that might be introduced 
during the generation of the recombinant virus. In a separate study, an 
independent B8-knockout W R recombinant was generated and it was shown that 
this virus was less virulent in BALB/c x C57B1/6 F| mice (Verardi et al., 2001). 
However, no revertant virus was included. For WR-delB8-miniB8 used in this 
chapter, the reduction of immunogenicity could be due to the introduction of the 
B8-20 minigene or a random mutation in the viral genome. One approach to 
discriminate between the two possibilities is to include an independent 
recombinant in the experiments, similar to the two independent MVA-dellll-SllN-
delTK viruses used in Figure 4-17. 
In summary, similar to WR . epitopes expressed as minigenes from M V A to 
facilitate direct presentation allow effective CD8^ T cell priming in vivo. 
However, this is dependent on the location of the insertion site o f M V A . 
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5.1 Introduction 
In Chapter 4 an unexpected finding was observed, the ER-targeted PR8NP-366 
minigene was less immunogenic than the full-length PR8NP antigen when 
expressed from VACV strain WR. This finding not only differs from the results 
obtained with the other WR recombinants used in Chapter 4, but also contradicts 
the long-held paradigm that ER-targeted minigenes expressed from WR should be 
at least as immunogenic, if not more than, full-length constructs (Restifo et al.. 
1995). Understanding this phenomenon may reveal new aspects of antigen 
processing pathways. 
Full-length NP is the structural protein associated with the segmented single-
stranded negative-sense RNA genomes of lAV (Pons et al., 1969; Content and 
Duesberg. 1970; Compans et a l , 1972; Arranz et al., 2012). Multiple NP 
molecules are bound to individual RNA genome segments to form 
ribonucleoprotein complexes which are required for viral RNA transcription and 
replication (together with viral RNA polymerase subunits; Compans et al.. 1972; 
Murti et al.. 1988; Coloma et al., 2009; Arranz et al., 2012). Within newly-
infected cells, NP is an essential component required for importing 
ribonucleoprotein complexes into the nucleus, a critical step for viral RNA 
transcription and replication (Davey et al., 1985; Martin and Helenius, 1991; 
O'Neill et al., 1995; Neumann et al., 1997; Wang et al., 1997). 
There are several immunogenic peptides within lAV NP that can bind to murine 
or human MHC-I and are recognised by anti-IAV CD8^ T cells during lAV 
infection (McMichael et al., 1986a; McMichael et al., 1986b; Townsend et a l , 
1986b; Taylor et al., 1987; Rotzschke et al., 1990; DiBrino et al., 1993; Wu et al., 
2011; Grant et al., 2013). One such peptide is NP-366 at position 366-374 and this 
peptide is restricted to the murine MHC-I H-2D'' (Rotzschke et al., 1990). This 
peptide was one of the first mapped peptides found to bind to MHC-I. Multiple 
natural variants of the NP-366 peptide have been identified in different lAV 
strains (Zhong et al., 2010). Most research has focused on two variants of this 
peptide. One is expressed by lAV strain PR8 and it has the amino acid sequence 
ASNENMETM (Rotzschke et al., 1990; Falk et al., 1991a). In this thesis, the NP 
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antigen expressed by PR8 is called PR8NP and the antigenic peptide is called 
PR8NP-366. Another variant of the NP-366 peptide with an amino acid sequence 
of ASNENMDAM is expressed by the lAV strain NT60 (Townsend et al., 1985; 
Townsend et al., 1986b). Here, the NP antigen from strain NT60 is named 
NT60NP and its NP-366 peptide NT60NP-366. It has been shown that PR8NP-
366 and NT60NP-366 bind to H-ZD" with similar affinity (Williams et al., 1996; 
Tourdot et al., 1997). During an acute infection with lAV strain PR8 in C57BI/6 
mice, PR8NP-366 is co-dominant with the lAV PA-224 peptide (Belz et al., 
2000). This immunodominance hierarchy changes in the secondary response, in 
which PR8NP-366 becomes the immunodominant peptide over all other lAV 
antigenic peptides (Belz et al., 2000; Belz et al., 2001). Similar to PR8NP-366, 
NT60NP-366 is co-immunodominant with PA-224 in mice immunised with lAV 
strain NT60 (Cho et al., 2003). An advantage of NT60NP-366 is that this peptide 
presented on H-2D'' can be recognised by a TCR-transgenic mouse strain, known 
as the F5 mouse strain (Mamalaki et al., 1992; Mamalaki et al., 1993). Most T 
cells in F5 transgenic mice express the TCR from a CD8^ T cell clone that is 
specific for the NT60-NP366/H-2D'' complex (Townsend et al., 1984; Townsend 
et al., 1985; Townsend et al., 1986b). It should be noted that the F5 CD8^ T cells 
do not cross react with the PR8NP-366 peptide. 
In this chapter, we firstly confirmed and extended our findings from Chapter 4, 
demonstrating that the CD8^ T cell responses against PR8NP-366 and NT60-
NP366 were not effectively primed when they were expressed from VACV strain 
WR as constructs that allow effective direct presentation. These constructs 
included a cytosolic minigene, ER-targeted minigene and rapidly-degraded 
antigen. A series of experiments were then conducted to examine the mechanisms 
behind these findings. 
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5.2 Results 
5.2.1 The ER-targeted PR8NP-366 minigene expressed from WR allows 
effective MHC-I presentation of PR8NP-366 on Infected cells in vitro 
(I 'inises used in this chapter are listed in Table A-4 in the Appendix) 
Before any further in vivo examination, the direct presentation ability of PR8NP-
366 expressed as an ER-targeted minigene from WR was examined. This is an 
important question because the lack of immunogenicity of the minigene might 
simply be due to its inability to display the PR8NP-366 peptide on MHC-I. 
Similar to the PB1F2-62 peptide focused in Section 4.2.2.2. there is a reagent 
which detects the PR8NP-366/H-2D'' complex on infected cells (Lev et al.. 2008). 
However, it is not sensitive enough to detect the presentation of PR8NP-366 
processed from the full-length PR8NP antigen (J.W. Yewdell. personal 
communication). So. we exploited the in vitro direct presentation assay used in 
Section 4.2.1.1. In brief. DC2.4 cells were infected with WR-ESmini-PR8NP or 
WR-Full-PR8NP. which express the ER-targeted PR8NP-366 minigene or the 
full-length PR8NP antigen respectively. These infected DC2.4 cells were used to 
stimulate splenocytes isolated from a mouse infected with lAV strain PR8 seven 
days earlier. There are peptides other than PR8NP-366 in the full-length PR8NP 
antigen that may be presented on the WR-Full-PR8-NP-infected DC2.4 cells, but 
it has been shown that these peptides are not immunogenic and cannot be 
recognised by the CD8^ T cells isolated from mice infected with lAV strain PR8 
(Zhong et al., 2003). In addition, similar to the result shown in Figure 4-5, the 
WR-delTK-infected cells did not re-stimulate the lAV-immune CD8^ T cells. This 
confirms that there was no cross-reactivity between the lAV-specific CDS"^  T cells 
and the native VACV peptides presented on the infected DC2.4 cells (Figure 5-1). 
As seen in Figure 5-1, DC2.4 cells infected with WR-ESmini-PR8NP re-
stimulated more €08"" T cells isolated from the lAV-infected mouse to produce 
IFN-y than cells infected with WR-Full-PR8NP when stimulator:effector ratios of 
1:5, 1:25 or 1:50 were used. A similar level of stimulation was detected when a 
stimulator:effector ratio of 1:1 was used. This data suggested that PR8NP-366 
expressed as an ER-targeted minigene allowed at least as much, if not more, direct 
presentation of PR8NP-366 on the surface of infected cells as the full-length 
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Figure 5-11 Expressing PR8NP-366 as an ER-targeted minigene from VACV WR 
allows effective direct presentation. DC2.4 cells were infected with the indicated 
recombinant WR at a m.o.i. of 5 for 5 h. The infected cells (stimulators) were then co-
cultured with splenocytes (effectors) from a mouse immunised i.p. with 500 
hemagglutinin units (HAU) of lAV strain PR8 seven days before, at different 
stimulator:effector ratios. BFA was added 1 h later, followed by another 3 h of co-
culturing. ICS was then performed to measure the percentage of CDS' T cells that 
produced IFN-y. A standard ICS assay with a synthetic PR8NP-366 peptide was also 
performed in parallel to measure the total PR8NP-366-specific T cell response. Data 
show the level of PR8NP-366-specific CD8 T cell activation by the infected DC2.4 
cells, after being standardised to the percentage of ma.\imal activation as induced by the 
synthetic PR8NP-366 peptide. Data are representative of three independent 
experiments. Similar results were also obtained when 293-D'' cells or BMDCs were 
used as stimulators. 
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PR8NP antigen. As well as DC2.4 cells, BMDCs and 293-D^ a human 293A cell 
line stably expressing H-2D'' (Tscharke et al., 2005). have been used as 
stimulators in this assay. Experiments with these cells also produced similar 
results as those shown in Figure 5-1 (data not shown). Overall, this experiment 
indicates that PR8NP-366 is not defective in direct presentation when expressed 
as an ER-targeted minigene. compared to the full-length PR8NP antigen. 
5.2.2 PR8NP-366 expressed as a minigene from WR is less able to prime CD8^ 
T cells than full-length PR8NP 
The data shown in Figure 4-4D represented only one single experiment. To 
confirm this result, the experiment was repeated here by measuring anti-PR8NP-
366 CD8^ T cell responses in mice immunised with WR-ESmini-PR8NP or WR-
Full-PR8NP seven days post immunisation. In addition to the standard ICS assay, 
DimerX loaded with the PR8NP-366 peptide was used to enumerate the PR8NP-
366-specific CD8^ T cells. Similar to peptide/MHC-l tetramers (Altman et al., 
1996), peptide-loaded DimerX binds to TCRs that recognise the loaded peptide 
(Flesch et a l . 2012). Importantly, this assay does not rely on the ability of CD8^ T 
cells to respond to ex vivo peptide stimulation, allowing us to detect a peptide-
specific CD8^ T cell response independent of the functionality of the cells. 
Seven days after immunisation. WR-ESmini-PR8NP elicited a PR8NP-366-
specific response of around 0.15% of splenic CD8^ T cells as determined by ex 
vivo peptide stimulation and ICS (Figure 5-2A). This was significantly lower than 
the response induced by WR-Full-PR8NP. in which around 0.55% of splenic 
CD8^ T cells were specific to PR8NP-366. A similar result was observed when 
the total number of responding CD8^ T cells was calculated (Figure 5-2B). In 
addition, the data obtained from PR8NP-366-loaded DimerX staining confirmed 
the ICS results, in which a much smaller anti-PR8NP-366 CD8^ T cell population 
was induced by the ER-targeted minigene, compared to the full-length antigen 
(Figure 5-2C, D and E). It should be noted that results shown in Figure 5-2D and 
E were calculated by subtracting the background values determined by using 
DimerX loaded with an irrelevant adenovirus type 5 E lA-324 peptide (sequence 
SGPSNTPPEI; Kast and Melief, 1991) from the measured values determined 
Chapter 5 
Figure 5-2| The full-lenglh lAV PR8NP antigen is more immunogenic than the 
ER-targeted PR8NP-366 minigene for inducing a PR8NP-366-specfic CDS"^  T cell 
response in vivo. Groups of three mice were immunised i.p. with IxlO*" PFU of WR-
ES-mini-PR8NP or WR-Fuil-PR8NP. Seven days later, splenocytes from the 
immunised mice were either stimulated with peptides ex vivo followed by ICS (A and 
B) or stained with DimerX loaded with the indicated peptides (C. D and E). Percentages 
(A) and absolute numbers (B) of IFN-y-producing cells after stimulation with peptides 
indicated are shown. (C) Representative flow cytometric plots showing CDS' T cells 
from mice immunised with WR-ESmini-PR8NP {first row) or WR-Full-PR8NP 
(second row) labelled with DimerX loaded with adenovirus type 5 EIA-324 (first 
column). lAV PR8NP-366 (second column) or VACV A23-297 peptides (third 
column). The number on each plot shows the percentage of DimerX" cells of the CDS" 
T cell population. (D and E) Percentages (D) and absolute numbers (E) of CD8' T cells 
stained with DimerX loaded with peptides indicated were shown. Backgrounds were 
determined by using DimerX loaded with adenovirus type 5 EIA-324 peptide and these 
values were subtracted from the measured values using DimerX loaded with the 
peptides indicated. (A, B, D and E) Data represent results compiled from two 
independent experiments (mean ± SEM; n = 6). * denotes statistical significance (p < 
0.05). 
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with DimerX loaded with VACV A23-297 or PR8NP-366 peptides. In this 
experiment, there were variations between the CDS"^ T cell responses induced 
against native VACV peptides by the two WR recombinants. For instance, WR-
Full-PR8NP induced significantly fewer K3 CD8^ T cells specific for K3-6 than 
WR-ESmini-PR8NP (Figure 5-2B). However, this variation should not affect our 
conclusion that the ER-targeted PR8NP-366 minigene is less immunogenic than 
full-length PR8NP. 
In addition to the ER-targeted minigene, we also examined the cytosolic PR8NP-
366 minigene expressed by WR-mini-PR8NP and this minigene also had a lower 
immunogenicity than the full-length PR8NP antigen (Figure 5-3). The difference 
between the size of the anti-PR8NP-366 CD8^ T cell response induced by WR-
mini-PR8NP and WR-Full-PR8NP (Figure 5-3) was similar to the 4-fold 
difference between WR-ESmini-PR8NP and WR-Full-PR8NP (Figure 5-2). 
Overall, these experiments confirm that the ER-targeted and cytosolic minigene 
constructs of PR8NP-366 are less immunogenic than full-length PR8NP when 
expressed from WR. 
5.2.3 The ER-targeted PR8NP-366 minigene elicits less potent memory and 
recall CD8^ T cell responses 
The previous experiments focused on the primary CD8^ T cell responses. Here we 
examined whether the ER-targeted PR8NP-366 minigene was also less capable of 
eliciting a response that persist into memory. Seven to eight weeks post 
immunisation, a much smaller anti-PR8NP-366 €08"" T cell response was induced 
by the ER-targeted minigene than the full-length antigen. By using the standard 
ICS assay, we detected around 0.05% of CD8^ T cells that responded to the 
PR8NP-366 peptide stimulation in mice immunised with WR-ESmini-PR8NP 
(Figure 5-4A). In comparison, around 0.18% of the total CDS"^ T cell population 
was specific to PR8NP-3366 after WR-Full-PR8NP immunisation (Figure 5-4A). 
The response of the PR8NP-366-specific CD8^ T cells measured as an absolute 
number produced a similar observation (Figure 5-4B). This experiment suggests 
that in addition to the reduced acute response, the ER-targeted minigene also 
induces a smaller memory response. 
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Figure 5-3| The cytosolic PR8NP-366 minigene induces a significantly lower 
PR8NP-366-specif ic CDS"^ T cell response than the full-length PR8NP antigen 
when expressed from WR. Mice were immunised i.p. with IxlO" PFU of WR-mini-
PR8NP or WR-Full-PR8NP. Seven days later, antigen-specific CD8 T cell responses 
were determined by ex vivo peptide stimulation and ICS. Percentages (A) and absolute 
numbers (B) of CD8 ' T cells responding to the indicated peptides are shown as mean ± 
SEM. Results are compiled from two independent experiments (WR-mini-PR8NP: n = 
6; WR-Ful l -PR8NP: n = 2). * denotes statistical significance (/; < 0.05). 
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Figure 5-4| PR8NP-366 expressed as an ER-targeted minigene is less able to induce 
a memory CD8^ T cell response than its full-length counterpart. Groups of three 
mice were immunised i.p. with IxlO" PFU of WR-ES-mini-PR8NP or WR-Full-
PR8NP. After 7 to 8 weeks, splenocytes from the immunised mice were isolated and 
stimulated with peptides ex vivo followed by ICS. Data are shown as percentages (A) 
or absolute numbers (B) of CD8'^ T cells responding to the peptides indicated and are 
compiled from two independent experiments (as mean ± SEM ; n = 6). * denotes 
statistical significance (/; < 0.05). 
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The ability of tine ER-targeted minigene expressed from WR to re-stimulate a 
memory response was then determined. Mice were infected i.p. with lAV strain 
PR8. Four weeks later, these mice were immunised with the PR8NP-expressing 
WR recombinants . CDS"^ T cell responses against several native VACV peptides 
and PR8NP-366 were measured 7 days later. WR-ESmini -PR8NP allowed re-
stimulation of the PR8NP-366-speci t lc memory CD8^ T cells in vivo, when 
compared to the very small memory CD8^ T cell population induced by the lAV 
infection (Figure 5-5A). However , the response induced by WR-ESmini-PR8NP 
remained substantially smaller than that induced by WR-Full-PR8NP. by around 
2-fold. These data showed that the ER-targeted minigene was able to re-stimulate 
the PR8NP-366-specif ic memory CD8* T cells in vivo, but was less efficient than 
the full-length antigen. When the total number of responding CD8'^ T cells was 
measured, we also found that the PR8NP-366-specif ic CD8* T cell population 
induced by WR-Ful l -PR8NP was more than double the size of the population 
induced by WR-ESmin i -PR8NP (Figure 5-5B). However, the difference observed 
was not significant, probably due to higher variation in responses amongst 
individual animals. As a side note, the B8-20 specific CD8^ T cell response 
induced by WR-ESmin i -PR8NP was significantly higher than that of WR-Full-
PR8NP after immunisat ion (Figure 5-5A). One possible explanation is that the 
strong PR8NP-366-specif ic recall response induced by WR-Full-PR8NP might 
negatively influence the primary B8-20-specific CD8^ T cell priming. It has been 
previously shown that prior priming with lAV does not influence the 
immunogenici ty of native V A C V peptides induced by immunisation with WR 
expressing an ER-targeted lAV PA-224 minigene (WR-ESmini-PA; Wang et al., 
2009). Therefore, this may be an antigen-specific phenomenon. It is likely that the 
size of the response against the lAV peptide examined plays a role here as it 
seems that the PR8NP-366-specif ic response re-stimulated by WR-Ful l -PR8NP 
(as shown in Figure 5-5) was bigger than the response against PA-244 re-
stimulated by WR-ESmin i -PA (as shown in Wang et al. 2009). 
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Figure 5-5| ER-targeted PR8NP-366 minigene elicits a smaller secondary CD8^ 
response than the full-length PR8NP antigen. Mice were infected with 500 HAU 
IAV-PR8 via the i.p. route. Four weeks later, these mice were either left un-immunised 
or immunised with Ix lO ' PFU of the indicated recombinant WR. Seven days after the 
VACV immunisation, epitope-specific CDS*^ T cell responses were determined by ex 
vivo peptide stimulation and ICS. Results are shown as percentage (A) or absolute 
number (B) of CDS' T cells specific to the indicated peptides. Data are compiled from 
two independent experiments (mean ± SEM; WR-ESmini-PR8NP and WR-Full-
PRSNP; n = 5; IAV-PR8 primed only; n = 2). * denotes statistical significance (p < 
0.05). 
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5.2.4 The ER-targeted NT60NP-366 minigene elicits a smaller NT60NP-366-
specific CDS"^ T cell response in vivo 
To investigate winether tiie observations above were specific to PR8NP-366 or if 
tiiey also applied to other NP-366 variants, the immunogenicity of NT60NP-366 
expressed as a minigene from W R was examined. In addition. NT60NP-366 
presented on H-2D'' can be recognised by F5 TCR transgenic CD8^ T cells as 
discussed in Section 5,1 (Mamalaki et al., 1992; Mamalaki et al., 1993). With this 
tool, events that occurred early after priming could be traced. Two W R 
recombinants were used, namely WR-ESmini-NT60NP and WR-Fuil-NT60NP. 
The former recombinant virus expresses NT60NP-366 as an ER-targeted 
minigene. It should be noted that the ER-targeting sequence is derived from the 
signal sequence of the lAV hemagglutinin protein (Elliott et al., 1995). WR-Full-
NT60NP expresses the full-length NT60 NP antigen. 
The direct presentation capacity of the ER-targeted NT60NP-366 minigene 
expressed from W R was first measured with an in vitro direct presentation assay 
similar to that shown in Figure 5-1 with some modifications. Instead of using 
splenocytes from infected mice as effectors, in vitro-activated F5 CDS"^ T cells 
were used. To generate these activated cells, splenocytes from a F5 mouse were 
stimulated with NT60NP-366 peptide in the presence of IL-2 for 4 days. The in 
vitro-activated CDS"^ T cells were mixed with C57BI/6 BMDCs that were infected 
with WR-ESmini-NT60NP. WR-Full-NT60NP or WR-delTK. The level of re-
stimulation of the activated F5 CD8^ T cells was detected as the frequency of 
IFN-y-producing CDS"^ T cells using ICS and the result is shown in Figure 5-6. 
BMDCs infected with the control virus, WR-delTK, did not restimulate the F5 
CDS"^ T cells, demonstrating that these TCR-transgenic cells did not cross-react 
with the presented native V A C V peptides. Compared to WR-Full-NT60NP. 
BMDCs infected with WR-ESmini-NT60NP re-stimulated a larger population of 
activated F5 CD8^ T cells (Figure 5-6). This suggests that the ER-targeted 
NT60NP-366 minigene expressed from W R allows better direct presentation of 
the NT60NP-366 peptide on infected cells than the full-length NT60NP antigen. 
It should be noted that the in vitro activation of F5 cells with the cognate 
NT60NP-366 peptide is not very efficient. After in vitro activation, only around 
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Figure 5-6| The in vitro direct presentation efficiency of NT60NP-366 is improved 
when it is expressed as an ER-targeted minigene from WR, compared to the full-
length NT60NP antigen. Splenocytes from a TCR-transgenic F5 mouse were isolated 
and cultured with the NT60NP-366 peptide in the presence of lL-2 for three days to 
activate F5 CD8 T cells. In-vitro-cultured BMDCs from a C57BI/6 mouse were 
infected with the indicated recombinant WR at a m.o.i. of 5 for 5 h. The infected 
BMDCs (stimulators) were then co-cultured with the activated F5 cells (effectors) at a 
stimulator:effector ratio of 1:1. BFA was added 1 h after cells were mixed, followed by 
another 3 h of co-culturing. ICS was then perfonned to measure the percentage of F5 
CD8* T cells that produced IFN-y. The maximum level of responding F5 CD8 T cells 
was determined by simulation with BMDCs pulsed with l^iM of the NT60NP-366 
peptide. Data show the level of IFN-y-producing F5 CD8^ T cells after stimulation with 
the infected BMDCs, normalised to the percentage of maximal potential stimulation as 
induced by the NT60NP-366-pulsed BMDCs. Data for the NT60NP-366-expressing 
recombinants are shown as mean ± SEM from triplicate samples while data for WR-
delTK (control) represents a single measurement. Data are representative of two 
independent experiments. * denotes statistical significance (p < 0.05). 
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15% of F5 CD8 ' T cells could respond to stimulation with BMDCs pulsed with 
the synthetic NT60NP-366 peptide (data not shown). For comparison, this 
protocol has also been used to activate CD8^ T cells from OT-I TCR transgenic 
mice, which are specific to OVA-257/H-2K' ' (Hogquist et al., 1994). At least 50% 
of the in vitro-activated OT-I CD8* T cells would produce IFN-y after a short 
period of re-stimulation with the synthetic OVA-257 peptide as measured by ICS 
(data not shown). The reduced ability of the F5 CD8^ T cells to be activated in 
vitro as measured in our experiments was in agreement with a previous study 
which suggested that in vitro activation of F5 CD8^ T cells requires additional 
inflammatory signals (Schell et al.. 2010). 
The in vivo immunogenicity of WR-Full-NT60NP and WR-ESmini-NT60NP was 
then checked. Seven days after immunisation, mice immunised with WR-ESmini-
NT60NP had a significantly smaller population of CD8^ T cells specific for 
NT60NP-366 than those immunised with WR-Full-NT60NP (Figure 5-7). The 
full-length NT60NP antigen elicited an anti-NT60NP-366 response of around 
0.2% of CD8^ T cells in spleens (equivalent to around 6x10'' NT60NP-366-
specific CD8^ T cells), which was around 6-fold higher than that the response 
induced by the ER-targeted minigene. This suggests that the phenomenon of the 
low immunogenicity of a minigene is not specific to the PR8NP-366 petpide. but 
also applicable to the NT60NP-366 peptide. 
5.2.5 The ER-targeted NT60NP-366 minigene elicits a smaller F5 TCR 
transgenic CD8^ T cell response in recipient mice 
We then investigated whether F5 CD8'^ T cells would behave like the endogenous 
polyclonal CD8^ T cells in mice immunised with WR-ESmini-NT60NP. CD8^ T 
cells were purified from F5 mice using negative magnetic bead separation. As the 
F5 mice were on a C57BI/6 background, they carry the CD45.2 allelic marker. 
5x10^ isolated F5 CD8^ T cells were adoptively transferred via i.v. injection into 
B6.SJL mice, which carry the CD45.1 congenic marker. Mice were immunised 
with WR-Full-NT60NP. WR-ESmini-NT60NP or WR delTK one day later. Seven 
days post-immunisation, endogenous and transferred F5 CD8^ T cell responses 
were measured. We found that WR-ESmini-NT60NP induced a smaller 
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Figure 5-7| Similar to the PR8NP-366 epitope, NT60NP-366 expressed as an ER-
targeted niinigene elicits a smaller NT60NP-366-specific CD8^ T cell response than 
the full-length NT60NP antigen when expressed from WR. Groups of three mice 
were immunised i.p. with the indicated WR recombinants (at a dose of Ix lO ' 
PFU/mouse). Seven days after the immunisation, CD8^ T cell responses were 
determined by ex vivo peptide stimulation and ICS. Results are shown as percentages 
(A) or absolute numbers (B) of CDS' T cells specific to the peptides indicated. Data 
represent results compiled from two independent experiments (mean ± SEM; n = 6). * 
denotes statistical significance (/> < 0.05). 
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population of IFN-y-producing F5 CD8^ T cells than WR-Full-NT60NP after ex 
vivo peptide stimulation (F5 cells were CD45.2^ Figure 5-8A and B). The 
difference was significant when the response was measured either as the 
percentage of IFN-/ F5 CDS" T cells in relation to the overall CD8^ T cell 
population (Figure 5-8A) or as the total number of responding F5 CD8" T cells 
(Figure 5-8B). In addition to the reduction of the transferred F5 CD8" T cell 
response, the endogenous anti-NT60NP-366 CD8" T cell response (CD45.2") was 
also significantly lower in mice immunised with WR-ESmini-NT60NP. compared 
with mice immunised with WR-Full-NT60NP (Figure 5-8C and D). This 
demonstrates that the F5 CDS* T cells accurately reflects the phenomenon 
observed in the endogenous response. 
The kinetics o f the transferred F5 CD8" T cell responses in the recipient mice 
were also measured. Similar percentages (0.2-0.3%) and numbers (2-4x10'*) of 
IFN-y-producing F5 CDS" T cells were detected in mice immunised with WR-
ESmini-NT60NP or WR-Full-NT60NP at an early time point, four days post 
immunisation (Figure 5-9A and B). For WR-Full-NT60NP. the F5 CD8" T cell 
response peaked at day 6 after immunisation at approximately 2.2% of total CDS" 
T cells and then reduced to around 1% eight days after immunisation (Figure 5-
9A). In contrast to WR-Full-NT60NP. the percentage of IFN-y-producing F5 
CDS" T cells relative to the total CDS" T cell population in mice immunised with 
WR-ESmini-NT60NP plateaued from 6 days after immunisation, remaining at 
around 0.3%. Compared to WR-Full-NT60NP. the transferred F5 responses, as 
measured as percentage of IFN-y-producing F5 CDS" T cells of the total CDS" T 
cells, at six and eight days post-immunisation were significantly lower in mice 
immunised with WR-ESmini-NT60NP (Figure 5-9A). A similar situation was 
seen when the total number of IFN-y-producing F5 CDS" T cells was measured 
(Figure 5-9B). 
An interesting finding about the ability of the transferred F5 CDS" T cells to 
produce IFN-y was also noticed. After stimulation with NT60NP-366 peptide ex 
vivo, more than 70% of the CD45.2" F5 CDS" T cells from WR-Full-NT60NP-
immunised mice produced IFN-y (Figure 5-9C). In contrast, in mice immunised 
with WR-ESmini-NT60NP, a significantly lower percent of F5 CDS" T cells 
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Figure 5-8| The NT60NP-366 minigene expressed from WR primes a smaller F5 
TCR-transgenic CDS"^  T cell response than the full-length NT60NP antigen. CD8^ 
T cells from a naive F5 TCR-transgenic mouse, wliich express the CD45.2 allelic 
marker, were isolated using magnetic bead separation. 5xlO'' isolated F5 CDS' T cells 
were i.v. injected into B6.SJL mice ( C D 4 5 . r ) . One day later, these mice were 
immunised i.p. with the indicated recombinant WR at a dose of IxlO*" PFU. Seven days 
after the immunisation, splenocytes from the immunised mice were stimulated ex vivo 
with the synthetic peptides as indicated. These cells were labelled with FITC-
conjugated anti-CD45.2 and PE-conjugated anti-CD8 antibodies, followed by standard 
ICS. The transferred CDS' CD45.2' cells producing IFN-y after ex vivo stimulation 
with the NT60NP-366 peptide are shown as a percentage of the total CDS^ population 
(A) or as an absolute number (B). Endogenous CD45.2' CDS' T cell responses specific 
to peptides indicated are shown as percentages of total CDS' T cells (C) or as an 
absolute numbers (D). Data represent results compiled from two independent 
experiments (mean ± SEM; WR-ESmini-NT60NP and WR-Full-NT60NP: n = 6; WR-
delTK: n = 2). * denotes statistical significance (p < 0.05). 
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(around 40-50%) could produce IFN-y after cognate peptide stimulation. 
Although it is not statistically significantly. CD8^ T cells induced by WR-ESmini-
NT60NP seemed to express lower level of IFN-y than those primed by WR-Full-
NT60NP (as measured by MFI; Figure 5-9D). This implies that the F5 CD8^ T 
cells induced by WR-ESmini-NP60NP may not be as functional. To control for 
the level of infection across the viruses used, the endogenous (CD45.2 ) B8-20-
specific CD8^ T cell responses were measured. The responses elicited by the three 
WR recombinants were similar over the course of immunisation (Figure 5-9E and 
F). Overall, the data here suggests that the ER-targeted NT60NP-366 minigene 
induces a smaller and less responsive F5 CD8^ T cell response. 
5.2.6 The ER-targcted NT60NP-366 minigene allows a similar level of early 
activation and proliferation of F5 CDS"^ T cells as the full-length NT60NP 
We tracked whether the reduction of F5 CD8^ T cell response induced by the ER-
targeted NT60NP minigene was caused by a defective activation early during 
immunisation. One million purified F5 CD8^ T cells were injected i.v. into 
B6.SJL mice, followed by immunisation with WR recombinants one day later. 
Splenocytes were isolated one day after immunisation and the expression level of 
the early activation marker CD69 on the transferred F5 CD8^ T cells was 
determined (Figure 5-IOA). The results shown in Figure 5-lOB illustrate that the 
percentage of F5 CD8^ T cells expressing CD69 in mice immunised with WR-
ESmini-NT60NP seemed to be lower, but it was not significantly different from 
those immunised with WR-Full-NT60NP. Similarly, there was no statistical 
difference between the expression level of CD69 on the F5 008"^ cells that were 
CD69^ (as measured by MFI; Figure 5-IOC). Because F5 CDS"^ T cells in mice 
immunised with WR-delTK did not up-regulate CD69. the activation by 
NT60NP-366-expressing viruses was peptide-specific. 
The magnitude of a CD8^ T cell response induced depends on the proliferation of 
responding CD8^ T cells during the priming phase. Furthermore, CD25. the IL-2 
receptor a-subunit whose expression is induced early during CD8^ T cell 
activation (Kalia et al., 2010), is required for optimal priming of primary anti-
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Figure 5-9| A smaller and less reactive F5 transgenic CD8^ T cell response is 
elicited by the NT60NP-366 niinigene when expressed from WR. Isolated 5x10"' 
CD45.2 F5 CD8* T cells were adoptively transferred via i.v. injection into CD45. r 
B6.SJL mice. One day later, these mice were immunised i.p. with the indicated WR 
recombinants at a dose of at a dose of 1 x 1 P F U . At times indicated, splenocytes from 
the immunised mice were stimulated ex vivo with synthetic NT60NP-366 or B8-20 
peptides. Cells were then labelled with FlTC-conjugated anti-CD45.2 and PE-
conjugated anti-CD8 antibodies, followed by standard ICS. Responses were determined 
as percentages of CDS CD45.2' cells producing IFN-y relative to the overall CD8^ 
population (A) or as absolute numbers (B). (C) Percentages of CD8 CD45.2 F5 T 
cells that produced IFN-y after ex vivo stimulation with the NT60NP-366 peptide. (D) 
MFI of APC-anti-IFN-y of the CDS CD45.2 I F N y cells after ex vivo stimulation 
with the NT60NP-366 peptide. (E and F) Endogenous CD45.2" CDS* T cell responses 
specific to BS-20 was also determined and are shown as percentages of total CDS' T 
cells (E) or as absolute numbers (F). (A-C, E-F) Data represent results compiled from 
two independent experiments (mean ± SEM; WR-ESmini-NT60NP and WR-Full-
NT60NP: n = 6; WR-delTK: n = 2). Data are representatives from two independent 
experiments. * denotes statistical significance {p < 0.05). 
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Figure 5-10| NT60NP-366 expressed as an ER-targeted minigene or a full-length 
antigen from W R activates a similar level of NT60NP-366-specif ic CDS"^ T cells 
early during immunisation. IxlO' ' F5 CD8 T cells were adoptively transferred into 
CD45.1 B6.SJL mice. One day later, these mice were immunised i.p. with 1 xlO*^ PFU 
of the WR recombinants indicated. One day later, splenocytes from the immunised 
mice were labelled with anti-CD45.2, anti-CD8 and anti-CD69 antibodies. The labelled 
cells were then analysed with flow cytometi^. (A) A representative histogram 
illustrating the CD69 expression level of the gated CDS" CD45.2 ' T cells from three 
individual mice, each immunised with WR-ESmini-NT60NP (green). WR-Full-
NT60NP (blue), or WR-delTK (red). Percentages of the transferred CDS" CD45.2^ cells 
that were CD69 are shown in (B) while the MFI of CD69 within the CD45.2" CDS' 
C D 6 9 ' cells are shown in (C). The results in (B and C) are shown as mean ± SEM and 
represent compiled data from four independent experiments (WR-ESmin i -NT60NP and 
WR-Full-NT60NP: n = 12: WR-delTK: n = 4), 
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V A C V C D S ' T cell responses (Obar et al., 2010). Therefore, the ability of the ER-
targeted N T 6 0 N P - 3 6 6 minigene and the full-length N T 6 0 N P antigen to drive 
early proliferation and CD25 expression by F5 C D S ' T cells in vivo was 
investigated. B6.S.IL mice were adoptively transferred with IxlO*" F5 C D S ' T 
cells that were labelled with CFSE and the mice were immunised with WR 
recombinants one day later. Two days after immunisation, splenocytes were 
collected and the proliferation of and CD25 expression by F5 C D S ' T cells was 
determined by How cytometric analysis. After a round of cell division, a CFSE-
labelled cell gives rise to two daughter cells with half the initial amount of CFSE 
(Lyons and Parish. 1994). Therefore. F5 C D S ' T cells with reduced CFSE 
intensity represent cells that have undergone proliferation. In this assay, the 
percentage of CFSE'" F5 C D S ' T cells was similar in mice immunised with either 
W R - E S m i n i - N T 6 0 N P or WR-Ful l -NT60NP (Figure 5-11A and B). In addition, 
there was no difference between the extent of division of the F5 C D S ' T cells 
induced by the ER-targeted minigene or the full-length antigen. This was shown 
by the similar division index, which represents the average number of division for 
every transferred F5 CDS' T cell (Figure 5-1IC) . Moreover. WR-ESmini-
N T 6 0 N P and WR-Ful l -NT60NP induced a similar percentage of F5 C D S ' T cells 
to express CD25 two days after immunisation (Figure 5-11A and D). 
Furthermore, the percentages of CFSE'" C D 2 5 ' cells within the F5 C D S ' T cell 
populat ion were similar between mice immunised with WR-ESmini -NT60NP and 
WR-Fu l l -NT60NP (Figure 5-1 IE). Collectively, results in Figures 5-10 and 5-11 
demonstra tes that early activation and proliferation of NT60NP-366-specif ic 
C D S ' T cells induced by the ER-targeted NT60NP-366 minigene are not 
significantly different f rom that of the full-length N T 6 0 N P antigen. These data 
suggests that any differences happening early after immunisation must be subtle. 
In addition, our data points to a role of the differences in proliferation and/or 
survival of F5 C D S ' T cells during the later stage of immunisation in affecting the 
ou tcome observed. 
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Figure 5-11| NT60NP-366 expressed as an ER-targeted minigene or as a full-length 
antigen from WR allows a similar level of proliferation and activation of F5 TCR 
transgenic CDS"^ T cells early after immunisation. CFSE-labelled CD45.2 F5 CD8 
T cells were adoptively transferred into CD45.1 ' B6.SJL mice ( Ix lO" cells per mouse). 
One day later, mice were immunised i.p. with at IxlO" PFU of the viruses indicated. 
Two days post immunisation, expression of CD25 and the CFSE level of the transferred 
F5 CD8* T cells from the immunised mice were analysed by flow cytometry. (A) 
Representative flow cytometric plots illustrating the CFSE and CD25 levels of the 
transferred CD45.2^ CD8 F5 cells from mice immunised with viruses indicated. On 
each plot. CD25 ' population is gated with a red-coloured gate, and the number in red 
represents the percentage of CD25 ' events of the CDS CD45.2 population. The 
CFSE'° population is gated with a blue-coloured gate, and the number in blue represents 
the percentage of the CFSE'" population relative to the CDS CD45.2^ population. (B) 
Percentages of the CD45.2 CDS' cells that were CFSE'°. (C) The division index of the 
0045.2"^ CDS cells, representing the average number of cell divisions of all the 
transferred F5 CDS' T cells. (D) Percentages of the CD45.2 ' CDS cells that were 
CD25 . (E) Percentages of CFSE'" CD25 ' cells within the CDS" CD45.2 population. 
Results shown in (B-E) are pooled from four independent experiments and are shown as 
mean ± SEM (WR-ESmini-NT60NP and WR-Full-NT60NP: n = 12; WR-delTK: n = 
4). 
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5.2.7 Increasing the proteasomal processing of PR8NP fails to elicit a strong 
PR8NP-366-specific CD8^ T cell response in vivo 
The previous data confirm that lAV NP-366 minigenes are less immunogenic than 
the full-length NP antigens. To investigate the mechanisms responsible, a series of 
studies was performed. 
The previous experiments focus on minigene constructs of NP-366 and it seems 
that the direct presentation efficiency of the lAV NP constructs is inversely 
proportional to their immunogenicity. Whether enhancing proteasomal processing 
of full-length lAV NP would affect the priming of the PR8NP-366-specific 
response remained unknown. Here we took advantage of a set of two recombinant 
WR viruses expressing a genetically-engineered PR8NP antigen under the control 
of the VACV p7.5 promoter (Anton et al.. 1999; Princiotta et al., 2003). These 
two viruses are named WR-NP-S-GFP and WR-UbR-NP-S-GFP. The first 
recombinant have been used in Section 3.2.6. It expresses an antigen called NP-S-
GFP which consists of the full-length PR8NP antigen at the amino-terminus, 
followed by an OVA-257 antigenic peptide and eOFP at the carboxyl-terminus 
(Anton et al., 1999). WR-UbR-NP-S-GFP expresses a rapidly-degraded version of 
NP-S-GFP which contains an extra ubiquitin polypeptide and an arginine amino 
acid residue at the amino-terminus of the NP-S-GFP antigen (Princiotta et al., 
2003). The ubiquitin subunit is rapidly cleaved off precisely after the last amino 
acid residue at its carboxyl-terminus from the fusion antigen by deubiquitinating 
enzymes soon after translation (Wilkinson et al., 1989). The arginine residue at 
the amino-terminus of the cleaved antigen will be exposed and it is recognised by 
E3 ubiquitin ligases to mediate polyubiquitylation of the antigen, which results in 
rapid degradation of the antigen by the proteasome (Bachmair et al., 1986; Chau 
et al., 1989; Gonda et al.. 1989; Tasaki et al., 2005). The unmodified NP-S-GFP 
antigen is very stable while UbR-NP-S-GFP is rapidly degraded with a half life of 
10 minutes (Princiotta et al., 2003). 
WR-NP-S-GFP and WR-UbR-NP-S-GFP have been examined before and it has 
been shown that the rapidly degraded UbR-NP-S-GFP construct allows better 
OVA-257/H-2K'' presentation on the surface of infected cells (Princiotta et al., 
2003). However, the effect on PR8NP-366 presentation has not been studied. Here 
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we used the in vitro direct presentation assay described in Section 5.2.1 to 
measure the direct presentation efficiency of the PR8NP-366 peptide from WR-
NP-S-GFP or WR-UbR-NP-S-GFP. Firstly, aliquots of DC2.4 cells infected with 
WR-NP-S-GFP and WR-UbR-NP-S-GFP for five hours were examined with 
25D1.16 antibody and flow cytometric analysis to determine the expression level 
of GFP and OVA-257/H-2K^ The results in Figure 5-12A and B demonstrate that 
DC2.4 cells infected with WR-UbR-NP-S-GFP had lower GFP expression but 
higher OVA/H-2K'' surface expression when compared to cells infected with WR-
NP-S-GFP. This confirms the published studies by Princiotta et al. (2003). 
Aliquots of the infected DC2.4 cells (as stimulators) were also co-cultured with 
splenocytes isolated from mouse infected with lAV strain PR8 seven days earlier 
(as effectors). From this in vitro presentation assay, we found that DC2.4 cells 
expressing the rapidly degraded UbR-NP-S-GFP induced a slightly highly 
frequency of IFN-y-producing CDS" T cells than the stable NP-S-GFP (Figure 5-
12C). A similar result was observed when infected BMDCs or 293-D'' were used 
as stimulators (data not shown). This suggests that WR-UbR-NP-S-GFP allows 
effective direct presentation of PR8NP-366 on the infected cells surface. 
The immunogenicity of WR-UbR-NP-S-GFP to prime PR8NP-366-specific CDS' 
T cell response in vivo was then measured. Similar to the results of the PR8NP-
366 minigene constructs, mice immunised with WR-UbR-NP-S-GFP showed a 
smaller PR8NP-366-specific CD8" T cell response than mice immunised with 
WR-NP-S-GFP (Figure 5-13). The difference observed in the i.p. immunisation 
experiment was not significant because of variations in the responses amongst 
individual mice (Figure 5-13A and B). In contrast, there was a significant 
difference between the PR8NP-366-specific CDS' T cell response, measured as 
percentage or absolute number, induced by i.d. injection with WR-NP-S-GFP and 
WR-UbR-NP-S-GFP (Figure 5-13C and D). Taken together with the previous 
results shown in this chapter, it seems that expressing PR8NP-366 as antigenic 
constructs that facilitate direct presentation does not effectively induce PRSNP-
366-specific CD8" T cell response in vivo. 
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Figure 5-12| Expressing PR8NP-366 as a rapidly-degraded construct from W R 
allows effective direct presentation of the PR8NP-366 peptide. DC2.4 cells were 
infected with the indicated recombinant WR at a ni.o.i. of 5 for 5 h. (A and B) Aliquots 
of cells were taken and stained with 25D1.16 antibody and were analysed by flow 
cytometry. Representative histograms illustrate the level of GFP expression (A) and 
25D1.16 antibody staining (B) of cells infected with the indicated viruses. (C) Aliquots 
of the infected cells were also co-cultured with splenocytes from a mouse immunised 
i.p. with 500 HAU IAV-PR8 seven days before, at different stimulator:effector ratios as 
indicated. BFA was added 1 h later, followed by another 3 h of co-culturing. ICS was 
then perfoniied. The overall PR8NP-366-specific CD8 T cell response of the 
splenocytes was determined in parallel by standard ICS with synthetic PR8NP-366 
peptide. Data show the level of PR8NP-366-specific CD8 T cell activation by the 
infected DC2.4 cells, after normalisation to the percentage of maximal potential 
activation as induced by the synthetic PR8NP-366 peptide. (A, B and C) Results shown 
are from a single experiment. This whole experiment has been repeated using BMDCs 
as stimulators and showed similar results. Data in (A) and (B) was conf inned with two 
independent experiments with DC2.4 cells. Data in (C) was confirmed with an 
independent experiment with DC2.4 cells. Another experiment using 293D' ' cells as 
stimulators also produced similar results. 
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Figure 5-13 | Enhanc ing the proteasonial degradat ion of recombinant N P - S - G F P 
antigen results in a reduction of the PR8NP-366-spec i f i c CD8^ T cell response. 
Groups of three mice were immunised with Ix lO" PFU W R - U b R - N P - S - G F P or W R -
N P - S - G F P via i.p. (A and B) or i.d. (C and D) injection. C D 8 T cell responses were 
determined by ex vivo pept ide stimulation and ICS 7 days later. Percentages (A and C ) 
and absolute numbers (B and D) of responding CDS ' T cells to the indicated pept ides 
are shown as mean ± SEM. Data represent results compiled f rom t w o independent 
exper iments (n = 6 for each immunisat ion route). * denotes statistical s ign i f icance {p < 
0.05). 
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5.2.8 There is no evidence to support cross presentation of PR8NP-366 from 
VACV-infected cells 
The above results show that PR8NP-366 expressed as directly presented 
constructs do not allow optimal inductions of CD8^ T cell responses. One possible 
reason is that PR8NP-366-specific CDS"^ T cells are cross primed during VACV 
infection. To test this hypothesis, the in vivo cross presentation assay was used. 
293A cells were infected with WR-ESmini-PR8NP or WR-Full-PR8NP. These 
infected cells were heat treated at 60°C for 60 min to inactivate all the residual 
viruses and the cells were then injected i.p. into mice at a dose of 1x10^ infected 
cells per mouse. Seven days later. CD8^ T cell responses against several native 
VACV peptides and PR8NP-366 were determined in spleens. 
As seen in Figure 5-14A and B. CD8^ T cell responses against several VACV 
peptides were induced by the 293A cells infected with WR-ESmini-PR8NP or 
WR-Full-PR8NP. By contrast, these infected cells did not prime a measurable 
PR8NP-366-specific CD8^ T cell response in mice. Another experiment using 
2 x l 0 ' infected cells to immunise individual mice was conducted. However, 
PR8NP-366-speciric CDS"^ T cell responses were still not detectable (data not 
shown). In a separate experiment in which mice were immunised with 293A cells 
infected with either WR-NP-S-GFP or WR-UbR-NP-S-GFP. a higher OVA-257-
specific CD8^ T cell response was induced by cells infected with WR-NP-S-GFP. 
compared to WR-UbR-NP-S-GFP (the difference was not significant; Figure 5-
I4C and D). This confirmed the findings by Norbury. et al. (2004) which showed 
that rapidly degraded antigens cannot be cross presented from infected cells. 
However, the same recombinant NP-S-GFP antigen available in the WR-NP-S-
GFP-infected cells did not induce any detectable PR8NP-366-specific CDS"^ T cell 
response (Figure 5-14C and D). In summary, we found no evidence suggesting 
that PR8NP-366 specific CD8^ T cells are cross primed from VACV-infected 
cells. 
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Figure 5-14| The PR8NP-366-specific CD8^ T cell response cannot be cross primed 
from cells infected with PR8NP-366-expressing WR. 293A cells were infected with 
the indicated viruses at a moi of 5 for 6 h, followed by heat treatment at 60°C for 60 
min. Groups of three mice were then i.p. immunised with I x i o ' of these infected, heat-
treated cells. Seven days later, antigen-specific CDS' T cell responses were detennined 
by ex vivo peptide stimulation and ICS. Percentages (A and C) and absolute numbers 
(B and D) of CDS T cells responding to the indicated peptides are shown as means ± 
SEM. (A and B) Data represent results from one experiment (n = 3). Another 
independent experiment in which mice were immunised with 2x10^ infected, heat-
treated cells showed similar results. (C and D) Data represent results f rom one single 
experiment (WR-UbR-NP-S-GFP: n = 2; WR-NP-S-GFP: n = 3). * denotes statistical 
significance (/? < 0.05). 
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5.2.9 BMDCs pulsed with PR8NP-NP-366 and a T cell epitope peptide 
does not elicit a PR8NP-NP-366-specific CD8^ T cell response 
A requirement of CD4 ' T cell help for a CD8^ T cell response can be epitope-
specific. that is only some epitope-specific CD8^ T cell responses require T 
cell help (Snyder et al.. 2009; Reiser et al., 2011). This might reflect a scenario in 
which DCs expressing both CD4^ and CD8^ T cell epitopes can firstly be 
activated by CD4" T cells, which are then able to prime CD8^ T cell responses 
(Bennett et al.. 1998; Ridge et al., 1998; Schoenberger et al.. 1998; Smith et al., 
2004; Beuneu et al., 2006). Alternatively, activated CD4^ T cells might be 
attracted by DCs in an antigen-specific manner to provide help directly to the 
activating CD8^ T cells (Bourgeois et al., 2002). In the classical pathway, peptides 
bound on MHC-II are processed from exogenous antigens in the endosomes of 
APCs (reviewed in Jensen. 2007; Blum et al.. 2013). However, it is also known 
that some endogenously synthesised antigens can be processed within APCs to 
liberate peptides for MHC-ll presentation (Eisenlohr and Hackett. 1989; 
.laraquemada et al., 1990; Loss et al.. 1993; Rudensky et a l . 1994: Oxenius et al., 
1995; Dani et al.. 2004). This might be the pathway that allows both MHC-I- and 
MHC-ll-restricted peptides from the same antigen/pathogen to be displayed on the 
same DCs. 
lAV NP contains several CD4^ T cell epitopes specific to MHC-II I-A'' molecules 
of C57B1/6 mice (Gao et al.. 1990b; Crowe et al., 2006). However, the minigene 
constructs examined in this thesis do not contain any CD4^ T cell epitopes. In 
addition, endogenously-synthesised antigens that are rapidly degraded by the 
proteasome do not allow effective MHC-II presentation (Gueguen and Long, 
1996). Therefore, a special requirement for direct CD4'^ T cell help might explain 
why minigenes and rapidly-degraded constructs were less able to induce CD8^ T 
cell responses against lAV NP-366 peptides in vivo. However, this effect needs be 
specific to the lAV NP-366 minigene when expressed from VACV. This is 
because CD8^ T cell response against lAV NP-366 can be induced in CD4^-T-
cell-deficient mice after primary lAV infection (Belz et al., 2002). In addhion. 
minigenes of other antigens were highly immunogenic when expressed from WR. 
as shown in Chapter 4. It should be noted that there are CD4^ T cell epitopes 
available from VACV proteins (Jing et al., 2007; Moutaftsi et al., 2007). Although 
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it is reasonable to assume that they are presented on the same DCs with together 
the CD8^ T cell epitopes, it has not been formally examined. 
To test this hypothesis, peptide-pulsed BMDCs were used as immunogens. Here, 
B M D C s generated f rom C57B1/6 mice were pulsed with a synthetic CD8^ T cell 
epitope peptide together with the HBcAg-128 peptide. The HBcAg-128 peptide is 
a CD4^ T ceil epitope from the hepatitis B virus core antigen, restricted to M H C -
II I-A" (sequence TPPAYRPPNAPIL; Milich et al.. 1988; Alexander et al., 1994). 
After peptide pulsing. BMDCs were injected i.v. into mice and CD8^ T cell 
responses were measured seven days later. This priming assay allowed induction 
of CD8^ T cells against VACV A47-171 peptide if BMDCs were pulsed with a 
synthetic A47-171 peptide (Figure 5-15). In contrast, an anti-PR8NP-366 CD8^ T 
cell response was not induced when the PR8NP-366 peptide was used for pulsing 
BMDCs (Figure 5-15). implying that an addition of CD4^ T cell epitope on the 
PR8NP-366-presenting DCs might not be enough for priming CD8^ T cell 
responses against PR8NP-366. 
5.2.10 The sub-cellular localisation of full-length PR8NP does not influence its 
ininiunogenicit>' 
As discussed in the introduction of this chapter. lAV NP can be found within the 
nucleus of lAV-infected cells. Similarly, when PR8NP is expressed from VACV, 
it is localised in the nucleus (Anton et al., 1999; Golovina et al., 2002). It has been 
suggested that proteasomes within the nucleus (Reits et al., 2003. Reits et al., 
1997) can process nuclear antigens for MHC-I presentation (Anton et al., 1999). 
The nuclear localisation of the full-length lAV NP antigen might influence how it 
is processed. Alternatively, the antigen might be post-translationally modified 
within the nucleus and affect the antigenicity of the presented lAV NP-366 
peptide. 
To investigate if the nuclear localisation property of PR8NP influences the 
PR8NP-366-specific CD8^ T cell response, two WR recombinants expressing 
modified forms of PR8NP were tested. The first recombinant, known as WR-cyto-
PR8NP. expresses an antigen with the amino acid residues 13-498 of PR8NP, 
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Figure 5 - I 5 | B M D C s pulsed with PR8NP-NP-366 and a CD4'^ T cell ep i tope 
peptide fail to pr ime PR8NP-NP-366-spec i f i c CD8^ T ceils. In vi tro-generated 
B M D C s were pulsed with the synthetic MHC-l l -b ind ing HBcAg-128 peptide together 
with the P R 8 N P - 3 6 6 or V A C V A47-171 peptides. Tliese pulsed cells were injected i.p. 
into g roups of two mice (2x10 ' ' cel ls /mouse) . Seven days later. CD8^ T cell responses 
were de termined by ex v ivo peptide stimulation and ICS. Percentages (A) and absolute 
number s (B) of C D S T cells specif ic to PR8NP-366 and A47-171 are shown as mean ± 
S E M f rom a single exper iment (n = 2). Ar rows illustrate the absence of responses 
induced by B M D C s pulsed with PR8NP-366 . This experiment has only been pe r fo rmed 
once. 
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excluding the nuclear localisation signal corresponding to the amino acid 
sequence 1-12 of the full-length PR8NP (Golovina et a l , 2002). The loss of this 
nuclear localisation signal sequence prevents PR8NP from entering into the 
nucleus and results in the cytoplasmic retention of the modified PR8NP (Golovina 
et al.. 2002). The second recombinant, which is known as WR-ES-PR8NP, 
expresses a polypeptide consisting of the amino acid residues 13-498 of PR8NP 
tagged with an ER-targeted sequence of the lAV hemagglutinin protein at the 
amino-terminus (Golovina et al., 2002). This modification of PR8NP causes the 
antigen to localise to the ER (Golovina et al., 2002). It has been shown that these 
modifications to PR8NP do not alter the PR8NP-366/H-2D'' presentation on the 
surface of VACV-infected cells in vitro (Golovina et al., 2002). However, it 
remained undetermined whether these variants might affect how the antigen is 
processed in vivo for priming PR8NP-366-specific CD8^ T cell responses. 
Mice were immunised with WR recombinants expressing the wildtype or 
localisation variants of PR8NP via the i.p. route and CD8^ T cell responses were 
measured 7 days later. Figure 5-16 shows that the induced PR8NP-366-specific 
CD8^ T cell responses were similar amongst mice immunised with WR-cyto-
PR8NP. WR-ES-PR8NP or WR-Full-PR8NP. This suggests that the sub-cellular 
location of the stable full-length PR8NP antigen does not affect the priming of 
PR8NP-366-specific CD8^ T cell in vivo. This also implies that wildtype PR8NP 
is not exclusively processed within the nucleus to liberate PR8NP-366 for MHC-1 
presentation, confirming the published in vitro studies (Golovina et al., 2002). 
Together with results from Figure 5-13, the data imply that a stable full-length 
protein may be required to prime an effective CD8^ T cell response against 
PR8NP-366 when expressed from VACV. 
5.2.11 The serine residue at position 2 of the PR8NP-366 peptide is not 
phosphorylated 
In addition to presenting natural peptides on MHC-I, peptides carrying post-
translational modification can also bind to MHC-I to induce CD8^ T cell 
responses (Haurum et al., 1994; Skipper et al., 1996; Meadows et al., 1997; 
Haurum et al., 1999; Zarling et al., 2000; Zarling et al., 2006). One such 
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Figure 5-16| The sub-cellular localisation of the full-length PR8NP antigen does 
not determine its abilit)' to prime anti-PR8NP-366 CD8^ T cells when expressed 
from WR. Groups of three mice were immunised with the indicated recombinant WR 
( I x l O ' PFU) via the i.p. route. Seven days later. CDS' T cell responses were 
determined by ex vivo peptide stimulation and ICS and the results are shown as 
percentages (A) or absolute numbers (B) of CDS' T cells specific to the peptides 
indicated. Data shown represent results compiled from two independent experiments 
(mean ± SEM; n = 6). 
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modification is phosphorylation (Zarling et al., 2000; Zarling et al., 2006), which 
can occur on serine, threonine, or tyrosine residues (reviewed in Ubersax and 
Ferrell Jr. 2007). Due to the specificity of CD8^ T cells, responses specific to 
modified peptides may not cross-react with unmodified peptides. As seen in 
Section 5.1, there is a serine residue at position 2 of the PR8NP-366 peptide (as 
well as the NT60NP-366 peptide). With the use of two online programs, namely 
NetPhos 2.0' (Blom et al., 1999) and DISPHOS 1.3^ (lakoucheva et al., 2004), to 
predict putative phosphorylation sites on full-length PR8NP, it was found that the 
serine residue on PR8NP-366 has a phosphorylation potential above the cut-off 
values of each software. However, it has not been shown whether this serine 
residue represents a real phosphorylation site experimentally (Kistner et al., 1989; 
Hutchinson et al., 2012). In addition, it has been shown that the natural PR8NP-
366 peptide extracted from H-2D'' of lAV-infected cells was eluted in the same 
fraction as the synthetic unmodified PR8NP-366 peptide using reverse-phase 
high-performance liquid chromatography (Rotzschke et al., 1990; Falk et al., 
1991a). However, the assay used was based on in vitro killing of APCs pulsed 
with eluted peptides by in vitro-generated CD8^ T cell clones (Rotzschke et al., 
1990; Falk et al., 1991a), which could limit any diversity of peptides that can be 
identified. Therefore, it was possible that the serine residue on PR8NP-366 might 
be phosphorylated when expressed as a full-length PR8NP antigen from VACV 
strain WR and the response induced was specific to the modified peptide. In 
contrast, minigenes and rapidly-degraded constructs might not be recognised as 
substrates for phosphorylation and therefore no responses against PR8NP-366 
could be induced. If this is the case, the unmodified peptide was able to re-
stimulate the response specific to the phosphorylated PR8NP-366 ex vivo in the 
ICS assay only when an unphysiologically high, not low, concentration of the 
peptide was used. 
To examine this hypothesis, we examined how well a synthetic peptide of amino 
acid sequence ASNENMETM with the serine phosphorylated can be used to 
stimulate polyclonal PR8NP-366-specific €08"^ T cells ex vivo. In brief. 
' NetPhos 2.0. Website: http://www.cbs.dtu.dk/services/NetPhos/ 
^ DISPHOS 1.3. Website: http://www.dabi.temple.edu/disphos/pred.html 
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splenocytes isolated from a mouse immunised with WR-Full-PR8NP seven days 
earlier were ex vivo stimulated with serial dilutions of the unmodified PR8NP-
366 peptide or the serine-phosphorylated (PR8NP-366-pS) peptide, followed by 
ICS. Stimulation with either peptide at a concentration of 10"''M induced a similar 
proportion of CDS" T cells from the WR-Full-PR8NP-immunised mouse to 
produce IFN-y (Figure 5-17), However, when the peptide concentration was 
diluted, the potency of the phosphorylated PR8NP-366 peptide to stimulate the 
WR-Full-PR8NP-immune CD8' T cells decreased rapidly and it was below the 
detection limit when lO'^M was used. In comparison, the unmodified PR8NP-366 
peptide was still able to induce IFN-y expression from the CD8" T cells when a 
concentration of 10""M was used (Figure 5-17). This study suggests that the 
PR8NP-366-speciric CD8" T cells induced by the full-length PR8NP expressed 
from WR does not recognise the serine-phosphorylated PR8NP-366 peptide. 
Therefore, the naturally-occurring PR8NP-366 peptide on MHC-1 during in vivo 
immunisation is not phosphorylated at the serine residue at the 2nd position of the 
peptide. 
5.3 Discussion 
Results in this chapter show that lAV NP expressed as constructs to facilitate 
direct presentation were unable to prime a potent CD8" T cell response against the 
NP-366 epitope. This phenomenon occurs for two well-studied variants of the 
epitope, PR8NP-366 and NT60NP-366. There are several studies showing that 
minigene constructs of certain antigens do not induce CDS"^  T cell immunity in 
mouse models when expressed from VACV strain WR. However, in most cases, 
the full-length antigens are also unable to prime CD8" T cell responses and the 
lack of immunogenicity was not because of a defect of minigene constructs. 
The first example is the antigenic peptide from sequence 209-217 (ITDQVPFSV) 
of the tumour-associated antigen gplOO (Kawakami et al., 1995), which was not 
immunogenic when expressed as an ER-targeted minigene or as a full-length 
antigen from WR (Irvine et al., 1999). The lack of immunogenicity of this peptide 
was attributed to its relatively low affinity for its restricted human MHC-I LA-
Chapter 5 
0.8 
oo 9. 0.6 O M-
+ 0.4 
0.2 
0.0 
PR8NP-366 
PR8NP-366-pS 
—r-
-7 
—I— 
-8 -9 -10 -11 -12 -13 
Peptide conncentration (Ioqiq M) 
—I— 
-11 
—I— 
-12 
Figure 5-17| Tlie recognised PR8NP-366 peptide is not pliospliorylated when 
expressed as a full-length antigen from WR. A mouse was immunised with IxlO' ' 
PFU WR-Full-PR8NP. Seven days later, splenocytes from the immunised mouse were 
stimulated ex vivo with either an unmodified PR8NP-366 peptide or with a modified 
version of the peptide carrying a phosphorylated serine residue (PR8NP-366-pS; amino 
acid sequence: A[pS]NENMETM) at the concentration indicated. The results are shown 
as percentages of CDS' T cells that produced IFN-y after peptide stimulation. Data are 
representative of two independent experiments. 
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A*0201 molecule (Parkhurst et a l , 1996; Irvine et al., 1999). Enhancing the 
binding affinity by modifying the anchor sequence in this peptide and expressing 
it as an ER-targeted minigene from W R resulted in an induction of a robust CD8^ 
T cell response against this peptide (Irvine et al., 1999). Another similar example 
was the antigenic peptide with amino acid sequence RSPWFTTL from the 
envelope protein of Friend/Moloney/Rauscher murine leukemia retroviruses 
(Coppola and Green. 1994; Sijts et al., 1994). This peptide binds to its restricted 
MHC-I H-2K'' with a similar affinity and dissociation rate as another related 
antigenic peptide with sequence KSPWFTTL from AKR/Gross murine leukemia 
retroviruses (Sijts et al., 1994; Kim and Green. 1998). However in C57B1/6 mice, 
only the KSPWFTTL peptide, but not RSPWFTTL. was able to induce CDS" T 
cell responses when expressed as a full-length or as a minigene construct from 
W R (Coppola and Green. 1994; Coppola et al., 1995; Kim and Green. 1998). The 
lack of immunogenicity of the RSPWFTTL-containing construct expressed from 
W R is because there are no naive CDS" T cells recognising this peptide in 
wildtype mice (Kim et al., 2000). As the last example, two studies have examined 
W R recombinants expressing a model tumour-associated antigen P IA (Restifo et 
al., 1995; Imai et al., 2010). P I A contains a H-2L''-restricted antigenic peptide 
known as PlA-35 with the amino acid sequence LPYLGWLVF (Lethe et a l , 
1992). Full-length P IA antigen expressed from W R was more immunogenic, even 
though both constructs were directly presented in vitro with a similar efficiency 
(Irvine et al., 1995; Restifo et al.. 1995). However, an ER-targeted PlA-35 
minigene, which also allowed effective direct presentation in vitro, was highly 
immunogenic, inducing a greater CDS" T cell response than the full-length 
antigen (Irvine et al., 1995; Restifo et al., 1995). It was hypothesised that the 
reduced immunogenicity of the cytosolic minigene was caused by a reduction of 
antigen presentation by the relevant APC in vivo, probably due to degradation of 
peptide in the cytosol or relatively poor transport by TAP in vivo (Irvine et al., 
1995; Restifo et al., 1995). However, no experiments were performed to test these 
hypotheses. 
Our findings that PR8NP-366 and NT60NP-366 were not immunogenic when 
expressed as constructs from W R to facilitate direct presentation is clearly 
different from the examples mentioned above. Besides the minigene and rapidly-
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degraded constructs examined in this chapter. PR8NP-366 expressed as part of a 
string of muhiple antigenic peptides, icnown as a poiytope, from VACV strain WR 
also failed to induce any detectable PR8NP-366-specific CDS"^ T ceil response 
with an ex vivo peptide stimulation assay (Flesch et a!., 2010). Our results showed 
that WR expressing ER-targeted PR8NP-366 minigene induced a secondary 
expansion of memory PR8NP-366 specific CD8^ T cells in mice previously 
infected with lAV strain PR8 although the expansion level was significantly less 
than WR expressing the full-length PR8NP antigen. This suggested that the anti-
PR8NP-366 CD8^ T cell response induced by the ER-targeted minigene was poor, 
but not absent. Our data with UbR-NP-S-GFP suggests that increasing the 
proteasomal processing rate of PR8NP did not translate to an improved ability to 
induce PR8NP-366 responses in vivo. However, the PR8NP-366 peptide from 
UbR-NP-S-GFP can be readily presented in vitro, indicating a dissociation of in 
vitro presentation from the in vivo immunogenicity of this CD8^ T cell epitope. 
One possibility is that over-stimulation of NP-366-specific CD8^ T cells with a 
high level of peptide/MHC-l complexes may be detrimental to the immune 
outcome. Other than the NP-366 peptide. lAV NP also contains a H-2K''-binding 
peptide in position 147-155 (NP-147, sequence TYQRTRALV; Falk et a l , 
1991a). It has been shown that generation of this peptide for MHC-I presentation 
in vitro from cells infected with WR expressing full-length lAV NP was either not 
affected or even enhanced in the presence of proteasome inhibitors (Yellen-Shaw 
et al., 1997; Anton et al., 1998). Interestingly, enhancing proteasomal degradation 
of IAV NP by adding an ubiquitin and an arginine residue at the N terminus of the 
lAV NP antigen did not inhibit MHC-I presentation of NP-147 (Golovina et al., 
2005). It was later suggested that the enhanced presentation of NP-147 on cells 
treated with proteasome inhibitors was because of a change in the proteasomal 
cleavage specificity (Wherry et al., 2006). Together with the data of lAV NP-366 
shown in this chapter, it clearly suggests that our understanding of antigen 
processing, antigen presentation level and immunogenicity is still limited., 
Experiments with F5 TCR transgenic CD8^ T cells demonstrate that the NT60NP-
366 minigene expressed from WR induced a smaller F5 CD8^ T cell response 
than full-length NT60NP starting from six days post immunisation. However, this 
minigene induced similar levels of early activation (CD69 and CD25) and 
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proliferation (CFSE dilution) o f F5 CD8^ T ceils as the fuil-lengtli NT60NP 
antigen two days after immunisation. The magnitude of a CD8^ T cell response is 
determined by both the proliferation and the survival o f the antigen-specific CD8^ 
T cells. CD25 expression and cell proliferation of the F5 CD8^ T cells were only 
measured two days post immunisation in this study. It is possible that the 
NT60NP-366 minigene fails to maintain CD25 expression at later stages of the 
priming phase. The kinetics o f CD25 expression and F5 CD8^ T cell proliferation 
should be examined. In addition, it is likely that the ER-targeted NT60NP-366 
minigene fails to promote survival of the responding CD8^ T cells. Expression of 
pro-survival proteins, including Bcl-2 or B-cell lymphoma-extra large (Bcl-Xi ) 
(Nakayama et al., 1994. Boise et al., 1995. Grayson et al.. 2000. Veis et al.. 1993), 
and pro-apoptotic proteins, such as Bim (O'Connor et al., 1998, Bouillet et al., 
1999), can influence the survival o f activated CD8^ T cells in vivo (Kurtulus et 
al., 2011, Hildeman et al.. 2002. Pellegrini et al.. 2003, Lee et al., 2002. Song et 
al., 2005). The expression of these genes should be determined in future studies to 
determine whether and how the survival o f NT60NP-366-specific CD8^ T cells is 
influenced by priming with the ER-targeted NT60NP-366 minigene. The studies 
with the F5 CD8^ T cells also suggested that any differences occurring early after 
immunisation are subtle, but these changes ultimately suppress optimal induction 
of a NT60NP-366-specific CD8^ T cell response. 
Because only stable antigens can be used as substrates for cross presentation 
(Norbury et al., 2004; Shen and Rock, 2004; Wolkers et al., 2004), it might 
explain why antigenic constructs that facilitate direct presentation of PR8NP-366 
were not immunogenic in vivo. However, we did not detect cross priming of 
PR8NP-366-specific CD8^ T cells in mice immunised with MHC-I mismatched 
cells infected with W R expressing stable PR8NP antigens. As discussed 
previously in Section 3.3, one major limitation of this assay is that it does not 
necessarily represent the natural cross priming mechanism for all antigens. 
However, it should be noted that lAV-infected cells have been shown to cross 
prime PR8NP-366-specific CD8" T cells (Chen et al., 2004; Lev et a l , 2009). 
Similarly, MHC-I-deficient RMA-S cells stably expressing a recombinant GFP 
construct containing the NT60NP-366 peptide could cross prime NT60NP-366-
specific CD8^ T cells in vivo (Wolkers et a l , 2001). This suggests that the lAV 
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NP antigen can be cross presented from antigen donor ceils. Tlierefore, tlie 
absence of lAV NP cross presentation from VACV-infected cells as seen in our 
studies is likely to be a result of VAC V infection. One possible explanation is that 
the vast amount of VACV antigens expressed within infected cells may influence 
the cross presentation of NP in vivo. 
Dependence on CD4^ T cell help for priming optimal CDS"^ T cells can be 
epitope-specific (Snyder et al.. 2009; Reiser et al.. 2011). Priming PR8NP-366-
specific CD8^ T cells might require such CD4^ T cell help in vivo. However, we 
did not detect any measureable response in mice primed with BMDCs with 
PR8NP-366 and a CD4^ T cell epitope peptide. One limitation of the priming 
strategy used in Figure 5-15 is that it does not completely recapitulate the priming 
mechanisms that occur during VACV immunisation. In addition. BMDCs used for 
immunisation were pulsed with high concentrations of peptides and this might 
reduce the level of the response induced in the immunised mice. BMDCs pulsed 
with lower concentrations of peptides could be tested in further studies. An 
alternative explanation is that the induction of a PR8NP-366-specific CD8'^ T cell 
response may require homologous help from CD4'^ T cells specific to peptides 
available on the NP antigen itself, but not by other heterologous epitopes. A 
similar requirement for a homologous CD4^ T cell epitope for priming functional 
CD8^ T cells has been reported (Sabarth et al.. 2010). The reasons for this were 
not explored in that study. One strategy that could be used here is to generate a 
recombinant WR that expresses a transgene encoding the PR8NP-366 minigene 
together with a recombinant full-length NP antigen with the PR8NP-366 peptide 
deleted, separated by an internal ribosome entry site (Jang et al., 1988; Pelletier 
and Sonenberg, 1988). DCs infected with this virus should express both the 
PR8NP-366 peptide and homologous CD4'^ T cell epitopes from PR8NP for 
MHC-I and MHC-II presentation respectively. The use of an internal ribosome 
entry site is essential because it ensures that both antigenic constructs will be 
expressed within the same cells, without influencing the characteristics of the 
individual antigens, which would occur if the antigens were expressed as a single 
fusion protein. 
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A theory that lAV NP-366 peptides expressed from directly-presented constructs 
might be slightly different from those expressed from full-length stable antigens 
was also investigated. Using a mouse infection model with LM expressing OVA-
257 variant peptides, it has been shown that the OVA-257 variant peptides with 
lower affinity to the TCR of OT-I cells still allowed early activation and 
proliferation o f the OT-I cells in vivo (Zehn et al., 2009). However, further 
expansion of the activated OT-1 cells were not sustained by the weak TCR-
peptide/MHC-I interactions (Zehn et al., 2009). These results were similar to our 
results shown in this chapter, in which no significant differences were detected 
between the early activation and proliferation o f F5 CD8^ T cells induced by WR-
ESmini-NT60NP or WR-Full-NT60NP. Recently, a report has demonstrated that 
the low affinity OVA-257 variant peptides limited the up-regulation of 
transcription factor interferon regulatory factor 4 (1RF4) in OT-1 cells (Man et a l , 
2013). The lower expression of IRF4 reduced metabolic functions of the 
activating CDS' T cells and resulted in a decrease in the magnitude of the CD8^ T 
cell response induced (Man et al., 2013). The role of 1RF4 in our models should 
be investigated. This may provide a clue if the presented peptide is somehow 
modified. In this thesis, two possible mechanisms which might affect the TCR 
affmity o f the presented lAV NP-366 peptide were examined by focusing on the 
PR8NP-366 peptide. Firstly, the effect of the nuclear localisation of PR8NP on its 
immunogenicity was tested. Here we hypothesised that the nuclear localisation o f 
PR8NP might influence the processing of the antigen for MHC-I presentation. 
Alternatively, the presented PR8NP-366 peptide may be modified post-
translationally within the nucleus. However, our experiments revealed that the 
nuclear localisation of NP does not influence its ability to induce PR8NP-366-
speciflc CD8^ T cells in vivo. Secondly, we have formally ruled out the possibility 
that the serine residue at position 2 on PR8NP-366 was phosphorylated when 
presented in vivo for CD8^ T cell priming. 
Another possible modification of the presented NP-366 peptide that may occur is 
oxidation o f the methionine residues. Methionine contains a thioether side chain, 
which consists of a sulphur atom. The sulphur atom can be oxidised to generate 
methionine sulfoxide by oxidants in vitro and in vivo (Vogt, 1995; Ghesquiere et 
al., 2011). There are two methionine residues on the PR8NP-366 and NT60NP-
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366 peptides, one in position 6 and one in position 9. The structure of PR8NP-366 
peptide bound on H-2D'' has been solved by X-ray crystallography (Young et al., 
1994) and it allows us to deduce the effects of methionine oxidation on the overall 
peptide/MHC-I structure. Firstly, the methionine in position 9 is one of the major 
anchor residues and is important for the H-2D'' binding by forming hydrogen 
bonds with three amino acid residues of H-2D'' (Young et al., 1994). Oxidation of 
the methionine in this position may be detrimental to the MHC-1 affinity of the 
peptide. For the methionine residue in position 6, its side chain is exposed to the 
surface of the top of the PR8NP-366/H-2D'' structure and forms a hydrogen bond 
with the imidazole side chain of the histidine at position 155 of H-2D'' (Young et 
al., 1994; Turner et al., 2005). Structures of H-2D'' bound with PR8NP-366 with 
the methionine at position 6 replaced with different amino acid residues have been 
analysed (Kedzierska et al., 2008; Valkenburg et al.. 2013). All amino acid 
substitutions resulted in various degrees of conformational changes to the bound 
peptide and the H-2D'' molecule surrounding the modified residue (Kedzierska et 
al., 2008; Valkenburg et al.. 2013). Importantly, amino acid substitutions at 
position 6 of PR8NP-366 expressed from lAV alters the TCR repertoires of the 
responding CDS"^  T cells in vivo and thereby influences the primed CD8^ T cell 
responses as measured during acute infection (Kedzierska et al., 2008; 
Valkenburg et al., 2013). We hypothesise that oxidation of methionine in position 
6 may result in a subtle change in the peptide/MHC-1 structure. All peptide stocks 
used in this thesis were prepared in DMSO before further dilution in culture 
media. It has been shown that methionine and cysteine can be oxidised in DMSO 
under certain conditions (Shechter, 1986). Thus, it is possible that peptides used in 
ICS and DimerX assays might have already been oxidised. If this assumption is 
true, the difference between the antigenicity of the oxidised and unoxidised 
peptides would be subtle because the DimerX binding and the performance of 
peptides prepared in DMSO in ex vivo ICS assays seemed not to be affected. 
Such a modification may subtly reduce the in vivo priming of CD8^ T cells early 
after immunisation, but eventually greatly affect the immunogenicity at the peak 
of the response. 
The oxidation state of amino acid residues on lAV NP has not been examined 
before. NP expressed as a native full-length antigen may be protected from 
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ox ida t ion wiiile the N P - 3 6 6 pept ide m a y be p rone to oxidisat ion when expressed 
f r o m recombinan t cons t ruc t s that facil i tate direct presentat ion, it has been shown 
that an ant igenic pept ide conta in ing a cys te ine res idue expressed as a minigene 
f r o m V A C V W R can be oxidised and fo rm a disul f ide bond with a f ree cysteine 
res idue (known as cys te inyla t ion) wi thin infected cells (Chen et al., 1999). 
Impor tan t ly , this cys te inyla ted pept ide can be presented onto MHC-I (Chen et al., 
1999). W e a t tempted to address whe ther unoxidised P R 8 N P - 3 6 6 pept ide could 
p r ime a C D S ' T cell response in vivo. Here mice were immunised with B M D C s 
pulsed wi th the H B c A g - 1 2 8 C D 4 ' T cell epi tope pept ide together with PR8NP-
366 pept ide prepared in water , which should prevent meth ionine oxidat ion. N o 
de tec tab le C D 8 ' T cell response against P R 8 N P - 3 6 6 was induced in this 
expe r imen t (data not shown) . The main l imitat ion of this exper iment was that the 
oxida t ion state of the pept ide stocks prepared in D M S O or water was not 
de te rmined . In addit ion, it r emains unclear whe the r the pept ide would become 
ox id i sed dur ing pept ide-puls ing. A n e w exper imenta l approach is required here. 
T o fo rmal ly de te rmine whe ther the chemica l identity of the presented PR8NP-
366 . m a s s spect rometr ic analysis of P R 8 N P - 3 6 6 pept ides presented on DC2.4 
cel ls infected with W R - E S m i n i - P R 8 N P or W R - F u l l - P R 8 N P is being pursued 
( th rough col laborat ion with Dr. Na than Crof t and P r o f Anthony Purcell f rom the 
Univers i ty of Melbourne , Austral ia) . 
In s u m m a r y , results in this chapter show that CD8^ T cell responses specif ic to 
l A V N P - 3 6 6 cannot be induced by l A V N P const ructs that p romote direct 
presenta t ion w h e n expressed f rom V A C V strain W R . However , the mechan i sm 
involved r ema ins elusive. 
Chapter 5 
Chapter 6 
Chapter 6 The application of heat-inactivated 
vaccinia virus a recombinant CD8^ 
T cell vaccine 
Chapter 6 
Chapter 6 
6.1 Introduction 
As seen in Chapter 3, antigens from VACV-infected MHC-1 mismatched cells can 
cross prime CDS"^ T cells against multiple native VACV peptides. Interestingly, 
some of these peptides originate from antigens that are found within VACV 
virions. These antigens include A3, a VACV major core protein. A42. a profilin-
like protein, and J3. a multi-functional protein involved in VACV gene 
transcription (.lensen et al., 1996: Chung et al., 2006; Yoder et al.. 2006; Resch et 
al.. 2007). It is possible that some VACV particles remained associated on the 
surface of the infected cells and their role in CD8" T cell priming has not been 
determined. 
Cross presentation of antigens from virion particles has been observed for lAV. 
Using in vitro systems, it has been shown that APCs co-cultured with UV-
inactivated or heat-inactivated lAV were recognised by anti-lAV CD8^ T cells 
(Hosaka et al.. 1985; Bender et al.. 1995). Another study reported a similar 
finding with UV-inactivated lAV. but only when the virus was subject to further 
heat inactivation (Yewdell et al., 1988). Importantly, the induction of MHC-I 
presentation on cells pulsed with inactivated lAV does not require viral protein 
synthesis (Hosaka et al., 1985; Yewdell et al., 1988; Bender et al., 1995). 
demonstrating that the source of the presented peptides on MHC-1 is the 
inactivated virus particles. In vivo cross priming of CD8^ T cells of antigens from 
exogenous NP fractionated from lAV virions and heat-inactivated lAV has also 
been reported (Wraith and Askonas. 1985; Cho et al., 2003). 
Besides using live recombinant viruses to induce immunity against foreign 
antigens, virus-like particles have also been used as recombinant vaccines. In 
general, virus-like particles are microscopic structures formed by multiple copies 
of one or more viral proteins from a single virus (reviewed in Roldao et al., 2010). 
These particles do not contain any viral genomes and so they are not infectious. 
Several vaccines based on virus-like particle technology are commercially 
available, including the human Papillomavirus vaccine Gardasil (reviewed in 
Roldao et al., 2010). Vaccines based on chimeric virus-like particles have also 
been studied (e.g. Sedlik et al., 1997; Neirynck et al., 1999). These particles 
Chapter 6 
contain antigens of different origins that are tagged to the components on the 
virus-like particles, allowing induction of immune responses against the foreign 
antigens (Moron et al., 2004; Roldao et a l , 2010). Importantly, virus-like particles 
have been shown to cross prime CD8^ T cell responses in vivo (Sedlik et al., 
1997; Win et al., 2011; Hemann et al., 2013). Further studies have shown that 
virus-like particles can be taken up by DCs readily, resuhing in DC activation and 
allowing antigens on the particles to be processed for MHC-I presentation (Ruedl 
et a l , 2002; Fausch et al., 2003; Moron et al., 2003; Barth et al., 2005; Song et al., 
2010; Win et al., 2011). These data suggest that antigens available on virions or 
on virus-like particles induce CD8^ T cell responses via cross priming, without the 
requirement for nascent protein synthesis. 
In this chapter, the ability of heat-inactivated VACV virion particles to induce 
CD8^ T cell responses was determined. We found that heat-inactivated VACV 
cross primed CDS"^  T cell responses against peptides from VACV virion antigens. 
The application of this finding for recombinant vaccines to induce CDB"^  T cell 
responses against foreign antigens was also investigated. 
6.2 Results 
6.2.1 Heat-inactivated VACV particles prime CD8^ T cell responses against 
several VACV antigens 
(Viruses used in this chapter are listed in Table A-5 in the Appendix) 
In order to examine whether heat-inactivated VACV particles induce CDS"^  T cell 
responses in vivo, mice were immunised with VACV strains WR or MVA that 
were heat-treated at 60°C for 60 min. As shown in Section 3.2.2, this heat 
inactivation treatment completely inhibits viral gene expression and viral 
replication. Seven days post immunisation, CD8^ T cell responses were 
determined in spleens. As seen in Figure 6-1, CD8^ T cell responses specific to 
several VACV peptides were induced. For mice immunised with heat-inactivated 
WR. around 0.9% of CDB"^  T cells were specific to A3-270, which was equivalent 
to 8x10" A3-270-specific CD8^ T cells (Figure 6 - lA and B). The next most 
dominant were A42-88 and A3-I91, in which each was recognised by around 
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Figure 6-11 CDS"^ T cell responses against several V A C V peptides can be induced 
by heat-inactivated VACV virions. VACV strains WR (A and B) and MVA (C and D) 
were heat-inactivated at 60°C for 60 min and then used for immunise groups of three 
mice via i.d. injection at a dose of 2x10" PFU/mouse, as calculated from the pre-treated 
value. Seven days post immunisation, peptide-specific CD8 T cell responses were 
determined by ex vivo peptide stimulation and ICS. Percentages (A and C) and absolute 
numbers (B and D) of CDS ' T cells responding to the indicated peptides are shown as 
mean ± SEM. Results are compiled from two independent experiments (n = 6 for each 
virus). 
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0.2% of CD8^ T cells. This translates to around 2x10" peptide-specific CD8^ T 
cells. The least immunogenic peptide tested was J3-289, which was recognised by 
around 0.05% of CD8^ T cells (equivalent to 2.5x10^ cells). Some of these 
responses were surprisingly robust, considering that no VACV antigens were 
expressed within the immunised animals. However, they remained weak 
compared with untreated, live WR as shown in Figure 3 - I B and C. Importantly, 
no anti-B8-20 response was induced by heat-inactivated WR. 
When mice were immunised whh heat-inactivated MVA, CDS"^ T cell responses 
against a slightly different panel of peptides were induced (Figure 6 - l C and D). 
Firstly, CD8^ T cell responses against A3-270, A3-191, and .13-289 were induced, 
at similar levels as seen in mice immunised with heat-inactivated WR. On the 
other hand, an A42-88-specific CDS'" T cell response was not induced by heat-
killed MVA. In addition, heat-inactivated MVA elicited CD8^ T cell responses 
against 88-20 and L2-53, which were not detected in mice immunised with heat-
inactivated WR. A very low response, just above background level, against G8-34 
was also detected in mice immunised with heat-inactivated MVA. Similar to WR, 
the CD8^ T cell responses against the immunogenic peptides induced by the heat-
inactivated MVA were lower than those induced by live MVA (Figure 3 - ID and 
E). It has been shown that a small amount of L2 was associated with mature 
VACV virion particles using conventional biochemical methods based on western 
blot analysis of proteins isolated from virion particles and immunogold labelling 
with electron microscopy (Maruri-Avidal et a l , 2011). However, the B8 and G8 
antigens, which contain B8-20 and G8-34 peptides respectively, have not been 
shown to be associated with virions from other VACV strains. Therefore, the 
mechanism by which heat-inactivated MVA was able to induce CD8^ T cell 
responses against these two VACV peptides is unclear. These antigens may 
somehow be trapped within MVA virion particles. No studies have been done to 
examine which VACV antigens are associated with MVA virions, so the latter 
hypothesis remains untested. 
One possible explanation for the priming of CD8^ T cell responses by the heat-
inactivated VACV is that the source of the presented peptides originated from 
protein impurities present in the virus stock used, but not from the intact VACV 
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virion particles. The VACV stocks used in this thesis were semi-purified 
from homogenised VACV-infected cell extracts through sucrose cushion 
centrifugation. Sucrose cushion centrifugation removes many of the soluble 
proteins and small debris, but some non-incorporated viral proteins are still 
present within the prepared VACV stock (Joklik. 1962; Madalinski et al., 1977). 
The virus stock could also contain other non-antigenic immunoregulatory 
impurities. It has been suggested that these types of impurities contributes to the 
immunostimulatory activity of virus-like particles (Demi et al., 2005). It is 
possible that non-antigenic impurities may have an effect on the CD8^ T cell 
priming against individual peptides. 
To investigate how the purity of VACV stocks influenced the CD8^ T cell 
immune responses induced by heat-inactivated VACV. two new stocks of WR 
with different degrees of purity were prepared. A crude stock of WR was prepared 
by lysing VACV-infected cells through three rounds of freeze-thaw cycles. In 
addition, a more purified WR stock was prepared through sucrose cushion 
centrifugation of infected cell extracts, followed by sucrose gradient 
centrifugation. It has been reported that VACV purified by this process contained 
minimal level of protein impurities (Joklik, 1962; Zwartouw et a l , 1962; 
Madalinski et al., 1977). Heat-inactivated WR inocula were prepared from these 
virus preparations, and were injected into mice via the i.d. route. Seven days later, 
the CDS"^ T cells responses against A3-270, A3-191, J3-289 and A42-88 were 
induced by the heat-inactivated, gradient-purified WR (Figure 6-2). These 
responses were at similar levels to those detected from mice immunised with heat-
inactivated cushion-purified WR (Figure 6-1A and B). One exception was that the 
heat-inactivated gradient-purified WR seemed to induce a lower anti-A42-88 
CDS"^ T cell response. Overall, the result here demonstrated that CDS"^  T cell 
responses induced by the inactivated WR were indeed induced by antigens 
originating from virion particles. When mice were immunised with heat-
inactivated crude WR. responses against three additional VACV peptides, namely 
B8-20, K3-6, and L2-53, were induced, in comparison to the heat-inactivated 
gradient-purified WR (Figure 6-2). It should be noted that due to variations in 
responses induced by the heat-inactivated crude WR, the differences in responses 
against these peptides were not statistically significant when compared with those 
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Figure 6-2| CD8'^ T cell responses against non-virion proteins can be induced by 
heat-inactivated WR in a low purity. VACV strain WR prepared as a crude stock 
(crude) or purified througli sequential sucrose cusiiion and sucrose gradient 
centrifugation steps (gradient) were heat-treated at 60°C for 60 min. Groups of three 
mice were immunised i.d. with 2x10" PFU of these heat-inactivated viruses. Seven days 
later, CD8 T cell responses were detemiined by ex vivo peptide stimulation and ICS. 
Data are shown as mean ± SEM of percentages (A) and absolute numbers (B) of CD8^ T 
cells responding to the indicated peptides. Results are compiled from two independent 
experiments (n = 6 for each virus). * denotes statistical significance (p < 0.05). 
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by heat-inactivated gradient-purified WR (Figure 6-2A). However, there was a 
significant increase in B8-20-specific CD8^ T ceil numbers induced by the heat-
inactivated crude WR compared to heat-inactivated gradient-purified WR (Figure 
6-2B). In addition, the inactivated crude WR induced a significantly higher CD8^ 
T cell response specific to A42-88 than the inactivated gradient-purified WR 
(Figure 6-2A and B). These data suggests that impurities within the heat-
inactivated inoculum can contribute to CDS"^  T cell priming in vivo. 
We then investigated whether the induction of a B8-20-specific response by heat-
inactivated MVA was due to the presence of MVA B8 antigen within the MVA 
stock used in Figure 6 - lC and D. which was semi-purified by sucrose cushion 
centrifugation. A new stock of MVA was purified from extracts of MVA-infected 
cells via sucrose cushion and sucrose gradient centrifugations. The newly 
prepared gradient-purified MVA as well as the cushion-purified MVA were heat 
inactivated and were injected into mice. The heat-inactivated gradient-purified 
MVA induced CD8^ T cell responses against a similar panel of peptides as the 
heat-inactivated cushion-purified MVA. with some variations in the magnitude of 
the responses (Figure 6-3). For instance, MVA that was purified via sucrose 
gradient primed lower CD8'^ T cell responses against B8-20. L2-53 and G8-34 
than MVA purified via sucrose cushion after heat inactivation. suggesting a role 
for protein impurities in inducing these responses. Interestingly, a B8-20-specific 
responses was still elicited by the heat-inactivated gradient-purified MVA. 
suggesting that the B8 antigen might remain associated with MVA virions after 
the further purification step. Increasing the purity of the MVA stock also led to an 
enhancement of responses against A3-270 and J3-289. This effect might be 
caused by a reduction of competition for MHC-1 presentation of peptides sourced 
from the impurities in the virus stock. Alternatively, the reduction of CD8^ T cell 
responses against 88-20 might favour priming of €08"^ T cell responses against 
A3-270 and J3-289. It should be noted that the CD8^ T cell response against A3-
191. another €08"^ T cell epitope from the A3 antigen, was not significantly 
affected by the purity of the virus stock. This suggests that the purity of virus does 
not influence all the responses equally. 
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Figure 6-3| A CD8^ T cell response against B8-20 is induced by heat-inactivated 
gradient-purified MVA virions. MVA purified through a sucrose cushion 
centrifugation (cushion) or through sequential sucrose cushion and sucrose gradient 
centrifugation steps (gradient) were heat-treated at 60°C for 60 min. Groups of three 
mice were then immunised i.d. with the heat-inactivated MVA (2x10" PFU/mouse). 
Seven days post immunisation, peptide-speciflc CDS' T cell responses were measured 
by ex vivo peptide stimulation and ICS and percentages (A) and absolute numbers (B) 
of CDS T cells responding to the indicated peptides were calculated. Results shown are 
mean ± SEM and are compiled from five independent experiments (n = 15 for each 
virus). * denotes statistical significance (p < 0.05). 
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6.2.2 The design of a recombinant W R expressing antigenic peptides fused 
with the A3 core antigen 
The results above clearly indicate that CDS'" T cell responses can be primed by 
heat-inactivated V A C V virions. Next, the potential application of heat-inactivated 
V A C V as a recombinant vaccine to induce CD8^ T cell responses against foreign 
antigens was explored. One criterion for such vaccines to work is that foreign 
antigens need to be attached to a V A C V virion antigen. For this purpose, the A3 
core antigen was chosen for the following reasons. Firstly, data in Figure 6-1 
shows that the A3 antigen from VACV particles can be used as a substrate for 
cross priming. Secondly. A3 is relatively abundant within VACV virions (Sarov 
and .loklik. 1972; Chung et al.. 2006). Tagging recombinant antigens to A3 
ensures the availability of the foreign antigens on VACV virions for cross 
priming. Thirdly. W R recombinants expressing A3 fused with fluorescent proteins 
have been generated (Arakawa et al.. 2007; Dodding et al.. 2009; Weisswange et 
al.. 2009; Horsington et al.. 2012). In all these recombinants, fluorescent proteins 
are fused to the amino-temiinus o f A3 and result in fluorescent labelling of the 
virion particles. These W R recombinants have been used to study how VACV 
virions are transported within infected cells with fluorescence microscopy 
(Arakawa et al., 2007; Dodding et al., 2009; Weisswange et al.. 2009). Attaching 
recombinant proteins at the amino-terminus of A3 has been show n not to affect in 
vitro viral replication and plaque morphology compared to wildtype W R 
(Arakawa et al.. 2007). It should be noted that in wildtype VACV, the first 61 
amino acid residues of the amino-terminus of the newly expressed A3 antigen is 
cleaved to produce the mature core antigen (Moss and Rosenblum. 1973; 
VanSlyke et al., 1991). However, the successful generation of the fluorescence-
labelled V A C V particles with fluorescent proteins fused to the amino-terminus of 
A3 suggests that the removal of the amino-terminal end of the full-length A3 
protein may not be necessary. 
A recombinant WR . namely WR-eGFP-STS-A3, was generated here. This virus 
expresses a recombinant antigen, consisting o f an eGFP protein, followed by 
OVA-257, B8-20 and HSV-gB-498 peptides, fused to the amino-terminus of the 
native full-length A3 antigen (Figure 6-4A). The recombinant antigen tagged to 
A3 is called eGFP-STS and was designed by Tijana Stefanovic and David 
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Figure 6-4| The recombinant eGFP-STS-A3 antigen expressed by WR-eGFP-STS-
A3. (A) A diagram showing the structure of the recombinant antigen eGFP-STS-A3. 
consisting of eGFP, OVA-257 peptide, VACV B8-20 peptide and HSV gB-498 peptide 
tagged onto the amino-terminus of VACV A3 antigen. (B) The amino acid sequence 
between the end of eGFP and the start of the A3 antigen (position 237 to position 272), is 
shown. The sequence within the green box represents the last three amino acid residues at 
the carboxyl-tenninus of eGFP. The sequence within the red-, purple- and cyan-coloured 
boxes represent the sequences of OVA-257, B8-20 and gB-498 peptides respectively. 
These sequences are separated by a lysine and an alanine residue. The sequence within 
the blue box corresponds to the first three amino acid residues at the amino-teniiinus of 
A3 antigen. (C) The DNA sequence encoding the amino acids in (B) is shown. The 
sequence in green corresponds to the 3'-end of the sequence encoding eGFP. The DNA 
sequences highlighted in red, purple and cyan encode the OVA-257, B8-20 and gB-498 
peptides respectively. The sequence in blue represents the 5' end of the A3L gene 
encoding the A3 antigen. 
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Tscharke (unpublished data). The whole recombinant A3 antigen is called eGFP-
STS-A3. The three antigenic peptides on eGFP-STS-A3 are separated by a lysine 
and an alanine residue (Figure 6-4B and C). These amino acid residues have been 
shown to allow efficient processing of the flanked peptides from antigens for 
MHC-I presentation(Eggers at al., 1995; Vijh et al.. 1998; Livingston et a l . 2001). 
WR-eGFP-STS-A3 was firstly characterised in vitro. The plaques formed by the 
recombinant virus on BSC-1 cells after three days of infection were significantly 
smaller than WR (Figure 6-5A and B). To determine whether this correlated with 
a growth defect of WR-eGFP-STS-A3. the yield of infectious intracellular virus 
produced by BSC-1 cells infected with WR or WR-eGFP-STS-A3 at m.o.i of 0.01 
was compared. The amount of virus produced by cells infected with WR-eGFP-
STS-A3 was significantly lower than WR by at least 2 logio over the three-day 
infection period (Figure 6-5C). These results suggest that tagging A3 at the 
amino-terminus with eGFP-STS antigen results in an attenuation of the 
recombinant virus in vitro. 
The pathogenesis of WR-eGFP-STS-A3 was then examined in vivo. Mice were 
immunised with live wildtype WR or WR-eGFP-STS-A3 via the i.d. route and the 
diameter of lesions formed on the infected ear pinna was measured (Tscharke and 
Smith. 1999). Lesions started to appear on the infected ears at four days post 
immunisation for both WR and WR-eGFP-STS-A3 (Figure 6-6A). Lesions were 
significantly smaller for WR-eGFP-STS-A3 than WR from five days post 
immunisation until the end of experiment seven days after immunisation (Figure 
6-6A). After seven days of immunisation, the mice were sacrificed and virus in 
the infected ears was titrated. The amount of infectious virus found in the ears 
infected with WR-eGFP-STS-A3 was significantly lower than ears infected with 
WR. The reduced lesion size and virus growth in the infected ears suggest that 
WR-eGFP-STS-A3 is less virulent in vivo. 
Primary CD8^ T cell responses were also measured in spleens from the 
immunised mice seven days after immunisation. Only the recombinant virus 
induced responses against OVA-257 and gB-498 peptides (Figure 6-6C and D), 
suggesting that the antigenic construct tagged to A3 was immunogenic in vivo. 
When measured as a percentage of total CD8^ T cells, the anti-B8-20 CD8" T cell 
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Figure 6-5| WR-eGFP-STS-A3 is attenuated in vitro. (A and B) Confluent BSC-1 
cell monolayers in 6-vvell plates were infected with WR or WR-eGFP-STS-A3 in 10-
fold serial dilution for 90 min. Infectious inocula were then replaced with D2 media 
with 0.4% CMC and incubated at 37°C. Three days later, media were removed and cell 
monolayers were stained with crystal violet. (A) Representative plaques formed by 
WR-eGFP-STS-A3 (left) or WR are shown (right). (B) The area of plaques formed by 
the indicated viruses in cells were measured and are shown as mean ± SEM. (C) the in 
vitro growth ability of WR-eGFP-STS-A3 was compared with that of wildtype WR. 
Procedures described in Section 2.2.24.3 were followed. Data are shown as mean ± 
SEM from triplicate samples (C). (A and B) Data shown are representatives of two 
similar e.xperiments. (C) Data represent one single experiment. * denotes statistical 
significance (/? < 0.05). 
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Figure 6-6| WR-eGFP-STS-A3 is attenuated in vivo but can induce CD8* T cell 
responses against the inserted antigenic peptides. Groups of three mice were 
immunised i.d. with 2x10" PFU live WR or WR-eGFP-STS-A3. (A) Lesion 
development was measured on infected ear pinna daily until seven days after 
immunisation. (B) Seven days after immunisation, infected ears were homogenised and 
infectious virus levels were determined by standard plaque assay. Virus titres are shown 
as PFU/ear. (C and D) Seven days post immunisation. CD8^ T cell responses were 
determined by ex vivo peptide stimulation and ICS. Percentages (C) and absolute 
numbers (D) of CD8^ T cells responding to the indicated peptides are shown. All data 
are shown as mean ± SEM. Data in (A and B) are representatives of two independent 
experiments while results in (B and C) are compiled from two independent experiments 
(n = 6 for each virus). * denotes statistical significance (/; < 0.05). 
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response was not further increased in mice immunised with WR-eGFP-STS-A3 
(Figure 6-6C). For most native VACV peptides, WR-eGFP-STS-A3 primed a 
lower percentage of CD8^ T cells against multiple VACV peptides, including 
A47-138, K3-6, A23-297, and A3-270, compared to WR (Figure 6-6C). In 
contrast, mice primed with WR-eGFP-STS-A3 showed a higher percentage of 
CD8^ T cells that were specific to A47-I71 than mice immunised with WR. 
However, when the total numbers of responding CD8^ T cells were measured, 
significantly less CD8^ T cells against multiple VACV peptides were induced by 
WR-eGFP-STS-A3 than WR. These peptides included A42-88, A3-191, A47-138, 
K3-6, A23-297, A3-270 and B8-20 (Figure 6-6D). This reduction of CDS" T cell 
responses was caused by a reduced number of CD8^ T cells present in WR-eGFP-
STS-A3-immunised mice, implying that the reduced virulence of the virus may 
prevent it from priming a maximal anti-VACV CD8" T cell response. Despite the 
lower immunogenicity of WR-eGFP-STS-A3, this experiment indicates that 
antigenic peptides attached on the A3 core antigen can be processed and presented 
on MHC-I for CD8" T cell priming in vivo. 
6.2.3 CD8^ T cell responses against the inserted peptides are elicited by heat-
inactivated WR-eGFP-STS-A3 
CDS'" T cell priming by heat-inactivated WR-eGFP-STS-A3 was then studied. 
Mice were immunised i.d. with live or heat-inactivated WR-eGFP-STS-A3 and 
the primary CDS"^  T cell responses were determined seven days later. The 
responses were firstly measured as percentages of total CD8" T cells (Figure 6-
7A). We found that CDS"^  T cell responses against OVA-257, gB-498 and B8-20 
were induced by heat-inactivated WR-eGFP-STS-A3, demonstrating that antigens 
tagged to the A3 core antigen can be cross presented from virion particles in vivo 
for CD8" T cell priming. The OVA-257-specific response induced by the heat-
inactivated virus was significantly higher than that induced by the live virus. A 
similar CD8" T cell response against gB-498 was primed by live and heat-
inactivated WR-eGFP-STS-A3. A B8-20-specific CD8" T cell response was also 
induced by heat-inactivated WR-eGFP-STS-A3, although it was significantly 
lower than that of the live virus (Figure 6-1 A). However because wildtype WR 
failed to induce a B8-20-specific CD8" T cell response in vivo after heat 
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Figure 6-7| Heat-inactivated WR-eGFP-STS-A3 induces T cell responses 
against the inserted antigenic peptides. Groups of three mice were immunised i d. 
with live or heat-inactivated WR-eGFP-STS-A3 (axlO"^ PFU/mouse). Seven days later. 
CDS' T cell responses in spleens were determined by ex vivo peptide stimulation and 
ICS. Data are shown as percentages (A) or absolute numbers (B) of CDS T cells 
responding to the peptides indicated. Data are compiled from four independent 
experiments (n = 12 for each virus). * denotes statistical significance (p < 0.05). 
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inactivation (refer to Figure 6-1), this result suggests that the B8-20-speciric CD8^ 
T cell response was primed by the B8-20 peptide attached to the recombinant A3 
antigen. Responses against a panel of native VACV peptides were also measured 
(Figure 6-7A). In contrast to live eGFP-STS-A3, the heat-inactivated virus failed 
to prime CD8^ T cell responses against A47-171, A47-138, K3-6 and A23-297 
peptides, similar to the results from heat-inactivated WR (refer to Figure 6-1). In 
addition, responses against J3-289 and A3-270 were minimal, just around the 
background level (Figure 6-1 A). These two responses were lower than those 
detected in mice immunised with heat-inactivated WR (refer to Figure 6-1). A 
CD8'^  T cell response was induced against the A3-191 peptide by heat-inactivated 
WR-eGFP-STS-A3. suggesting that native A3 antigenic peptides on the 
recombinant A3 antigen could still be processed and cross presented from the 
virions. When total numbers of peptide-specific CD8^ T cells were determined, a 
similar result was observed (Figure 6-7B). One major difference was that there 
was a lower number of gB-498-specific CD8* T cells induced by heat-inactivated 
WR-eGFP-STS-A3 than live WR-eGFP-STS-A3. This finding reflects that a 
smaller CD8^ T cell population was induced by the heat-inactivated virus in mice. 
To confirm that virion particles, and not simply protein impurities, were 
responsible for priming CD8^ T cells against the inserted antigenic peptides in 
WR-eGFP-STS-A3, a stock of WR-eGFP-STS-A3 was prepared through sucrose 
cushion and sucrose gradient centrifugations. Mice were immunised with heat-
inactivated gradient-purified WR-eGFP-STS-A3 or with heat-inactivated cushion-
purified WR-eGFP-STS-A3. Seven days post immunisation, similar levels of 
CD8^ T cell responses against OVA-257, gB-498, and B8-20 were induced by 
these heat-inactivated virus preparations (Figure 6-8). The gradient-purified virus 
induced a lower CD8^ T cell response specific to A42-88 which was statistically 
significant when measured as a total number of A42-88-specific CD8^ T cells 
(Figure 6-8B). This confirms the previous data with the use of heat-inactivated 
gradient-purified WR, which also induced a lower A42-88-specific CDS"^  T cell 
response (refer to Figure 6-2). This similarity suggests that the gradient-purified 
WR-eGFP-STS-A3 indeed contained less impurities than the virus only purified 
through sucrose cushion centrifugation. Overall results in Figure 6-7 and Figure 6-
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Figure 6-8| Further virus purif ication does not inf luence the pr iming of CD8^ T cell 
responses against the inserted antigenic peptides by heat-inactivated W R - e G F P -
STS-A3. W R - e G F P - S T S - A 3 purif ied througli sucrose cushion centr i fugat ion (cushion) 
or fur ther pur i f ied with sucrose gradient centr i fugat ion (gradient) was heat-treated at 
60°C for 60 min. Groups of three mice were immunised i.d. with 2x10" PFU of the heat-
inactivated W R - e G F P - S T S - A 3 . Seven days af ter immunisat ion, splenic C D 8 T cell 
responses were determined by ex vivo peptide stimulation and ICS. Data are shown as 
percentages (A) or absolute numbers (B) of C D S ' T cells responding to the pept ides 
indicated. Data are compi led f rom two independent exper iments (n = 6 for each virus). * 
deno tes statistical s ignif icance (/; < 0.05). 
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8 indicate antigenic peptides tagged to the A3 VACV core antigen can be cross 
presented to prime CD8^ T cells after complete inactivation of the virus. 
6.2.4 The functionalitj of CDS"^  T cells induced by heat-inactivated WR-eGFP-
STS-A3 
Polyfunctional CD8^ T cells have been associated with better protection against 
different diseases (Migueles et al., 2002; Betts et al., 2006; Badr et al., 2008; 
Reyes-Sandoval et al.. 2010). Highly polyfunctional anti-VACV CD8^ T cells are 
induced in humans vaccinated with MVA or Dr j vax (Precopio et al., 2007). 
Similarly, around 60% of anti-VACV CD8^ T cells in mice immunised with live 
WR are able to exert at least three effector functions, including degranulation and 
production of various cytokines and granzyme B (Hersperger et al., 2012). 
Therefore, it was of interest to examine the functionality of CD8^ T cells primed 
by heat-inactivated VACV. For this purpose, mice were immunised with live or 
heat-inactivated WR-eGFP-STS-A3. Seven days later. CD8^ T cells producing 
IFN-y. TNF-a and IL-2 were simultaneously measured after ex vivo stimulation 
with synthetic OVA-257, gB-498 or B8-20 peptides. The percentage of each 
possible combination of cytokine production by peptide-specific CD8^ T cells was 
determined using Boolean analysis in FlowJo and SPICE softwares. Figures 6-9A, 
C and E illustrate the overall magnitude of CD8'' T cells specific to OVA-257, 
gB-498 and B8-20 respectively as a percentage of total CD8^ T cells. The data 
were calculated by adding the percentages of CD8^ T cells that were expressing at 
least one cytokine after peptide stimulation. These results are similar to Figure 6-
7, where responses are shown as percentages of CD8^ T cell producing IFN-y. In 
brief, heat-inactivated WR-eGFP-STS-A3 induced a stronger CDS^ T cell 
response specific for OVA-257, a similar response to gB-498, and a weaker, but 
measurable. B8-20-specific response than live WR-eGFP-STS-A3. 
In terms of the cytokine expression profile of CD8^ T cells, heat-inactivated 
eGFP-STS-A3 induced CD8'^ T cell responses with similar functionality as the 
live virus (Figure 6-9B, D and F). The most prominent CD8^ T cell populations 
against OVA-257, gB-498 and B8-20 induced by either live or heat-inactivated 
WR-eGFP-STS-A3 were comprised of cells co-expressing IFN-y and TNF-a. 
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H o w e v e r , ca re fu l ana lys i s s h o w e d that there were some variat ions be tween the 
pe rcen tages o f r e spond ing cel ls express ing individual cytokine combinat ions . In 
par t icular , it s eemed that the heat inact ivated virus induced larger popula t ions of 
CD8^ T cel ls spec i f ic to the three examined pept ides that co-express IFN-y and 
T N F - a than the l ive virus . In contras t , h igher f requenc ies of CD8^ T cells against 
O V A - 2 5 7 , g B - 4 9 8 and B 8 - 2 0 express ing only one cytokine were induced by live 
e G F P - S T S - A 3 , in c o m p a r i s o n to heat- inact ivated eGFP-STS-A3 . Overal l , these 
da ta sugges t that CD8^ J cell r esponses induced by heat- inact ivated V A C V are 
s imilar to. if not bet ter than, those induced by live V A C V in te rms of mul t ip le 
cy tok ine product ion . 
The in v ivo cytolyt ic func t ion of CD8'^ T cells w a s also compared . Seven days 
a f te r immuni sa t ion with live or heat- inact ivated W R - e G F P - S T S - A 3 . mice were 
in jec ted i.v. wi th a mix tu re o f syngene ic spleen cells that were either pulsed with 
synthet ic g B - 4 9 8 pept ide and labelled with low C F S E intensity or left unpulsed 
and labelled wi th a h igher concent ra t ion o f C F S E at a 1:1 ratio. These cells were 
label led wi th the same intensi ty of Vybran t DiD cell labelling dye. a l lowing the 
t racking of the t ransfer red cells . The gB-498-pu lsed cells were the targets for gB-
498-spec i f i c CDS'" T cel ls wh i l e the unpulsed cells acted as an internal control for 
any non-spec i f i c e l iminat ion o f t ransferred cells. Four hours af ter cell t ransfer , 
sp leens were harves ted f r o m the immunised mice , the t ransferred cell popula t ion 
w a s de te rmined based on D i D labell ing, and the extent of lysis of gB-498-pu lsed 
cells w a s measu red . In naive mice , a s imilar f requency of gB-498-pu lused 
(CFSE'") and unpulsed (CFSE" ' ) cel ls w a s isolated (Figure 6-1 OA). Similar ly, 
wi th in the sp leens o f mice immuni sed with heat- inact ivated W R . there w a s a 
s imilar level o f the t w o t ransfer red popula t ions , suggest ing that there w a s a 
min imal ki l l ing o f gB-498-pu l sed cells in v ivo in these mice (Figure 6-1 OA and 
B). In m i c e i m m u n i s e d with ei ther live or heat- inact ivated W R - e G F P - S T S - A 3 . 
howeve r , there w a s a great loss of gB-498-pu l sed cells, but not the unpulsed cells. 
Th is t ransla ted to a round 8 0 % speci f ic ki l l ing of gB-498-pu lsed cells. There w a s 
no statistical d i f f e r ence be tween mice immuni sed with heat- inact ivated or live 
W R - e G F P - S T S - A 3 . Th is expe r imen t indicates that the gB-498-spec i f ic CD8'^ T 
cel ls induced by l ive and heat- inact ivated W R - e G F P - S T S - A 3 share an 
equ iva len t ly h igh cytolyt ic abili ty in vivo. 
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Figure 6-9| A comparison of the poly-functionality of CD8^ T cell responses induced 
by live and heat-inactivated WR-eGFP-STS-A3. Live or heat-inactivated WR-eGFP-
STS-A3 were used to immunise groups of three mice (2x10'' PFU) via the i.d. route. 
Seven days after immunisation, splenocytes were stimulated ex vivo with synthetic 
peptides. CD8 T cells producing IFN-y, TNF-a and IL-2 were detected with antibody 
labelling and ICS. The data were then subjected to Boolean analysis with FlowJo 
software and were further analysed with SPICE software (NIH), Total CD8 T cell 
responses against OVA-257 (A). gB-498 (C) and B8-20 (E) were calculated by summing 
responses of all possible combinations of IFN-y, TNF-a and IL-2 expression after 
peptide stimulation. Percentages of CD8 T cells expressing individual cytokine 
combinations relative to the total peptide-specific CD8* T cell responses are shown for 
OVA-257 (B). gB-498 (D) and 88-20 (F). Data are shown as mean ± SEM and are 
compiled from two independent experiments (n = 6 for each virus). * denotes statistical 
significance (p < 0.05). 
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Figure 6-10| A similar cytolytic ability of CDS"^  T cells induced by heat-inactivated 
and live WR-eGFP-STS-A3. Mice were immunised i.d. with 2x10" PFU heat-
inactivated WR. live or heat-inactivated WR-eGFP-STS-A3 or left unimmunised (naive). 
Seven days later, in vivo cytotoxicity assay were perfomied. (A) Representative 
histograms showing the transferred unpulsed (CFSE"") and gB-498-pulsed targeted cells 
(CFSE'°) gated on the transferred cell population in the recipient mice immunised with 
the indicated viruses. The number in each graph illustrates the percentage of specific 
killing of gB-498-pulsed targets calculated. (B) The specific killing of gB-498-pulsed 
targets are shown as mean ± SEM. Data are compiled from two independent experiments 
with n = 6 for each virus. * denotes statistical significance (p < 0.05). 
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6.2.5 M e m o n and secondary responses induced by the heat-killed WR-eGFP-
STS-A3 
Previous data showed that primary CD8^ T cell responses can be induced by heat-
inactivated VACV virions. The ability of these CD8^ T cells to be maintained into 
the memory phase was examined. Memory CDS"^ T cell responses against 
multiple VACV and the inserted peptides were detected at seven weeks after 
immunisation with live or heat-inactivated WR-eGFP-STS-A3. Memory CD8^ T 
cells recognised a panel of native VACV peptides that was similar to that seen in 
the primary response, although as expected the magnitude of the memory 
responses was lower (Figure 6-11). For the inserted antigenic peptides on WR-
eGFP-STS-A3, the heat-inactivated virus induced a gB-498-specific CD8^ T cell 
response with a similar magnitude as the live virus, when measured as a 
percentage or as a total number of responding CD8^ T cells. Although the anti-
OVA-257 CD8^ T cell response was slightly higher in mice immunised with heat-
inactivated WR-eGFP-STS-A3 than live eGFP-STS-A3. the difference was not 
statistically significant. On the other hand, heat-inactivated eGFP-STS-A3 
induced a significantly lower memory CD8^ T cell response against B8-20 than 
live eGFP-STS-A3. consistent with the finding in the primary response (refer to 
Figure 6-7). Importantly, heat-inactivated WR failed to induce any detectable B8-
20-specific memory CD8^ T cell immunity, confirming that the B8-20-specific 
response in mice immunised with heat-inactivated WR-eGFP-STS-A3 was 
induced by the B8-20 peptide originating from the eGFP-STS-A3 construct. 
Having established that a memory CD8^ T cell response was induced by heat-
inactivated WR-eGFP-STS-A3, we examined whether this could lead to an 
induction of an enhanced CD8^ T cell response during a heterologous challenge 
with HSV-1. Mice were immunised i.d. on the left ear with heat-inactivated or 
live WR-eGFP-STS-A3, live WR-ESmini-gB, live WR or PBS. Seven to eight 
weeks later, mice were challenged with HSV-1 strain KOS via i.d. injection into 
the right ear and CD8^ T cell responses against gB-498 were detected seven days 
later. The results showed that at least 10% of CD8^ T cells in mice primed with 
heat-inactivated or live WR-eGFP-STS-A3, or live WR-ESmini-gB recognised 
the gB-498 peptide after HSV-1 infection (Figure 6-12A). In comparison, mice 
primed with live W R or left unimmunised (mock immunised with PBS) had 
307 
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Figure 6-11| Memory CD8^ T cell responses against the inserted antigenic peptides 
are induced by heat-inactivated WR-eGFP-STS-A3. Groups of three mice were 
immunised i.d. with 2x10" PFU of live or heat-inactivated WR-eGFP-STS-A3. Seven to 
eight weeks later, CD8 T cell responses in spleens were determined by ex vivo peptide 
stimulation and ICS. Percentages (A) or absolute numbers (B) of CD8 T cells 
responding to the peptides indicated are shown as mean ± SEM. Data are compiled from 
three independent experiments (n = 9 for each virus). * denotes statistical significance (j? 
<0.05) . 
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Figure 6-12| Priming with heat-inactivated WR-eGFP-STS-A3 does not enhance the 
gB-498-specific CD8^ T cell response seven days after HSV-1 challenge. Groups of 
three mice were injected with PBS or with 2 x l 0 ' PFU of the indicated viruses via i.d. 
injection into left ear pinna. Seven weetcs later, these immunised mice were infected with 
5 x I 0 ' PFU HSV-1 by i.d. injection into right ear pinna. Seven days after HSV-1 
challenge, gB-498-specific CDS T cell responses in spleens were detennined by ex vivo 
peptide stimulation and ICS. Percentages (A) or absolute numbers (B) are shown as 
mean ± SEM. Data are compiled from two independent experiments (n = 6 for each 
virus). * denotes statistical significance (p < 0.05). 
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around or less than 8% of CD8^ T cells specific to gB-498 after the heterologous 
challenge. However, the only statistical difference detected was between the 
responses induced by live WR-ESmini-gB and live WR (Figure 6-12A). In 
addition, there were great variations between the total numbers of gB-498-specific 
CD8^ T cells induced in individual mice immunised with the same reagent (e.g. 
mice primed with live WR), and no statistical significance was detected across all 
the immunisation regimes (Figure 6-12B). One limitation of this assay was that 
the secondary response was measured seven days post HSV-1 challenge. Any 
improvement of the magnitude of gB-498-speciric CD8^ T cell responses which 
occurred early after the challenge would not be detected. 
We then changed our focus to the use of heat-inactivated VACV in a prime-boost 
strategy to induce strong immune responses against the foreign antigens. Mice 
were firstly primed with heat-inactivated or live WR-eGFP-STS-A3 (or mock 
immunised with PBS). These mice were then boosted with live WR-eGFP-STS-
A3 five weeks later. Under this prime-boost regime, mice primed with heat-
inactivated WR-eGFP-STS-A3 allowed better induction of secondary CD8^ T cell 
responses against OVA-257 and gB-498 than mice that were primed with live 
WR-eGFP-STS-A3 or mock-primed (Figure 6-13). The B8-20 responses were not 
significantly different across all the priming reagents tested. As seen in Figure 6-
11. the live eGFP-STS-A3 induced a relatively strong memory CD8^ T cell 
responses against B8-20 compared to heat-inactivated virus. This large B8-20-
specific memory population might interfere with the successive induction of 
secondary responses against other antigenic peptides. Furthermore, the antibody 
level induced by the live virus might be substantially higher than that induced by 
the heat-inactivated virus during the priming phase (Madeley. 1968; Turner et al., 
1970). This might suppress the ability of WR-eGFP-STS-A3 to induce secondary 
responses as a homologous boosting vaccine. In summary, these data show that 
priming with heat-inactivated virus and boosting with live virus is superior to a 
live-prime-live-boost strategy. 
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Figure 6-13| Priming with heat-inactivated WR-eGFP~STS-A3 improves the 
secondary CD8^ T cell responses against the inserted antigenic peptides after 
boosting with live WR-eGFP-STS-A3. Groups of three mice were injected with PBS or 
with 2x10" PFU of live or heat-inactivated WR-EGFP-STS-A3 via i.d. injection into left 
ear pinnae. Five weeks later, the immunised mice were boosted with IMOt PFU live WR-
eGFP-STS-A3 by i.d. injection into right ear pinnae. Seven days later, peptide-specific 
CDS' T cell responses in spleens were determined by ex vivo peptide stimulation and ICS 
and shown as percentages (A) or absolute numbers (B) of CD8^ T cells responding to the 
peptides indicated. Data are shown as mean ± SEM and are compiled from three 
independent experiments with n = 9 for each experimental group. * denotes statistical 
significance (p < 0.05). 
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6.2.6 The design of VACV recombinants expressing foreign antigenic peptides 
tagged to the A4 core antigen 
The above experiments were focused on the use of the A3 core antigen as a carrier 
for foreign antigens. It remained unknown whether this was a general role that 
could apply to other virion antigen or was specific to the A3 antigen. It is known 
that A3 has several CD8^ T cell epitopes that are restricted to human and murine 
MHC-I, including HLA-B*4403. H - 2 D \ H-2K'' and H-2K'' (Jing et al., 2005; 
Oseroff et al., 2005; Moutaftsi et al., 2006; Moutaftsi et al.. 2010). This 
immunoprevalent nature of A3 might be somehow associated with its ability to be 
cross presented from VACV virion particles. To answer this question, a different 
VACV virion antigen, known as A4. was chosen as a foreign antigen carrier. 
A4 is a late VACV protein and it is required for transforming immature VACV 
virions into mature virions with the correct morphology (Maa and Esteban, 1987; 
Williams et al., 1999; Chung et al.. 2006; Resch et a l , 2007). This antigen is an 
abundant antigen within the VACV core (Maa and Esteban, 1987). It is also found 
to be associated with the VACV envelope membrane (Cudmore et al., 1996; 
Jensen et al., 1996). In temis of immunogenicity, it is one of the targets of the 
antibody response induced during WR immunisation in C57B1/6 mice (Sette et al., 
2008). In addition, it contains a peptide restricted to MHC-II H-2-IA'' (Sette et al., 
2008). One study suggested that A4 contains several putative CD8^ T cell 
epitopes, in which their responses could be induced by immunisation with DNA 
encoding the A4 antigen (Otero et al., 2006). However, in contrast to A3, no CD8^ 
T cell epitopes have been defined in the context of VACV immunisation of mice 
or humans. Similar to the A3 antigen, the A4 antigen has also been used as a 
fusion target for fluorescent proteins to generate fluorescently-labelled VACV 
particles (Carter et al.. 2003; Carter et al.. 2005; Herrero-Marti'nez et al., 2005; 
Huang et al., 2008; Mercer and Helenius, 2008). 
For our study, a slightly different antigenic construct used for tagging A3 was 
used here. The construct was called eOFP-SKS, which consists of a eGFP protein, 
followed by OVA-257, D3E-I28 and gB-498 peptides (Figure 6-14). The D3E-
128 peptide is a newly mapped CD8^ T cell epitope at position 128-135 of dengue 
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Figure 6-14| The recombinant eGFP-SKS-A4 antigen expressetl by WR-eGFP-
SKS-A4 and MVA-eGFP-SKS-A4. (A) A schematic showing the antigenic construct 
consisting cGFP, OVA-257 peptide. D3E-128 peptide and HSV gB-498 peptide tagged 
onto the amino-terininus of VACV A4 antigen, creating the recombinant eGFP-SKS-A4 
protein. (B) The amino acid sequence between the end of eGFP and the start of A4 
antigen, corresponding to position 237 to position 272 of the recombinant eGFP-SKS-
A4 antigen, is shown. The sequence highlighted within the green box represents the last 
three amino acid residues at the carboxyl-tenninus of eGFP. The sequence within the 
red-, purple- and cyan-coloured boxes represent OVA-257, D3E-I28 and gB-498 
peptide sequences respectively. The sequence within the blue box corresponds to the 
first three amino acid residues at the amino-terminus of A4 antigen. (C) The DNA 
sequence encoding the amino acids illustrated in (B) is shown. The sequence in green 
corresponds to the 3'-end of the sequence encoding eGFP. The DNA sequences 
highlighted in red. purple and cyan encode the OVA-257. D3E-I28 and gB-498 peptides 
respectively. The sequence in blue represents the 5' end of the A4L gene encoding the 
A4 antigen. 
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virus type 3 envelope protein that is predicted to bind to H-2K'' (amino acid 
sequence KVVQYENL; Barbara Quinan and David Tscharke, unpublished data). 
We generated a set of two virus recombinants from VACV strains WR and MVA. 
The recombinants were named WR-eGFP-SKS-A4 and MVA-eGFP-SKS-A4 
respectively. These two recombinants express the eGFP-SKS construct that is 
fused to the amino-terminus of the native full-length A4 antigen (Figure 6-14). 
6.2.7 CD8^ T cell responses induced by WR-eGFP-SKS-A4 
The replication ability of WR-eGFP-SKS-A4 was first examined. This 
recombinant virus had a reduced replication ability of around 2 logio in BSC-1 
cells infected at m.o.i. of 0.01. compared to wildtype WR (Figure 6-I5A). WR-
eGFP-SKS-A4 was also attenuated in vivo, producing significantly smaller 
lesions on the infected ears in mice, as measured between four to seven days post 
immunisation, compared to WR (Figure 6-158). When the primary CDS" T cell 
responses induced by WR and WR-eGFP-SKS-A4 were compared, it was found 
that responses against OVA-257, D3E-128 and gB-498 were only induced by the 
recombinant virus, but not by the wildtype WR (Figure 6-15C and D). Similar to 
WR-eGFP-STS-A3 (Figure 6-6), the responses against several native VACV 
peptides, namely A47-138. K3-6, and A23-297. induced by eGFP-SKS-A4 were 
significantly less than those of WR when the responses were measured as 
percentages of total CD8^ T cells (Figure 6-15C). Because a smaller population of 
CD8" T cells were present in mice immunised with WR-eGFP-SKS-A4 than WR. 
the total number of CDS"^ T cells specific to A47-138. K3-6. A23-297. A3-270 
and B8-20 were also decreased (Figure 6-15D). Overall. eGFP-SKS-A4 seemed to 
behave similarly to WR-eGFP-STS-A3: both are attenuated and induce a less 
potent anti-VACV response. 
The immunogenicity of heat-inactivated WR-eGFP-SKS-A4 was then 
investigated. When mice were immunised with heat-inactivated WR-eGFP-SKS-
A4 purified though sucrose cushion centrifugation. responses against OVA-257, 
D3E-128. and gB-498 were induced (Figure 6-16). A very low level CD8^ T cell 
response against B8-20 was also primed by the heat-inactivated virus, unlike 
previous findings with heat-inactivated WR (Figure 6-1A to C). However, this 
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minute B8-20-specific response was not detected in mice immunised with heat-
inactivated WR-eGFP-SKS-A4 that was purified via sucrose cushion and sucrose 
gradient centrifugations (Figure 6-16). This suggests that B8 antigen was a 
contaminant in the cushion-purified virus stoci<. In comparison, further virus 
purification did not influence the CD8^ T cell immunity against the antigenic 
peptides tagged on the A4 antigen primed by the heat-inactivated virus. A direct 
comparison between live and heat-inactivated WR-eGFP-SKS-A4 was not 
performed. However, when compared with the results on Figure 6-15. live and 
heat-inactivated WR-EGFP-SKS-A4 appeared to induce similar levels of OVA-
257- and D3E-128-specific responses while the response against gB-498 seemed 
to be smaller. Overall, this result demonstrates that antigenic peptides on A4 can 
be cross presented from virion particles to prime CD8^ T cell responses. 
6.2.8 CDS"^ T cell responses induced by IVIVA-eGFP-SKS-A4 
To examine whether recombinant MVA could also be used as a heat-inactivated 
vaccine to induce CDS" T cell responses against foreign antigens, the 
immunogenicity of live and heat-inactivated MVA-eGFP-SKS-A4 was compared. 
Live MVA-eGFP-SKS-A4 elicited primary CD8^ T cell responses against OVA-
257, D3E-128 and gB-498. the three antigenic peptides on the recombinant eGFP-
SKS-A4 antigen, as measured seven days post immunisation (Figure 16-17). This 
experiment shows that antigenic peptides available on A4 were processed for 
CD8^ T cell priming when expressed from MVA. When mice were immunised 
with heat-inactivated MVA-eGFP-SKS-A4, these three foreign antigenic peptides 
remained immunogenic. However, the magnitude of the induced responses against 
OVA-257 and gB-498 were significantly lower than those induced by the live 
virus. As expected, the anti-B8-20 response was lower in mice immunised with 
heat-inactivated MVA-eGFP-SKS-A4, compared to live MVA-eGFP-SKS-A4. 
The data here suggests that antigenic peptides tagged on A4 can be cross 
presented from heat-inactivated MVA virion particles to prime CD"^ T cell 
responses although it is less immunogenic that the live MVA recombinant. 
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Figure 6-15| WR-eGFP-SKS-A4 is attenuated in vitro and in vivo. (A) In vitro 
growth abilit> of WR-eGFP-SKS-A4 was compared to that ofwildtype WR. Procedures 
described in Section 2.2.24.3 were followed. Results are shown as mean ± SEM from 
triplicate samples. (B. C and D) Groups of three mice were immunised i.d. with 2x10" 
PFU of live WR-eGFP-SKS-A4 or live WR. (B) Diameter of lesions was measured on 
infected ear pinna daily for seven days. (C and D) Seven days post immunisation. CD8 
T cell responses were determined by ex vivo peptide stimulation and ICS. The results 
are shown as mean ± SEM of percentages (C) and absolute numbers (D) of CDS"^ T cells 
responding to the indicated peptides. Data shown in (A) are from one single experiment. 
Data in (B) are representative of two independent experiments (n = 3 for each virus) 
while results in (C and D) are compiled from two independent experiments (n = 6 for 
each virus). * denotes statistical significance (/> < 0.05). 
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Figure 6-16| CD8^ T cell responses against the antigenic peptides tagged to the A4 
antigen are induced by heat-inactivated WR-eGFP-SKS-A4. Heat-inactivated WR-
eGFP-SKS-A4 purified through sucrose cushion centrifugation (cushion) or sucrose 
gradient centrifugation (gradient) were injected i.d. into groups of three mice (2x10'' 
PFU/inouse). Seven days later, splenic CD8^ T cell responses were determined by ex 
vivo peptide stimulation and ICS. Data are shown as percentages (A) or absolute 
numbers (B) of CDS' T cells responding to the peptides indicated (mean ± SEM). Data 
are compiled from two independent experiments with n = 6 for each virus. * denotes 
statistical significance (p < 0.05). 
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Figure 6-17| Heat-inactivated MVA-eGFP-SKS-A4 induces CD8* T cell responses 
against the antigenic peptides tagged to the A4 antigen. Groups of three mice were 
immunised i.d. with 2 x 1 0 ' PFU live or heat-inactivated MVA-eGFP-SKS-A4. Seven 
days later, CDS' T cell responses in spleens were determined by ex vivo peptide 
stimulation and ICS. Data are shown as percentages (A) or absolute numbers (B) of 
C D S ' T cells responding to the peptides indicated (mean ± SEM) and are compiled from 
two independent experiments (n = 6 for each virus). * denotes statistical significance (p 
< 0 . 0 5 ) . 
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6.3 Discussion 
It has long been known that heat-inactivated VACV can induce antibody 
responses in immunised animals in vivo (Madeley, 1968; Turner et al., 1970). 
However, the level of response is lower than those induced by live VACV 
(Madeley, 1968; Turner et al., 1970). In addition, heat-inactivated VACV are less 
able to protect immunised animals against subsequent challenges with live 
poxvirus (Madeley, 1968, Turner et al., 1970). VACV vaccines inactivated by 
other methods were also less able to prime protective immunity in vivo and were 
associated with induction of lower antibody responses (Boulter et al., 1971, 
Turner and Squires. 1971). However. anti-VACV CD8^ T cell immunity was not 
determined in these studies. Experiments in this chapter demonstrate for the first 
time that heat-inactivated VACV virions can prime CD8^ T cells in vivo. 
Other than the use of heat inactivation. other methods have been used to inactivate 
VACV. These include UV irradiation, chemical inactivation with formaldehyde 
and inactivation with various types of photoactive chemicals (Boulter et al.. 1971; 
Turner and Squires. 1971; Hearst and Thiry. 1977; Tsung et al., 1996; Fischer et 
al., 2007; Sagripanti et al., 2011). More recently, it has been shown that WR 
inactivated with hydrogen peroxide induces potent antibody responses against 
VACV in mice and provides protection against lethal VACV challenge (Amanna 
et al., 2012). This method can also inactivate LCMV and West Nile virus which 
can be used to induce a CD8^ T cell response in vivo (Amanna et al., 2012; 
Walker et al., 2012; Pinto et a l , 2013). These studies suggest that viral antigens 
on hydrogen peroxide-inactivated virion particles can be cross presented for CD8^ 
T cell priming. However, it has yet to be confirmed that hydrogen peroxide can 
completely abolish viral gene expression. In contrast, data shown in Section 3.2.2 
illustrated that heat-inactivation completely inhibits VACV viral replication and 
gene expression. 
Results shown in this chapter clearly demonstrate that VACV antigens from heat-
inactivated virion particles can be used as the substrates for cross priming CD8^ T 
cells in vivo. This mode of cross priming has not been previously reported for 
VACV. Furthermore, CD8'' T cell responses could also be induced by protein 
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impur i t i e s wi th in the heat - inact ivated V A C V that was used for immunisa t ion . 
H o w e v e r , it r e m a i n s puzz l ing h o w B8-20-specir ic CD8^ T cells were pr imed by 
hea t - inac t iva ted grad ien t -pur i f ied M V A . The B8 ant igen expressed f r o m M V A is 
t runca ted c o m p a r e d to the B8 ant igen expressed f rom W R (Anto ine et al., 1998). 
O n e poss ib i l i ty is that t runcated 8 8 protein might be trapped wi th in M V A vir ion 
par t ic les du r ing v i rus packing . An al ternat ive reason is that M V A vir ion part icles 
m a y be m o r e st icky and it may be harder to r emove protein impuri t ies f rom the 
M V A s tocks . A recombinan t M V A express ing the ful l - length B8 ant igen of W R 
cou ld be m a d e and used to test the first possibil i ty. For test ing the second 
poss ib i l i ty . a M V A stock fur ther purif ied using caes ium chlor ide gradient 
cen t r i fuga t ion could be used. This method is sensit ive enough to separate var ious 
types o f V A C V vir ion part icles (Planterose et al.. 1962; Payne and Nor rby , 1976). 
A n o t h e r u n e x a m i n e d aspect o f cross pr iming f rom V A C V par t ic les is whether this 
m e c h a n i s m happens natural ly during immunisa t ion with live V A C V . It is diff icul t 
to separa te in v ivo p r iming induced by newly-expressed viral an t igens and those 
induced by ant igens f r o m virus particles. One possible strategy is to create a 
r e c o m b i n a n t vi rus that expresses the virion ant igen of interest under an inducible 
p romote r . Th i s virus can be g rown in vitro with the presence of the inducer . Af t e r 
i m m u n i s a t i o n wi th this virus, the virion ant igen will not be expressed in vivo. 
Th i s r e c o m b i n a n t vi rus is p robably unable to replicate in v ivo and so it is as best 
to c o m p a r e wi th M V A which cannot replicate. However , this r ecombinan t would 
not m i m i c a s i tuat ion whe re the virus is replicated in v ivo , as for W R . It is 
poss ib le that viral part ic les generated in v ivo can be used as substrate for cross 
p r iming . O n the o ther hand, perhaps heat inact ivat ion structural ly m o d i f i e s V A C V 
vi r ions in a w a y that p romotes cross presentat ion in vivo. A d i f fe ren t inactivation 
m e t h o d , such as irradiat ion of V A C V with germicidal U V (i.e. U V in 254 n m 
w a v e l e n g t h ; N o r b u r y et al., 2004; Lev et al., 2009) , could be used to examine 
w h e t h e r inact ivat ion me thod inf luences cross presenta t ion o f an t igens f r o m 
V A C V part ic les . 
Th i s chap te r also sugges ts that recombinant an t igens fused wi th V A C V core 
p ro te ins can be incorpora ted into V A C V vir ions and can be p rocessed f r o m 
inac t iva ted V A C V par t ic les for CD8^ T cell p r iming in v ivo . H o w e v e r , several 
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questions remain to be answered. Firstly the uptake mechanism of heat-
inactivated VACV has not been examined. It has been shown that the live VACV 
particle can be taken up by cells, including DCs, via macropinocytosis into an 
intracellular vesicle (Mercer and Helenius, 2008; Mercer et al., 2010; Sandgren et 
al., 2010). The VACV core is then released into the cytoplasm via fusion of the 
VACV envelope membrane with the vesicle membrane, which requires 
interactions between multiple VACV and cellular proteins (Laliberte et al., 2011). 
The internalisation process of VACV mature virions via macropinocytosis 
requires the presence of phosphatidylserine or other similar anionic phospholipids 
on the viral envelope membrane (Ichihashi and Oie. 1983; Mercer and Helenius, 
2008; Mercer et al., 2010). Phosphatidylserine is heat stable (Ichihashi and Oie, 
1983). Therefore, this lipid may still be available on heat-inactivated VACV to 
trigger macropinocytosis. so long as the viral envelope membrane remains intact 
after heat treatment. However, because heat denatures proteins, the release of the 
heat-inactivated VACV core into the cytoplasm might not be allowed. It has been 
shown that HIV particles taken up by macrophages via macropinocytosis are 
degraded within the vesicles (Marechal et al., 2001; Gobeil et al., 2013). Heat-
inactivated VACV internalised by DCs might be partially degraded to release 
viral antigens (either as intact or partially processed forms). These virion antigens 
might then be further processed by the possible processing pathways discussed in 
Section 1.7.2 for cross presentation. 
Alternatively, heat-inactivated VACV may be taken up by APCs via a completely 
different pathway from live VACV. Two recent reports have identified actin 
filament (formed from polymerisation of actin subunits) as the ligand for the 
Clec9A receptor (Ahrens et al., 2012; Zhang et al., 2012), an important receptor 
on DCs for sensing dead cells and for promoting cross presentation of antigens 
associated with dead cells (Sancho et a l , 2009). This receptor plays a role in 
directing captured dead-cell-associated antigens into endosomes, which favour 
cross presentation onto MHC-I, instead of lysosomes that would lead to extensive 
antigen degradation (Sancho et al., 2009; Zelenay et al., 2012). Targeting 
recombinant antigens to Clec9A by conjugating with anti-clec9A antibody 
promotes enodocytosis and cross presentation of the antigens (Caminschi et al., 
2008; Sancho et al., 2008; Lahoud et al., 2011). Interestingly, actin subunits have 
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been identified on V A C V virion particles (Jensen et a!., 1996; Chung et al., 2006; 
Resch et a!., 2007). I f the virion-associated actin is in the forrn o f filaments, it is 
possible that heat-inactivated VACV binds to Clec-9A directly and promotes 
cross presentation. Finally, heat-inactivated viruses may form large antigenic 
aggregates which are captured by DCs. 
We have established an in vitro cross presentation assay for detecting antigen 
presentation on cells co-cultured with heat-inactivated VACV. In this assay. 
BMDCs are co-cultured with heat-inactivated WR-eGFP-STS-A3 and are then 
used as stimulators to drive the proliferation of CFSE-labelled naive CD8^ T cells 
isolated from OT-1 mice. Using this assay, OVA-257 presentation was detected on 
cells co-cultured with heat-inactivated WR-eGFP-STS-A3, but not with heat 
inactivated WR-mini-OVA, which expresses the cytosolic OVA-257 minigene 
(data not shown). Together with inhibitors to stop specific antigen processing 
pathways or with BMDCs generated from mice deficient in certain antigen 
presentation pathways, this assay would allow in vitro dissection of how antigens 
from heat-inactivated V A C V virions are captured and processed for cross 
presentation. 
How antigen-presenting DCs are activated by heat-inactivated V A C V was not 
examined in this chapter. Several publications have shown that UV-inactivated 
M V A and W R can activate co-cultured DCs or macrophages in vitro to produce 
inflammatory cytokines (Zhu et al., 2007; Delaloye et al., 2009; Waibler et al., 
2009). In addition, VACV strains Copenhagen and M V A inactivated by UV or 
heat (at 55°C) induced expression of the costimulatory molecule CD86 on co-
cultured DCs (Drillien et al.. 2004). Several TLR might be involved (Zhu et al.. 
2007; Samuelsson et al., 2008; Delaloye et al., 2009; Bauer et al., 2010; Martinez 
et a l , 2010a) but their precise roles remain controversial (Cervantes et al., 2012). 
More recently, Ferguson et al. (2012) found that DNA-dependent protein kinase 
can bind to transfected DNA isolated from VACV to activate innate immune 
responses pathway in fibroblasts in vitro. The investigators further demonstrated 
that DNA-dependent protein kinase contributes to lL-6 and IFN-P production in 
the infected ears after M V A immunisation via i.d. injection in vivo (Ferguson et 
al., 2012). However, its role for heat-inactivated V A C V remains unknown. 
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Overall, the mechanism of DC activation by heat-inactivated VACV should be 
investigated. The use of BMDCs generated from mice that are TLR-deficient 
could be a start. However, DCs involved in CDS"^ T cell priming in vivo during 
irnmunisation with heat VACV should first be identified as they might require a 
different activation pathway compared with the in vitro-generated APCs. 
The recombinant VACV generated in this chapter expressed foreign antigens that 
are fused to either the A3 or A4 VACV core antigen. It remains unclear whether 
VACV envelope antigens can be used as antigen carriers in heat-inactivated 
VACV. None of the native VACV peptides tested in this thesis originated from 
envelope membrane proteins. Peptides from such proteins have been reported as 
CD8^ T cell epitopes in mice or humans immunised with live VACV although 
they are under-represented (Oseroff et al., 2005; Pasquetto et al.. 2005; Moutaftsi 
et al., 2006; Tang et al., 2006; Oseroff et al.. 2008). Whether these proteins are 
also immunogenic after VACV inactivation needs to be examined and this may 
provide more possible VACV antigens for fusing with recombinant antigens. 
There are several difficulties which need to be tackled to improve heat-inactivated 
VACV as recombinant vaccines. Firstly, as seen for WR-eGFP-STS-A3 and WR-
eGFP-SKS-A4, the in vitro growth of recombinant VACV expressing core 
antigens fused with foreign antigens were reduced compared to wildtype VACV, 
affecting vaccine production efficiency. This problem could be due to the 
bulkiness of the foreign antigens chosen in our studies. Reducing the sizes of the 
fused antigen on a VACV core antigen may prevent any interference of VACV 
core packaging. Fusing foreign antigens to the carboxyl-terminus of the chosen 
core protein or choosing other core proteins could also be explored. Likewise, the 
use of other virion proteins as antigen carriers in VACV should be investigated to 
identify a more immunogenic substitute. The possibility of tagging multiple virion 
antigens with foreign antigens in a single VACV recombinant should also be 
explored. Secondly, the effect of immunodomination may still limit the use of 
heat-inactivated VACV as a recombinant vaccine vector. This study demonstrates 
that the anti-VACV CDS'" T cell response is reduced after heat inactivation. but 
the responses against inserted antigens may compete with each other. For 
instance, the gB-498-specific CDS"^ T cell response was higher than those of 
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OVA-257 and D3E-128 after immunisation witi: heat-inactivated WR-eGFP-
SKS-A4 or MVA- eGFP-SKS-A4. All three of these peptides are presented on H-
2K . One possibility is that the gB-498-specilic response has a strong 
immunodomination effect on responses specific to H-2K''-binding peptides, 
compared to peptides that are presented on other MHC-I molecules (H-2D'' in 
C57BL/6 mice). MHC-l-specific immundomination has been detected during lAV 
infection in mice (Jenkins et al.. 2006). To test whether immunodomination play a 
role here, new V A C V recombinants that contain individual epitopes tagged onto 
the A4 protein can be generated and their ability to elicit CD8^ T cell responses 
against the inserted peptides can be compared to WR-eGFP-SKS-A4 after heat 
inactivation. 
Thirdly, whether heat-inactivated VACV can be used as a vaccine to induce 
protective immunity against heterologous pathogens needs to be investigated. We 
did not detect any significant enhancement of CDS"^ T cell responses against HSV 
gB-498 in mice primed with heat-inactivated WR-eGFP-STS-A3 compared to 
non-immunised mice after HSV-1 challenge. Similarly, immunisation with heat-
inactivated WR-eGFP-STS-A3 did not reduce virus load in the HSV-1-infected 
ears from mice that were challenged with HSV-1 seven weeks after immunisation, 
compared to mice that were immunised with live wildtype W R (data not shown). 
More positively, priming mice with heat-inactivated WR-eGFP-STS-A3 and 
boosting with live WR-eGFP-STS-A3 elicited a better recall CD8^ T cell 
responses against foreign antigens than a homologous prime-boost regime using 
only live WR-eGFP-STS-A3. Perhaps a higher anti-VACV antibody response 
might be induced in mice primed with live VACV than those immunised with the 
heat-inactivated virus, and this might result in a greater neutralisation of the 
booster vaccine. An advantage of our prime-boost strategy is that only one single 
vaccine is needed, overcoming the requirement for the use of different types of 
vaccine vectors as in a heterologous prime-boost strategy (Ramshaw and Ramsay. 
2000; Woodland. 2004). Whether our prime-boost strategy could induce 
protective immunity against heterologous pathogen challenges, such as HSV-1 
infection, should be examined. Fourthly, heat-inactivated MVA-eGFP-SKS-A4 
seemed to prime a reduced level of CD8^ T cells responses against the inserted 
antigenic peptides compared to WR-eGFP-SKS-A4. One possibility is that a 
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decreased amount of recombinant A4 was incorporated into tiie MVA virion 
particles compared to WR. The use of otiier virion antigens for MVA should be 
examined. In summary, heat-inactivated recombinant VACV is a new vaccine 
strategy that is worthy of further exploration. 
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CD8^ T cells play an important role in controlling infections caused by 
intracellular pathogens as well as tumours. Induction of protective CD8^ T cell 
immunity with recombinant vaccines is the subject of ongoing research. In order 
to optimise the immunogenicity of a targeted antigen from a given recombinant 
vaccine vector, it is necessary to identify the priming pathway involved. 
Understanding the general rules determining priming pathway for a given vaccine 
vector would provide crucial information for designing better vaccines. This 
thesis focuses on the in vivo antigen presentation pathway for CD8^ T cell 
priming by two strains o f VACV , namely W R and MVA. Most of the basic 
research on V A C V biology has used WR. although its clinical use is limited due 
to its virulence. M V A . in contrast, is now being used as a recombinant vaccine 
vector in clinical trials. Literature in the field suggests that the priming 
mechanisms for antigens expressed by these two strains of VACV differ. 
However, results shown in this thesis suggest that findings from W R can 
generally be applied to M V A . Importantly, the characteristics of the examined 
antigen dictate how an antigen is presented for CD8^ T cell priming. Therefore, 
this thesis has implications for the design of VACV-based recombinant vaccines. 
The first strategy used to dissect priming pathways of VACV in this thesis was to 
selective inhibit cross priming in vivo with the use of inhibitors, namely CpG and 
cytc (Chapter 3). However, treatment of mice with CpG and cytc, which have 
both been reported to selectively inactivate cross priming in vivo (Wilson et al., 
2006; Lin et al., 2008), did not produce any meaningful insights regarding the 
priming mechanisms for individual native VACV antigens during VACV 
immunisation. Instead, the outcome of these two treatments was strongly linked to 
the replicative ability o f the strain of VACV tested. For CpG treatment, we 
demonstrated that antigen dose was also an important factor dictating the ability 
o f CpG to inhibit CD8'^ T cell priming. Furthermore, results with cytc implied that 
direct and cross presentation o f viral antigens cannot be separated according to 
DC subsets. Although most published studies have focused on the cross priming 
ability o f CD8a^ DCs (den Haan et al., 2000: Bedoui et al., 2009; Henri et al., 
2010; Desch et al., 2011), CDSa"^ DCs are likely to present peptides on MHC-1 via 
direct presentation pathways as well (as discussed in Section 3.3). Elimination o f 
these DCs by cytc may explain the inhibition observed of both pathways. 
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In the literature other mouse models have been suggested or already been used for 
dissecting antigen presentation pathways in vivo. Firstly, it has been suggested 
that Batt3-deficient mice, which lack both CD8a^ and CD103^ DCs (Hildner et 
al.. 2008), could be used as models to dissect antigen presentation (Yewdell, 
2010; Hickman et al., 201 la). This is mainly based on the premise that these two 
types of DCs are the main DC subsets responsible for cross priming CD8^ T cells. 
As discussed above, because of a potential role for these CD8a^ DCs in direct 
priming, it is highly questionable whether these mutant mice would constitute a 
reliable model for antigen presentation, especially for viruses that do not replicate 
in vivo. A further limitation on the use of this model for studying presentation of 
viral antigens is that it has been shown that development of functional CD8a^ 
DCs can be restored in these mice after infection with various pathogens 
(Tussiwand et al., 2012). This caveat would further complicate any meaningful 
analysis of CD8^ T cell priming pathways using this model. 
Secondly, two reports have shown that MyD88-deficient mice have a decreased 
ability to induce CD8^ T cells responses against antigen donor cells infected with 
Semliki Forest virus and a soluble HSP fusion antigen (Palliser et al., 2004; Chen 
et al., 2005). MyD88 is the main adaptor signalling molecules for IL-1 receptors 
and TLRs, such as the TLR-9 mentioned in Section 3.1 (reviewed in Akira and 
Takeda, 2004). In DCs, MyD88 acts as the main switch for their maturation state 
after TLR ligation (Hacker et al., 2000; Schnare et al., 2000). However, MyD88-
deficient DCs co-cultured with antigen-donor cells infected with Semliki Forest 
virus have a similar maturation status as wildtype DCs (Chen et al., 2005). In 
addition, MyD88-deficient DCs co-cultured with a HSP fusion antigen fused to a 
antigenic peptide had a reduced ability to re-stimulate a pre-activated peptide-
specific CD8^ T cell clone (which could simply be stimulated with a synthetic 
cognate peptide; Palliser et al., 2004). These results suggested that the lack of 
antigen processing and cross presentation of the captured antigens was responsible 
for the reduced CD8^ T cell priming in the MyD88-deficient mice in the cross 
priming models examined. One study has found that MyD88 in DCs is important 
for recruiting TAP to the endosomes, a proposed compartment for MHC-I peptide 
loading in the phagosome-to-cytosol cross presentation pathway (Section 1.7.2.1; 
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Figure 1-3), as well as the subsequent MHC-1 presentation of captured antigens in 
vitro in the presence of the TLR-4 ligand lipopolysaccharide (Burgdorf et al., 
2008). However, results generated with this mutant mouse strain should be 
analysed with caution, especially during in vivo immunisation/infection models. 
This is because MyDSS is an important signalling molecule and it not only affects 
DCs. but also other components of the immune system. Importantly, expression of 
MyD88 in CD8* T cells is essential for their survival and expansion during 
VACV immunisation (Quigley et al.. 2009; Zhao et al., 2009). In addition, it has 
been shown that DCs isolated from MyD88-deficient mice immunised with WR-
TK-OVA could stimulate the proliferation of naive wildtype OT-1 cells in vitro 
(Zhao et al., 2009). This suggested that the priming ability of MyD88-deficient 
DCs is not affected in the VACV immunisation model. Therefore, this model is 
not useful for dissecting presentation pathway of VACV antigens. 
Thirdly, experiments with mice deficient for the Clec9A receptor have shown that 
this receptor is required for cross presentation of antigens associated with dead 
cells in vivo for CD8" T cell priming (Sancho et al., 2009; Zelenay et al., 2012). 
Although Clec9A is not involved in the uptake of dead cell materials, this receptor 
helps the transfer of captured dead-cell-associated antigens into endosomes that 
favour cross presentation of antigens (Sancho et a l . 2009; Zelenay et al., 2012). 
Recently, it has been shown a reduced CD8'^ T cell response was induced in 
Clec9A-deficient mice immunised with VACV-infected cells, compared to 
wildtype mice (Iborra et al., 2012). Interestingly, the same study found that the 
anti-VACV CD8^ T cell response induced by dermal VACV immunisation in 
these mutant mice was lower. More importantly, a VACV-strain-specific effect 
was observed, in which responses induced by MVA seemed to be affected to a 
greater extent than WR (Iborra et a l , 2012). The authors suggested a role for cross 
priming of CDS"^ T cells during VACV immunisation (Iborra et al., 2012). These 
findings do not necessarily contradict our findings with the minigene constructs, 
which are purposely designed for enhancing direct presentation efficiency. It 
should be noted that the study by Iborra et al. (2012) demonstrated that direct 
presentation of VACV antigens was not affected in the Clec9A-deficient DCs in 
vitro. However, it remains unclear whether this is also true in vivo. This should be 
demonstrated empirically before a firm conclusion on the role of cross priming of 
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anti-VACV CD8^ T cells can be drawn. VACV recombinants expressing the 
directly-presented OVA minigene could be used for this purpose (as in Chapter 
3). Overall, in vivo presentation pathways for CDS"^ T cell priming cannot be 
easily separated based on the mouse models that eliminate cross presentation as 
discussed above. 
Another strategy to dissect the presentation pathways for individual native VACV 
peptides was to use VACV recombinants to compensate for the antigen 
presentation deficiency in the mouse model examined. As mentioned in Section 
3.1. Xu et al. (2010) generated MHC-l-deficient->wildtype bone marrow chimera, 
and then immunised these chimeric mice with a WR recombinant expressing H-
2K'', compensating for the loss of direct presentation ability of the infected APCs 
in vivo. From this experiment, it was demonstrated that the CD8^ T cell response 
specific to B8-20 is induced by direct presentation by infected bone marrow-
derived APCs (Xu et al., 2010). We have used a similar strategy to dissect how a 
large panel VACV peptides are presented for CD8^ T cell priming in vivo. Instead 
of targeting peptides restricted to one MHC-1 allele as in Xu et al. (2010). we 
decided to target both H-2D''- and H-2K''-presented VACV peptides by using 
TAP-deficient mice (Theodoratos et al.. 2010). TAP- l^wi ld type bone marrow 
chimera were generated. In these chimera, all DCs would be TAP-1-deficient and. 
therefore, be unable to directly present most peptides (excluding peptides that can 
be presented via a TAP-independent pathway). In addition, the proteasome-to-
cytosol cross presentation pathway, which requires TAP (Ackerman et al., 2003; 
Guermonprez et al., 2003; Burgdorf et a l , 2008), would be non-functional. If 
these mice were immunised with a TAP-1-expressing VACV, the direct 
presentation pathway would be rescued within infected cells. However, uninfected 
DCs within the immunised mice would still fail to cross present antigens. Using 
this model, we found that CD8'^ T cell responses against most peptides were 
significantly reduced in TAP-1 ^wi ld type chimera immunised with a control WR 
compared with wildtype^wildtype chimera. When TAP-1 ^wi ld type mice were 
immunised with WR expressing TAP-1, CDS"^  T cell responses against C4-125, 
A47-138, K3-6, and 88-20 were improved compared to the same chimera 
immunised with control WR (data not shown). These results suggested that these 
peptides are directly presented from infected bone-marrow derived APCs. 
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However, we later found that DCs originating from the wildtype recipients were 
not completely eliminated from the TAP-1 ^wi ld type chimera, probably because 
of the irradiation dose used. This complicated the analysis o f the results from the 
experiments and they were not included here (data not shown). 
Nevertheless, this thesis demonstrates that CDS"^ T cells specific to antigens 
expressed from both strains of V A C V , W R and MVA . can be effectively primed 
by direct presentation. Experiments with the directly-presented minigenes in 
Chapter 4 showed that these constructs expressed from W R and M V A are at least 
as potent as full-length antigens at inducing CD8^ T cell responses after i.d. 
immunisation. These data suggest effective direct priming for antigens expressed 
from both V A C V strains. This argument is supported by published studies with 
intravital microscopy, which showed direct interactions of naive CD8^ T cells 
with DCs infected with W R or M V A (Norbury et al., 2002; Hickman et al., 2008; 
KastenmUller et al., 2013). In addition, a recombinant M V A expressing CPXV12 
and CPXV203. which suppress peptide translocation via TAP and MHC-I export 
to the cell surface respectively (Byun et al.. 2007; Alzhanova et al.. 2009; Byun et 
al., 2009). has been generated in our laboratory recently (Lin. 2013). Results with 
this virus broadly suggest a role for direct CD8'^ T cell priming during M V A 
immunisation in mice (Lin. 2013). Therefore, it is reasonable to conclude that the 
priming mechanism of antigens expressed from W R and M V A is indeed similar, 
being direct presentation. 
Furthermore, our minigene experiments described above also argue against the 
suggestion that cross priming is the main pathway for CD8^ T cell priming during 
i.d. immunisation (Shen et al., 2002), irrespective of the strain of VACV used. 
Infection o f DCs in the draining LNs by W R and M V A occurs as early as two to 
four hours after local subcutaneous immunisation (Norbury et al., 2002; Hickman 
et al., 2008; KastenmUller et al., 2013). Similarly, infectious W R virus can be 
isolated from draining LNs six hours after i.d. immunisation (Lin et al., 2013). 
These studies suggest that DCs can be directly infected with injected virus very 
early after a local immunisation, before the initial round of virus replication in 
vivo. Our finding that the non-replicating TMP/UV-treated WR-TK-SIIN induced 
strong responses against the directly-presented OVA-257 minigene (Section 3.2.6) 
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further indicates that direct priming of anti-VACV CDS"^ T ceil responses does not 
require virus replication at the infection site during i.d. immunisation. 
After local immunisation. VACV is likely to have direct access to draining LNs. 
especially when a high level of infectious virus is used, such as the normal doses 
used in this thesis. Within the draining LNs. mainly macrophages are infected but 
they do not support CD8^ T cell priming (Norbury et al., 2002; Hickman et al.. 
2008; Hickman et al., 2011b). At the same time, some DCs are also infected 
which allow direct CD8^ T cell priming. Alternatively, infected DCs from the 
infection site may migrate into the draining LNs for CDS^ T cell priming. This 
phenomenon has been suggested after i.n. immunisation with VACV, where 
migratory CD 103^ DCs originating in the lungs from mice immunised with WR-
NP-S-GFP supported the proliferation of naive OT-I CD8^ T cell in vitro 
(Beauchamp et al., 2010). Whether this would occur during i.d. immunisation has 
yet to be tested. As discussed in Section 1.9.3, the DC subsets involved in CD8^ T 
cell priming during VACV immunisation have been investigated in several studies 
(Belz et al., 2004; He et al.. 2006; Abadie et al., 2009; Beauchamp et al.. 2010; 
Liard et al., 2012). However, their findings were not consistent with each other. 
For instance, CD8a'^ DCs were found to prime CD8^ T cells when mice were 
infected with WR subcutaneously in the footpads or through the i.v. route (Belz et 
al.. 2004; He et al.. 2006). Contrary to these findings and as described above. 
Beauchamp et al. (2010) showed that migratory CDIOS"^ DCs. but not CD8a^ 
DCs, prime CD8^ T cells after i.n. immunisation with WR. It is likely that the DC 
subset responsible for CD8^ T cell priming is dependent on immunisation route. 
Identification of the priming DCs during i.d. immunisation with VACV, which 
resembles human vaccination, remains crucial. As only when the physiological 
APCs are determined, can we start examining the relationship between in vitro 
presentation levels and in vivo priming capability of a given antigen expressed 
from VACV. To examine which DCs are involved in CD8^ T cell priming after 
VACV immunisation via the i.d. route, an in vitro proliferation assay could be 
used. This involves isolation of individual subsets of DCs from the draining LNs 
from mice immunised i.d. with recombinant WR or MVA expressing the OVA-
257 minigene, followed by co-culturing with CFSE-labelled naive OT-I cells in 
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vitro. The ability of eaci: DC subset to sustain the proliferation of the naive T cells 
is assessed. This method has been commonly used to identify the priming DC 
subsets in various infection models (Belz et al., 2004; Belz et al., 2005; He et al., 
2006: Bedoui et al., 2009; Beauchamp et al., 2010). One caveat of this assay is 
that the TCR transgenic CD8^ T cells used, such as OT-I cells, may have a 
relatively lower activation threshold to cognate peptide stimulation compared to 
the wildtype CD8" T cell population (Zehn et al., 2009). In addition, naive 
purified CDS' OT-1 cells can be activated simply by pulsing with synthetic OVA-
257 peptide only (data not shown). Therefore, the in vitro proliferation assay with 
TCR transgenic CDS" T cells probably only reflects the level of MHC-I 
presentation on the DCs isolated, but not the genuine CDS" T cell priming that 
requires additional signals from antigen-presenting DCs. such as co-stimulatory 
signalling. 
Another poxvirus genus that has clinical relevance in the context of vaccines is 
the avipoxvirus. including fowlpox virus and canarypox virus. Similar to MVA. 
these viruses only replicate in avian cells, but can infect mammalian cells 
abortively, allowing transgene expression (Taylor et al.. 1988; Tartaglia et a l , 
1992; Somogyi et al., 1993; Pacchioni el al., 2010). These viruses are also well 
tolerated in immunodeficient mice (Leong et al.. 1994). Therefore, research has 
been done to examine the usefulness of these viruses as recombinant vaccine 
vectors in clinical trials (Jager et al., 2006; Kaufman et al., 2008; Rerks-Ngarm et 
al., 2009). It has been shown that CDS" T cell epitopes from the tumor-associated 
antigen, gplOO, expressed as minigenes from canarypox virus are able to induce 
CDS" T cell responses in mice (Tine et al., 2005). In an independent study, the 
immunogenicity of recombinant fowlpox viruses expressing a gplOO CD8" T cell 
epitope as an ER-targeted minigene or as a full-length antigen were examined in 
human patients (Rosenberg et al., 2003). In both constructs, the encoded epitope 
was modified to enhance the binding affinity to the restricting MHC-I (Rosenberg 
et al., 2003). The study found that after two rounds of immunisation, fowlpox 
virus expressing the ER-targeted minigene induced an epitope-specific CDS" T 
cell response in more human patients than fowlpox virus expressing the full-
length antigen (Rosenberg et al., 2003). Overall these reports suggest that 
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minigenes expressed from non-replicating poxviruses can prime CD8^ T cell 
responses effectively, in accordance with the experiments with MVA shown here. 
While antigen presentation pathways seem unaffected by poxvirus strain, this 
thesis suggests a major role for the characteristics of a given antigen in dictating 
how the antigen is presented. Firstly, only some, not all. native VACV antigens 
can be cross presented from VACV-infected cells or viral particles in vivo 
(Chapters 3 and 6). For all recombinant antigens examined, only full-length stable 
constructs can be cross presented (Chapters 4). For instance, it has been found that 
the PB1F2 antigen is unstable (Chen et al.. 2001a), and this may explain why no 
PBlF2-62-speciric CD8^ T cell response was induced by cells infected with WR 
or MVA expressing full-length PB1F2. Moreover, all minigenes examined in this 
thesis fail to be cross presented in vivo from infected cells. Interestingly, Lev et 
al. (2008) found that the PA-224 minigene expressed in VACV-infected cells can 
induce CD8^ T cell responses via cross priming. This is because the minimal 
peptide is stabilised within infected cells (Lev et al., 2008). allowing it to survive 
long enough for cross presentation. This discovery is an exception to the findings 
shown in this thesis and published work (Norbury et al., 2004; Basta et al., 2005; 
Lev et al., 2008), representing only one out of seven minigenes expressed from 
VACV that have been examined to our knowledge. 
Besides suitability for cross priming, various characteristics of a given antigen can 
also influence the immunogenicity of the directly-presented constructs. For 
instance, results in Chapter 5 show that the immunodominant NP-366 from lAV 
was much less immunogenic when expressed from WR as constructs that 
facilitate direct presentation, contradicting the general rule reported for other 
antigens in Chapter 4, as well as the vast number of published studies (Irvine et 
al., 1995; Restifo et al.. 1995; Tobery and Siliciano. 1997; Fu et a l , 1998; Tobery 
and Siliciano. 1999; Norbury et al., 2004). Similar to our results with the PR8NP-
366 peptide from WR-UbR-NP-S-GFP, a recent report showed that expressing the 
LCMV NP antigen as a rapidly-degraded construct from WR was less 
immunogenic and resulted in a reduction of CDS"^ T cell responses against two 
CD8^ T cell epitopes available on the antigen in C57BI/6 mice (Schliehe et al., 
2012). However, a minigene version of one of the two CDS"^ T cell epitopes from 
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the LCMV NP antigen tested has been found to be immunogenic in vivo when 
expressed from WR (Probst et al.. 2003). Therefore, the mechanism involved 
might be different from that of lAV NP, which was poorly immunogenic when 
expressed as a minigene or a rapidly-degraded construct. Based on the results and 
studies discussed above, it is reasonable to conclude that the nature of a given 
antigen, but not the strain of VACV, governs the priming pathway used. 
Therefore, although there may be general rules that are applicable to many 
epitopes, each of them must be examined individually to identify the optimal 
constructs. 
It should be noted that for most of the recombinant viruses used in this thesis, only 
one single final recombinant was generated (except for MVA-dellll-SIIN-delTK 
used in Section 4.2.6). Multiple rounds of plaque purification are involved in 
generating a VACV recombinant and it is possible that a virus with unfavourable 
random mutations might be inadvertently selected. Without an independent 
biological replicate, this possible adverse event cannot be controlled. In this 
thesis, this problem was overcome by studying several recombinant antigens and 
focusing on the general conclusions. However, for effects observed with 
individual recombinants, such as the reduced overall immunogenicity of WR-
delB8-miniB8 observed in Section 4.2.3, it would be unwise to conclude that the 
observed phenomenon was only due to the intended mutation. In these cases, a 
second independent recombinant virus is required. This important control is rarely 
considered in most studies in the field of vaccinology and immunology which use 
recombinant viruses. This practice contrasts greatly with that of virology, where 
the use of independent lineages of recombinant viruses or revertant viruses is the 
norm. 
This thesis also has implications for designing VACV-based recombinant 
vaccines. Firstly, the insertion site, and possibly function of VACV TK, 
modulates the relative immunogenicity of the minigenes compared with the full-
length antigens, highlighting the importance of vector design. This explained the 
disparity between the high immunogenicity of minigenes expressed from the TK 
locus of MVA, as shown in Chapter 4, and the study by Gasteiger et al. (2007), 
which found that the OVA-257 minigene expressed from the dellll region was 
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less immunogenic than full-length OVA. Although the mechanism responsible has 
not been identified, results here suggest that insertion site should be chosen based 
on the immunogenicity of the inserted antigens, not because of historical 
precedent or a simple rationale to preserve all VACV genes. 
Secondly, in this thesis as well as most published studies, the possibility that the 
functions of foreign antigens expressed from VACV could affect the immune 
responses induced was not examined. As minigenes are unlikely to retain any 
functional capacity, this is probably more relevant to full-length antigens than 
minigenes. It is known that antigens that were intended to be used as priming 
substrates for inducing immune responses can exert unforeseen functions. For 
instance, insertion of transgenes expressing HIV envelope (Env) protein and a 
group-specific-antigen-polymerase (Gag-Pol) fusion protein into MVA can resuh 
in an unstable recombinant virus (Wyatt et al., 2009). It has been suggested that 
expression of the HIV genes is detrimental to VACV replication, and so they pose 
a strong selective pressure for recombinant viruses that do not express the inserted 
genes (Wyatt et al.. 2009). Similarly, expression of an parainfluenza virus 3 
antigen from WR or MVA also significantly reduces virus replication in vhro 
(Wyatt et al., 1996). Expression of the HIV Env and Gag-Pol proteins from MVA 
enhances apoptosis of the infected cells (Zhang et a l . 2007). How this would 
affect the induction of a immune response has not been examined. One might 
assume that cross priming might be the dominant pathway for inducing CD8^ T 
cell responses against the inserted antigens if such a recombinant virus was used 
as DCs infected with the virus might die before allowing proper CD8^ T cell 
priming. In addition, antigens within necrotic cells and apoptotic cells could be 
captured and processed by different cross presentation pathways (Albert et al., 
1998: Sauter et al., 2000: Sancho et al., 2009). The nature of cellular death could 
influence the outcome of cross priming. Therefore, the influence of foreign 
antigens expressed from vaccine vectors on the biology of infected cells and, as a 
result, antigen presentation should not be overlooked. 
Thirdly, there are also implications for the clinical translation of research from 
mice to human use. Because different epitopes are targeted to murine and human 
MHC-1, they may be processed and presented by different pathways even when 
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expressed from the same antigen. Transgenic mice expressing human MHC-i 
molecules, such as HDD mice (Pascolo et al., 1997), have been used as an in vivo 
model to investigate CD8' T cell responses against epitopes specific to human 
MHC-1 during viral infection (Wentworth et al., 1996; Drexler et al., 2003; 
Kotturi et al., 2009; Tan et al., 2011). However, it should be noted that the details 
of antigen processing and presentation pathways in these mice will be different 
from that of human. Indeed, it has been shown that the specificity of proteasomal 
processing, TAP translocation, and peptide-loading with tapasin are slightly 
different between humans and mice (Neefjes et al.. 1995; Sesma et al.. 2003). 
Therefore, care should be taken when information obtained from mice are to be 
used for designing vaccines for use in humans. Furthermore, the results with lAV 
NP-366 peptide shown in Chapter 5 suggest that in vitro presentation level does 
not necessarily reflect CD8^ T cell priming in vivo. As a result, although the use 
of human cells to assess in vitro presentation levels may be useful for dictating 
possible priming outcomes for some antigens, care should be taken when 
translating the in vitro results for clinical uses. 
Fourthly, we have shown a potential use of heat-inactivated VACV as a carrier for 
recombinant antigens to induce CD8^ T cell responses. This was done by creating 
VACV recombinants with foreign peptides of interest attached to virion antigens. 
Even after complete inactivation of these VACV recombinants, we have shown 
that CDB^ T cell responses can be induced against the attached peptides in vivo 
(Chapter 6). The induction of responses against native VACV peptides was 
lowered in these inactivated viruses because most VACV antigens are not 
expressed by the inactivated virus in vivo and are not incorporated into VACV 
virions. This reduction of responses against vector could reduce the 
immunodomination of those directed towards the inserted antigen. A similar 
notion has been made previously in which minigene-expressing recombinant 
VACVs were treated with psoralen/UV (Fischer et al., 2007). This treatment 
selectively suppressed expression and MHC-1 presentation of long VACV 
antigens (Fischer et al., 2007). Furthermore, the anti-VACV CD8^ T cell response 
was reduced in mice immunised with psoralen/UV-treated WR-TK-OVA and 
resulted in an enhancement of the response against the OVA-257 minigene 
(Fischer et al., 2007). This study supports the idea that reduction of the anti-vector 
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response would be beneficial to the responses against the foreign antigens of 
interest. 
To summarise, results in this thesis demonstrate a general principle that direct 
presentation is highly effective for inducing T cell responses against 
antigens expressed from VACV strains WR and MVA. However, as for most of 
biology, exceptions to this general rule exist. Such deviations need to be taken 
into account during the examination of individual antigens and design of 
recombinant vaccine vectors. 
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Appendix 
Viruses used in Chapter 3 are shown in Table A-I. The information shown is 
reproduced from Section 2.1.8. 
Table A-l| Viruses used in Chapter 3 
V i rus 
WR 
Descript ion 
Wildtype WR 
MVA Wildtype MVA 
WR-TK-SIIN 
WR expressing a cytosolic OVA-257 niinigene by the 
VACV p7.5 promoter from tlie TK locus 
WR-TK-OVA 
WR expressing full-length OVA by the VACV 
p7.5 promoter from the TK locus 
WR expressing a recombinant NP-S-GFP antigen 
WR-NP-S-GFP consisting of PR8NP. OVA-257 peptide and eGFP by 
the p7.5 proinoter from the TK locus 
MVA-TK-SIIN 
MVA expressing a cytosolic OVA-257 minigene by the 
VACV p7.5 promoter from the TK locus 
A p p e n d i x 
Table A-2 shows some information regarding individual native VACV antigens 
that contain CD8^ T cell epitopes examined in this thesis. Differences in the 
putative promoter sequences for the corresponding VACV genes and the amino 
acid sequences of the antigens between WR and MVA are listed. 
Table A-2| Conservations of VACV antigens expressed from WR and MVA 
VACV 
peptide 
Peptide 
sequence 
Changes in the promoter and protein in MVA 
(relative to WR) 
Promoter Protein 
A 4 2 - 8 8 
A 8 - 7 0 
J 3 - 2 8 9 
C 4 - 1 2 5 
A 3 - 1 9 I 
A 4 7 - I 7 I 
L2-53 
A 4 7 - 1 3 8 
Y A P V S P I V I 
I H Y L F R C V 
S I F R F L N I 
L N F R F E N V 
Y S P S N H H I L 
Y A H I N A L E Y l 
V I Y I F T V R L 
A A F E F I N S L 
B 2 - 5 4 Y S Q V N K R Y I 
K 3 - 6 
A 2 3 - 2 9 7 
A 3 - 2 7 0 
A 8 - 1 8 9 
B 8 - 2 0 
insA-18 
Nil 
A - 7 7 G . A - 7 3 G 
d e l 4 5 - 4 9 
Nil 
Nil 
Y S L P N A G D V l 
I G M F N L T F I 
K S Y N Y M L L 
I T Y R F Y L I 
T S Y K F E S V 
T h e w h o l e C 4 L g e n e is de le ted f r o m the M V A g e n o m e 
G - 4 4 A . C - 8 5 T Q 5 1 K 
de l -36 d e l 2 9 - 3 3 , K 7 1 E . del 153-161, M 2 3 6 I 
Nil T 5 A 
Refe r to A 4 7 - 1 7 1 
T h e M V A B2 an t igen is t runca ted at pos i t ion 32, t he re fo re 
the B 2 - 5 4 pep t ide is not expres sed f r o m M V A 
Nil K 2 2 N , F 3 6 S 
Nil P 5 8 H 
R e f e r t o A 3 - 1 9 1 
R e f e r to A 8 - 7 0 
Nil de l95 -102 , del 115-121 , t m c 2 4 1 
1 Changes in the 85 bp upstream of the start codon (ATG) of the gene are shown. The number 
denoted the position upstream from the start codon. del: deletion; ins: insertion. 
2 del: deletion; Tmc: truncation, the sequence after the amino acid position shown is not produced. 
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Viruses used in Chapter 4 are listed in l able A-3. I he genetic modifications that 
were introduced into the viruses are shown. 
Table A-3| Viruses used in Chapter 4 
(Jcnctic modirication 
V i r u s Recombinant antigen 
expressed ' 
Insertion 
site 
G e n e 
knocked out 
WR-lull-gl5 Full-length IISVgl5 TK TK 
WR-i;Smini-gl$ [iR-targeted gB-498 minigene TK TK 
WR-dcllK - - TK 
MVA-l i i l l -gH Full-length IISV gU IK TK 
MVA-l-;Smini-gU FR-targeted gB-4')8 minigene IK TK 
MVA-dcHK - - IK 
WR-Pull-PA Fnll-lenglh lAV PA IK TK 
WR-i;Sniini-l'A FR-targeted PA-224 minigene IK TK 
WR-Fiill-l'Hl Full-length lAV PBI TK TK 
WR-KSniini-PBl FR-targeted PHI-703 minigene TK TK 
WR-Pull-NS2 Full-length lAV NS2 TK TK 
WR-ESmini-NS2 ER-targeted NS2-114 minigene TK TK 
WR-F11II-PR8NP Full-length lAV PR8NP TK TK 
WR-ESmini-PR8NP 
ER-targeted PR8NP-366 
minigene 
TK TK 
WR-Full-PBIF2 Full-length lAV PBIF2 TK TK 
WR-t-Smini-PBlF2 ER-targeted PBIF2-62 minigene TK TK 
MVA-F11II-PBIF2 Full-length lAV PBIF2 TK TK 
MVA-l-;Smini-PBlF2 ER-targeted PBIF2-62 minigene TK TK 
Appendix 
Table A-3 (Continued)l Viruses used in Chapter 4 
Genetic modification 
Virus Recombinant antigen 
expressed ' 
Insertion Gene 
site knocked out 
IVlVA-ESmini-PBlF2 
WR 
WR-delB8-miniB8 
WR-delB8 
MVA 
MVA-delB8-miniB8 
MVA-delB8 
WR-TK-OVA 
WR-TK-SIIN 
MVA-dellll-OVA 
MVA-dellll-SIIN 
MVA-TK-OVA 
MVA-TK-SIIN 
MVA-A11/A12-OVA 
ER-targeted PBl F2-62 minigene 
Cytosolic B8-20 minigene 
Cytosoiic B8-20 minigene 
Full-length OVA 
Cytosolic OVA-257 minigene 
Full-length OVA 
Cytosolic OVA-257 minigene 
Full-length OVA 
Cytosolic OVA-257 minigene 
Full-length OVA 
MVA-AI1/A12-SIIN Cytosolic OVA-257 minigene 
MVA-deilll-OVA-
delTK 
MVA-dellll-SllN-
delTK. 
Full-length OVA 
TK 
B8R 
B8R 
B8R 
B8R 
TK 
TK 
dellII region 
dellII region 
TK 
TK 
A11R/A12L 
intergenic 
region 
AI1R/AI2L 
intergenic 
region 
dellll region 
TK 
B8R 
B8R 
B8R 
B8R 
TK 
TK 
TK 
TK 
Cytosolic OVA-257 minigene dellll region 
TK 
TK 
1 It should be noted that for most of the recombinant viruses expressing transgenes fi-om the TK 
locus, a lacZ gene under the control of the late VACV pl 1 promoter was also inserted into the TK 
locus, except for the recombinant viruses WR-Full-PA and WR-Full-NS2. 
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I'able A-4 lists ail tlie viruses used in Chapter 5. Tiie in format ion is reproduced 
tVom Sect ion 2.1.8. A l l the W R recombinants used express a / acZ gene under the 
control o f the late V A C V p i 1 promoter f r om the TK locus . 
Table A-4| Virusc.s used in Chap te r 5 
V i r u s R e c o m b i n a n t an t i gen expressed 
WI<-1LIII-I'I<8NP 
WR-[;Smini-l>R8NI' 
WR-inini-l>R8NI' 
WR-l-ull-N r6()NP 
WR-ESni in i-Nr60NP 
l-iill-iength PR8NP 
ER-targeted PR8NP-366 miiiigene ' 
Cytosolic PR8NP-366 minigene 
I ull-length NT6()NP 
fiR-targeted NT6()NP-366 minigene" 
WR-NP-S-GIP 
WR-lJbR-NP-S-GFP 
WR-cytc-PR8NP 
WR-ES-PR8NP 
WR-delTK. 
lAV strain PR8 
NP-S-GFP antigen 
NP-S-GFP antigen tagged with an iibiquitin protein and an 
arginine residue at the aniino-terniinus 
A recombinant antigen consisting o f the amino acid 
residues of 13-498 of PR8NP (PR8NP13-498) 
ER-targeted PR8NP13-498 ^ 
1 The ER-targeted signal peptide from the adenovirus E3/19K protein was used. 
2 The ER-targeted signal peptide of the hemagglutinin from lAV strain PR8 was used. 
3 The ER-targeted signal peptide of the hemagglutinin from lAV strain A/WSN/33 was used. 
Appendix 
T h e v i ruses used in Chap te r 6 are hs ted in Tab ieA-5 . T h e i n fo rma t ion is 
r ep roduced f r o m Sect ion 2.1.8. 
Table A-5| Viruses used in Chapter 6 
V irus R e c o m b i n a n t ant igen expressed 
WR 
MVA 
WR-eGFP-STS-A3 
WR-eGFP-SKS-A4 
MVA-eGFP-SKS-A4 
WR. expressing a recombinant GFP-STS antigen, 
attached to tlie ainino-temiiniis of A3 protein 
WR. expressing a recombinant GFP-SKS antigen, 
attached to the amino-terminus of A4 protein 
MVA, expressing a recombinant GFP-SKS antigen, 
attached to the amino-tenninus of A4 protein 
Pliil ippians 3:13 
"I 'orgcll ing those things whicli are behind, and reaching forth unto those things 
which arc before" 
